Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Involving nucleic acid

Subclass of:

435 - Chemistry: molecular biology and microbiology

435004000 - MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20090061426Binary signaling assay using a split-polymerase - The present invention provides methods, kits and compositions for the detection of an analyte. In the methods of the invention, a complex is formed between two or more analyte specific probes (ASP) and an analyte. The analyte specific probes each have a portion of a polymerase which interact to form a functional polymerase complex upon binding of the ASP to the analyte. The functional polymerase complex then generates a detectable signal which is indicative of the presence and/or amount of the analyte in the sample.03-05-2009
20090117545Glycine riboswitches, methods for their use, and compositions for use with glycine riboswitches Cross-Reference to Related Applications - It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen-turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments.05-07-2009
20080293047Method for the Diagnosis of Aspirin Intolerance - The present invention relates to a method for the diagnosis of aspirin intolerance based on a biological sample from a patient, characterized in that it comprises the following steps: 11-27-2008
20100129806REGULATION OF CELL SURVIVAL BY HSP90 AND IP6K2 - Anti-cancer drugs are identified by screening for agents and compounds which inhibit the binding of HSP90 and IP6K2. In vitro and in vivo assays can be used. Any phenomenon associated with the binding or inhibition can be monitored, including cell death, subcellular localization, catalytic activity of IP6K2, and IP7 formation.05-27-2010
20100041042BREEDING AND MILKING COWS FOR MILK FREE OF BETA-CASEIN A1 - A milk or other dairy product, capable of minimising the onset of disease such as coronary heart disease or enhancing the immune response is derived from animals which are substantially free of the β-casein A allele. Bulk milk can be produced by testing for and culling cows who test positive for the β-casein A allele, or by producing immunoglobulins and other immune response proteins, in cow's milk from animals not possessing the β-casein A02-18-2010
20100112588METHODS FOR SANGER SEQUENCING USING PARTICLE ASSOCIATED CLONAL AMPLICONS AND HIGHLY PARALLEL ELECTROPHORETIC SIZE-BASED SEPARATION - Methods for highly parallel Sanger sequencing are discussed. In particular, provided herein are methods using particles to clonally amplify templates and to introduce the amplified nucleic acids into many parallel channels with a single template per channel. Once in the channels, the nucleic acids are separated by size using electrophoresis to produce long read length sequencing information. Methods involving optical detection of the size-separated nucleic acids and analysis of the resulting electropherograms to yield the sequences are disclosed.05-06-2010
20090208927Methods of detecting sequence-specific DNA binding proteins - Compositions and methods are provided for detecting and measuring DNA-binding proteins. The compositions and methods permit the simultaneous or near-simultaneous detection of multiple DNA-binding proteins in a multiplex or array format, and can be used to generate profiles of DNA binding activity by proteins, specifically, transcription factors. Multiple protein-DNA binding events in a single sample may be detected and quantitated in a high-throughput, format.08-20-2009
20090162854METHODS AND KITS FOR DIAGNOSIS OF SCHIZOPHRENIA - The present invention provides methods and kits for the diagnosis of schizophrenia, which employ mitochondrial complex I as a peripheral biological marker for schizophrenia. In an embodiment of the invention, the present invention provides a method for diagnosing schizophrenia in a subject by determining the level of m-RNA or protein mitochondrial complex I subunits and its activity by determining the cellular basal respiration through complex I enzyme.06-25-2009
20080280299Method for Specific Detection of Legionella Pneumophila - A method for specific detection of the presence of 11-13-2008
20090220973OBESITY AND BODY FAT DISTRIBUTION - Described are methods for predicting and diagnosing genetically-based obesity and body fat distribution, and for identifying compounds for the treatment and prevention of obesity.09-03-2009
20090220970MOLECULAR TOXICOLOGY MODELING - The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.09-03-2009
20090220953IDENTIFICATION OF ANCESTRAL HAPLOTYPES AND USES THEREOF - The present invention relates to the identification of haplospecific geometric elements (HGEs) in a multigene cluster comprising genes encoding complement control proteins. The present invention also relates to methods of performing genomic matching techniques (GMT) which enables the identification of HGEs of a duplicated region within a haplotype block. HGEs identified using the methods of the invention can also be analysed to determine if they are markers for a trait of interest such as a disease trait. Furthermore, the present invention relates to methods of determining an individual's susceptibility or predisposition to age-related macular degeneration, recurrent spontaneous abortion, Sjögren's Syndrome and/or psoriasis vulgaris by analysing the genotype of the individual within a multigene cluster comprising genes encoding complement control proteins.09-03-2009
20090061437Nucleotide Analogs - The invention provides for nucleotide analogs and methods of using the same, e.g., for sequencing nucleic acids.03-05-2009
20090208959FLUORESCENCE-LABELED OLIGONUCLEOTIDE TO DETECT NUCLEIC ACID AND METHOD FOR ACQUIRING INFORMATION ABOUT DOUBLE-STRAND FORMATION BY USING FLUORESCENCE-LABELED OLIGONUCLEOTIDE TO DETECT NUCLEIC ACID - A fluorescence-labeled oligonucleotide to detect nucleic acid has a base sequence complementary to the nucleic acid chain to be detected and changes in fluorescence characteristics upon double-strand formation with the nucleic acid chain to be detected. The label is an intercalating fluorescent dye and a non-intercalating fluorescent dye. The intercalating fluorescent dye acquires excited energy upon absorption of light and gives it to the non-intercalating fluorescent dye, and the non-intercalating fluorescent dye receives the excited energy to emit light.08-20-2009
20090305270ANTIGENIC SURFACE STRUCTURE OF SPERM CELLS ASSOCIATED WITH THE Y CHROMOSOME - The present invention relates to an antigenic surface structure of sperm cells associated with the Y chromosome, to the molecules, in particular antibodies, directed against this antigenic structure and to a method for characterizing cells carrying only the Y chromosome through the interaction between this antigenic structure and the molecules directed against said structure.12-10-2009
20090202999 METHOD FOR DNA BREAKPOINT ANALYSIS - The present invention relates to a method for identifying a DNA breakpoint and agents for use therein. More particularly, the present invention provides a method for identifying a gene translocation breakpoint based on the application of a novel multiplex DNA amplification technique. The method of the present invention facilitates not only the identification of the breakpoint position but, further, enables the isolation of the DNA segment across which the breakpoint occurs. This provides a valuable opportunity to conduct further analysis of the breakpoint region, such as to sequence across this region. The method of the present invention is useful in a range of applications including, but not limited to, providing a routine means to characterise the gene breakpoint associated with disease onset in a patient and thereby enable the design of patient specific probes and primers for ongoing monitoring of the subject disease condition. In addition to monitoring the progression of a condition characterised by the existence of the breakpoint, there is also enabled assessment of the effectiveness of existing therapeutic drugs and/or new therapeutic drugs and, to the extent that the condition is a neoplasm, prediction of the likelihood of a subject's relapse from a remissive state.08-13-2009
20090202993Use of DNA polymerases - Use of a DNA polymerase enzyme as a single stranded RNA exoribonuclease.08-13-2009
20090047681ENTROPIC TRAPPING AND SIEVING OF MOLECULES - Nanofluidic entropic traps, comprising alternating thin and thick regions, sieve small molecules such as DNA or protein polymers and other molecules. The thick region is comparable or substantially larger than the molecule to be separated, while the thin region is substantially smaller than the size of the molecules to be separated. Due to the molecular size dependence of the entropic trapping effect, separation of molecules may be achieved. In addition, entropic traps are used to collect, trap and control many molecules in the nanofluidic channel. A fabrication method is disclosed to provide an efficient way to make nanofluidic constrictions in any fluidic devices.02-19-2009
20100009355SELECTIVE AMPLIFICATION OF MINORITY MUTATIONS USING PRIMER BLOCKING HIGH-AFFINITY OLIGONUCLEOTIDES - In certain embodiments this invention pertains to methods of detecting and/or quantifying rare mutant nucleic acids in populations of nucleic acids in which the wild-type nucleic acids are in substantially greater abundance than the rare mutants. In various embodiments the methods utilize short high affinity oligonucleotides targeted to the wild type rather than the minority or mutant sequence. Rather than directly detecting mutant DNA, these probes block detection of wild type DNA. These “blocker” probes can be used in combination with longer “detection” probes or PCR primers to amplify and/or identify the minority mutation in, e.g., clinical specimens. The combination of short high affinity blocker probes and longer, lower affinity detection probes eliminates the single base specificity/complexity tradeoff in the design of nucleic acid probes.01-14-2010
20080206747Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation - This invention pertains to the field of combination oligomers, including the block synthesis of combination oligomers in the absence of a template, as well as related methods, kits, libraries and other compositions.08-28-2008
20090197266METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS - The present invention provides methods for optimizing clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. The methods of the present invention may further comprise determining the level of at least one long-chain methotrexate polyglutamate (MTXPG) in a sample obtained from the individual. The present invention also provides methods for generating a pharmacogenetic index for predicting clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. In addition, the present invention provides methods for optimizing therapeutic efficacy of chemotherapy in an individual by calculating the level of at least one long-chain MTXPG in a sample obtained from the individual.08-06-2009
20090197262BORDETELLA DETECTION ASSAY - Disclosed herein are methods and compositions for detecting 08-06-2009
20090136934TARGETING AND TRACING OF ANTIGENS IN LIVING CELLS - The present invention relates to a method of detecting the presence, amount or subcellular location of an antigenic structure of interest in a cell, comprising the steps of: (a) (i) expressing a fusion protein directed to the antigenic structure of interest in said cell or (ii) introducing a fusion protein directed to the antigenic structure of interest and coupled to a (poly) peptide capable of transducing into said cell; wherein said fusion protein comprises a first (poly) peptide sequence comprising the variable region of a heavy chain antibody of Camelidae and a second (poly) peptide sequence derivable from a fluorescent or chromophoric protein.05-28-2009
20100028873METHODS AND MEANS FOR NUCLEIC ACID SEQUENCING - The present invention provides a nucleic acid sequencing method. The method comprises enriching a nucleic acid sample for target nucleic acids, where the nucleic acid sample is enriched through at least a first round of hybridization selection and amplification, and a second round of hybridization selection and amplification. The enriched nucleic acids are in a form convenient for sequencing with the Cantaloupe sequencing technology, which employs shotgun sequencing by hybridization (SBH) of immobilized rolling circle amplicons.02-04-2010
20090035764Methods and systems for evaluating CGH candidate probe nucleic acid sequences - Methods of evaluating candidate CGH probe nucleic acid sequences are provided. Aspects of the methods include providing a candidate CGH probe nucleic acid sequence for a target sequence of a copy number variation (CNV) of a genome. A proximity score is then determined for the candidate CGH probe nucleic acid sequence and employed to evaluate the sequence. Aspects of the invention further include computer programming and systems that include the same which are configured to evaluate candidate CGH probe nucleic acid sequences using a proximity score.02-05-2009
20090220971Treatment Response in Generalized Social Phobia - This invention generally pertains to the field of psychiatry. In particular, this invention relates to, inter alia, the discovery that a subject's serotonin transporter gene promoter polymorphism genotype can be used to determine the subject's response to certain drug therapies.09-03-2009
20100035270Methods and Compositions for the Detection of Bovine Pregnancy - Provided herein are pregnancy specific marker genes, such as those shown in Tables I-III, and methods of detecting the same to determine bovine pregnancy.02-11-2010
20090311705METHOD OF DETERMINING EFFICIENCY OF OVUM COLLECTION IN BOVINE - The novel means by which an efficiency of ovum collection can be easily determined in bovine at gene level is disclosed. The present inventors performed the genomic linkage analysis using bovine populations with high and low efficiency of ovum collection and to identify GRIA1 gene, which encodes an ion channel protein, as a factor deeply related to an efficiency of ovum collection. Bovines having a mutation (e.g. the amino acid substitution of aa306) in GRIA1 produce significantly fewer ova on superovulatory treatment than those not having the mutation. Therefore, the efficiency of ovum collection can be determined based on the existence of a mutation in GRIA1 gene.12-17-2009
20100062436Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule - The present invention is related to a method for the detection of a nucleic acid molecule comprising at least a strand comprising a sequence of nucleotides in a sample, whereby the method comprises the following steps: 03-11-2010
20100062427METHOD FOR DETECTING DISEASE-ASSOCIATED MUTATIONS - A method is described for diagnosing individuals as having hypertrophic cardiomyopathy, e.g. familial or sporadic hypertrophic cardiomyopathy. The method provides a useful diagnostic tool which becomes particularly important when testing asymptomatic individuals suspected of having the disease. Symptomatic individuals have a much better chance of being diagnosed properly by a physician. Asymptomatic individuals from families having a history of familial hypertrophic cardiomyopathy may be selectively screened using the method of this invention allowing for a diagnosis prior to the appearance of any symptoms. Individuals having the mutation responsible for the disease may be counseled to take steps which hopefully would prolong their life, i.e. avoid rigorous exercise. The methodology used in the above method also has broad applicability and may be used to detect other disease-associated mutations in DNA obtained from subject being tested for other disease-associated mutations.03-11-2010
20100021920MUTATED ABL KINASE DOMAINS - The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.01-28-2010
20100021887PROBE FOR TAGGING VALUABLES BASED ON DNA-METAL COMPLEX - Methods are disclosed involving the formation of complex DNA-Metal and the detection of the complex, such as by employing several analytical methods, e.g., X-Ray Fluorescence, FT-IR and Raman spectroscopy.01-28-2010
20090197263Compare-MS: Method Rapid, Sensitive and Accurate Detection of DNA Methylation - The present invention provides methods and kits useful for enriching, identifying and quantifying methylated DNA3 particularly hypermethylated CpG islands by digesting a sample with a methylation-sensitive restriction endonuclease and capturing methylated restriction fragments with a methyl-binding capture reagent. The methods of the invention may be used in the detection of cancer, particularly detection of prostate cancer.08-06-2009
20090029383Polynucleotide Sequencing Method - The subject invention pertains to a method for determining the sequence of a polynucleotide comprising the steps of (i) contacting a polynucleotide processive enzyme immobilised in a fixed position, with a target polynucleotide under conditions sufficient to induce enzyme activity; (ii) detecting an effect consequent on the interaction of the enzyme and polynucleotide, wherein the effect is detected by measurement of a non-linear optical signal or a linear signal coupled to a non-linear signal.01-29-2009
20080213765Human Autism Susceptibility Genes Encoding a Neurotransmitter Transporter and Uses Thereof - The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the SLC6A1 or SLC6A11 gene on chromosome 3 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the SLC6A1 or SLC6A11 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of Asperger syndrome, pervasive developmental disorder, childhood disintegrative disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases including schizophrenia.09-04-2008
20080227108MOLECULAR IDENTIFICATION OF ASPERGILLUS SPECIES - Novel techniques for the detection of 09-18-2008
20100035252Methods for sequencing individual nucleic acids under tension - The invention provides apparatuses and methods of use thereof for sequencing nucleic acids subjected to a force, and thus considered under tension. The methods may employ but are not dependent upon incorporation of extrinsically detectably labeled nucleotides.02-11-2010
20090317797Non-Invasive, Prenatal, In-Vitro Method for Detecting the Normal Healthy Condition, the Condition of a Healthy Carrier or the Condition of a Carrier Inflicted with Cystic Fibrosis - The invention relates to a non-invasive, prenatal, in-vitro method for detecting the normal healthy condition, the condition of a healthy carrier or the condition of a carrier inflicted with cystic fibrosis, from the fetal cell(s) from a maternal sample, comprising the DNA of an individual to be tested. The invention also relates to oligonucleotide primers and to their use within the scope of a non-invasive, prenatal, in-vitro method for detecting the condition of a healthy carrier or of a carrier inflicted with cystic fibrosis.12-24-2009
20090081658GENEMAP OF THE HUMAN GENES ASSOCIATED WITH CROHN'S DISEASE - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs.03-26-2009
20090186359DETECTING PROSTATE CANCER - An assay for detecting prostate cancer includes reagents for detecting the methylation of GSTP1 and HIC-1 genes.07-23-2009
20090017452METHODS AND COMPOSITIONS RELATING TO THE PHARMACOGENETICS OF DIFFERENT GENE VARIANTS - The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2, UGT1A1, and/or SLCO1B1 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of ABCC2 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient or predicting their efficacy. Alterations in suggested therapy may ensue based on genotyping results.01-15-2009
20090291433Droplet-based nucleic acid amplification method and apparatus - The present invention relates to a droplet-based nucleic acid amplification method and apparatus. According to one embodiment, a method of amplifying a nucleic acid in a biological sample is provided, wherein the method includes: (a) providing a system comprising a droplet microactuator electronically coupled to and controlled by a processor capable of executing instructions, the droplet microactuator comprising: (i) a sample potentially comprising a target nucleic acid; (ii) a substrate comprising electrodes for conducting droplet operations; and (iii) one or more temperature control means arranged in proximity with one or more of the electrodes for heating a region of the droplet microactuator such that a droplet can be transported into the region for heating; (b) using droplet operations to combine on the droplet microactuator one or more amplification reagent droplets and one or more sample droplets to yield an amplification-ready droplet; and (c) thermal cycling the amplification-ready droplet sufficient to result in amplification of a target nucleic acid when present in the amplification-ready droplet.11-26-2009
20080261231DIABETES GENE - The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect human diabetes mellitus predisposing gene, specifically the angiotensinogen (AGT) gene, some mutant alleles of which cause susceptibility to insulin-dependent diabetes mellitus (IDDM). More specifically, the invention relates to germline mutations in the AGT gene and their use in the diagnosis of predisposition to diabetes. The invention also relates to the prophylaxis and/or therapy of diabetes associated with a mutation in the AGT gene. The invention further relates to the screening of drugs for diabetes therapy. Finally, the invention relates to the screening of the AGT gene for mutations, which are useful for diagnosing the predisposition to diabetes.10-23-2008
20080261218Detection of Biomarkers for Neuropsychiatric Disorders - Systems and methods provide a comprehensive high-throughput approach toward the sequential identification, prioritization, verification, and validation of etiologic factors in neuropsychiatric disorders, some of which can also be utilized as biomarkers for these illnesses. The systems and methods determine patterns of gene expression in various tissues from various samples under various experimental and non-experimental conditions, and uses the differences and similarities between the gene expression profiles observed under these conditions to delineate distinct gene expression profiles of risk and treatment of neuropsychiatric disorders.10-23-2008
20080261217Methylation Profile of Cancer - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides methods of identifying methylation patterns in genes associated with specific cancers.10-23-2008
200802612082'-Nitrobenzyl-Modified Ribonucleotides - This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided.10-23-2008
20100055704EXPRESSION PROFILE OF THYROID CANCER - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with thyroid cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of thyroid cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.03-04-2010
20090130683PREDICTING AND DIAGNOSING PATIENTS WITH AUTOIMMUNE DISEASE - The present invention provides methods for the prediction and diagnosis of autoimmune diseases, including Systemic Lupus Erythematosus, using single nucleotide polymorphism in TNFAIP3 (A20).05-21-2009
20090253134Cellular Pyrogen Test - The invention concerns methods, agents and kits for qualitative and quantitative detection and identification of pathogens and pathogen spectra based on endotoxins and other pyrogens.10-08-2009
20080318217Identification of Gene Associated with Reading Disability and Uses Therefor - The present invention relates to identification of a human gene, DCDC2 (MIM: 605755), associated with susceptibility for developing reading disability (RD), which is useful in identifying or aiding in identifying individuals at risk for developing RD, as well as for diagnosing or aiding in the diagnosis of RD.12-25-2008
20090042187COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT - This invention is directed to compositions and their uses for detection of markers. Such markers may be useful in the understanding of the underlying molecular event leading to a condition or a disease in a subject. These markers may also be useful for characterization of neoplastic cells and cancer cells and their response to certain therapeutical regimes. Therefore the invention as disclosed may contribute to the improvement of the stratification of patients for the best possible treatment.02-12-2009
20100055699METHOD OF MANUFACTURING A SEMICONDUCTOR SENSOR DEVICE AND SEMICONDUCTOR SENSOR DEVICE OBTAINED WITH SUCH METHOD - The invention relates to a method of manufacturing a semiconductor sensor device (03-04-2010
20100055695Method For Generating Aptamers with Improved Off-Rates - The present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. This invention relates to the field of diagnostic histology, cytology, histopathology, and cytopathology methods and reagents for the detection of various disease states. More specifically, the invention relates to the use of aptamers in histologic, cytologic, histopathic, and/or cytopathic diagnostic methods. Aptamers may be provided that react with specific target molecules contained within a histological or cytological sample. Aptamers may be used to assess localization, relative density, and presence or absence of one or more target. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. Aptamers may be used to introduce target specific signal moieties. Antigen retrieval methods may be applied to the sample prior to reaction with the specific aptamer/s to improve interaction of the aptamer and target within the sample. Or aptamers may be developed for the specific target that eliminates the need for the antigen retrieval process. In addition to target identification, aptamers may be used to amplify signal generation through a variety of methods.03-04-2010
20100055691SCREENING METHOD FOR THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS - The objective of the present invention is to provide methods of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis (ALS2). The invention provides a method of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis, comprising a step of assessing a substance that suppresses the expression of Tollip in cells as a therapeutic agent for juvenile familial amyotrophic lateral sclerosis; a method of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis, comprising a step of assessing a substance that promotes migration of Tollip in cells from the cytoplasm to the cell nucleus as a therapeutic agent for juvenile familial amyotrophic lateral sclerosis; and a method of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis, comprising a step of assessing a substance that inhibits the interaction between Tollip and IRAK-1 in cells as a therapeutic agent for juvenile familial amyotrophic lateral sclerosis.03-04-2010
20080199861Real-time microarray apparatus and methods related thereto - Embodiments of the invention relate to a real-time microarray apparatus comprising an upper substrate, a lower substrate, a buffer positioned between the upper and lower substrate, a microarray positioned on either the upper substrate or the lower substrate, a heater positioned near the microarray, a pump positioned near the buffer and microarray and an imaging sensor positioned near the microarray.08-21-2008
20100028893METHODS AND COMPOSITIONS FOR PHARMACOGENETIC ANALYSIS OF ANTI-INFLAMMATORY DRUGS IN THE TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER INFLAMMATORY DISEASES - The invention provides methods and compositions for the pharmacogenetic analysis of anti-inflammatory compounds, especially for the pharmacogenetic association of responsiveness to rheumatoid arthritis medications that target TNFα.02-04-2010
20090325168HOMO-DOUBLY LABELED COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES - The present invention provides for novel reagents whose fluorescence changes upon cleavage or a change in conformation of a backbone. The reagents comprise a backbone (e.g. nucleic acid, polypeptide, etc.) joining two fluorophores of the same species whereby the fluorophores form an H-dimer resulting in quenching of the fluorescence of the fluorophores. When the backbone is cleaved or changes conformation, the fluorophores are separated, no longer forming an H-type dimer, and are de-quenched thereby providing a detectable signal. The use of a single fluorophore rather than an “acceptor-donor” fluoresecence resonance energy transfer system offers synthesis and performance advantages.12-31-2009
20090325155Aureobasin a synthetase - Disclosed are polynucleotides encoding polypeptides having Aureobasidin A synthetase activity and Aureobasidin A synthetase-like activity. The invention also provides methods for detecting AbA synthetase proteins and nucleic acids and AbA synthetase-like proteins and nucleic acids in cells, and method for producing AbA synthetase polypeptides.12-31-2009
20090170110COMPOSITIONS AND METHODS TO DETECT CANDIDA ALBICANS NUCLEIC ACID - Compositions are disclosed as nucleic acid sequences that may be used as amplification oligomers, including primers, capture probes for sample preparation, and detection probes specific for 07-02-2009
20100021916MICROSATELLITE-BASED FINGERPRINTING SYSTEM FOR SACCHARUM COMPLEX - This invention relates to 01-28-2010
20100015631CONCATAMERIC LIGATION PRODUCTS: COMPOSITIONS METHODS AND KITS FOR SAME - The present teachings relate to methods, compositions, and kits for detecting one or more target polynucleotide sequences in a sample, and methods compositions and kits for forming concatameric ligation products. In some embodiments of the present teachings, oligonucleotides are hybridized to complementary target polynucleotides and are ligated together to form a concatameric ligation product. In some embodiments of the present teachings, the concatameric ligation product can be amplified, and the identity and quantity of the target polynucleotides determined based on sequence introduced in the ligation reaction. Some embodiments of the present teachings provide methods for removing unligated probes from the reaction mixture. Some embodiments of the present teachings provide for highly multiplexed detection, identification, and quantification of a plurality of target polynucleotides using a variety of analytical procedures.01-21-2010
20100086934Use of non-clonal chromosomal aberrations for cancer research and clinical diagnosis - A diagnostic method of determining tumorigenicity of a tissue specimen includes the steps of determining a magnitude of genome diversity in the tissue specimen, and diagnosing a likelihood of cancer in response to said step of determining the magnitude of genome diversity. The magnitude of genome diversity includes the determination of karyotypic heterogeneity in the tissue specimen, illustratively by detecting non-clonal chromosome aberrations (NCCAs). The detection of NCCAs includes the detection the frequency of NCCAs, and the diagnosis is responsive to the step of detecting the frequency of NCCAs. Detection of NCCAs advantageously includes the further step of screening lymphocytes. Also, the step of determining the presence of elevated genome diversity includes the step of applying Spectral Karyotyping to detect translocations throughout the genome. The diagnostic method is useful to determine drug resistance of a patient.04-08-2010
20100151462HUMAN DIABETES SUSCEPTIBILITY SHANK2 GENE - The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the SHANK2 gene locus in a biological sample of said subject.06-17-2010
20100151456METHOD FOR THE ASSAY OF LIVER FATTY ACID BINDING PROTEIN, ACE AND CA 19-9 FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - A method for the in vitro diagnosis of colorectal cancer by determining the presence of Liver Fatty Acid-Binding Protein, ACE and CA19-9 tumor markers in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.06-17-2010
20090239214Prognosis of breast cancer patients - The present invention relates to sets of genetic markers whose expression is correlated with prognosis of breast cancer in individuals having breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate individuals having a good prognosis, e.g., no reoccurrence or metastasis within five years of initial diagnosis, and individuals having a poor prognosis, e.g., reoccurrence or metastasis within five years of initial diagnosis. The invention relates to methods of prognosis using these markers. The invention also relates to microarrays containing probes to these markers, and to kits containing ready-to-use microarrays and computer software for data analysis using the prognostic and statistical methods disclosed herein.09-24-2009
20100015603Chimeric proteins for measuring atp concentrations in pericellular space and related screening method - The invention relates to luminescent chimeric proteins comprising a first N-terminal protein sequence, a second protein sequence and a third C-terminal protein sequence wherein: 01-21-2010
20080213779Nalp7-Based Diagnosis of Female Reproductive Conditions - Methods, reagents and kits are described for the diagnosis of a female reproductive condition, based on the detection of an alteration in a NALP7-encoding nucleic acid or a NALP7 polypeptide, relative to a corresponding wild-type NALP7-encoding nucleic acid or NALP7 polypeptide.09-04-2008
20090170076Polynucleotides for the detection of escherichia coli 0157:h7 and escherichia coli 0157:nm verotoxin producers - Polynucleotide primers and probes for the specific detection of 07-02-2009
20100009367MICRO RNAS AND THEIR METHODS OF USE FOR THE TREATMENT AND DIAGNOSIS OF SCHIZOPHRENIA AND SCHIZOPHRENIA SPECTRUM DISORDERS - A method of diagnosing, assessing susceptibility, and/or treating schizophrenia involving the identification and/or observation of microRNAs (miRNA) and variant miRNA are provided. Micro RNAs alleles associated with schizophrenia and schizophrenia spectrum disorders were identified and ultra-rare variants in the precursor or mature miRNA were identified. Functional analyses of ectopically expressed copies of the variant miRNA precursors demonstrate loss of function, gain of function and altered expression levels. The present invention also provides methods for selecting a preferred therapy for a particular subject or group of subjects or individuals at risk for or suffering from schizophrenia or psychosis by use of miRNAs.01-14-2010
20100009377METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTO IMMUNE AND CHRONIC INFLAMMATORY DISEASES - Methods of diagnosing or monitoring autoimmune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring autoimmune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis and kits or systems containing the same are also described.01-14-2010
20090004654METHOD FOR THE DETECTION OF BACTERIAL SPECIES OF THE GENERA ANAPLASMA/EHRLICHIA AND BARTONELLA - The present invention relates to a method for the detection and identification of bacterial species belonging to the genera 01-01-2009
20100041055NOVEL GENE NORMALIZATION METHODS - Measurement of gene expression relative to an endogenous control gene is prone to excessive variability between samples and even replicates. The disclosure provides methods for normalizing expression levels of a gene by scaling gene expression levels to that of the most highly expressed gene in the set of genes whose expression levels are measured, rather than a house-keeping gene.02-18-2010
20100159448METHOD FOR DETECTION AND MULTIPLE, SIMULTANEOUS QUANTIFICATION OF PATHOGENS BY MEANS OF REAL-TIME POLYMERASE CHAIN REACTION - A method for the detection and multiple, simultaneous quantification of any combination of 06-24-2010
20100159445METHOD FOR THE INDIVIDUAL STAGING OF TUMOR DISEASES - The present invention concerns a method for the individual staging of the tumor disease of an individual cancer patient, a method for the individual decision on the method of treatment as well as a method for treating a cancer patient as well as their use in the treatment of various cancer diseases like colorectal tumor, prostate tumor, breast tumor, lung tumor, as primary tumors, tumor relapse and/or metastases. The present invention further provides a new prognosis factor in cancer treatment. This inventive method includes the step of analyzing at least one disseminated tumor cell present in a sample taken from a patient for the expression of at least one mRNA of at least one of growth factors, growth factor receptors and tumor associated transcripts.06-24-2010
20100159446Detection Assays and Use Thereof - The invention provides compositions and methods for the detection and/or quantification of biological targets (e.g., nucleic acids and proteins) by the nucleic acid-templated creation of one or more reaction products, for example, epitopes, enzyme substrates, enzyme activators, and ligands. The reaction products can be detected and/or quantitated after signal amplification using an amplification system.06-24-2010
20100159452Method For Detecting a Target Nucleic Acid in a Sample - The invention relates to a method for detecting a target nucleic acid in a sample using fluorescent probe pairs which include fluorescent reporter and quencher molecules which may be used in hybridization assays and in nucleic acid amplification reactions, especially polymerase chain reactions (PCR).06-24-2010
20100003669Primer for Detection of Cytochrome P450 Hydroxylase Specific to Polyene - The present invention relates to a primer for detection of cytochrome P450 hydroxylase specific to polyene and a method for detecting a strain of bacteria which produces polyene, by using the primer. More particularly, the present invention is directed in a forward degenerate primer of following sequence (I) and a reverse degenerate primer of following sequence (II), which are complementary to conserved region which resides in the polyene-specific CYP (cytochrome P450 hydroxylose) encoding sequences: (I) 5′-TGGATCGGCGACGACCGSVYCGT-3′ and (II) 5′-CCGWASAGSAYSCCGTCOTACTT-3′, wherein S indicated Guanine or Cytosine, V indicates Adrenine, Guanine or Cytosine, Y indicates Thymine or Cytosine and W indicates Thymine or Adenine.01-07-2010
20090004665METHODS AND COMPOSITIONS FOR ISOLATING NUCLEIC ACID SEQUENCE VARIANTS - The invention is drawn to isolating sequence variants of a genetic locus of interest using a modified iterative primer extension method. The nucleic acids analyzed are generally single stranded and have a reference sequence which is used as a basis for performing iterative single nucleotide extension reactions from a hybridized polymerization primer. The iterative polymerization reactions are configured such that polymerization of the strand will continue if the sequence of the nucleic acid being analyzed matches the reference sequence, whereas polymerization will be terminated if the nucleic acid being analyzed does not match the reference sequence. Nucleic acid strands that have mutations can be isolated using a variety of methods and sequenced to determine the precise identity of the mutation/polymorphism. By performing the method on both strands of the nucleic acid being analyzed, virtually all possible mutations can be identified.01-01-2009
20100151467Methods and compositions for diagnosing and monitoring transplant rejection - Methods of diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection and kits or systems containing the same are also described.06-17-2010
20100151469SAMPLE-PROCESSING REAGENT COMPOSITIONS, METHODS, AND DEVICES - Stable compositions comprising a nucleic acid binding support material comprising a substrate with functional groups attached to the substrate; a lysing enzyme; a water dispersible matrix material; and a saccharide, methods of using the compositions, and products and devices which include the compositions are disclosed.06-17-2010
20100151477REDUCING NON-TARGET NUCLEIC ACID DEPENDENT AMPLIFICATIONS: AMPLIFYING REPETITIVE NUCLEIC ACID SEQUENCES - The present invention provides for compositions and methods for amplifying target nucleic acids using nucleic acid primers designed to limit non-target nucleic acid dependent priming events. The present invention permits amplifying and quantitating the number of repetitive units in a repetitive region, such as the number of telomere repetitive units.06-17-2010
20100151475Chemical reaction cartridge, its fabrication method, and a chemical reaction cartridge drive system - The present invention makes it possible to realize a chemical reaction cartridge, which enables prescribed protocols to be achieved easily without differences among operators, which is sealed and disposable, and which has a safe structure against viruses or dangerous drugs.06-17-2010
20100151470METHODS AND COMPOSITIONS FOR LOCATING SNP HETEROZYGOSITY FOR ALLELE SPECIFIC DIAGNOSIS AND THERAPY - The present invention provides methods for the rapid and cost effective identification of the presence of a disease-associated mutation and a particular SNP in the same allele of a gene without the need to clone and sequence the entire gene. The compositions and methods of the invention are useful for identification of patient to subpopulations amenable to treatment as part of a therapeutic strategy for treating genetic disorders, for example, dominant, gain-of-function gene mutations, for example, Huntington's Disease (HD).06-17-2010
20100086932BLADDER CANCER DIAGNOSIS AND/OR PROGNOSIS METHOD - The present invention relates to an in vitro non-invasive bladder cancer diagnosis and/or prognosis method based on the detection and quantification in bladder fluids of the gene expression of certain genes and/or combinations thereof acting as genetic markers of said disease. A bladder cancer diagnosis and/or prognosis kit based on the use of a set of probes suitable for the detection and quantification of the expression pattern of said genes is also contemplated.04-08-2010
20100086928DETECTION OF ORGAN REJECTION - The present invention features methods and compositions for the non-invasive detection of organ rejection using a microRNA score.04-08-2010
20090191569Mammalian Cytokines; Related Reagents - Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.07-30-2009
20090191567SEMICONDUCTOR NANOCRYSTAL PROBES FOR BIOLOGICAL APPLICATIONS AND PROCESS FOR MAKING AND USING SUCH PROBES - A semiconductor nanocrystal compound and probe are described. The compound is capable of linking to one or more affinity molecules. The compound comprises (1) one or more semiconductor nanocrystals capable of, in response to exposure to a first energy, providing a second energy, and (2) one or more linking agents, having a first portion linked to the one or more semiconductor nanocrystals and a second portion capable of linking to one or more affinity molecules. One or more semiconductor nanocrystal compounds are linked to one or more affinity molecules to form a semiconductor nanocrystal probe capable of bonding with one or more detectable substances in a material being analyzed, and capable of, in response to exposure to a first energy, providing a second energy. Also described are processes for respectively: making the semiconductor nanocrystal compound; making the semiconductor nanocrystal probe; and treating materials with the probe.07-30-2009
20090191566Kits for Isolating Nucleic Acids Using Multifunctional Group-Coated Solid Phase Carriers - The present invention is directed to a method of isolating a target species (e.g., target nucleic acid species) from a mixture. In the methods of the present invention, the mixture is combined with solid phase carriers having a surface comprising multiple functional groups one of which reversibly and selectively binds the target species. In a particular embodiment, the mixture is combined with solid phase carriers having a first functional group which reversibly binds nucleic acids and a second functional group which selectively and reversibly binds the target nucleic acid species, thereby producing a first combination. The first combination is maintained under conditions appropriate for binding of the nucleic acids to the first functional group and binding of the target nucleic acid species to the second functional group. The solid phase carriers are separated from the first combination, and combined with an agent (e.g., buffer) that selectively removes (e.g., elutes) either the nucleic acid from the first functional group or the target nucleic acid species from the second functional group of the solid phase carriers, thereby isolating a target nucleic acid species from a mixture comprising a plurality of nucleic acid species.07-30-2009
20090191565SHORT CYCLE METHODS FOR SEQUENCING POLYNUCLEOTIDES - The invention provides methods for sequencing a polynucleotide comprising stopping an extension cycle in a sequence by synthesis reaction before the reaction has run to near or fill completion.07-30-2009
20090191564DIAGNOSTICS AND THERAPEUTICS FOR CARDIOVASCULAR DISORDERS - The methods of the present invention relate to the diagnosis of cardiovascular disorders. In one aspect, the specification discloses methods for determining a subject's predisposition to increased risk for myocardial infarction.07-30-2009
20090191562METHOD FOR ASSAYING REG IV mRNA - In an RNA amplification process comprising steps of using a first primer and a second primer, at least one of which has a promoter sequence at the 5′ end, and reverse transcriptase, to produce double-stranded DNA containing the promoter sequence, using the double-stranded DNA as template to produce an RNA transcript with RNA polymerase, and using the RNA transcript in turn as template for DNA synthesis with the reverse transcriptase to produce the double-stranded DNA, the amount of amplified RNA product is measured with an intercalating fluorescent dye-labeled nucleic acid probe.07-30-2009
20090191560MUTANT DNA POLYMERASES AND USES THEROF - The present invention relates to mutant DNA polymerases which incorporate dideoxynucleotides with about the same efficiency as deoxynucleotides. The present invention also related to mutant DNA polymerases which also have substantially reduced 5′-to-3′ exonuclease activity or 3′-to-5′ exonuclease activity. The invention also relates to DNA molecules coding for the mutant DNA polymerases, and hosts containing the DNA molecules.07-30-2009
20090191559HER2 DIAGNOSTIC METHODS - In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression.07-30-2009
20090191557MN/CA IX/CA9 and renal cancer prognosis - Herein disclosed are methods that are prognostic for renal cell carcinoma, particularly renal clear cell carcinoma, afflicting a vertebrate. An exemplary prognostic method comprises detecting the presence of, and quantitating the level and/or extent of a MN/CA9 gene expression product in a sample from the affected subject, wherein if 50% or fewer cells are found to express the MN/CA9 gene, then the subject is considered to have a poorer prognosis. MN/CA9 gene expression products useful in the prognostic methods include MN protein, MN polypeptide and/or MN nucleic acids. The methods are useful as an aid in the selection of treatment for a patient with renal cell carcinoma, alone or in combination with conventional tumor stage and/or grade information. The methods of the invention can be used, for example, to identify those patients requiring more aggressive therapy regimens, or those patients most likely to respond to adjuvant immunotherapies, particularly MN/CA IX/CA9-targeted therapies.07-30-2009
20090191554MODIFIED GLASS FIBER WITH MONOLAYER OF AMINOCALIXARENE DERIVATIVES AND IMINECALIXARENE DERIVATIVES - Techniques for a surface-modified glass fiber with monolayer of aminocalixarene derivatives and iminecalixrene derivatives are provided.07-30-2009
20090191551Use of Secretor, Lewis and Sialyl Antigen Levels in Clinical Samples as Predictors of Risk for Disease - An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewis07-30-2009
20090191563UNIFORM FRAGMENTATION OF DNA USING BINDING PROTEINS - The invention provides a method for preparing and analysing a population of fragmented polynucleotide sequences having a substantially uniform size. The method can include steps of (a) binding at least some protection molecule to at least one polynucleotide sequence; (b) cleaving the at least one polynucleotide sequence to generate a plurality of polynucleotide fragment sequences of substantially uniform size; (c) amplifying the polynucleotide fragments; and (d) determining a sequence characteristic of a plurality of the polynucleotide fragments.07-30-2009
20090191550Diagnosis of whipple's disease - The invention relates to a method for in vitro seriological diagnosis of Whipple's disease, whereby the bacteria responsible for the disease are isolated and established in a culture and brought into contact with the serum or biological fluid of an infected patient. The invention also relates to useful oligonucleotides with a probe and a primer for amplifying, sequencing and detecting the gene rpoB of the bacteria, 07-30-2009
20090191548METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH TISSUE CLASSIFICATION - The present application provides methods and nucleic acids the classification of a biological sample. This is achieved by the analysis of the expression status of at least one of the genes selected from Table 1 as disclosed.07-30-2009
20090191547Exon grouping analysis - This invention pertains to the identification of specific disease-causing DNA sequences in a subject. The methods of the present invention can be used to identify genetic alterations, to determine the molecular basis for genetic diseases, and to provide carrier and prenatal diagnosis for genetic counseling.07-30-2009
20090191546ENGINEERED TOEHOLD REACTIONS AND NETWORKS - A catalytic system and method of catalyzing reactions that uses a novel toehold exchange mechanism that allows a specified input to catalyze the release of a specified output, which in turn can serve as a catalyst for other reactions is provided. This toehold exchange catalyst system, which can be driven forward by the configurational entropy of the released molecule, provides an amplifying circuit element that is simple, fast, modular, composable, and robust. Using this toehold exchange catalyst system it has been possible to construct and characterize several circuits that amplify nucleic acid signals, including a feed-forward cascade with quadratic kinetics and a positive feedback circuit with exponential growth kinetics.07-30-2009
20090191545Selection of High-Producing Cell Lines - The invention describes a method for screening antibody producing cell lines for selection of high expressing clones.07-30-2009
20090191544Correlating chemical and spatial data within pathology samples - A tissue sample to be analyzed is tested. Multiple different samples of multiple areas of said tissue sample, each of said multiple areas is a smaller area than an entire tissue sample to be analyzed. After analysis, the tissue sample is processed in a way that facilitates viewing tumor information on the sample, for example, by fixing or staining. An area is identified on the stained sample, and at least one of the samples that corresponds to an identified area is tested. This small area is tested using a technique that homogenizes the sample before testing.07-30-2009
20090191543IDENTIFICATION OF RAC1B AS A MARKER AND MEDIATOR OF METALLOPROTEINASE-INDUCED MALIGNANCY - The present invention provides compositions and methods for detecting MMP-induced malignancies by detecting Rac1b expression. The invention further provides compositions and in vitro and in vivo methods for inhibiting MMP-induced malignant transformation by modulating Rac1b expression and/or function.07-30-2009
20090191541Nucleic Acid Molecules and Other Molecules Associated with Plants - The present invention is in the field of plant genetics. More specifically the invention relates to nucleic acid molecules and nucleic acid molecules that contain markers, in particular, single nucleotide polymorphism (SNP) and repetitive element markers. In addition, the present invention provides nucleic acid molecules having regulatory elements or encoding proteins or fragments thereof. The invention also relates to proteins and fragments of proteins so encoded and antibodies capable of binding the proteins. The invention also relates to methods of using the nucleic acid molecules, markers, repetitive elements and fragments of repetitive elements, regulatory elements, proteins and fragments of proteins. 07-30-2009
20090191549SINGLE NUCLEOTIDE POLYMORPHISMS (SNP) AND THEIR ASSOCIATION WITH TICK RESISTANCE IN BOVINE ANIMALS - A method for assessing tick resistance in a bovine animal, comprising the steps of: 07-30-2009
20100081136CRTAC AS A BIOMARKER, THERAPEUTIC AND DIAGNOSTIC TARGET - The invention provides CRTAC, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CRTAC as well as pharmaceutical compositions comprising such compounds. The invention also provides CRTAC as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.04-01-2010
20100081132BIOSENSORS AND BIOSENSING INCORPORATING RF AND MICROWAVE REDIATION - Devices capable applying microwave and RF electromagnetic radiation to specific molecular interactions between a capture molecule and a target analyte and capable of sensing the specific molecular interaction are provided. Specific molecular interactions include, for example, specific recognition events such as, receptor-ligand, antigen-antibody, DNA-protein, sugar-lectin, RNA-ribosome, and enzyme substrate interactions and nucleic acid-nucleic acid hybridizations. Additionally, methods are provided for detecting the presence or absence of a target analyte in a sample. The presence or absence of the target analyte is detected, in part, through the detection of a binding complex between the target analyte and a capture molecule in the presence of microwave and or RF electromagnetic radiation.04-01-2010
20100081129Genemap of the human genes associated with crohn's disease - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs. 04-01-2010
20090111118METHOD FOR A RAPID ANTIBODY-BASED ANALYSIS OF PLATELET POPULATIONS - A method for identifying a platelet population, preferably a population of immature, reticulated platelets, in a biological sample involves incubating the biological sample for less than minutes with at least one labeled, ligand (e.g., monoclonal antibody) that binds to an epitope or antigen on platelets and with a nucleic acid dye. In one embodiment, the dye is Acridine Orange and the label on the ligand is PE-Cy7. The sample is then analyzed and one or more platelet populations is rapidly identified or quantified by passing the incubated sample through a sensing region of a flow cytometer. In one embodiment, this method occurs without a washing or physical cell separation step. The incubated sample is irradiated with a laser light source, and fluorescence of the labeled ligand and the nucleic acid dye are measured along with at least one additional parameter, e.g., light scatter, direct current, axial light loss, opacity, radio frequency, and fluorescence. These parameters are used to identify qualitatively or quantitatively the platelet populations in the sample. This rapid analytic method is particularly valuable in clinical situations where either low platelet counts or interfering conditions lead to inaccuracies of the platelet measurement. This method is suitable for performance in an automated hematology analyzer.04-30-2009
20080206748Methods for genetic analysis of DNA to detect sequence variances - Methods for determining genotypes and haplotypes of genes are described. Also described are single nucleotide polymorphisms and haplotypes in the ApoE gene and methods of using that information.08-28-2008
20090280489Ig genes specific oligonucleotides and uses thereof - The present invention provides oligonucleotides for detection of rearrangement of immunoglobulin genes for identifying clonality of cells, cancer cells, hypermutation in immunoglobulin gene, antibody isotype producing cell and/or assaying B cell repertoire in a sample. The oligonucleotides disclosed in the present invention are very specific to the immunoglobulin genes.11-12-2009
20100112580MEANS AND METHODS FOR HAPLOTYPING MHC-DRB LOCI IN MAMMALS AND USES THEREOF - The invention relates to the typing of MHC-DRB loci in mammals. In particular, the invention provides a typing procedure for the mammalian DRB region that allows an easy, economical, high resolution, fast and accurate haplotyping protocol. The invention further provides the use of said typing procedure in genetic applications, and provides a kit for typing of MHC-DRB loci.05-06-2010
20090104610Real-Time Multiplex Detection of Three Bacterial Species Responsible for Sexually Transmitted Diseases - The invention relates to the detection of three different bacterial species which are responsible for sexually-transmitted diseases, i.e., 04-23-2009
20090275022STAT6 EFFECTS ON LIVESTOCK ANIMAL GROWTH - The present invention provides for selection of livestock animals, including bovines, whose genotypes based in the STAT6 gene are correlated with phenotypes reflecting desirable carcass and feedlot traits. These phenotypes include back fat (BFAT), calculated yield grade (CALCYG), cutability (CUT), hot carcass weight (HCW), dry matter intake (DMI), days on feed (DOF), back fat rate (BFAT RATE) and average daily gain (ADG), based on the knowledge of the STAT6 genotypes. The predictive value is based in part on the discovery that certain single nucleotide polymorphisms (SNPs) within the STAT6 gene are linked to phenotypes of economically these important carcass and feedlot traits. Also provided are SNPs within the STAT6 gene useful in reliably distinguishing between a 11-05-2009
20090298072DNA Sequencing by Nanopore Using Modified Nucleotides - This invention provides a process for sequencing single-stranded DNA by employing a nanopore and modified nucleotides.12-03-2009
20090181396METHODS AND SYSTEMS FOR ANALYSIS OF FLUORESCENT REACTIONS WITH MODULATED EXCITATION - Methods, systems and their components for monitoring fluorescent signals and particularly transient fluorescent signals from reaction mixtures of interest, which methods and systems employ modulated excitation light sources to reduce impacts of excessive illumination on the reaction components or the data obtained therefrom.07-16-2009
20100047809PCA3, PCA3 GENES, AND METHODS OF USE - The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.02-25-2010
20100047803BIOMARKERS FOR ACETAMINOPHEN TOXICITY - Materials and methods for evaluating cellular responses to acetaminophen and assessing susceptibility to liver damage.02-25-2010
20100047787PROSTATE CANCER SURVIVAL AND RECURRENCE - The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to prostate cancer. In particular, the disclosure is based on the identities of genes that are correlated with patient survival and prostate cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with prostate cancer and to predict prostate cancer recurrence. The profiles may also be used in the study and/or diagnosis of prostate cancer cells and tissue as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of prostate cancer based upon probable life expectancy and cancer recurrence and/or metastasis.02-25-2010
20100047802NUCLEIC ACID SYNTHESIS COMPOSITIONS AND METHODS AND SYSTEMS FOR USING SAME - The Application relates to compositions, kits, methods, and systems for nucleotide sequencing comprising producing polymerase reactions that comprise both catalytic and non-catalytic divalent metal ions. Effective ratios and amounts of catalytic and non-catalytic divalent metal ions are described.02-25-2010
20090291450CATERPILLER GENE FAMILY - The present invention relates to a new family of structurally and functionally related nucleic acids and proteins, designed the CATERPILLER family, which is characterized by landmark structural motifs including a nucleotide binding domain and leucine-rich repeat domains.11-26-2009
20100120048ASSAYS FOR SHORT SEQUENCE VARIANTS - The invention provides assays that can detect multiple genetic variants of a gene (e.g., a mycobacterium gene) in a sample using a pool (using 2, 3, 4, or more) of oligonucletide hybridization probes.05-13-2010
20100120051CYANINE DYE COMPOUNDS - Cyanine dye compounds having a negatively charged substituent that are nucleic acid stains, particularly for fluorescent staining of DNA, including compounds having the formula05-13-2010
20100120042METHOD OF SCREENING MATERIAL FOR IMPROVING SKIN FUNCTIONS - A method of screening a material for improving skin functions includes: (a) treating a skin cell with a candidate material; (b) detecting a change in a relative expression level of membrane-associated protein 17 (MAP17) gene; and (c) selecting a candidate material inducing the change in the expression level of the gene as a material for improving skin functions. That is to say, a material for improving skin functions is screened using MAP17 gene as a marker, on the basis of the change in the expression level of the MAP17 gene. A material for improving skin functions, which is useful in improving skin barrier function, promoting skin moisturization, preventing skin aging, or ameliorating skin troubles, may be effectively screened.05-13-2010
20100120036METHOD FOR AMPLIFYING DNA FRAGMENT - To measure the methylation degree of a genomic DNA simply and correctly as well as exhaustively, there is provided a method for amplifying a DNA fragment, characterized by comprising the following steps (1) to (5): 05-13-2010
20100120046Genetic Markers for Assessing Risk of Developing Bipolar Disorder - This document provides methods and materials related to genetic markers of Bipolar Disorder (BD) and Schizophrenia (SZ). For example, methods for using such genetic markers to assess risk of developing BD and/or SZ are provided, as are methods for making a differential diagnosis between BD and SZ.05-13-2010
20100120045GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION - The invention relates to methods of risk assessment and diagnosis of susceptibility to coronary artery disease and myocardial infarction, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with coronary artery disease and myocardial infarction. The invention also relates to methods for use of such polymorphic markers for predicting drug response to drugs for treating cardiovascular disease, or for monitoring the effectiveness of such drugs. The invention further relates to kits encompassing reagents for use in these methods.05-13-2010
20100120044MODIFIED POLYNUCLEOTIDES COMPRISING RIBOSE RINGS - The invention pertains to different methods employing the use of a polynucleotide comprising ribose rings which carry a modification at the 2′-OH group.05-13-2010
20100120033METHOD FOR MEASURING DNA METHYLATION - The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on.05-13-2010
20100120040GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF - The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.05-13-2010
20100120038ASSAY METHODS FOR INCREASED THROUGHPUT OF SAMPLES AND/OR TARGETS - The present invention provides assay methods that increase the number of samples and/or target nucleic acids that can be analyzed in a single assay.05-13-2010
20100120034METHYLATION ANALYSIS OF MATE PAIRS - Various embodiments of the present teachings relate to methods for the methylation analysis of nucleic acids. The subject methods include methods that result in the preparation of mate-pair libraries suitable for highly multiplexed DNA sequencing. Embodiments include methods of preparing mate-pair libraries comprising a first tag sequence and a second tag sequence, wherein one of the tag sequences has been converted by a methylation conversion agent and the other tag sequence has not been converted by the methylation conversion agent. Other embodiments provided include intermediates for making the mate-pair library and kits for making the mate-pair libraries. Also provided is software and computer systems for analyzing the methylation levels of genomic DNA from which the tag sequences were derived.05-13-2010
20100120032TRANSGENIC PLANT EVENT DETECTION - The present invention relates to detection of materials derived from transgenic plant events. In particular, the invention provides methods, reagents, kits and reference materials for detecting the presence or absence in a sample of genetic material derived from and attributable to select transgenic plant events.05-13-2010
20100120030Extracellular serine protease - The present invention provides a DNA encoding a TADG-14 protein selected from the group consisting of: (a) isolated DNA which encodes a TADG-14 protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a TADG-14 protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-14 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell.05-13-2010
20100120025Compositions and Methods for Prognosis, Diagnosis, Prevention and Treatment of Cancers - The present invention provides compositions and methods of using the EPHB2 gene or its related signaling pathways to detect, prognosticate, assess the risk of, prevent, or treat cancers. Cancers amenable to the present invention include, but are not limited to, prostate cancer, breast cancer, and neuroblastoma. In one aspect, the present invention provides compositions which comprise an agent capable of eradicating or alleviating an abnormality in the EPHB2 gene or its related signaling pathways. This abnormality may cause or contribute to the development or progression of cancers. In another aspect, the present invention provides methods comprising detecting an abnormality in the EPHB2 gene or its related signaling pathways. The presence or absence of such an abnormality is indicative of the risk or disease status of cancer in a person of interest.05-13-2010
20100120024Materials and methods for the generation of transcripts comprising modified nucleotides - Materials and Methods are provided for producing aptamer therapeutics having modified nucleotide triphosphates incorporated into their sequence.05-13-2010
20100120047PURIFICATION OF TARGET CELLS FROM COMPLEX BIOLOGICAL FLUIDS - A method for conducting a molecular analysis on target cells of a complex biological fluid can include the steps of reducing the complexity by selectively depleting at least a portion of non-target cells from the biological fluid, labeling target cells or non-target cells for identification, isolating target cells from non-target cells based on (i) a size, or (ii) a label, of the target cells or the non-target cells using a microfluidic sorting apparatus, and molecularly analyzing the target cells. Reducing can include separating the non-target cells from the biological fluid using a Magnetic Activated Cell Sorting apparatus or using magnetic beads that include a plurality of different antibodies including one or more of CD45, CD16 and 235a. Labeling can include using a label selected from fluorescent, colorimetric, magnetic and biochemical labels. The biological fluid can be selected from blood sputum, peritoneal fluid, tissue cell suspension, fine needle aspirates, fecal matter and cerebral spinal fluid. The target cells can be selected from tumor cells, fetal cells, stem cells, endothelial cells, myocardial cells and lymphocytes. The step of molecularly analyzing the target cells can include one of RNA analysis, antigen expression and mutation profiling.05-13-2010
20100120049BIOMARKERS FOR SERIOUS SKIN RASH - The present invention provides a method for predicting the risk of a patient for developing adverse drug reactions, particularly Serious Skin Rash (SSR), including such severe adverse reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The invention also provides a method of identifying a subject afflicted with or at risk of developing SSR. In some aspects, the methods comprise analyzing at least one genetic marker, wherein the presence of the at least one genetic marker indicates that the subject is afflicted with or at risk of developing SSR. Genetic markers useful in accordance with the methods of the invention are disclosed.05-13-2010
20090233288PRIMER SET FOR GENE AMPLIFICATION, REAGENT FOR GENE AMPLIFICATION INCLUDING THE SAME, AND USES THEREOF - Primer sets for amplifying two genes (the CYP2C9 gene and the VKORC1 gene) by a gene amplification method are provided, wherein the primer sets can amplify respective target regions of the two genes specifically and efficiently in the same reaction system simultaneously. Two pairs of primer sets are used including forward primers consisting of the base sequences of SEQ ID NOs: 5 and 29 as well as reverse primers consisting of the base sequences of SEQ ID NOs: 18 and 38, respectively. The use of these primer sets makes it possible to specifically amplify target regions including sites where polymorphisms to be detected are generated in the CYP2C9 gene and the VKORC1 gene, in the same reaction solution simultaneously.09-17-2009
20100112592METHODS FOR IDENTIFYING AN INCREASED LIKELIHOOD OF RECURRENCE OF BREAST CANCER - Methods of identifying a mammal having an increased likelihood of recurrence of breast cancer includes identifying in a breast tissue sample of the mammal expression of at least two genes selected from the group consisting of Hs.125867 (EVL), Hs.591847 (NAT1), Hs.208124 (ESR1), Hs.26225 (GABRP), Hs.408614 (ST8SIA1), Hs.480819 (TBC1D9), Hs.504115 (TRIM29), Hs.523468 (SCUBE2), Hs.532082 (IL6ST), Hs.592121 (RABEP1), Hs.79136 (SLC39A6), Hs.82128 (TPBG), Hs.95243 (TCEAL1), Hs.95612 (DSC2), Hs.654961 (FUT8), Hs.1594 (CENPA), Hs.184339 (MELK), Hs.26010 (PFKP), Hs.592049 (PLK1), Hs.370834 (ATAD2), Hs.437638 (XBP1), Hs.444118 (MCM6), Hs.469649 (BUB1), Hs.470477 (PTP4A2), Hs.473583 (YBX1), Hs.480938 (LRBA), Hs.524134 (GATA3), Hs.531668 (CX3CL1), Hs.532824 (MAPRE2), Hs.591314 (GMPS), Hs.83758 (CKS2) and Hs.99962 (SLC43A3) and subsets of the genes.05-06-2010
20100112595Bisulfite Conversion Reagent - Disclosed, among other things, are packaged bisulfite solutions comprising bisulfite reagent in an oxygen-impermeable container and methods.05-06-2010
20100112564Methods for detecting therapeutic effects of anti-cancer drugs - precancerous lesions, and subject having precancerous lesions and being treated with an anti-cancer agent; (2) isolating total microbial genomic DNA from the fecal samples to provide total microbial genomic DNA; (3) comparing the total microbial genomic DNA using fingerprint spectrum analysis; (4) identifying key fingerprint bands correlated with the effect of the anti-cancer agent; (5) identifying key microorganisms associated with the key fingerprint bands; (6) designing microbial sequence-specific primers and probes; and (7) determining the quantitative differences of the key microorganisms in fecal samples to identify an indicator microorganism for monitoring the effect of the anti-cancer agent.05-06-2010
20100112587TRANSCRIPTOMIC BIOMARKERS FOR INDIVIDUAL RISK ASSESSMENT IN NEW ONSET HEART FAILURE - A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure.05-06-2010
20100112581METHODS FOR NORMALIZING AND FOR IDENTIFYING SMALL NUCLEIC ACIDS - The present teachings are generally directed to methods for normalizing at least one species of small nucleic acid that is present in a population of small nucleic acid species, wherein the relative concentration of at least one small nucleic acid species is substantially greater than the relative concentration of at least one other small nucleic acid species in the population. At least one small nucleic acid species is normalized using a multiplicity of primers comprising degenerate sequences. In some embodiments, a small nucleic acid species is identified by inserting at least part of an extension product from a normalized population into a vector and subsequently sequencing the insert. In some embodiments, a small nucleic acid species is identified by determining the sequence of at least part of an extension product.05-06-2010
20100112568METHODS AND KITS FOR DIAGNOSIS OF MULTIPLE SCLEROSIS IN PROBABLE MULTIPLE SCLEROSIS SUBJECTS - Provided are methods and kits for determining the probability of a subject diagnosed with probable multiple sclerosis to develop definite diagnosis of multiple sclerosis by determining the expression level of polynucleotides which are differentially expressed between subjects diagnosed with probable multiple sclerosis and which further develop definite multiple sclerosis and unaffected subjects. Also provided are methods and kits for selecting a treatment regimen of a subject diagnosed with probable multiple sclerosis.05-06-2010
20100112563MULTIPLEX ANALYSIS OF NUCLEIC ACIDS - A method for identifying target nucleic acids includes the steps of contacting a sample containing a plurality of target nucleic acids with at least one series of nucleotide primers under conditions that allow binding of said primers to at least one of said target nucleic acids and labeling of said bound primers with a detectable signal, wherein one member within each series has a lower level of specificity than other members of the series; and measuring said detectable signal of each labeled primer to determine the identity of said target nucleic acids.05-06-2010
20100112555METHOD FOR THE DIAGNOSIS OF COLORECTAL CANCER - The object of the present invention refers to an in vitro method for diagnosing colorectal cancer based on the determination from a biological sample obtained from a subject, of promoter methylation status of at least one of the genes APC, RARB2 and p14 and, optionally, MGMT and p16. Likewise, object of the present invention is a kit for performing the method of the invention.05-06-2010
20100112561FLUORESCENT NUCLEOSIDE ANALOGUES - Briefly described, embodiments of the present disclosure include novel fluorescent nucleoside analogs (fNAs) including a fluorescent nucleobase, selected from a purine and a pyrimidine base or analog thereof, and a modified sugar moiety that differs in structure from a sugar moiety of a naturally occurring nucleoside. In embodiments, the fNAs of the present disclosure are analogues of NA prodrugs used to treat viral disorders. Embodiments of the present disclosure also include methods of making the novel fNAs of the present disclosure.05-06-2010
20100112560MECHANISM TO SIGNAL RECEPTOR-LIGAND INTERACTIONS WITH LUMINESCENT QUANTUM DOTS - Semiconductor quantum dots are becoming valuable analytical tools for use in biomedical applications. Indeed, their unique properties offer the opportunity to design luminescent probes for imaging and sensing with unprecedented performance. In this context, we have identified operating principles to transduce supramolecular association of complementary receptor-ligand binding pairs into enhancement or suppression in the luminescence of sensitive quantum dots. Thus, complementary receptor-ligand binding pairs can be identified with luminescence measurements relying on our design logic. In fact, we have demonstrated with a representative example that our protocol can be adapted to signal receptor-ligand binding.05-06-2010
20100112552NUCLEIC ACID-BINDING CHIPS FOR DETECTING NITROGEN DEFICIENCIES AS PART OF BIOPROCESS CONTROL - The invention relates to nucleic acid-binding chips for monitoring bioprocesses, specifically for detecting nitrogen deficiencies. Said chips carry probes that are sensitive to at least three of the following 50 genes: kdgR, citA, htrA, ycn1, yppF, trpB, ggt, alsR, glnA, nrgA, yciC, yvtA, nrgB, ycnJ, glnR, yvlA, yncE, yvlB, trpF, ydfS, trpD, ycnK, trpB, trpC, nasD, ycdH, nasC, nasB, trpE, pckA, nasF, yrkC, and tnrA or the homolgs to SEQ ID NO: 91, 41, 53, 19, 55, 47, 21, 17, 9, 85, 45, 49, 95, 63, 15, 93, or 81 at a maximum of 80 different probes that are specific of nitrogen metabolism. The invention also relates to the use of corresponding gene probes, especially on the aforementioned chips, to corresponding methods and possible uses.05-06-2010
20100112557METHOD FOR HIGH RESOLUTION MELT GENOTYPING - Various methods are described that provide for high resolution melt (HRM) genotyping. The embodiments include providing a locus specific primer and two allele specific primers each having a 5′ end with a short tail, providing a nucleic acid having a single nucleotide polymorphism (SNP) base located within 1-20 base pairs of the 3′ end of nucleic acid, hybridizing the locus specific primer and the allele specific primers to the nucleic acid, amplifying the sample using pyrophosphorolysis activated polymerization (PAP) PCR enzyme, and determining the Tm of the amplicons using HRM. In other embodiments, reactions mixtures and kits for HRM genotyping are provided and disclosed. These kits comprise a locus specific primer, one or more allele specific primers each having a 5′ end with a short tail, a nucleic acid, and a pyrophosphorolysis activate polymerization (PAP) PCR enzyme.05-06-2010
20100112594METHOD FOR ENUMERATING MAMMALIAN CELL MICRONUCLEI WITH AN EMPHASIS ON DIFFERENTIALLY STAINING MICRONUCLEI AND THE CHROMATIN OF DEAD AND DYING CELLS - The present invention relates a method for the enumeration of mammalian cell micronuclei, while distinguishing micronuclei from the chromatin of dead and dying cells. The method utilizes differential staining of chromatin from dead and dying cells, to distinguish the chromatin from micronuclei and nuclei that can be detected based upon fluorescent emission and light scatter following exposure to an excitatory light source. Counting of micronuclei events relative to the number of nuclei can be used to assess the DNA-damaging potential of a chemical agent, the DNA-damaging potential of a physical agent, the effects of an agent which can modify endogenously-induced DNA damage, and the effects of an agent which can modify exogenously-induced DNA damage. Kits for practicing the invention are also disclosed.05-06-2010
20100112570Genetic Markers for Weight Management and Methods of Use Thereof - This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subject's metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subject's metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subject's responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information.05-06-2010
20090004664HCV NS3 replicon shuttle vectors - The present invention provides for novel HCV NS3 replicon shuttle vectors useful for cloning in HCV polynucleotide sequences from samples of HCV-infected patients and testing the resulting replicons for drug susceptibility.01-01-2009
20100075336SYSTEM FOR PERFORMING MULTI-FORMATTED ASSAYS - An automated analyzer for performing multiple diagnostic assays simultaneously includes multiple stations in which discrete aspects of the assay are performed on fluid samples contained in sample vessels. The analyzer includes stations for automatically preparing a sample, incubating the sample, preforming an analyte isolation procedure, ascertaining the presence of a target analyte, and analyzing the amount of a target analyte. An automated receptacle transporting system moves the sample vessels from one station to the next. A method for performing an automated diagnostic assay includes an automated process for isolating and amplifying a target analyte, and, in one embodiment, a method for real-time monitoring of the amplification process.03-25-2010
20100075335COLORIMETRIC METHOD AND KIT FOR THE DETECTION OF SPECIFIC NUCLEIC ACID SEQUENCES USING METAL NANOPARTICLES FUNCTIONALIZED WITH MODIFIED OLIGONUCLEOTIDES - The present invention relates to a colorimetric method for the detection of specific nucleic acids sequences, including mutations or single nucleotide polymorphisms within nucleic acid sequences, through the aggregation of nanoparticles functionalized with modified oligonucleotides, induced by an increase of the medium's ionic strength. Another aspect of the present invention relates with the development of a kit based on the method of the present invention, allowing for a quick and easy detection of specific nucleic acids sequences, including mutations or single nucleotide polymorphisms within nucleic acid sequences.03-25-2010
20100075334METHYLATION BIOMARKER FOR EARLY DETECTION OF GASTRIC CANCER - The present application describes a method of diagnosing gastric cancer or a stage in the progression of the cancer in a subject comprising assaying for loss of expression of a marker gene such as POPDC3, CCDC67, LRRC3B, PRKD1, CYP1B1, LIMS2, DCBLD2, LOC149351, ADCY8, BACH2, ALOX5, TCF4, CXXC4, CAMK2N2, EMX1, KCNK9, NCAM2, AMPD3, NOG, SP6, LOC100128675, or CHSY3, or a combination thereof.03-25-2010
20100075333METHOD OF DETERMINING THE RISK OF SCOLIOSIS - A method for determining the risk for developing a scoliosis comprising monitoring osteopontin (OPN) expression in a sample from a subject over time; wherein an OPN expression that increases in the subject sample over time is indicative that the subject is at risk for developing a scoliosis.03-25-2010
20100075332Engineering polymerases and reaction conditions for modified incorporation properties - Provided are methods for enhanced sequencing of nucleic acid templates. Also provided are reaction conditions that increase branching fractions during polymerization reactions. Also provided are compositions comprising modified recombinant polymerases that exhibit branching fractions that are higher than the branching fractions of the polymerases from which they were derived. Provided are compositions comprising modified recombinant polymerases that exhibit delayed translocation relative to the polymerases from which they were derived. Also provided are compositions comprising modified recombinant polymerases that exhibit increased nucleotide or nucleotide analog residence time at an active site of the polymerase. Provided are methods for generating polymerases with the aforementioned phenotypes and methods of using such polymerases to sequence a DNA template or make a DNA. Also provided are methods and nucleic acid sequencing systems for determining which labeled nucleotide is incorporated at a site during a template-dependent polymerization reaction.03-25-2010
20100075311CARTRIDGE SYSTEM - A cartridge system includes a reagent component for storing one or more reagents and a processing component for processing the one or more reagents in an assay. The reagent component and the processing component are configured to be coupled together to form a cartridge. The reagent component and/or the processing component include at least one compartment configured to accept waste from the assay. The reagent component does not take part in processing the reagents in the assay, except to accept waste from the processing component. In one aspect, the cartridge system further includes a sensing component with at least one sensing element for detecting an analyte. In another aspect, the cartridge system further includes a sample preparation component for preparing a sample for the assay.03-25-2010
20100075310Methods for Microorganism Detection and Identification - Methods for detecting and identifying microorganisms in a biologic sample are provided. The methods utilize identifying rRNA from microorganisms to both show the presence and identity for the majority of infectious agents present in clinical samples. The methods are preferably adapted for use in a clinical setting.03-25-2010
20100075331CpG island sequencing - The present invention is directed to a method for analyzing the methylation status of a genomic DNA sample, comprising the steps of (i) fragmenting said sample and enriching said sample for sequences comprising CpG islands, (ii) generating a single stranded DNA library, (iii) subjecting said sample to Bisulfite treatment, (iv) clonally amplifying individual members of said single stranded DNA library by means of emulsion PCR, and (v) sequencing said amplified clonally amplified single stranded DNA library.03-25-2010
20100075330APPARATUS AND METHODS FOR PARALLEL PROCESSING OF MICRO-VOLUME LIQUID REACTIONS - Disclosed herein are apparatuses and methods for conducting multiple simultaneous micro-volume chemical and biochemical reactions in an array format. In one embodiment, the format comprises an array of microholes in a substrate. Besides serving as an ordered array of sample chambers allowing the performance of multiple parallel reactions, the arrays can be used for reagent storage and transfer, library display, reagent synthesis, assembly of multiple identical reactions, dilution and desalting. Use of the arrays facilitates optical analysis of reactions, and allows optical analysis to be conducted in real time. Included within the invention are kits comprising a microhole apparatus and a reaction component of the method(s) to be carried out in the apparatus.03-25-2010
20100075318METHOD OF DETERMINING THE HAPLOTYPE OF MULTIPLE ALLELIC GENES - In amplifying a region containing two allelic genes, the polymorphism of one of the allelic genes is positioned at or near the 3′ end of an amplification primer, so that the chain would extend only from one of the two primers, one that matches the mutant type nucleotide(s) and one that matches the wild-type nucleotide(s). The other primer is unaffected by the allelic genes but is positioned to include the other allelic gene in the amplicon. The PCR amplifies only the target genomic DNA having one specific allele of the first allelic gene. The technique exploits the fact that the haplotype of the first and the second allelic genes can be determined if the allele of the second allelic gene in the amplicon can be identified. Designing probes with complementary sequences for identifying the two alleles (major and minor) of the second allelic gene, and fixing the probe set on a solid support and hybridizing them with the amplicon to identify the probe that forms a hybrid, are characteristic features of the present invention.03-25-2010
20100075325COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER - The invention relates to nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.03-25-2010
20100075324PROCESSES FOR DETECTING TOXIC SUBSTANCES - Biology-based processes for detecting toxic substances are provided. The processes comprise detecting mRNA that is expressed in the presence of toxic substances by a cell comprising a yeast gene as followed, or a gene that is homologous to the yeast genes and is derived from other species, wherein the mRNA corresponds to said yeast gene or said homologous gene thereof03-25-2010
20100075323MOLECULAR MARKERS FOR LUNG AND COLORECTAL CARCINOMAS - Molecular markers for lung and colorectal carcinomas and methods of using them in blood sample assays are disclosed. The method comprises measuring the expression of the markers in a blood sample from a subject for detecting the presence and/or severity of lung and/or colorectal cancer, and for monitoring and/or assessing the prognosis of the subject's response to a cancer therapy. Also disclosed are kits for detecting, diagnosing, and/or monitoring lung or colorectal carcinomas.03-25-2010
20100075322Methods and Compositions for Identifying Mycotoxins and Fungal Species - The invention relates to a method of testing for a mycotoxin in patient tissue or body fluid and testing for a fungal species in the patient tissue or body fluid. The method can also be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.03-25-2010
20100075321LABELED COMPOUND AND DETECTION METHOD USING THE SAME - A labeled compound is so designed that an aromatic tertiary amine compound is bondable with a biomolecule. One of S03-25-2010
20100075320PAXILLIN MUTATIONS, METHODS OF ASSESSING RISK OF METASTASIS AND METHODS OF STAGING TUMORS - Disclosed herein are methods for assessing risk of metastasis of a tumor in a mammal by determining the paxillin gene copy number per cell in the tumor or by detecting the presence of a paxillin mutation in the tumor. The presence of an increased paxillin gene copy number or a paxillin mutation is indicative of an increased risk of metastasis. Methods of staging tumors and methods of reducing invasiveness or metastasis of a cancer cell are also provided. Oligonucleotides comprising a paxillin mutation and antibodies capable of recognizing a paxillin mutant are disclosed.03-25-2010
20100075319Blocking Agents Comprising Non-Natural Nucleic Acids and Detection Methods Using such Blocking Agents - This invention relates to nucleic acid analog blocking agents that may reduce nonspecific interactions between components of a biological or chemical detection assay. The blocking agents may help to reduce the background observed in biological or chemical detection assays, such as in situ assays and blots, and may thus enhance the signal to noise in the assays. The invention also encompasses sets of nucleic acid analog segments, for instance, made from PNA and/or non-natural bases, which may act as blocking agents and/or detection reagents, reagent kits containing those sets, and related methods of detection. In some embodiments, the blocking agents are designed such that they block one or more sets of complementary strands of nucleic acids on a detection reagent or in a sample, but do not hybridize to each other. In some embodiments, the blocking agents may block genomic repeat sequences such as one or more of Alu repeats, Kpn repeats, di-nucleotide repeats, tri-nucleotide repeats, penta-nucleotide repeats, and hexa-nucleotide repeats.03-25-2010
20100075316METHOD FOR IDENTIFYING ALTERED VITAMIN D METABOLISM - A method is provided for identifying an individual as having altered vitamin D metabolism comprising analyzing a biological sample from the individual for the presence of CYP24 SNPs and/or aberrantly spliced CYP24 mRNA. The presence of the SNPs and/or the aberrantly spliced CYP24 mRNA indicates that the individual has altered vitamin D metabolism. Also provided are methods for customizing dosages of biologically active vitamin D compounds for individuals who are determined to have altered vitamin D metabolism.03-25-2010
20100075315Microvesicle-Based Compositions and Methods - Methods and compositions for diagnosis and/or analysis of a condition in a mammal are disclosed in which RNA from microvesicles is enriched and differentiated to so obtain a result that is indicative of the condition of tissue or organ from which the microvesicle originated. In especially preferred embodiments, the condition is a neoplastic disease of a human and can be identified and staged by differential analysis of one or more distinct RNAs, optionally together with identification and analysis of a non-RNA component of the microvesicle.03-25-2010
20100075314CHEMICALLY-MODIFIED GOLD NANOPARTICLES AND METHODS FOR USE IN DETECTING TARGET MOLECULES - The invention provides stable bioconjugate-nanoparticle probes which are useful for detecting nucleic acids and other target analytes, e.g., proteins, and methods of preparing those probes.03-25-2010
20100075313DEVICE FOR THE LYSIS OF MICROORGANISMS PRESENT IN AN ENVIRONMENTAL OR CLINICAL SAMPLE AND THE EXTRACTION OF NUCLEIC ACIDS FROM SAID MICROORGANISMS FOR ANALYSIS - The present invention relates to a cartridge which can be positioned inside an air collection means and receive a means for recovering nucleic acids, said cartridge being substantially cylindrical and comprising a microorganism retaining zone, said retaining zone comprising microorganism lysis means. The invention also relates to a device for collecting microorganisms contained in the air and a device for microorganism lysis.03-25-2010
20100075312QPCR ANALYSIS APPARATUS - An apparatus (03-25-2010
20100075308POLYMORPHISMS IN GENES AFFECTING CNS DISORDERS AND USES THEREOF - Diagnostic and prognostic methods, compositions, assays, and kits useful for predicting the phenotype of subjects who have, or are at risk of developing, a mental disorder. The methods also include predicting the prognostic outcome of a subject's mental disorder as well as the subject's responsiveness to drug treatments for the mental disorder. The methods and kits include determining the allelic status of polymorphisms in the MAOA, TPH2 and DRD2 genes.03-25-2010
20100075309INTERMITTENT DETECTION DURING ANALYTICAL REACTIONS - Methods, devices, and systems for performing intermittent detection during analytical reactions are provided. Such methods facilitate collection of reaction data from disparate reaction times. Further, such methods are useful for reducing photo-induced damage of one or more reactants in an illuminated analytical reaction at a given reaction time. In preferred embodiments, the reaction mixture is subjected to at least one illuminated and non-illuminated period and allowed to proceed such that the time in which the reaction mixture is illuminated is less than a photo-induced damage threshold period.03-25-2010
20100075328IMMOBILIZED NUCLEIC ACID COMPLEXES FOR SEQUENCE ANALYSIS - Provided are methods for sequencing a nucleic acid that include fixing a template to a surface through a template localizing moiety and sequencing the nucleic acid with a sequencing enzyme, e.g. a polymerase or exonuclease. The sequencing enzyme can optionally be exchanged with a second sequencing enzyme, which continues the sequencing of the nucleic acid. The template localizing moiety can optionally anneal with the nucleic acid and/or associate with the sequencing enzyme. Also provided are compositions comprising a nucleic acid fixed to a surface via a template localizing moiety, and a first sequencing enzyme, which can sequence the nucleic acid and optionally exchange with a second sequencing enzyme present in the composition. Compositions in which a template localizing moiety is immobilized on a surface are provided. Compositions for sequencing reactions are provided. Also provided are sequencing systems comprising reaction regions in which or near which template localizing moieties are immobilized.03-25-2010
20100075317Airborne Particulate Sampler - An airborne particulate sampling device is disclosed. The device includes a conduit whose interior allows the flow of air through the device. The conduit, or at least its surface, is a conductor. The device also includes an electrode with a sharp tip or edge on or near the output side of the conduit. An electrically conducting particle collector outside the conduit is positioned so that a surface is perpendicular or approximately perpendicular to the axis of the funnel. A fan or other blower forces air through the funnel. A power supply imparts an electrostatic potential difference between the electrode, on the one hand, and the holder and particle collector, on the other hand. The electrostatic potential difference produces a corona field in the air in the vicinity of the electrode's sharp tip. The corona field imparts a charge to airborne particles. The combined effect of the air flow, electrostatic repulsion from the funnel and electrode, and electrostatic attraction toward the particle collector causes the airborne particles to move toward and then to adhere to the particle collector.03-25-2010
20100075306METHOD FOR DIAGNOSIS OF AND FOLLOWING A BACTERIAL VAGINOSIS BY MOLECULAR QUANTIFICATION - The present invention relates to a method for in vitro diagnosis and follow-up of vaginal bacterial flora status in relation to the presence of bacterial vaginosis, and for monitoring its treatment where applicable, wherein the presence of bacterial vaginosis or failure of on-going treatment is determined if the concentrations of specific sequences present in a single copy in the DNA of the bacteria 03-25-2010
20100075303METHODS FOR TARGETTED MUTAGENESIS IN GRAM-POSITIVE BACTERIA - The present invention provides a method of targeted mutagenesis in Gram-positive bacteria. In particular, the present invention provides a method that effectively integrates a suicide integrative vector into a target gene in the chromosome of a Gram-positive bacterium, resulting in inactivation of the target gene.03-25-2010
20100075302Assays for Resistance to Echinocandin-Class Drugs - Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.03-25-2010
20100075305Detection of bacterium by utilizing dnaj gene and use thereof - Disclosed is a method for detecting the species of a bacterium in a simple manner. Specifically disclosed is a method for detecting the species of a bacterium, which can detect at least one bacterial species selected from 03-25-2010
20100075307ANALYTE DETECTION ASSAYS - The present invention provides methods, kits and compositions for the detection of an analyte. In the methods of the invention, a binding molecule coupled to a first polymerase is incubated with a modified polynucleotide template to form a copy of the modified polynucleotide template without any modified nucleotides. The unmodified copy is detected in a second amplification/primer extension reaction using a second polymerase that is unable to amplify the modified polynucleotide template. Detection of the unmodified copy is indicative of the presence and/or amount of the analyte in the sample. In place of the binding molecule coupled to a first polymerase, a pair of analyte-specific probes can also be used. The first analyte specific probe comprises a first binding moiety and a first portion of a first polymerase and the second analyte specific probe comprises a second binding moiety and a second portion of the first polymerase. When the binding moieties are bound to the analyte the first and second portions of the polymerase interact to form a functional polymerase complex that is used to form a copy of the modified polynucleotide template without any modified nucleotides.03-25-2010
20100099094METHOD OF DETECTING NUCLEIC ACID AMPLIFICATION REACTION - The present invention provides a method of detecting a nucleic acid amplification reaction, including the steps of adding a sample nucleic acid to a nucleic acid amplification buffer containing a reducing agent molecule, a redox molecule and a magnesium ion, to conduct an amplification reaction, measuring a reduction current produced by a reduction reaction of the reducing agent molecule with the redox molecule, under the conditions that when the amplification reaction of the sample nucleic acid has proceeded in the buffer, pyrophosphoric acid formed with the progress of amplification of the sample nucleic acid forms magnesium pyrophosphate with the magnesium ion, thereby decreasing a magnesium ion concentration of the buffer, and determining, from the magnitude of the reduction current measured above, whether the sample nucleic acid has been amplified or not.04-22-2010
20080268431Information Code System Using Dna Sequences - The present invention provides a molecular level of DNA information code which uses a base pair sequence as an information code unit. Also, the present invention provides a molecular code system which includes designing and coding DNA which is an information code unit; stabilizing the DNA information code by encapsulating it with an inorganic capsule and coating the DNA-inorganic capsule to a medium; taking and extracting the coated DNA information code which is present in a trace amount, collecting the DNA information code using a polypyrrole-maghemite nanohybrid; and amplifying the collected DNA information code using a polymerase chain reaction and reading the amplified DNA information code. According to the present invention, the DNA information code having high security is prepared by assigning a security unit to a DNA which has an excellent accumulating capacity, and then the DNA information code is stabilized so as to be coated to a medium. Only the DNA information code may be extracted, collected, and read, if necessary. Thus, a unified molecular code system can be established.10-30-2008
20090246776Modulators of scarb-1 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of the SCARB-1 receptor, and the use of modulators of the expression or activity of this receptor for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described.10-01-2009
20090246756Thermostable polypeptide having polynucleotide kinase activity and/or phosphatase activity - Isolated polypeptides having 5′-kinase and/or 3′-phosphatase activity and temperature optimum of at least 60° C. are described. The invention also relates to isolated nucleic acids encoding the polypeptides, nucleic acid constructs and host cells comprising the nucleic acid sequences as well as methods using the polypeptides and kits for practicing the methods.10-01-2009
20100105062Genetic Markers for Optimizing Treatment for Schizophrenia - This document provides methods and materials related to genetic markers for predicting response to a treatment for schizophrenia (SZ). For example, methods for using such genetic markers to select optimal treatments are provided.04-29-2010
20100075304PROCESS FOR MONITORING COLORECTAL CANCER - Disclosed in this specification is a method for determining the stage of colorectal cancer by observing regulatory changes in select miRNA sequences. These sequences may include hsa-miR-31, hsa-miR-7, hsa-miR-99b, hsa-miR-378*, hsa-miR-133a, hsa-miR-125a and combinations of these sequences.03-25-2010
20100143898USE OF PRODUCTS OF PCR AMPLIFICATION CARRYING ELEMENTS OF SECONDARY STRUCTURE TO IMPROVE PCR-BASED NUCLEIC ACID DETECTION - Particular aspects comprise amplifying target nucleic acid using PCR and an oligonucleotide primer pair wherein at least one of the primers is designed to incorporate a 5′-specialty sequence to provide for an amplification product that intramolecularly folds into a secondary structure; and detecting the amplification product by a method comprising: providing an oligonucleotide cleavage component, hybridizing said oligonucleotide cleavage component with the amplification product to form a three-strand cleavage structure wherein two strands of the three-strand cleavage structure are provided by the secondary structure of the amplification product, cleaving 3′- or 5′-strands of the three-strand cleavage structure using a duplex-specific nuclease activity resulting in a cleavage product, and detecting the cleavage product indicative of the presence of the target nucleic acid. In certain aspects both primers incorporate a 5′-specialty sequence and detecting comprises cleaving 3′- or 5′-strands of a three-strand cleavage structure using duplex-specific nuclease to provide a cleavage product.06-10-2010
20090068644METHOD FOR PRODUCING HIGHLY SENSITIVE ENDONUCLEASES, NOVEL PREPARATIONS OF ENDONUCLEASES AND USES THEREOF - The present invention pertains to methods for producing recombinant endonucleases having a high sensitivity, as well as to endonucleases preparations obtained by said methods, and uses thereof, especially for the detection of mismatches.03-12-2009
20100035263BIOMARKERS FOR RENAL DISEASE - The invention provides methods and kits for diagnosing a renal disease in a patient or for predicting the risk of a patient for developing a renal disease. In one embodiment, the invention provides a method for diagnosing a renal disease in a patient, comprising determining the level of a ubiquitin fragment having a mass-to-charge ratio (m/z) of 6188 (ubiquitin m/z 6188), or the level of a nucleic acid encoding ubiquitin m/z 6188, in a sample derived from said patient, wherein the substantial absence or a reduced level of less than 25% of ubiquitin m/z 6188 or the nucleic acid encoding ubiquitin m/z 6188 compared to a control is indicative of the renal disease in said patient.02-11-2010
20100035267Detection of Individual T-Cell Reaction Patterns Against Tumor-Associated Antigens (TAA) in Tumor Patients as a Basis for the Individual Therapeutic Vaccination of Patients - The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs. The present invention furthermore relates to a method for producing an individualized tumour vaccine or individualized tumour therapeutic, as well as corresponding methods for treating a tumourous disease using the individualised tumour vaccine or individualised tumour therapeutic.02-11-2010
20100035262METHOD FOR DETECTING THYROID CARCINOMA - It is an object of the present invention to identify a gene that exhibits behavior which is characteristic of carcinomas such as thyroid carcinoma, so as to provide a method for detecting carcinoma and a cell growth suppressing agent. The present invention provides a method for detecting carcinoma, which comprises detecting malignant transformation by detecting at least one alteration of gene existing in chromosomal regions 1q41, 3q28, 7q31.2, 8p12, 8q22.2, 8q24.21, 11q4.1, 17q12, 20q11, 9p21.3, 16q13.2, and 16q23.1 in a specimen.02-11-2010
20100035250USE OF PHENANTHRIDIUM DERIVATIVES FOR DISTINGUISHING BETWEEN INTACT AND MEMBRANE COMPROMISED CELLS USING MOLECULAR NUCLEIC ACID-BASED TECHNIQUES - The present invention provides novel chemicals and methods for selectively excluding DNA of dead cells from a mixture containing live and dead cells from molecular detection.02-11-2010
20090197246Haplotypes and polymorphisms linked to human thiopurine s-methyltransferase deficiencies - Haplotypes and polymorphisms of thiopurine S-methyltransferase (TPMT) are described that are linked to TPMT deficiencies which can cause potentially fatal toxicity when patients are treated with thiopurines like mercaptopurine, azathioprine, or thioguanine. The mutant alleles as well as PCR fragments, kits and methods for assaying the TPMT genotype of individual patients are disclosed. Furthermore, algorithms are disclosed that combine the genotypes of a set of single nucleotide polymorphisms to haplotypes that give a distinct information about the TPMT phenotype.08-06-2009
20090142766METHODS FOR MEASURING THE METABOLISM OF CNS DERIVED BIOMOLECULES IN VIVO - The present invention provides methods for measuring the metabolism of a central nervous system derived biomolecule implicated in a neurological and neurodegenerative disease or disorder. In particular, the method comprises measuring the in vivo metabolism of the biomolecule in the central nervous system of a subject. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule.06-04-2009
20080261215Method for Evaluating the Allergen Sensitivity of an Individual - The present invention discloses a method for evaluating the allergen sensitivity of an individual and/or the clinical efficacy of an allergen immunotherapy comprising the steps: providing at least two samples selected from the group consisting of blood or fractions thereof, connective tissue, nasal, bronchial, skin or gut biopsy material from an individual subjected or intended to be subjected to an immunotherapy with at least one pure allergen or derivative thereof, wherein the samples contain cells capable of releasing mediators in response to said allergen, contacting said sample with said allergen or derivative thereof, and determining the amounts of mediators released from said sample and evaluating the allergen sensitivity of the individual prior to therapy and/or the clinical efficacy of the immunotherapy by comparing said amounts.10-23-2008
20100015615Identification and Isolation of Adult Stem Cells and Related Methods of Use - Inhibitor of DNA Binding-1 (Id-1) is a marker protein found in stem cells, including adult stem cells, which can be used an indicator of the “stem-ness” of the cells. This allows Id1 expression to be used in a method for identifying cells as potential stem cells involving the step of screening the cells for expression of Id1; and a method for isolating cells as potential stem cells comprising the step of separating cells that express Id1 from cells that do not. Expression of GFAP can be used as a secondary screen to isolate rare B1 type adult neuronal stem cells.01-21-2010
20090068670STRATIFIN DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE - Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of stratifin in the test cell sample or fluid sample as compared to the level of expression of stratifin in a control cell sample or fluid sample isolated from a normal subject.03-12-2009
20100062438NATURAL SELECTION AND CELLULAR IMMORTALITY - The invention provides new insights into the manner in which cells evolve and age thereby providing methods for assessing and studying those processes.03-11-2010
20090181399INSECT RESISTANT COTON PLANTS AND METHODS OF DETECTING THE SAME - The present application relates to an insect resistant transgenic cotton event designated COT202. The application also relates to polynucleotides which are characteristic of the COT202 event, plants comprising said polynucleotides, and methods of detecting the COT202 event.07-16-2009
20100068703ENHANCED MEDICAL TREATMENTS RESULTING FROM CHEMICAL IDENTIFICATION OF CALCIUM INFLUX FACTOR, IDENTITY WITH THE FACTOR ACTIVATING PHOSPHOLIPOLYSIS AND PRECIPITATING SUDDEN DEATH DURING MYOCARDIAL INFARCTION, AND DETERMINATION OF SIMILAR ACTIVATING MECHANISMS IN MULTIPLE CELL TYPES THROUGH DISINHIBITION OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2BETA - A method for treating a mammal comprises administering at least one of a gene, enzyme and pharmaceutical which modulates the concentration of iPLA03-18-2010
20090011406Method of Judging Fatigue - A method of judging fatigue, which comprises judging fatigue by using, as an index, a value obtained by quantitatively analyzing an adenine nucleotide in a sample to be measured.01-08-2009
20090081657Genetic Identification And Validation Of Echinacea Species - A method for identification and validation of 03-26-2009
20090258352Pin1 as a marker for abnormal cell growth - Methods for the use of Pin1 as a marker of abnormal cell growth are disclosed. In one embodiment, the method includes detecting a level of Pin1 to stage an abnormal cell growth, such as breast or prostate cancer. In another embodiment, the method includes evaluating the efficacy of a treatment of an abnormal cell growth, such as cancer, by monitoring the levels of Pin1. In another embodiment, the method includes evaluating the extent of metastasis of abnormal cell growth, such as cancer. The levels of Pin1 can be protein levels or nucleic acid levels.10-15-2009
20090311685NMU-GHSR1b/NTSR1 oncogenic signaling pathway as a therapeutic target for lung cancer - The present invention relates to a method of and a kit for assessing the prognosis of lung cancer by detecting the expression level of the neuromedin U (NMU) gene in a patient-derived biological sample. The method and kit are particularly preferred for assessing the prognosis of non-small cell lung cancer (NSCLC). Furthermore, the present invention relates to a method of screening for a therapeutic agent for cancer, in particular, lung cancer, by detecting compounds that inhibit the binding of the NMU protein with the heterodimer of growth hormone secretagogue receptor 112-17-2009
20090130680SOLID SUPPORT - The present invention provides a solid support for performing steps of isolation of cell or extraction and purification of nucleic acid, safely, easily, efficiently, and with high yield in the genetic test for investigating the presence of pathogenic bacterial infection. A solid support for binding with cell as an embodiment of the above-described solid support, comprises a polypeptide having capability of binding with mycolic acid-containing glycolipid which is immobilized on the surface of a carrier. In addition, a solid support for binding with nucleic acid as another embodiment of the above-described solid support, comprises a polypeptide having capability of binding with nucleic acid which is immobilized on the surface of a carrier.05-21-2009
20090023143Predicting agent for metastasis - By disclosing part of metastasis mechanisms in cancer cells, the metastatic potential of cancer cells will be determinable. Anti-galectin-9 Ab against galectin-9 is contained as an effective component with or without others, thereby enabling the evaluation or detection of galectin-9 expression levels in cancer cells wherein the metastatic potential of the cancer cells can be assessed or detected.01-22-2009
20100099108Method for Detecting, Isolating, and Characterizing Cells from Body Samples by Transfection with Nucleic Acid Constructs - A method for detecting or isolating disease-associated cells or pluripotent stem cells from body samples is provided where cells of a body sample are transfected with nucleic acid constructs that include the following components: (a) a promoter element containing at least one DNA site for binding one or more transcription factors; and (b) a reporter gene that enables the diseased or stem cells to be detected. When the method is used for detecting disease-associated cells, the transcription factor initiates at least one signalling activity in the disease-associated cells that is not present in healthy cells.04-22-2010
20100099106CELL DEATH INHIBITOR - The cell death inhibitor comprising a substance capable of binding to macrophage migration inhibitory factor is useful as a preventive/therapeutic agent for, e.g., heart diseases, neurodegenerative diseases, cerebrovascular diseases, central nervous infections, traumatic diseases, demyelinating diseases, bone/joint diseases, kidney diseases, liver diseases, myelodysplastic diseases, arteriosclerosis, diabetes, pulmonary hypertension, sepsis, inflammatory bowel diseases, autoimmune diseases, failure accompanying rejection in organ transplantation, AIDS, cancer, etc.04-22-2010
20100099096Compositions and Methods for Identifying Factors Affecting Protein Stability - The present invention is directed to retroviral vectors, and libraries generated from the vectors that can be used in assessing the stability of proteins and in correlating degradation with a specific E3 ubiquitin ligase. The libraries can also be used to identify factors that alter the degradation of proteins of therapeutic value and which have potential use clinically.04-22-2010
20100099089REPORTER UNIT FOR DETECTION OF TARGET MOLECULES USING POLYMERISABLE SUBSTRATE - The invention relates to a reporter unit for detecting a target molecule comprising at least one component attached to a target molecule specific probe, wherein said at least one component is liberated from said probe by the activity of a first enzyme thereby making the at least one component available as a substrate for a second enzyme which employs the substrate in a polymerization reaction to obtain a detectable structure.04-22-2010
20100099084DETECTION OF NPM1 NUCLEIC ACID IN ACELLULAR BODY FLUIDS - The present inventions relates to methods for detecting NPM1 nucleic acid in acellular body fluid samples and determining whether the nucleic acid contains one or more mutations including insertions and deletions. The methods are useful for predicting prognosis of AML patients that have cells with mutations in the NPM1 gene.04-22-2010
20100099083CROHN DISEASE SUSCEPTIBILITY GENE - The present invention relates to the ATG16l1 gene and genetic variants associated with Crohn's disease. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs.04-22-2010
20090170088GENE METHYLATION IN CANCER DIAGNOSIS - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of cancer.07-02-2009
20090162849IDENTIFICATION OF A JAK2 MUTATION IN POLYCYTHEMIA VERA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.06-25-2009
20100124749COMPOSITIONS, KITS AND METHODS FOR DETECTION OF CAMPYLOBACTER NUCLEIC ACID - The disclosed invention is related to compositions, kits and methods comprising one or more oligomers targeting 16S rRNA target nucleic acid from 05-20-2010
20100055678Method of profiling a cell population - The present invention relates to a method of profiling a cell population comprising a step of detecting the presence or absence of at least two biological markers in said cell population, wherein at least one of said markers is a cell surface marker, which is a sialylated N-glycan marker with structure NeuNAcα3Gal, and at least one of said markers is a mRNA marker related to glycoproteins and/or glycosynthase proteins. The invention also relates to method for purification of cord blood cell population and to a complete cell population from cord blood purified by said method.03-04-2010
20090269770METHODS FOR EVALUATION PROGNOSIS AND FOLLOW-UP OF DRUG TREATMENT OF PSYCHIATRIC DISEASES OR DISORDERS - The present invention provides methods for evaluating the pharmacological efficacy of drugs or drug candidates in treatment of psychiatric diseases or disorders, particularly schizophrenia, and for predicting the efficacy of drugs or drug combinations indicated for treatment of both positive and negative symptoms of psychiatric diseases or disorders in an individual having such a disease or disorder. In both methods, the drugs or drug candidates evaluated are assessed for their ability to produce certain changes in the expression of specific genes in peripheral mononuclear cells in blood of psychiatric patients, which are similar to the changes obtained following treatments with reference drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders.10-29-2009
20090136944Aberrantly Methylated Genes as Markers of Breast Malignancy - The invention is directed to a method of diagnosing a cell proliferative disorder of breast tissue by determining the methylation status of nucleic acids obtained from a subject. Aberrant methylation of several genes including TWIST, HOXA5, NES-1, retinoic acid receptor beta (RARβ), estrogen receptor (ER), cyclin D2, WT-1, 14.3.3 sigma, HIN-1, RASSF1A, and combinations of such genes serve as markers of breast malignancy.05-28-2009
20100120052Orotate Transporter Encoding Marker Genes - A recombinant marker gene encoding an orotate transporter polypeptide comprising an amino acid sequence at least 60% identical to SEQ ID NO: 2, a polynucleotide construct comprising at least one copy of the recombinant marker gene, a cell comprising at least one exogenous copy of the marker gene, and a method of selecting or identifying a cell comprising at least one copy of the recombinant marker gene, and/or selecting or identifying a cell which has been cured of the recombinant marker gene.05-13-2010
20090155809SUBTRACTIVE SINGLE LABEL COMPARATIVE HYBRIDIZATION - Provided are methods of determining differences between nucleic acids in a test sample and a reference sample. In certain embodiments the methods are used for detecting and mapping chromosomal or genetic abnormalities associated with various diseases or with predisposition to various diseases, or to detecting the phenomena of large scale copy number variants. In particular, provided are advanced methods of performing array-based comparative hybridization that allow reproducibility between samples and enhanced sensitivity by using the same detectable label for both test sample and reference sample nucleic acids. Invention methods are useful for the detection or diagnosis of particular disease conditions such as cancer, and detecting predisposition to cancer based on detection of chromosomal or genetic abnormalities and gene expression level. Invention methods are also useful for the detection or diagnosis of hereditary genetic disorders or predisposition thereto, especially in prenatal samples. Moreover, invention methods are also useful for the detection or diagnosis of de novo genetic aberrations associated with post-natal developmental abnormalities.06-18-2009
20090155806Genomic Sequence of the 5-Lipoxygenase-Activating Protein (FLAP), Polymorphic Markers Thereof and Methods for Detection of Asthma - The invention concerns the genomic sequence of the FLAP gene. The invention also concerns biallelic markers of a FLAP gene and the association established between these markers and diseases involving the leukotriene pathway such as asthma. The invention provides means to determine the predisposition of individuals to diseases involving the leukotriene pathway as well as means for the diagnosis of such diseases and for the prognosis/detection of an eventual treatment response to agents acting on the leukotriene pathway.06-18-2009
20090155804DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS - The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.06-18-2009
20090155803METHODS FOR TISSUE ANALYSIS - This invention relates to methods of analyzing a tissue sample from a subject. In particular the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods.06-18-2009
20090155802Mutant DNA Polymerases with Improved Pyrophasphorolysis Activated Polymerization (PAP) Ability - Disclosed are mutant DNA polymerases having improved extension rates relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the mutant DNA polymerases.06-18-2009
20090155805COPY NUMBER ALTERATIONS THAT PREDICT METASTATIC CAPABILITY OF HUMAN BREAST CANCER - Disclosed in this specification is a method of defining chromosome regions of prognostic value by summarizing the significance of all SNPs (single nucleotide polymorphism) in a predetermined section of a chromosome to define chromosome regions of prognostic value. Based on the SNPs in specified genes, a more accurate prognosis for breast cancer may be provided.06-18-2009
20090155801METHOD OF SEQUENCING DNA - The present invention provides a method of identifying a base at a target position in a sample nucleic acid sequence, said method comprising: subjecting a primer hybridised to said sample nucleic acid immediately adjacent to the target position, to a polymerase primer extension reaction in the presence of a nucleotide, whereby the nucleotide will only become incorporated if it is complementary to the base in the target position, and determining whether or not said nucleotide is incorporated by detecting whether PPi is released, the identity of the target base being determined from the identity of any nucleotide incorporated, wherein, where said nucleotide comprises an adenine base, an α-thio triphosphate analogue of said nucleotide is used, ant the Rp isomer of said analogue and/or the degradation products of said analogue are eliminated from the polymerase reaction step.06-18-2009
20090155800BIOSENSOR HAVING NANO WIRE AND MANUFACTURING METHOD THEREOF - There is provided a biosensor capable of increasing a detecting sensitivity of a target substance by using a nano wire having excellent electrical characteristics and by immobilizing a receptor of the target substance to be detected on a substrate which is disposed between a nano wire and another nano wire and a method for manufacturing the same. A biosensor according to the present invention can be manufactured with an arrangement in which the nano wire is selectively arranged on a solid substrate in a matrix and, therefore, many materials can be detected at the same time. Particularly, since the degradation of electrical characteristics of the nano wire can be prevented in the present invention, a target substance is very sensitively detected through a small amount thereof.06-18-2009
20090155794CLONING MULTIPLE CONTROL SEQUENCES INTO CHROMOSOMES OR INTO ARTIFICIAL CENTROMERES - Artificially synthesizing 29 homozygous cystic fibrosis core panel controls demonstrates placing multiple homozygous mutant sequences on the same single control DNA sequence to streamline quality control by minimizing extra control assays, time, and costly formatted test materials and testing all controls during every test. Any rare or unavailable reported DNA sequence can be PCR amplified using primer pairs synthesized with the designated mutation or variant sequence with paired adjacent upstream and downstream primers to amplify target sequences in total genomic DNA.06-18-2009
20090155798TLE3 AS A MARKER FOR CHEMOTHERAPY - Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.06-18-2009
20090155797Methods For Generating Enhanced Antibody-Producing Cell Lines With Improved Growth Characteristics - The use of mismatch repair (MMR) defective antibody producer cells offers a method to generate subclone variants with elevated protein production such as antibodies. Using MMR defective cells and animals, new cell lines and animal varieties with novel and useful properties such as enhanced protein production can be generated more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within host cells to alter endogenous genes that can yield increased titer levels of protein production. By employing this method, two genes were discovered whose suppressed expression is associated with enhanced antibody production. Suppressed expression of these genes by a variety of methods leads to increased antibody production for manufacturing as well as strategies for modulating antibody production in immunological disorders. Moreover, the suppression of these two genes in host cells can be useful for generating universal high titer protein production lines.06-18-2009
20090155796MARKER FOR CANCER PROGNOSIS AND METHODS RELATED THERETO - The present invention is related to the novel discovery that HIF-06-18-2009
20090155795BASELESS NUCLEOTIDE ANALOGUES AND USES THEREOF - A method of detecting a target nucleic acid.06-18-2009
20090155793APPARATUS FOR HIGH THROUGHPUT SEQUENCING OF NUCLEIC ACIDS - A scalable reaction and detection system for automated high throughput sequencing of nucleic acids involving a combination of chemical processes and observation processes independent of the chemistry processes. Discrete functional units may be configured in a manner that allows the system to interchangeably utilize different sequencing reaction components in conjunction with discrete apparatus components for optical image collection and/or analysis.06-18-2009
20090155792PREDICTORS OF LONG-TERM MORTALITY FOLLOWING CORONARY ARTERY BYPASS GRAFT SURGERY - The present invention relates, in general, to perioperative depression and, in particular, to methods of identifying individuals at risk of perioperative depression.06-18-2009
20090155776Fetal methylation markers - This application describes the discovery that, in a pregnant woman, certain genes (such as RASSF1A, APC, CASP8, RARB, SCGB3A1, DAB2IP, PTPN6, THY1, TMEFF2, and PYCARD) originated from a fetus are highly methylated, whereas the same genes of maternal origin are unmethylated. This discovery allows the easy detection of one or more of these methylated fetal genes in a biological sample from a pregnant woman, serving as a universal indicator of the presence of fetal DNA in the sample. These fetal methylation markers are particularly useful as positive controls for a non-invasive analytical process during which the quality and quantity of fetal DNA are monitored. These newly identified fetal markers can also be measured directly for diagnosis of certain pregnancy-related conditions.06-18-2009
20090155789GENES FROM THE 20Q13 AMPLICON AND THEIR USES - The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases.06-18-2009
20090155780Methods for determining genetic haplotypes and DNA mapping - Improved methods of genetic haplotyping and DNA sequencing and mapping, including methods for making amplified ssDNA, methods for allele determination, and a DNA barcoding strategy based on direct imaging of individual DNA molecules and localization of multiple sequence motifs or polymorphic sites on a single DNA molecule.06-18-2009
20090155787Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.06-18-2009
20090155786COMPOSITIONS AND METHODS FOR DETECTING MARKERS OF CANCER - Disclosed herein are compositions and methods for detecting one or more markers indicative of cancer. In one instance the marker is one or more methylated genes, such as SFRPs. In another instance the marker is an altered protein, such as p53.06-18-2009
20090155785REAL-TIME COLORIMETRIC SCREENING INHIBITORS OF ENDONUCLEASE WITH GOLD NANOPARTICLE SUBSTRATE - The invention provides methods for screening a compound for its effect on endonuclease activity. The methods comprise providing a compound to be screened utilizing a gold nanoparticle aggregate as the substrate for the endonuclease. The gold nanoparticle aggregate is formed by the hybridization of oligonucleotides attached to the nanoparticles, with or without the presence of a third linker oligonucleotide. The hybridized oligonucleotide duplex serves as a substrate for the endonuclease. A detectable change is brought about in the presence of the endonuclease activity. A decrease in the detectable change reflects the reduced levels of endonuclease activities as a result of the effects of endonuclease inhibitors. The present invention also provides kits for screening an endonuclease inhibitor.06-18-2009
20090155784ASSESSMENT OF ASTHMA AND ALLERGEN-DEPENDENT GENE EXPRESSION - The present invention provides methods for the assessment, diagnosis, or prognosis of asthma including methods for providing an assessment, diagnosis, or prognosis comprising the step of exposing a sample derived from a patient to an allergen in vitro. The present invention also provides methods for selecting, as well as evaluating the effectiveness of, asthma treatments. The markers of the present invention can be used in methods to identify or evaluate agents capable of modulating marker expression levels in subjects with asthma06-18-2009
20090155783Method of preparing a biological specimen slide - A method of preparing a slide of a biological specimen, including the steps of (a) providing a slide containing a biological specimen and a cover slip, (b) placing a liquid non-evaporating sealing compound such as mineral oil at spaced locations around an area on the slide and (c) placing the cover slip over the specimen area whereby the specimen and reagent is between the slide and the cover slip and the sealing compound spreads to define a closed boundary around the specimen in the space between the slide and the cover slip. Testing of the biological specimen may then be performed automatically.06-18-2009
20090155781High throughput genome sequencing on DNA arrays - The present invention is directed to methods and compositions for acquiring nucleotide sequence information of target sequences using adaptors interspersed in target polynucleotides. The sequence information can be new, e.g. sequencing unknown nucleic acids, re-sequencing, or genotyping. The invention preferably includes methods for inserting a plurality of adaptors at spaced locations within a target polynucleotide or a fragment of a polynucleotide. Such adaptors may serve as platforms for interrogating adjacent sequences using various sequencing chemistries, such as those that identify nucleotides by primer extension, probe ligation, and the like. Encompassed in the invention are methods and compositions for the insertion of known adaptor sequences into target sequences, such that there is an interruption of contiguous target sequence with the adaptors. By sequencing both “upstream” and “downstream” of the adaptors, identification of entire target sequences may be accomplished.06-18-2009
20090155779APTAMERS THAT BIND TO PRION PROTEIN - Compositions are provided in the form of nucleotide aptamerss that are capapble of binding PrP, and in some embodiments, differentially binding PrP isoforms. Also provided are methods for identifying PrP in a sample, and in some embodiments, either selectively removing PrP or PrP isoforms from a sample, or inactivating them within a sample.06-18-2009
20090155777Methods for performing direct enzymatic reactions involving nucleic acid molecules - Methods for performing a direct enzymatic reaction involving a nucleic acid molecule include performing the enzymatic reaction directly using a biological specimen in a reaction mixture containing a zwitterionic buffer and/or a non-reducing carbohydrate to prevent the biological specimen from inhibiting the enzymatic reaction, in which a nucleic acid molecule present in the biological specimen is not purified before the enzymatic reaction, and obtaining a product from the enzymatic reaction.06-18-2009
20090155782Homoeologous Region Determining Method by Homo Junction Fingerprint Method, Homoeologous Region Determining Device, and Gene Screening Method - To provide a method for efficiently searching for a recessive disease gene without needing any pedigree analysis. In a homoeologous region determining method, the following steps are conducted. It is determined whether or not the base constituting a polymorphic marker of a sample DNA of diploid or higher polyploidy is a homojunction. Homojunction region information representing the region of the sample DNA where polymorphic markers determined as continuous homojunctions acquired. If the continuous probability and/or continuous distance of the polymorphic markers contained in the homojunction region information satisfy a predetermined determination condition, the homojunction region is determined as a homoeologous region. A homoeologous region determining device and a gene screening method for identifying a disease susceptibility gene from the determined homoeologous region are also provided.06-18-2009
20090155775CLONED DNA POLYMERASES FROM THERMOTOGA AND MUTANTS THEREOF - The invention relates to a substantially pure thermostable DNA polymerase from 06-18-2009
20100105066Tissue Rejection - This document relates to methods and materials involved in detecting tissue rejection (e.g., organ rejection). For example, this document relates to methods and materials involved in the early detection of kidney tissue rejection.04-29-2010
20100105065Miniaturized Fluid Delivery and Analysis System - The present invention provides a method for combining a fluid delivery system with an analysis system for performing immunological or other chemical of biological assays. The method comprises a miniature plastic fluidic cartridge containing a reaction chamber with a plurality of immobilized species, a capillary channel, and a pump structure along with an external linear actuator corresponding to the pump structure to provide force for the fluid delivery. The plastic fluidic cartridge can be configured in a variety of ways to affect the performance and complexity of the assay performed.04-29-2010
20100105061AUTOIMMUNE GENES IDENTIFIED IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - The present invention relates to a genes and autoimmunity. More specifically, the invention relates to the identification of genes that are associated with Systemic Lupus Erythematosus (SLE) in children and/or adults. Also disclosed are methods for making and using the genetic selection tool used to identify SLE associated genes, and their uses in diagnosis and treatment of the disease.04-29-2010
20100105063Methods for evaluating the methylation status of a polynucleotide - The invention provides methods related to evaluating the methylation status of a polynucleotide that includes an internal control.04-29-2010
20100105060FAST RESULTS HYBRID CAPTURE ASSAY ON AN AUTOMATED PLATFORM - The present invention comprises a method that provides fast and reliable results for detecting the presence of a target nucleic acid molecule in a sample.04-29-2010
20100105048FUNCTIONALIZED FLUORESCENT NANOCRYSTAL DETECTION SYSTEM - The present invention include fluorescent nanocrystals which have high fluorescence intensity, are water soluble, exhibit physical and chemical stability, and whose spectral properties are detectably modified as the size of functional groups bonded to the nanocrystal surface change when contacted with target molecules in a sample. The molecules in the sample add to or reduce the size of functional groups on the fluorescent nanocrystal proportional to the activity and amount of the target molecules. The present invention may be used to detect telomerase in a sample.04-29-2010
20100105055SYSTEMS AND METHODS OF ANALYZING NUCLEIC ACID POLYMERS AND RELATED COMPONENTS - Systems and methods of identifying, sequencing and/or detecting nucleic acid polymers, as well as related components (e.g., substrates, software and the like) are disclosed.04-29-2010
20100105052Nucleic acid sequencing and process - The present invention is directed to compositions and methods for nucleic acid identification and detection. Compositions and methods of the present invention include extracting and fragmenting target nucleic acids from a sample, using the fragmented target nucleic acids to produce target nucleic acid templates and subjecting those target nucleic acid templates to amplification methods to form nucleic acid nanoballs. The invention also includes methods of detecting and identifying sequences using various sequencing applications, including sequencing by ligation methods.04-29-2010
20100105053APTAMER BASED SENSORS AND RELATED METHODS AND SYSTEMS - An aptamer based-sensor comprising: a target binding aptamer attaching a Raman probe and a metal coated surface; and related methods and systems04-29-2010
20100105050REAL TIME DETECTION OF GENETIC SEQUENCES USING A BIPARTITE PROBE - The present invention concerns a method for detection or quantification of a Target Genetic Sequence in a Genetic Sample using a Bipartite Probe. A Bipartite Probe is made of a Target Binding Sequence capable of hybridizing a Target Genetic Sequence and a Nucleic Acid Binding Probe Sequence capable of being transcribed during PCR into the Capture Probe Sequence where it can hybridize with a Signal Generation Molecule. The Signal Generation Molecule participates in the PCR reaction and confers a fluorescent quality to the PCR amplified product. The reaction temperature of each PCR cycle is reduced below the Tm of the Quencher Oligonucleotide thereby allowing quenching of the fluorescence of the non-incorporated Signal Generation Molecule. Fluorescent detection of each PCR cycle establishes a quantitative PCR result.04-29-2010
20100105049PROCESSES AND COMPOSITIONS FOR METHYLATION-BASED ENRICHMENT OF FETAL NUCLEIC ACID FROM A MATERNAL SAMPLE USEFUL FOR NON INVASIVE PRENATAL DIAGNOSES - Provided are compositions and processes that utilize genomic regions differentially methylated between a mother and her fetus to separate, isolate or enrich fetal nucleic acid from a maternal sample. The compositions and processes described herein are useful for non-invasive prenatal diagnostics, including the detection of chromosomal aneuplodies.04-29-2010
20100105044ILEAL POUCH-ANAL ANASTOMOSIS (IPAA) FACTORS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - A common long term problem after Ileal Pouch-Anal Anastomosis (IPAA) is the inflammation of the pouch, called pouchitis. Additionally, about 5-10% of patients undergoing IPAA with a diagnosis of ulcerative colitis at the time of surgery are subsequently diagnosed with Crohn's disease. In one embodiment, the present invention provides methods of diagnosing and predicting susceptibility to pouchitis after IPAA by detecting the presence or absence of pANCA and/or Cbir1 Flagellin expression.04-29-2010
20100105041REAGENTS AND METHODS FOR DETECTING CYP2D6 POLYMORPHISMS - The present invention relates to oligonucleotide sequences for amplification primers and detection probes and their use in nucleic acid amplification methods for the specific detection of clinically relevant CYP2D6 polymorphisms, in particular CYP2D6 polymorphisms associated with adverse drug response. The oligonucleotide sequences are also provided assembled as kits that can be used to predict how an individual will respond to drugs or other xenobiotic compounds that are metabolized, at least in part, by CYP2D6.04-29-2010
20100105039LABEL-FREE COLORIMETRIC DETECTION - The present invention provides a sensor system kit for detecting an analyte, consisting essentially of: a nucleic acid enzyme, wherein the nucleic acid enzyme cleaves a substrate in the presence of the analyte; the substrate for the nucleic acid enzyme, comprising a polynucleotide; an aggregator; and particles.04-29-2010
20100105038GENETIC MARKERS FOR WEIGHT MANAGEMENT AND METHODS OF USE THEREOF - This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subject's metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subject's metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subject's responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information.04-29-2010
20100105035ELECTROLUMINESCENT-BASED FLUORESCENCE DETECTION DEVICE - The present invention provides compositions providing and methods using fluorescence detection device, comprising an electroluminescent light (EL) source, for measuring fluorescence in biological samples. In particularly preferred embodiments, the present invention provides an economical, battery powered and Hand-held device for detecting fluorescent light emitted from reporter molecules incorporated into DNA, RNA, proteins or other biological samples, such as a fluorescence emitting biological sample on a microarray chip. Further, a real-time hand-held PCR Analyzer device comprising an EL light source for measuring fluorescence emissions from amplified DNA is provided.04-29-2010
20100105057HUMAN DIABETES SUSCEPTIBILITY TNFRSF10D GENE - The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the TNFRSF10D gene locus in a biological sample of said subject.04-29-2010
20100105058Method for Measuring DNA Methylation - The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on.04-29-2010
20100105043METHODS FOR MODULATING EMBRYONIC STEM CELL DIFFERENTIATION - Described herein is Zscan4, a gene exhibiting 2-cell embryonic stage and embryonic stem cell specific expression. Identification of nine Zscan4 co-expressed genes is also described Inhibition of Zscan4 expression inhibits the 2-cell to 4-cell embryonic transition and prevents blastocyst implantation, expansion and outgrowth. Provided herein are methods of inhibiting differentiation of a stem cell, promoting blastocyst outgrowth of embryonic stem cells and identifying a subpopulation of stem cells expressing Zscan4. Further described is the identification of Trim43 as a gene exhibiting morula-specific expression. Also provided are isolated expression vectors comprising a Zscan4 promoter, or a Trim43 promoter operably linked to a heterologous polypeptide and uses thereof. Further provided are transgenic animals comprising transgenes encoding marker proteins operably linked to Zscan4 and Trim43 promoters.04-29-2010
20100105051COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.04-29-2010
20100105056Method and apparatus for performing multiple simultaneous manipulations of biomolecules in a two dimentional array - This invention relates to methods and apparati for performing multiple simultaneous manipulations of biomolecules in a two-dimensional array, such as a gel, membrane, tissue biopsy, etc. Such manipulations particularly include assays and nucleic acid amplification protocols.04-29-2010
20100105054GENE EXPRESSION IN DUCHENNE MUSCULAR DYSTROPHY - Gene expression in peripheral blood from individuals with Duchenne muscular dystrophy (DMD), compared to control individuals, demonstrated differential gene sets that could be used in a method to diagnose DMD, to evaluate effect of DMD therapy, and/or to evaluate propensity to DMD.04-29-2010
20100105059ASSAY FOR CHLAMYDIA TRACHOMATIS BY AMPLIFICATION AND DETECTION OF CHLAMYDIA TRACHOMATIS PMPA GENE - A region of the 04-29-2010
20100105042NOVEL METHODS - The present invention provides methods for site-specifically integrating at least one first nucleic acid into a genome of at least one cell, comprising: 04-29-2010
20100105034DETECTING AND TREATING DEMENTIA - This document relates to methods and materials for detecting mutations that can be linked to dementia. For example, methods and materials for detecting one or more mutations within PGRN nucleic acid are provided. This document also provides methods and materials for detecting the level of progranulin expression. In addition, this document relates to methods and materials for treating mammals having a neurodegenerative disorder (e.g., dementia). For example, methods and materials for increasing PGRN polypeptide levels in mammals are provided, as are methods and materials for identifying agents that can be used to increase PGRN polypeptide levels in mammals.04-29-2010
20100105032HIGHLY SENSITIVE MULTIPLEX SINGLE NUCLEOTIDE POLYMORPHISM AND MUTATION DETECTION USING REAL TIME LIGASE CHAIN REACTION MICROARRAY - A method and apparatus for real-time, simultaneous, quantitative measurement of one or more single nucleotide polymorphisms in one or more target nucleic acids is provided. This method involves combining a ligase chain reaction (LCR), a ligase detection reaction (LDR), and/or a polymerase chain reaction (PCR) technique with an evanescent wave technique.04-29-2010
20090311693METHOD FOR THE IN VITRO SCREENING OF ANTI-CANCER COMPOUNDS THAT INHIBITS SK3 ACTIVITY, AND SAID ANTI-CANCER COMPOUNDS - The present invention relates to methods for the in vitro screening of an anti-metastatic compound that inhibits activity, methods for determining in vitro the presence or absence of a metastatic cancer in a subject by quantifying SK3 activity, methods for the in vitro assessment of the progression of the metastatic property of a cancer by quantifying SK3.12-17-2009
20100041058PIM-3 KINASE AS A TARGET FOR TYPE 2 DIABETES MELLITUS - The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.02-18-2010
20100041051Prostate Cancer Methylation Assay - An assay for diagnosing or prognosticating prostate cancer incorporates the detection of hypermethylation of SEQ ID NO 1, SEQ ID NO 3, and SEQ ID NO 2 genes and may be incorporated into a nomogram.02-18-2010
20100041057DNA METHYLATION DETECTION METHODS - The present teachings provide DNA methylation quantification methods that avoid bisulfite treatment of DNA. Methylation-specific binding proteins (MeDNA binding proteins) and non-methylation specific binding proteins (non-MeDNA binding proteins) are employed in various embodiments to modulate the accessibility of nucleic acids to primer extension reactions. After selectively removing the target nucleic acids, the extension products can be analyzed and methylation quantitated. In some embodiments, the analysis comprises real-time PCR.02-18-2010
20100041054METHODS FOR THE PRODUCTION OF IPS CELLS - Methods and composition of induction of pluripotent stem cells are disclosed. For example, in certain aspects methods for generating induced pluripotent stem cells using reporter genes are described. Furthermore, the invention provides novel reprogramming vectors employing reporter genes.02-18-2010
20100041053PROOFREADING PRIMER EXTENSION - The present invention provides for primer extension reactions, including polymerase chain reactions, in which a polymerase having 3′-5′ exonuclease activity edits a primer that is not fully complementary thereby allowing for amplification and detection of target nucleic acids that may have variability in their sequences.02-18-2010
20100041052Receptor Tyrosine Kinase Assays - Methods for detecting phosphorylation of receptor tyrosine kinases (“RTKs”) upon activation are provided. The method employs cells comprising two fusion products: (1) an RTK fused to a small fragment of β-galactosidase and (2) a phosphotyrosine binding peptide fused to the large fragment of β-galactosidase, where the 2 fragments weakly complex to form an active enzyme, and optionally a construct for a cytosolic RTK phosphorylating kinase, when the RTK does not autophosphoryate. To detect phosphorylation a β-galactosidase substrate is added to the cells, whereby product formation indicates the occurrence of phosphorylation.02-18-2010
20100041056TEMPERATURE CONTROLLED NUCLEIC-ACID DETECTION METHOD SUITABLE FOR PRACTICE IN A CLOSED-SYSTEM - The invention relates to a method that utilizes thermophilic proteases for the treatment of nucleic acids in a closed-system to be used in tandem with methods for the rapid detection of target nucleic acids present in a sample. These combined methods enable simplified, temperature-controlled devices to be used for accurate, streamline testing at the point of care for a wide variety of applications in the medical, industrial, environmental, quality control, security and research fields.02-18-2010
20100041060IRON-REGULATING PROTEIN-2(IRP-2) AS A DIAGNOSTIC FOR NEURODEGENERATIVE DISEASE - The present invention relates to the discovery of markers for neurodegenerative disease. More particularly, it was discovered that forms of IRP-2 protein that are unable to undergo oxidation at critical cysteine residues are diagnostic for neurodegenerative disease including, but not limited to Alzheimer's disease. Embodiments include nucleic acids that encode mutant IRP-2 proteins and fragments thereof, mutant IRP-2 proteins and fragments thereof, antibodies directed to epitopes present on mutant IRP-2 proteins and fragments thereof, methods of making these nucleic acids and polypeptides, as well as, approaches to diagnose neurodegenerative disease in animals, such as humans at risk of contracting Alzheimer's disease.02-18-2010
20100041044AMPLICON MELTING ANALYSIS WITH SATURATION DYES - Methods are provided for nucleic acid analysis wherein a target nucleic acid that is at least partially double stranded is mixed with a dsDNA binding dye having a percent saturation of at least 50% to form a mixture. In one embodiment, the nucleic acid is amplified in the presence of the dsDNA binding dye, and in another embodiment a melting curve is generated for the target nucleic acid by measuring fluorescence from the dsDNA binding dye as the mixture is heated. Dyes for use in nucleic acid analysis and methods for making dyes are also provided.02-18-2010
20100041043METHOD FOR THE DIAGNOSIS AND FOLLOW-UP OF SCHIZOPHRENIA AND OTHER MENTAL AND NEUROLOGICAL DISORDERS - A method for the diagnosis and follow up of a mental disorder or of a neurodegenerative disorder in an individual, comprises: (i) measuring mRNA of D02-18-2010
20100041041NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING - The present invention relates generally to labeled and unlabled cleavable terminating groups and methods for DNA sequencing and other types of DNA analysis. More particularly, the invention relates in part to nucleotides and nucleosides with chemically cleavable, photocleavable, enzymatically cleavable, or non-photocleavable groups and methods for their use in DNA sequencing and its application in biomedical research.02-18-2010
20100041050Disposable Reactor Module and Detection System - A disposable reactor module, monitoring/optical detection system and related hardware for, inter alia, chemical reactions including Polymerase Chain Reactions.02-18-2010
20100041049DETECTING NUCLEIC ACID - This document provides methods and materials for detecting target nucleic acid. For example, methods and materials for detecting the presence or absence of target nucleic acid, methods and materials for detecting the amount of target nucleic acid present within a sample, kits for detecting the presence or absence of target nucleic acid, kits for detecting the amount of target nucleic acid present within a sample, and methods for making such kits are provided.02-18-2010
20100041047EFFICIENT REDUCTION OF TARGET RNA'S BY SINGLE- AND DOUBLE-STRANDED OLIGOMERIC COMPOUNDS - The present invention provides, inter alia, methods of selecting a single-stranded oligomeric compounds for inhibiting RNA expression, methods of generating double-stranded oligomeric compounds, methods of identifying optimized double-stranded oligomeric compounds, methods of selecting optimized single-stranded oligomeric compounds, methods of selecting optimized double-stranded oligomeric compounds, methods of identifying multifunctional oligomeric compounds, methods for optimizing target region selection for modulation of RNA expression, methods of optimizing expression modulation of RNA, and the like. The present invention further provides oligomeric compounds, 8-80 nucleobases in length targeted to a target RNA, wherein said oligomeric compound hybridizes to said target RNA and inhibits RNA levels by at least 50% in both single-stranded and double-stranded forms, and multifunctional oligomeric compounds.02-18-2010
20100041046METHOD AND APPARATUS FOR THE DISCRETIZATION AND MANIPULATION OF SAMPLE VOLUMES - Embodiments of the present invention relate to methods and apparatuses for the discretization and manipulation of sample volumes that is simple, robust, and versatile. It is a fluidic device that partitions a sample by exploiting the interplay between fluidic forces, interfacial tension, channel geometry, and the final stability of the formed droplet and/or discretized volume. These compartmentalized volumes allow for isolation of samples and partitioning into a localized array that can subsequently be manipulated and analyzed. The isolation of the discretized volumes along with the device's inherent portability render our invention versatile for use in many areas, including but not limited to PCR, digital PCR, biological assays for diagnostics and prognostics, cancer diagnosis and prognosis, high throughput screening, single molecule and single cell reactions or assays, the study crystallization and other statistical processes, protein crystallization, drug screening, environmental testing, and the coupling to a wide range of analytical detection techniques for biomedical assays and measurements. The minimal fluid interconnects and simple flow geometry makes the device easy to use and implement, economical to fabricate and operate, and robust in its operations.02-18-2010
20100041045NUCLEIC ACID FLUORESCENT STAINS - The present invention provides fluorescent dye compounds and methods of using the compounds for the staining of nucleic acids including qPCR applications. In particular, the dye compounds comprise heterocyclic molecules with hydroxy alkyl and aromatic substituents, and the dye compounds form highly fluorescent complexes upon nucleic acid binding.02-18-2010
20100041048Circulating Mutant DNA to Assess Tumor Dynamics - DNA containing somatic mutations is highly tumor specific and thus, in theory, can provide optimum markers. However, the number of circulating mutant gene fragments is small compared to the number of normal circulating DNA fragments, making it difficult to detect and quantify them with the sensitivity required for meaningful clinical use. We apply a highly sensitive approach to quantify circulating tumor DNA (ctDNA) in body samples of patients. Measurements of ctDNA can be used to reliably monitor tumor dynamics in subjects with cancer, especially those who are undergoing surgery or chemotherapy. This personalized genetic approach can be generally applied.02-18-2010
20100041033SITE SPECIFIC SYSTEM FOR GENERATING DIVERSITY PROTEIN SEQUENCES - This invention relates to the diversification of nucleic acid sequences by use of a nucleic acid molecule containing a region of sequence that acts as a template for diversification. The invention thus provides nucleic acid molecules to be diversified, as well as those which act as the template region (TR) and in concert with the TR for directional, site-specific diversification. Further provided are methods of preparing and using these nucleic acid sequences.02-18-2010
20100041031Optoelectronic detection system - The invention described herein provides methods for the detection of soluble antigens. In particular, the methods provide for the detection of soluble proteins and chemicals. In addition, the invention provides methods of detecting a nucleic acid sequence in a sample. Also described is an emittor cell comprising an Fc receptor and an emittor molecule for the detection of a target particle in a sample wherein the target particle to be detected is bound by one or more antibodies. Also provided is an optoelectronic sensor device for detecting a target particle in a plurality of samples.02-18-2010
20100041039Analysis of nucleic acid obtained from nucleated red blood cells - The present invention is particularly useful for extracting DNA from nucleated RBCs. Therefore, the methods of the invention can be applied towards the genetic analysis of avians, fish, reptiles and amphibians.02-18-2010
20100041038METHOD FOR DISCRIMINATING SINGLE NUCLEOTIDE POLYMORPHISMS - A method for discriminating single nucleotide polymorphisms (SNPs) offers improved sensitivity and specificity. A test kit is also provided. The method may be for genotyping in typing assays applied to a biological sample. The method may include steps of performing a real-time amplification of the target, generating multiple copies of amplicons, in presence of at least two different labeled probes, each probe allowing real-time detection at the SNP position of both the wildtype and at least one possible mutation, assessing the discriminatory variable value(s) based on the signals of each combination of two detection probes, and discriminating between the genotypes. The methods may be for diagnostic, preventive and therapeutic applications.02-18-2010
20100041037GENETIC VARIANTS CONTRIBUTING TO RISK OF PROSTATE CANCER - The present invention is characterised by certain genetic variants being susceptibility variants for prostate cancer. The invention relates to methods of determining increased susceptibility to prostate cancer, as well as methods of determining decreased susceptibility to prostate cancer, using such variants. The invention further relates to kits for determining a susceptibility to prostate cancer.02-18-2010
20100041036GENOMIC MORSE CODE - The present invention relates to a method of detection of the presence of at least one domain of interest on a macromolecule to test, wherein said method comprises the following steps: a) determining beforehand at least two target regions on the domain of interest, designing and obtaining corresponding labeled probes of each target region, named set of probe of the domain of interest, the position of these probes one compared to the others being chosen and forming the specific signature of said domain of interest on the macromolecule to test; b) after spreading of the macromolecule to test on which the probes obtained in step a) are bound, detection of the position one compared to the others of the probes bound on the linearized macromolecule, the detection of the signature of a domain of interest indicating the presence of said domain of interest on the macromolecule to test, and conversely the absence of detection of signature or part of signature of a domain of interest indicating the absence of said domain or part of said domain of interest on the macromolecule to test.02-18-2010
20100041035IDENTIFICATION OF CENTROMERE SEQUENCES AND USES THEREFOR - Provided herein are methods for identifying centromeres and centromeres identified by such methods. Centromeres of organisms such as algae, fungi, and protists can be used, for example, for constructing artificial chromosomes and cells containing such artificial chromosomes.02-18-2010
20100041034METHOD FOR MANIPULATING SAMPLES WITH MAGNETIC NUCLEATION NANOPARTICLES - A method for manipulating a sample by utilizing a nucleic acid binding substance which has affinity for nucleic acid polymers. The nucleic acid binding substance is comprised of a nucleic acid binding element capable of specific binding to nucleic acid molecules and connected to a nucleation nanoparticle having paramagnetic properties.02-18-2010
20100041040Internally Controlled Multiplex Detection and Quantification of Microbial Nucleic Acids - The present invention relates to new methods and uses for the detection and quantification of microbial nucleic acids employing an internal quantitative reference. Preferred methods are based on the amplification of nucleic acids, preferably the polymerase chain reaction. Further provided are kits comprising components for performing said methods and uses. Moreover, an analytical system for advantageously performing the method according to the invention is disclosed.02-18-2010
20100041032COMPOSITION AND METHODS FOR THE DETECTION OF CRIPTO-3 - The present invention is based, at least in part, on the discovery that the pseudogene TDGF3 (Cripto-3) is expressed in cells and, in particular, that TDGF3 overexpression is associated with transformation of a cell, e.g., TDGF3 is overexpressed in cancer cell lines and cells from tumor tissue. Accordingly, the invention provides compositions, kits, and methods for detecting the presence of a TDGF3 polynucleotide or polypeptide in a sample. The invention further provides compositions, kits and methods for assessing whether a cell is transformed as well as for assessing whether a patient is a suitable candidate for an anti-Cripto antibody therapy.02-18-2010
20100041029SYNTHESIS OF FOUR COLOR 3'O-ALLYL, MODIFIED PHOTOCLEAVABLE FLUORESCENT NUCLEOTIDES AND RELATED METHODS - This invention provides a process for making 3′-O-allyl-dGTP-PC-Biodopy-FL-510, 3′-O-allyl-dATP-PC-ROX, 3′-O-allyl-dCTP-PC- and 3′-O-allyl-dUTP-PC-R6G, and related methods.02-18-2010
20100041028Zinc finger binding domains for GNN - Zinc finger-nucleotide binding polypeptides having binding specificity for target nucleotides containing one or GNN triplets are provided. Compositions containing such polypeptides and the use of such polypeptides and compositions for regulating gene expression are also provided.02-18-2010
20100041027METHODS OF ASSESSING CORONARY ARTERY DISEASE - An association between the Ala allele of the P12A variant of the human PPARγ gene and development of CAD, particularly premature CAD, in individuals, and specifically in women, particularly Caucasian women, is described, as are methods of assessing or predicting the likelihood or risk that an individual, such as a woman, will develop premature CAD. Single nucleotide polymorphisms in the human resistin gene, human resistin gene variants, gender-related increase in premature coronary artery disease, methods of assessing or aiding in assessing the risk that an individual will develop premature CAD, and methods of predicting the likelihood or aiding in predicting the likelihood that an individual will develop premature CAD are described.02-18-2010
20100041025Compositons, methods and kits for real-time nucleic acid analysis in live cells - The present invention includes compositions, methods and kits for the real-time detection of transcription and translation in live cells, tissues and organisms. The present invention further provides method for the rapid sequencing of nucleic acids without using conventional sequencing techniques or reactions.02-18-2010
20100041024Bisulfite Conversion of DNA - The present invention relates to an improved method for the bisulfite conversion of DNA. In certain time-temperature ranges the efficacy of the bisulfite conversion is clearly improved. By combination with denaturating solvents, new reaction conditions and new purification methods the efficacy can be further increased The converted DNA can subsequently be analysed by different methods. The present invention facilitates the analysis of cytosine methylation.02-18-2010
20100041030DISPLACEMENT ASSAY FOR DETECTING NUCLEIC ACID OLIGOMER HYBRIDIZATION EVENTS - Described is a method for detecting nucleic acid oligomer hybridization events that comprises the steps providing a modified surface, the modification consisting in attaching at least one type of probe nucleic acid oligomer, providing at least one type of signal nucleic acid oligomer, the signal nucleic acid oligomers being modified with at least one detection label and the signal nucleic acid oligomers having a section that is complementary or largely complementary to the probe nucleic acid oligomers, providing a sample having target nucleic acid oligomers, bringing a defined quantity of the signal nucleic acid oligomers into contact with the modified surface, bringing the sample and the target nucleic acid oligomers contained therein into contact with the modified surface, detecting the signal nucleic acid oligomers and comparing the values obtained when detecting the signal nucleic acid oligomers with reference values. According to the present invention, the signal nucleic acid oligomers have a larger number of bases than the probe nucleic acid oligomers and exhibit at least one docking section, the docking section exhibiting no structure that is complementary or largely complementary to any section of the probe nucleic acid oligomers, and the target nucleic acid oligomers having a section that is complementary or largely complementary to the docking section.02-18-2010
20100041023Inactivated FCV vaccines - The present invention relates to improved inactivated feline calicivirus (FCV) vaccines. The invention also provides a process for producing stabilized inactivated FCV, and the use of such stabilized inactivated FCV, in the production of FCV immunogenic compositions. The invention further provides methods of inducing an immune response in an animal of the Felidae family, preferably a cat, using the immunogenic compositions according to the invention. 02-18-2010
20090325153ANALYSIS OF HETEROGENEOUS NUCLEIC ACID SAMPLES - Methods for capturing and characterizing low frequency nucleic acid molecules indicative of diseases such as cancer (e.g. adenomas or early stage cancers) are provided. In some aspects, a low complexity capture technique is combined with a high complexity analytical technique. In some aspects, samples may be analyzed using a digital analysis and/or a single molecule sequencing technique.12-31-2009
20100267041SERIAL ANALYSIS OF BIOMARKERS FOR DISEASE DIAGNOSIS - The present invention generally relates to serial analysis of biomarkers for disease diagnosis. In certain embodiments, the invention provides methods for diagnosing a disease including obtaining a sample from a subject, conducting a first assay to determine whether a first biomarker in the sample is positive or negative for a disease, and conducting a second assay to determine whether a second biomarker in the sample is positive or negative for the disease if the first assay produced a negative result.10-21-2010
20090239232METHODS OF RNA AMPLIFICATION IN THE PRESENCE OF DNA - The invention provides methods for amplification of RNA. The methods are particularly suitable for specifically amplifying RNA in the presence of DNA. The methods involve producing a marked first primer extension product from a target RNA in the presence of a DNA-dependent DNA polymerase inhibitor, which prevents replication of DNA by the reverse transcriptase enzyme. The marked nucleic acid products are subsequently selectively amplified in the presence on non-marked nucleic acids. The methods are useful for production and analysis of polynucleotide sequences complementary to an RNA sequence. The methods are useful for preparation of nucleic acid libraries and substrates for analysis of gene expression of cells in biological samples. The invention also provides compositions and kits for practicing the amplification methods, as well as methods which use the amplification products.09-24-2009
20100143913COMBINED SCALABLE IN VITRO DIFFERENTIATION SYSTEM FOR HUMAN BLASTOCYST-DERIVED STEM (HBS) CELLS OR CELLS DERIVED FROM HBS CELLS FOR DIRECT ASSAY APPLICATION IN MULTIWELL PLATES - A combined scalable in vitro differentiation and assay system based on human blastocyst-derived stem (hBS) cells or cells derived from hBS cells is provided. This system makes it possible to merge both the differentiation and the assay parts of the system into one. The advantage of the combined assay system is that the hBS cells or the cells derived from hBS cells in the differentiation system are directly applicable for assays, in a large variety of assay units, such as different multiwell plates. The system offers a major improvement compared to the prior art, since the cells are differentiated in the same format as when further being subject to analysis. The starting cell material can be homogenously distributed across a variety of different plates, for use and can be cultured when attached, when semi-attached or when in suspension.06-10-2010
20100143930Biological indicator - A biological indicator for monitoring the effectiveness of a sterilizing or disinfecting treatment or process. A compound or condition is disclosed which comprises a substrate having a surface layer containing functional groups thereon desirably free of silicon linking groups. The functional groups are desirably in the form of a monolayer of a uniformed distribution and of a selected quantity. Various types of microorganism indicators, such as spores, and/or etiological agent indicators are covalently bonded to the surface layer functional groups through a crosslinking reagent and thus form a uniform number and distribution of the microorganism and/or etiological agent indicators. After being subjected to sterilization or other similar disinfecting treatments or processes, along with various articles such as instruments, the indicator can be cultivated to determine the effectiveness of the sterilization, disinfection, etc. treatment or process.06-10-2010
20100143906METHOD AND COMPUTER PROGRAM PRODUCT FOR DISTINGUISHING AND SORTING SEEDS CONTAINING A GENETIC ELEMENT OF INTEREST - A method for distinguishing and sorting seeds containing a genetic element of interest from a bulk sample. In various embodiments, the present invention comprises associating a marker with at least some of the seeds containing a genetic element of interest of the bulk sample, exciting the seeds using an photonic emitting device, evaluating at least some of the seeds of the bulk sample for the presence or absence of the marker, and sorting the seeds containing a genetic element of interest based on the presence or absence of the marker. In various other embodiments, the method may comprise associating a red fluorescent protein marker with at least some of the seeds containing a genetic element of interest of the bulk sample, evaluating at least some of the seeds of the bulk sample for the presence of the red fluorescent protein marker using an evaluating device, and sorting the seeds containing a genetic element of interest based on the presence of the red fluorescent protein marker. In some embodiments, the red fluorescent protein marker is discernable when excited by a certain energy and the evaluating step comprises exciting the seeds containing a genetic element of interest with the certain energy and detecting an emission resulting at least in part from the exciting step.06-10-2010
20100143903Methods of Detecting and Monitoring Cancer Using 3D Analysis of Centromeres - The present application relates to a method of detecting and monitoring cancer or precancer in a cell using three-dimensional analysis to assess centromere organization. In addition, the application relates to a method and system for characterizing the 3D organization of centromeres.06-10-2010
20090269761Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof - Disclosed is a method for identifying an individual who has an altered risk for developing age related macular degeneration comprising detecting a single nucleotide polymorphism (SNP)10-29-2009
20090246762NUCLEIC ACID TERMINATORS INCORPORATING A CATIONIC MOIETY AND METHODS FOR THEIR USE - Disclosed are methods and kits applicable to sequencing methods, such as Sanger dideoxy sequencing methods. The methods and kits disclosed utilize a cationically charged nucleic acid terminator in combination with a discriminatory polymerase.10-01-2009
20100028876DIAGNOSTIC TESTS USING GENE EXPRESSION RATIOS - The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from cell or tissue samples, such as cancer cell or tissue samples. The invention also provides sets of genes that are expressed differentially in normal and cancer lung cells and tissues. These sets of genes can be used to discriminate between normal and malignant cells or tissues, and between classes of malignant cells or tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumour progression/regression also are provided.02-04-2010
20100028864REAGENTS AND METHODS FOR DETECTING NEISSERIA GONORRHOEAE - This invention provides compositions and methods for detecting 02-04-2010
20100105045DNP63A Gene and Screening Methods of Anticancer Agent by Using it - This invention relates to a gene encoding ΔNp63α and screening methods of anticancer-drugs thereof, more specifically a gene encoding ΔNp63α and a protein which is transported from nucleus to cytoplasm by contacting with potential anti-cancer-drugs in an epithelial cell carcinoma, a recombinant vector comprising said gene and reporter genes, and carcinoma cells comprising said vector. Also, This invention relates to high throughput screening methods of anticancer-drug comprising identifying the transportation of ΔNp63α protein from nucleus to cytoplasm by contacting with potential anticancer-drug in a carcinoma cell.04-29-2010
20100105040MICROFLUIDIC SYSTEMS INCLUDING POROUS POLYMER ELECTRODES - Microfluidic devices that incorporate a porous polymer electrode assemblies, including microfluidic device useful for detection of nucleic acids, as well as methods of using the microfluidic devices.04-29-2010
20100105047Method for the Simultaneous Determination of Blood Group and Platelet Antigen Genotypes - RBC and platelet (Plt) alloimmunization requires antigen-matched blood to avoid adverse transfusion reactions. Some blood collection facilities use unregulated Abs to reduce the cost of mass screening, and later confirm the phenotype with government approved reagents. Alternatively, RBC and Plt antigens can be screened by virtue of their associated single nucleotide polymorphisms (SNPs). We developed a multiplex PCR-oligonucleotide extension assay using the GenomeLab SNPStream platform to genotype blood for a plurality of blood group antigen-associated SNPs, including but not limited to: RhD (2), RhC/c, RhE/e, S/s, K/k, Kp04-29-2010
20100105046METHODS OF DIAGNOSING CARDIOVASCULAR DISEASE - The invention relates to predicting which individuals are at risk of developing atherosclerotic vascular disease, and once having disease, which individuals are at risk of experiencing plaque rupture which, depending on the site of the plaque, could produce myocardial infarction, stroke, critical limb ischemia, or other vascular event. The invention further relates to methods of diagnosing and aiding in the diagnosis of vascular conditions such as atherosclerosis, premature coronary artery disease and coronary artery disease, by detecting a resistin gene product in an individual. The invention further relates to methods of predicting, and aiding in predicting, the likelihood that an individual will experience a vascular event, such as but not limited to, a myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack (TIA), or critical limb ischemia.04-29-2010
20100105037METHODS FOR AMPLIFYING AND DETECTING NUCLEIC ACID SEQUENCES - The present invention, in different aspects and embodiments, provides nucleic acid amplification and detection methods that are both sensitive and fast. In various aspects there are disclosed amplification methods employing different combinations of primers to which can achieve exponential amplification and strand displacement, such as to generate a more than two fold increase of the amount of a target nucleic acid sequence during repeated cycles, while additionally permitting the production of single stranded products. Also provided are detection systems and kits.04-29-2010
20100105031METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR - Disclosed is a method for the prediction of the efficacy of a vascularization inhibitor. In the method, the anti-tumor effect of a vascularization inhibitor can be predicted by measuring the number of blood vessels surrounded by pericytes in a tumor and using the measurement value as a measure for the anti-tumor effect.04-29-2010
20100105036SIR2 Activity - This invention relates to methods of screening compounds that modulate cellular and organismal processes by modification of the activity of SIR2 and/or transcription factors, e.g., p53, particularly methods of screening for compounds that modify lifespan and/or metabolism of a cell or an organism by modulation of the activity of SIR2 and/or transcription factors, e.g., p53, and more particularly to methods of screening for compounds that modulate the activity of Sir2 and/or transcription factors, e.g., p53. In particular, the present invention relates to a method for screening a compound, by providing a test mixture comprising a transcription factor, Sir2, and a Sir2 cofactor with the compound, and evaluating an activity of a component of the test mixture in the presence of the compound. The invention further relates to therapeutic uses of said compounds. The invention further relates to a method of modifying the acetylation status of a transcription factor binding site on histone or DNA by raising local concentrations of Sir2.04-29-2010
20100105030NUCLEIC ACID BASE PAIRS - The invention relates to non-natural bases and base pairs that expand the normal DNA-based encoding system. Compositions herein may comprise at least one non-natural base that may interact with another base via a Watson Crick-type hydrogen bonding geometry and/or a Hoogsteen-type hydrogen bonding geometry. The bases may be used in a molecular entity, such as an oligomer or any other entity wherein the bases are attached to a backbone. For example, they may be comprised in DNA, RNA, or PNA, or a variety of other nucleic acid-type systems.04-29-2010
20100105029Self-contained biological analysis - Devices, containers, and methods are provided for performing biological analysis in a closed environment. Illustrative biological analyses include nucleic acid amplification and detection and immuno-PCR.04-29-2010
20100105028PROBE FOR DETECTING NUCLEIC ACIDS - The invention relates to a probe for detecting nucleic acids, to a method for producing the probe, methods for carrying out analytical reactions and test kits containing the reagents that are required for carrying out the probe-based analytical reaction.04-29-2010
20090092966COLLOIDAL METAL AGGREGATES AND METHODS OF USE - Metal colloidal aggregates substrates useful for metal enhanced fluorescence applications, are disclosed. Method of making and using these colloidal aggregates for enhancing the fluorescent signal in biological assays are also described.04-09-2009
20090035760CalDAG-GEF1 Gene Mutations Associated with Thrombopathy - The present invention relates to methods and compositions for detecting mutations associated with thrombopathy. In particular, the invention relates to methods and composition for detecting mutations in the CalDAG-GEF1 gene that are associated with thrombopathy.02-05-2009
20100068723MICROFLUIDIC DEVICES - Methods and devices for the interfacing of microchips to various types of modules are disclosed. The technology disclosed can be used as sample preparation and analysis systems for various applications, such asDNA sequencing and genotyping, proteomics, pathogen detection, diagnostics and biodefense.03-18-2010
20100330581METHOD FOR IN VITRO DIAGNOSIS OR PROGNOSIS OF TESTICULAR CANCER - The invention relates to a method for in vitro diagnosis or prognosis of testicular cancer which comprises a step of detecting the presence or absence of at least one expression product from at least one nucleic acid sequence selected from the sequences identified in SEQ ID NOS: 1 to 6 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 6, to isolated nucleic acid sequences and to the use thereof as a testicular cancer marker.12-30-2010
20100330574CHIMERIC PRIMERS WITH HAIRPIN CONFORMATIONS AND METHODS OF USING SAME - Methods and compositions for nucleic acid amplification, detection, and genotyping techniques are disclosed. In one embodiment, a nucleic acid molecule having a target-specific primer sequence; an anti-tag sequence 5′ of the target-specific primer sequence; a tag sequence 5′ of the anti-tag sequence; and a blocker between the anti-tag sequence and the tag sequence is disclosed. Compositions containing such a nucleic acid molecule and methods of using such a nucleic acid molecule are also disclosed.12-30-2010
20100330573OPTIMIZED OLIGONUCLEOTIDES AND METHODS OF USING SAME FOR THE DETECTION, ISOLATION, QUANTIFICATION, MONITORING AND SEQUENCING OF BORDETELLA - Described herein are oligonucleotides useful for detecting, isolating, quantitating, monitoring and sequencing 12-30-2010
20100330568ASSAY AND METHOD FOR THE ASSESSMENT OF RESPONDERS AND NON-RESPONDERS TO NK CELL MODULATION BY IMMUNOGLOBULIN THERAPY - A method of determining a patient's susceptibility for NK cell modulation by immunoglobulins in response to a treatment of a disease or prophylaxis of a disease with immunoglobulins wherein a modulation of natural killer cells caused by said immunoglobulins is determined.12-30-2010
20100330567DNA MARKERS FOR MANAGEMENT OF CANCER - A method is provided for assessing allelic losses and hypermethylation of genes in CpG tumor promotor region on specific chromosomal regions in cancer patients, including melanoma, neuroblastoma breast, colorectal, and prostate cancer patients. The method relies on the evidence that free DNA and hypermethylation of genes in CpG tumor promotor region may be identified in the bone marrow, serum, plasma, and tumor tissue samples of cancer patients. Methods of melanoma, neuroblastoma, colorectal cancer, breast cancer and prostate cancer detection, staging, and prognosis are also provided.12-30-2010
20100330562Unique Calibrator Polynucleotides and Methods of Using in Quantitative Nucleic Acid Assays - Disclosed herein are are polynucleotides which may be used to calibrate or standardize quantitative nucleic acid assays. As disclosed, the polynucleotides comprise a sequence derived from a plant viroid polynucleotide or a bacterial or chloroplast Type II intron polynucleotide. Also disclosed are methods of making and using the polynucleotides.12-30-2010
20090191553Chase Ligation Sequencing - In various embodiments, the present teachings provide sequencing methods which facilitate enhancing the efficiency of ligation and/or increasing sequencing reads. Various embodiments of the methods enable sequencing through template regions for which complementary labeled extension probes are unavailable or insufficient. In various embodiments, one or more rounds of ligation with unlabeled extension probes can be used in addition to a round of ligation with labeled extension probe. In various embodiments, for example, such methods can facilitate extension on template polynucleotides that do not bind labeled extension probe in the first round of ligation.07-30-2009
20100092979METHODS AND COMPOSITIONS FOR ISOLATING NUCLEIC ACID - The present invention relates to compositions and methods for isolating and purifying nucleic acid. In particular, the present invention relates to methods of isolating nucleic acid from cells for use in further analysis.04-15-2010
20100092976THERMOSTABLE DUPLEX-SPECIFIC NUCLEASE - The present invention provides a thermostable duplex-specific nuclease (DSN) and a method for digesting a nucleic acid using said DSN, namely, a protein having a Brachyura-derived duplex-specific nuclease activity, a gene encoding for said protein, a recombinant vector comprising said gene and a transformed cell or transduced cell comprising said vector and a method for producing a protein having a duplex-specific nuclease activity, which comprises culturing said transformed cell or transduced cell using a medium and collecting the protein having a duplex-specific nuclease activity from the cultured mixture, a method for digesting a nucleic acid using said protein having duplex-specific nuclease activity, a method for detecting RNA using said DSN and a reagent kit to be used in the aforementioned methods.04-15-2010
20100092981METHODS OF DETECTING HYPERMETHYLATION - Aspects of the invention relate to methods of detecting cancer, such as colon cancer. In aspects of the invention, methods for detecting the presence of hypermethylated genomic DNA in a biological sample are disclosed. Methods of the invention relate to detecting small amounts of hypermethylated nucleic acids in a biological sample.04-15-2010
20100092951METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID - The present invention relates to a method for methylation analysis. It comprises the providing of a double stranded nucleic acid; its conversion, whereby unmethylated bases become distinguishable in their base-pairing behavior from methylated bases, and the analysis of both of the converted nucleic acid strands.04-15-2010
20100092968Method and Means for Enrichment, Removal and Detection of Gram-Positive Bacteria - The present invention relates to polypeptides comprising a enzymatically non-active cell wall binding domain of an endolysin or another cell wall lysing enzyme, and a sequence according to SEQ ID NO: 1 or derivatives thereof, wherein the polypeptide besides the cell wall binding domain comprises no further domains of an endolysin, as well as means for their preparation. The present invention further relates to methods for binding, enriching, removing from a sample, capturing and/or detecting bacteria, particularly gram positive bacteria.04-15-2010
20100092948BIOLOGICAL BAR CODE - The invention provides compositions and methods useful for identifying, verifying or authenticating any type of sample, whether the sample, is biological or non-biological.04-15-2010
20100092946Genetic methods for speciating Campylobacter - The phylogeny of twelve 04-15-2010
20100143932SINGLE MOLECULE SEQUENCING OF CAPTURED NUCLEIC ACIDS - The invention provides methods and devices for detecting, enumerating or identifying target nucleic acid molecules using immobilized capture probes and single molecule sequencing techniques.06-10-2010
20090186340Gene Analysis - This invention relates to a series of PCR primers that will allow the simultaneous amplification of regions of the clinically significant ABO and RHD genes.07-23-2009
20090246789Gene Mutation Profiling of CSMD1 - A method for assessing risk of node-positive colorectal cancer in an individual is described. The method includes detecting mutations in CSMD1 genes in a tumor sample from the individual, the mutations being associated with increased risk of node-positive colorectal cancer.10-01-2009
20080318226Signal Amplification Method - Provided are a signal amplification method of improving signal sensitivity, qualifying properties and handling property in detection of a target gene by using a PALSAR method, a method of detecting a target gene by using the method, and an oligonucleotide probe to be used in the method. A signal amplification method in detection of a target gene using a polymer formed by the use of a plurality of kinds of oligonucleotide probes having complementary base sequence regions capable of hybridizing with each other, including labeling at least one of the plurality of kinds of oligonucleotide probes with acridinium ester for detection.12-25-2008
20100068704OLIGONUCLEOTIDES COMPRISING SIGNALLING PAIRS AND HYDROPHOBIC NUCLEOTIDES, STEMLESS BEACONS, FOR DETECTION OF NUCLEIC ACIDS, METHYLATION STATUS AND MUTANTS OF NUCLEIC ACIDS - The invention relates to novel oligonucleotides comprising a signalling pair and at least hydrophobic nucleotide. The oligonucleotide analogues are useful for detecting the status of nucleic acid sequences, such as presence, expression, methylation and/or mutation, in particular single point mutations and other sequences where the variation between the correct target and other targets may vary in as little as one nucleotide. The invention also relates to new ways of detecting sequence differences and optimizing conditions by using oligonucleotide analogues and readily available instruments. In particular the invention relates to specifically detecting quantity of a target nucleic acids or detecting one sequence over others that may vary in as little as one nucleotide using oligonucleotides or oligonucleotide analogues comprising a signalling pair and at least one hydrophobic nucleotide, such as a nucleotide analogue comprising an intercalator.03-18-2010
20080318241Methods and Systems for Detecting Antiangiogenesis - The present invention provides methods and systems for the detection of tumor vessel response to antiangiogenic therapies. The present invention also provides compositions and methods for therapeutic and research applications. In particular, the present invention provides systems and methods that employ CD26, HIF-1, and HIF-1 pathway components as biomarkers for monitoring antiangiogenic therapies and as therapeutic targets.12-25-2008
20090155799METHODS FOR DIAGNOSING PANCREATIC CANCER USING REG4 PROTEIN - REG4, a new member of REG family was identified as a biomarker of pancreatic adenocarcinoma. The present invention provides sandwich ELISA to detect serum REG4 in patients with resectable pancreatic cancers i.e. PDACs. The present invention also provides a method for diagnosing a pancreatic cancer using REG4 as a serological marker.06-18-2009
20090123934Inhibition of polo kinase by matrimony maintains G2 arrest in the meiotic cell cycle - Matrimony (Mtrm) acts as a negative regulator of Polo kinase (Polo) during the later stages of G2 arrest. Indeed, both the repression of Polo expression until stage 11 and the inactivation of newly synthesized Polo by Mtrm until stage 13 play critical roles in maintaining and properly terminating G2 arrest. Our data suggest a model in which the eventual activation of Cdc25 by an excess of Polo at stage 13 triggers NEB and entry into prometaphase. In view of the foregoing, methods for modulating oocyte maturation are provided. More particularly, methods are provided for in vitro maturation of an oocyte. Further provided are methods for identifying functional orthologs of a 05-14-2009
20090123933MICRORNA BIOMARKERS IN LUPUS - The present invention provides methods of screening a subject for systemic lupus erythematosus (SLE), comprising detecting an increase in an amount of one or more markers associated with SLE in a biological sample from the subject, wherein the one or more markers is selected from the group consisting of miR-16-1, miR-16-2, miR-223, let7a-1, let7a-2. let7a-3, let 7c, let7g, and any combination thereof, whereby detection of the increase in the amount of the one or more markers identifies the subject as having SLE. The invention further provides methods of screening a subject for SLE comprising detecting a decrease in miR-95 in a biological sample from the subject, whereby detection of the decrease in the amount of miR-95 identifies the subject as having SLE.05-14-2009
20090123932QUANTITATIVE TEST TO DETECT DISEASE PROGRESSION MARKERS OF EPITHELIAL OVARIAN CANCER PATIENTS - The present invention concerns a method of prognosing the risk of early ovarian cancer relapse in a subject having ovarian cancer comprising: a) detecting the level of at least one marker selected from the group consisting of BTF4, GCS and HLA-DRbeta1; and b) comparing the level of the above at least one marker with that of a corresponding control sample, wherein the detection of a lower level of the at least one marker compared to that in the control sample is indicative that the subject is at risk of early cancer relapse. Also provided is a method of stratifying a subject suffering from ovarian cancer based on the expression levels of the disclosed markers and kits for practicing the methods of the present invention.05-14-2009
20090123931IDENTIFICATION OF TISSUE FOR DEBRIDEMENT - Provided are methods of determining whether a cell in a tissue site is viable or nonviable. Also provided are methods of debriding tissue from a tissue site. Further provided are kits comprising a compound that distinguishes between viable and nonviable cells and instructions for using the compound on a tissue site. Additionally, the use of a compound that distinguishes between viable and nonviable cells is provided, where the use is to determine whether a cell in a tissue site is viable or nonviable. Also provided is a use of a compound that distinguishes between viable and nonviable cells, where the use is for the manufacture of the above-described kit.05-14-2009
20090123928Genomic Landscapes of Human Breast and Colorectal Cancers - Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalogue the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11 colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples. Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene “mountains” and a much larger number of gene “hills” that are mutated at low frequency. We describe statistical and bioinformatic tools that may help identify mutations with a role in tumorigenesis. These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy.05-14-2009
20090123927ISOLATION OF PRECURSOR CELLS AND THEIR USE FOR TISSUE REPAIR - Cartilage-derived morphogenetic protein CDMP-1 or a transforming growth factor β having at least 80% homology with CDMP-1, or a factor co-expressed and/or co-detectable therewith, is used as a marker of skeletal precursor cells from any part of a mammalian body.05-14-2009
20090123924Method for Breast Cancer Diagnosis - The invention relates to a method for the in vitro diagnosis of breast cancer in a patient who may be suffering from a breast cancer, characterized in that it comprises the following steps: 05-14-2009
20090123922Bead Bound Combinatorial Oligonucleoside Phosphorothioate And Phosphorodithioate Aptamer Libraries - The present invention includes composition and methods for making and using a combinatorial library having two or more beads, wherein attached to each bead is a unique nucleic acid aptamer that have disposed thereon a unique sequence. The library aptamers may be attached covalently to the one or more beads, which may be polystyrene beads. The aptamers may include phosphorothioate, phosphorodithioate and/or methylphosphonate linkages and may be single or double stranded DNA, RNA or even PNAs.05-14-2009
20090123921IMMUNOGLOBULIN LIBRARIES - Methods and compositions for the screening and isolation of ligand-binding polypeptides, such as antibodies. In some aspects, methods of the invention enable the isolation of intact soluble antibodies comprising a constant domain. Screening methods that employ genetic packages such as bacteria and bacteriophages enable high through-put identification of ligand binding molecules.05-14-2009
20090123920JAK2 MUTATIONS - The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides methods and compositions useful for diagnosing neoplastic diseases including, for example, myeloproliferative diseases. The invention also provides methods and compositions useful for determining a prognosis of an individual diagnosed as having a neoplastic disease.05-14-2009
20090123917METHODS FOR QUANTIFYING MICRORNA PRECURSORS - Provided herein is a sensitive, high throughput, real-time PCR assay to monitor the expression of miRNA precursors. Gene specific primers and reverse transcriptase were used to convert the primary precursors and pre-miRNAs to cDNA. The expression of 23 miRNA precursors in six human cancer cell lines was assayed using the PCR assay. The miRNA precursors accumulated to different levels when compared to each other or when a single precursor is compared in the various cell lines. The precursor expression profile of three miRNAs determined by the PCR assay was identical to the mature miRNA expression profile determined by Northern blotting. We propose that the PCR assay may be scaled up to include all of the 150+ known human miRNA genes and can easily be adaptable to other organisms such as plants, 05-14-2009
20090123914Genomic Assay - A method of detecting a nucleic acid sequence in a genomic sample, includes: providing the genomic sample containing a target nucleic acid sequence of a duplex nucleic acid; providing, a probe containing a probe nucleic acid sequence; providing a hybridization mixture containing the genomic sample, the probe, a hybridization promoting agent and labels; incubating the hybridization mixture; irradiating the incubated mixture with radiation effective to stimulate at least some of the labels to emit energy; and detecting from a fluorescent signal whether the probe perfectly matches the target nucleic acid sequence, wherein the detecting is completed within sixty minutes of the hybridization mixture providing, and the method is conducted without denaturing and without PCR amplifying the duplex nucleic acid. A kit for practicing the method includes the probe, the hybridization promoting agent, and labels.05-14-2009
20090123913Detection of nucleic acid differences using endonuclease cleavage/ligase resealing reactions and capillary electrophoresis or microarrays - The present invention is directed to various methods for detecting DNA sequence differences, including single nucleotide mutations or polymorphisms, one or more nucleotide insertions, and one or more nucleotide deletions. Labeled heteroduplex PCR fragments containing base mismatches are prepared. Endonuclease cleaves the heteroduplex PCR fragments both at the position containing the variation (one or more mismatched bases) and, to a lesser extent, at non-variant (perfectly matched) positions. Ligation of the cleavage products with a DNA ligase corrects non-variant cleavages and thus substantially reduces background. This is then followed by a detection step in which the reaction products are detected, and the position of the sequence variations are determined.05-14-2009
20090123912Methods for quantitating small RNA molecules - In one aspect, the present invention provides methods for amplifying a microRNA molecule to produce DNA molecules. The methods each include the steps of: (a) using primer extension to make a DNA molecule that is complementary to a target microRNA molecule; and (b) using a universal forward primer and a reverse primer to amplify the DNA molecule to produce amplified DNA molecules. In some embodiments of the method, at least one of the forward primer and the reverse primer comprise at least one locked nucleic acid molecule.05-14-2009
20090123918Human Protooncogene TRG and Protein Encoded Therein - Disclosed are a protooncogene and a protein encoded by the same. The protooncogene of the present invention, known to be involved in human carcinogenesis, may be effectively used for diagnosing various cancers including uterine cancer, leukemia, lymphoma, colon cancer, lung cancer, skin cancer, etc.05-14-2009
20090298073Kidney Toxicity Biomarkers - Novel biomarkers for kidney toxicity. Said biomarkers may be useful for optimization of lead compounds, or in safety assessment.12-03-2009
20090047682Method of detecting and predicting bronchodilatory response to beta agonist - Present invention relates to a method for predicting an individual's bronchodilatory response to a β agonist. Present invention particularly relates to the detection of specific allelic variants of the β2AR gene and their use as pharmacogenetic markers towards response to β agonist.02-19-2009
20090130687FORMULATIONS AND METHOD ISOLATING NUCLEIC ACIDS FROM ARBITRARY COMPLEX STARTING MATERIALS AND SUBSEQUENT COMPLEX GENETIC MATERIALS - The object of the invention is formulations and methods without chaotropic components for the isolation of nucleic acids with binding to a solid phase, in particular of DNA, from arbitrary complex starting materials containing a lysis/binding buffer system manifesting at least one anti-chaotropic salt component, the concentration of the anti-chaotropic salt components being between 0.001 mM and 0.1 M, preferably 0.1 mM, and further a solid phase and washing and elution buffers which are known per se.05-21-2009
20110008795MARKER FOR DETECTION OF IL-17-PRODUCING HELPER T-CELL, AND METHOD FOR DETECTION OF IL-17-PRODUCING HELPER T-CELL - Disclosed is a polynucleotide marker or a protein marker for use in the specific detection of an IL-17-producing helper T-cell (a Th17 cell). Also disclosed is a method for detecting a Th17 cell, which is characterized by detecting the occurrence of the polynucleotide marker or the protein marker.01-13-2011
20110008787DETECTION PRIMERS FOR NUCLEIC ACID EXTENSION OR AMPLIFICATION REACTIONS - Disclosed are methods and compositions related to real-time PCR and other nucleic acid extension or amplification reactions.01-13-2011
20110008785METHODS FOR FORENSIC DNA QUANTITATION - Described herein are methods and devices for nucleic acid quantification and, in particular, to microfluidic methods and devices for nucleic acid quantification. In certain embodiments methods of quantifying a target nucleic acid without the need for amplification are provided. The methods involve, in some embodiments, allowing a binding agent to become immobilized with respect to the target nucleic acid. In some cases, the binding agent comprises a signaling moiety that can be used to quantify the amount of target nucleic acid. In another aspect, the quantification can be carried out rapidly. For example, in certain embodiments, the quantification can be completed within 5 minutes. In yet another aspect, samples containing a low amount of target nucleic acid can be quantified. For instance, in some cases, samples containing less than 100 nanograms per microliter may be quantified. Also described are devices and kits for performing such methods, or the like.01-13-2011
20110008784METHODS AND COMPOSITIONS FOR IDENTIFYING UNDIFFERENTIATED STEM CELLS AND ASSESSING CELL HEALTH - Disclosed herein are methods and compositions for the identification of teloRNA marks to assess the differentiation status of an individual stem cell or a population of stem cells, to diagnose whether and to what extent a stem cell or stem cell culture has already initiated cell differentiation, and to monitor the differentiation status of an individual stem cell or a stem cell culture during passage. The use of these methods and compositions to monitor the pluripotency and differentiation status of a stem cell or stem cell culture during differentiation enables the identification of undifferentiated and pluripotent stem cells prior to the initiation of differentiation. The methods and compositions can also be used to assess and maintain cell viability; to identify cells or a population of cells that are in a state of poor cell health; and to reduce cell growth or treat a diseased cell including, for example, pre-cancerous cells, cancerous cells, apoptotic cells, aging cells, cells undergoing stress, and otherwise diseased or dysfunctional cells.01-13-2011
20090215053Vitro Method for the Prognosis of Progression of a Cancer and of the Outcome in a Patient and Means for Performing Said Method - The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.08-27-2009
20100136556DETECTION DEVICE FOR DETECTING BIOLOGICAL MICROPARTICLES SUCH AS BACTERIA, VIRUSES, SPORES, POLLEN OR BIOLOGICAL TOXINS, AND DETECTION METHOD - A device for the detection of micro particles that can be marked by probes or antibodies capable of being detected by radiation has a filter, a supply system, and a detection system. Fluid to be examined is passed over a filter to filter out the micro particles and to perform the marking steps by supplying corresponding marking substances to the filter.06-03-2010
20100136568Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat - Compositions and methods for regulating CD154 gene expression are provided that rely on the interaction of hnRNP L with the CA-dinucleotide rich sequence of the 3′-untranslated region of CD154.06-03-2010
20100136555Burkholderia Pseudomallei Diagnostic Genetic Elements that Predict Mortality in Melioidosis - The present invention provides methods for predicting the likelihood of mortality from melioidosis and detecting the presence of 06-03-2010
20100136567CYANINE DYES - The invention provides a novel class of cyanine dyes that are functionalized with a linker moiety that facilitates their conjugation to other species. Also provided are conjugates of the dyes, methods of using the dyes and their conjugates and kits including the dyes and their conjugates.06-03-2010
20100136538MARKING REAGENTS BEARING DIAZO AND NITRO FUNCTIONS, METHODS FOR THE SYNTHESIS OF SUCH REAGENTS AND METHODS FOR DETECTING BIOLOGICAL MOLECULES - The present invention relates to a labeling reagent of formula:06-03-2010
20100003684SINGLE COPY GENOMIC HYBRIDIZATION PROBES AND METHODS OF GENERATING SAME - Nucleic acid (e.g., DNA) hybridization probes are described which comprise a labeled, single copy nucleic acid which hybridizes to a deduced single copy sequence interval in target nucleic acid of known sequence. The probes, which are essentially free of repetitive sequences, can be used in hybridization analyses without adding repetitive sequence-blocking nucleic acids. This allows rapid and accurate detection of chromosomal abnormalities. The probes are preferably designed by first determining the sequence of at least one single copy interval in a target nucleic acid sequence, and developing corresponding hybridization probes which hybridize to at least a part of the deduced single copy sequence. In practice, the sequences of the target and of known genomic repetitive sequence representatives are compared in order to deduce locations of the single copy sequence intervals. The single copy probes can be developed by any variety of methods, such as PCR amplification, restriction or exonuclease digestion of purified genomic fragments, or direct synthesis of DNA sequences. This is followed by labeling of the probes and hybridization to a target sequence.01-07-2010
20100136522ENDOGENOUS RETROVIRUSES UP-REGULATED IN PROSTATE CANCER - Human endogenous retroviruses of the HML-2 family show up-regulated expression in prostate tumors. This finding can be used in prostate cancer screening, diagnosis and therapy.06-03-2010
20090325171Vesicles for use in biosensors - Vesicles for use in biosensors that have both high specificity and high sensitivity, where the vesicles include a receptor specific for the intended analyte and a signal generating component.12-31-2009
20090317811TWO PORE CHANNELS AS REGULATORS OF PROLIFERATION IN CANCER - The present invention relates to the discovery that two pore K+ channel (2PK) gene expression is increased in tumors and tumor cell lines, especially prostate tumor cells. The present invention encompasses methods for disease diagnosis, drug screening and the treatment of cancer.12-24-2009
20090311702TESTS TO PREDICT RESPONSIVENESS OF CANCER PATIENTS TO CHEMOTHERAPY TREATMENT OPTIONS - The present disclosure provides methods and compositions to facilitate prediction of the likelihood of responsiveness of cancer patients to treatment including a taxane and/or a cyclophosphamide.12-17-2009
20090311675Apparatus for Monitoring Thrombus Formation and Method of Mointoring Thrombus Formation - An apparatus for monitoring thrombus formation wherein anticoagulated blood is flown through a channel simulating a blood vessel while releasing the anticoagulant treatment or promoting blood coagulation to thereby monitor thrombus formation. This apparatus for monitoring thrombus formation comprises: a thrombus formation chamber in at least a part of which a thrombus formation inducer inducing thrombus formation is provided; an inlet tube which is connected to the thrombus formation chamber and through which blood is flown into the thrombus formation chamber; and a drug tube which is connected to the inlet tube and through which a drug releasing the anticoagulant treatment or a drug promoting blood coagulation is supplied. A method of monitoring thrombus formation which comprises flowing anticoagulated blood into a thrombus formation chamber, in at least a part of which a thrombus formation inducer inducing thrombus formation is provided, while releasing the anticoagulant treatment or promoting blood coagulation to thereby monitor thrombus formation.12-17-2009
20090311699METHOD OF SURFACE PLASMON RESONANCE (SPR) TO DETECT GENOMIC ABERRATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA - This invention discloses using SPR technology to detect CLL related genomic aberrations in peripheral blood samples. An efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of CLL related DNA markers used for the detection of genomic aberrations for patients with chronic lymphocytic leukemia (CLL) is also disclosed.12-17-2009
20100267024MUTATIONS IN THE MACROPHAGE SCAVENGER RECEPTOR 1 GENE ALTER RISK OF PROSTATE CANCER, ASTHMA, AND CARDIOVASCULAR DISEASE - The present invention discloses methods of screening a subject for increased likelihood or risk of certain diseases or disorders. This method comprises detecting the presence or absence of at least one mutation in the MSR1 gene wherein the presence or absence of such mutation indicates an increased risk for certain diseases, such as cancer asthma and/or cardiovascular diseases.10-21-2010
20100267018OLIGONUCLEOTIDE ANALOGUES - The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.10-21-2010
20100267015NUCLEIC ACID DETECTION - The invention provides methods for the detection of the amount of a nucleic acid in a sample. The described methods exploit the ability to disrupt and redirect a PCR direction, and the ability to physically pair nucleic acid molecules in a sample that have a reference sequence with nucleic acid molecules in the sample that have a target sequence. The redirection of the PCR reaction enables partial amplification as a preparatory step to other techniques within the same tube. The pairing can result in the presence of unpaired target or reference sequence indicating a difference in the amount of the target sequence versus the reference sequence. The methods are broadly applicable for the determination of differences in the amount of nucleic acids in diagnostic and research applications.10-21-2010
20100129816Microbial Population Analysis - The current invention relates to a method for analysis of a population of micro-organisms (e.g. bacterial population) of different taxonomic groups in an environment suspected to contain said bacteria, primers, primer sets and pair of primer sets suitable for use is such method, and use of such method in determining the effect of external factors like drugs, nutrients and pesticides on bacterial populations of different taxonomic groups.05-27-2010
20090275028METHOD OF DETECTING TARGET NUCLEIC ACID - The present invention provides a method of detecting a target nucleic acid which includes a step of examining whether a washing step has been normally conducted. In an aspect of the invention, a monitoring nucleic acid probe to monitor the washing level is used. The probe shows a change in signal intensity by washing at a washing temperature changed in the optimum temperature range for washing the target nucleic acid and in a temperature range in the vicinity of the optimum temperature range for washing.11-05-2009
20090042208Assays for erectile and bladder dysfunction and vascular health - Assays are provided for erectile and bladder dysfunction and vascular health (e.g., cardiovascular disease, hypertension), where the assays detect the expression of one or more of the human Vcsa1 gene family. The assays are also useful for monitoring the efficacy of treatment of these disorders.02-12-2009
20090042201Biomarkers for multiple sclerosis and methods of use thereof - Disclosed are biomarkers, the expression of which is differentially regulated in subjects with multiple sclerosis (MS) as compared to subjects that do not have MS. Also described are methods of identification of such biomarkers, and methods of using such biomarkers as targets for the development and identification of therapeutic compounds and strategies for the treatment of MS, as well as methods and kits for the diagnosis of MS.02-12-2009
20090042197METHOD FOR DETECTING AND AMPLIFYING NUCLEIC ACID - Problem to be Solved There is provided a method for detecting and/or amplifying a nucleic acid contained in a biological sample such as blood or cells conveniently, rapidly, and effectively.02-12-2009
20090042194Predicting a response to risperidone - The invention relates generally to the relative effect of specific genetic polymorphisms in predicting the clinical outcome of risperidone therapy in patients suffering from a psychiatric disease such as schizophrenia.02-12-2009
20090042190Method of detecting gene - A method of detecting a gene including immobilizing a primer for DNA elongation onto an insoluble carrier having on the surface thereof a polymer substance containing a first unit having a phosphorylcholine group and a second unit having a carboxylic acid-derived group having an electron-attractive substituent bound to a carbonyl group; annealing the template DNA fragments or RNA fragments with the primer for DNA elongation, so as to elongate the DNA primer while incorporating therein an enzyme, thereby allowing coloration of a chromogenic reagent by its enzymatic action; and judging whether the DNA fragments or RNA fragments of the gene presents or not, based on the degree of coloration.02-12-2009
20090042195METHODS AND SYSTEMS FOR SCREENING FOR AND DIAGNOSING DNA METHYLATION ASSOCIATED ABNORMALITIES AND SEX CHROMOSOME ANEUPLOIDIES - Methods and systems for population screening and diagnostics are provided. In particular methods and systems for population screening of individuals for genetic disorders due to alterations in DNA methylation and for the diagnostic testing for such disorders are provided.02-12-2009
20110003308NANOPARTICLE-MEDIATED SIGNAL AMPLIFICATION - There is described a new class or type of initiators for polymerization as a means of signal enhancement, nanoparticle initiators, and methods for amplifying signal resulting from recognition events, thereby enhancing the detection of those recognition events. Methods include amplification achieved through polymerization using a nanoparticle initiator conjugated recognition element that is not consumed during the reaction. The polymer formed as a result of the absorption of light by the nanoparticle initiator and introduction of reactive species into a surrounding polymerizable monomer solution occurs in a spatially-limited region directly surrounding the nanoparticle initiator and is indicative of the recognition event(s). In one embodiment, a semiconductor quantum dot nanoparticle initiator is utilized. In another embodiment, a metal nanoparticle is utilized. In another embodiment, the signal is detected without instrumentation. In yet another embodiment, the signal is detected via a transmission-based instrument which captures an image of the formed polymer.01-06-2011
20110003304METHOD AND KIT FOR DETECTION OF AUTOIMMUNE CHRONIC URTICARIA - Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria.01-06-2011
20110003303SHEATH FLOW DEVICES AND METHODS - The invention relates generally to fluid processing and, in particular aspects, processing fluids for detection, selection, trapping and/or sorting of particulate moieties. Sheath flow devices described allow isolation of target species from fluid samples while avoiding non-specific binding of unwanted species to the surfaces of the separation device. Biological fluid processing, detection, sorting or selection of cells, proteins, and nucleic acids is described. The invention finds particular use in diagnostic settings, analyzing a patient's medical condition, monitoring and/or adjusting a therapeutic regimen and producing cell based products.01-06-2011
20110003300RAPID STERILITY MICROASSAY - The present invention relates to a method for detecting a viable microorganism in a pharmaceutical composition comprising the steps of providing a filterable pharmaceutical composition; filtering the pharmaceutical composition to provide at least three membranes upon which the pharmaceutical composition is deposited, placing the three membranes onto solid culture media to produce at least three filtrand cultures, culturing under aerobic and anaerobic conditions and detecting a viable microorganism cell, micro-colony or colony, wherein the presence of a viable cell, micro-colony or colony on the membrane indicates the presence of a viable microorganism in the pharmaceutical composition.01-06-2011
20110003289METHOD FOR DETECTION OF PRE-NEOPLASTIC FIELDS AS A CANCER BIOMARKER IN ULCERATIVE COLITIS - Among other aspects, the present invention provides biomarkers and methods of identifying precancerous fields in a subject in need thereof. Methods of diagnosing and for providing a prognosis for a subject with an increased risk of developing cancer are also provided, along with methods of determining surgical margins for a tumor or tissue resection procedure. Additionally, reagents and kits are provided for the practice of the methods disclosed herein.01-06-2011
20090305295IDENTIFICATION OF A GENE EXPRESSION PROFILE THAT DIFFERENTIATES ISCHEMIC AND NONISCHEMIC CARDIOMYOPATHY - A method of preparing a gene expression prediction profile for distinguishing ischemic and nonischemic cardiomyopathy comprises the steps of obtaining clinical specimens from patients suffering from ischemic or nonischemic cardiomyopathy, isolating nucleic acid sequences from at least a plurality of said specimens, obtaining a gene expression level corresponding to each individual of said nucleic acid sequence by a gene expression profiling method, identifying genes having differences in gene expression by comparing the gene expression level of an ischemic specimen with the gene expression level of a nonischemic specimen, and identifying a gene expression prediction profile comprises genes identified as having differences in gene expression so that said prediction profile distinguishes ischemic and nonischemic cardiomyopathy.12-10-2009
20090305294METHOD OF ISOLATING NUCLEIC ACIDS FROM STOOL SAMPLES - The present invention relates to a method of isolating a nucleic acid molecule form a biological sample. More particularly, the present invention relates to a method of isolating ribonucleic acid molecule from a biological sample. The method of the present invention is useful in a range of applications including, but not limited to, diagnostic applications and research and development applications, to the extent that the isolation of nucleic acid molecules, and in particular ribonucleic acid molecules, is required. Most particularly, the method of the present invention provides for the isolation of ribonucleic acid molecules which are suitable for analysis by reverse transcriptase-PCR.12-10-2009
20090305293COMPOSITIONS AND METHODS TO DETECT CANDIDA ALBICANS NUCLEIC ACID - Compositions are disclosed as nucleic acid sequences that may be used as amplification oligomers, including primers, capture probes for sample preparation, and detection probes specific for 12-10-2009
20090305291 METHOD AND A MICRODEVICE FOR THE IDENTIFICATION AND/OR QUANTIFICATION OF AN ANALYTE IN A BIOLOGICAL SAMPLE - A method and device, based on a film of a luminescent substance, such as colloidal semiconductor nanocrystals dispersed in a polymer matrix, for conducting quantitative and real-time analyses of PCR processes or of biomolecular interactions in genomics and/or proteomics. The optical detection system is based on FRET processes between the luminescent substance (which acts as the donor in the FRET process) and a suitable fluorophore (which acts as the acceptor species) with which the DNA or other biomolecule is marked. The device is essentially composed of a reaction microchamber with a wall formed by a thin film made of polymer material, in which the nanocrystals are uniformly dispersed, or made of a photoluminescent or electroluminescent polymer. Molecular probes are chemically immobilized on the surface of the polymer film for the specific recognition of the analyte which is to be determined in real time. The film of nanocrystals is excited by radiation at low wavelength (for example, UV/blue), and the radiation in the spectral emission window characteristic of the fluorescent marker of the biomolecule is detected. The specific photophysical characteristics of FRET processes make it possible to monitor in a selective way, in real time and in quantitative mode, the biomolecular interactions, which take place in the close proximity of the surface of the film (typically at distances of <10 nanometres), thus almost completely reducing possible interference caused by background signals and by the free biomolecules in solution (which have not interacted with the corresponding recognition sites). The characteristics of the device also enable simultaneous analyses to be conducted in parallel on different biomolecules (multiplexing).12-10-2009
20090305290LATERAL FLOW NUCLEIC ACID DETECTOR - Point-of-care binding assays include at least one target nucleic acid binding in a multiplex structure with at least one sequence in a partner nucleic acid associated with a label, due to complementary base pairings between at least one sequence in the target nucleic acid and at least one sequence in the partner nucleic acid. The assays overcome the inherent deficiencies of antibody-protein antigen assays. In a preferred embodiment, color tagged nucleic acid sequences are used to bind a complementary target nucleic acid. The tagged nucleic acid sequences are preferably made from deoxyribonucleotides, ribonucleotides, or peptide nucleotides.12-10-2009
20090305289SCREENING METHOD TO IDENTIFY PROTECTIVE SUBSTANCES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR ISCHAEMIC DISEASES - The present invention relates to a screening method for the identification of protective substances which influence haemoglobin formation in neuronal, myocardial and/or skeletomuscular cells, as well as to recombinant constructs, host cells and transgenic animals for the implementation of this method. In addition, the present invention relates to a diagnostic method for the differential diagnosis of neurodegenerative and/or ischaemic diseases in mammals and the use of haemoglobin, a globin or a mutein or fusion protein thereof or a corresponding nucleic acid for the treatment of neurodegenerative and/or ischaemic diseases in mammals. The invention furthermore relates to constructs for gene therapy of such diseases.12-10-2009
20090305288METHODS FOR AMPLIFYING NUCLEIC ACIDS AND FOR ANALYZING NUCLEIC ACIDS THEREWITH - An object of the present invention is to control the increase in amplification errors generated during the nucleic acid amplification and thus to obtain an amplification product having a good reproducibility. The present invention is characterized in that a target nucleic acid to be amplified is amplified through a two-stage amplification process in which the amplification only of a single strand is first performed and a strand which is complementary to its amplified product is then amplified. The amplification uses a first primer which is employed for the first-stage amplification and a second primer which is employed for the second-stage amplification. These primers are each used separately, or alternatively designed to have a different stringency and used at the same time.12-10-2009
20090305287Method and System for Multiplex Genetic Analysis - A method for identifying nucleotides in a nucleic acid sequence is disclosed. A plurality of polymerization complexes are provided within a plurality of confined reaction environments. Each complex comprises a polymerase enzyme and a template nucleic acid. The plurality of complexes are contacted with a plurality of types of nucleotide analogs labeled with distinguishable fluorescent labels under conditions suitable for polymerization. Fluorescent signals associated with incorporation of a nucleotide analog are transmitted to a detector, wherein the location of the fluorescent signal on the detector is indicative of the individual confined reaction environment and the type of nucleotide incorporated. The nucleotide in a nucleic acid sequence is identified based upon the type of nucleotide incorporated and the confined reaction environment.12-10-2009
20090305285ASYMMETRIC CYANINE COMPOUNDS, THEIR PREPARATION METHODS AND THEIR USES - Asymmetric cyanine compounds represented by general formula I are provided, wherein X, n, R12-10-2009
20090305284Methods for Identifying Risk of Breast Cancer and Treatments Thereof - Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.12-10-2009
20090305283CLEAVAGE OF NUCLEIC ACIDS - The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.12-10-2009
20090305282NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION AND USES THEREOF - The present invention provides the complete genomic sequence of a novel human coronavirus, coined as coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong from a patient who had a recent history of visit to Schenzhen. China. The virus belongs to the order Nidovirales of the family Coronavirdae, being a single-stranded RNA virus of positive polarity. The invention also provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.12-10-2009
20090305281NOVEL INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTACE - Disclosed are nucleic acid molecules, and methods of their use, which have a specific structure including a double helical domain and a G-quadruplex domain physically connected by a linker domain which may be nucleosidic or non-nucleosidic. These aptamers demonstrate potent inhibition of phylogenetically diverse primate lentiviral reverse transcriptases, which effect is largely independent of aptamer sequence provided that the aptamer has the specified structure.12-10-2009
20090305279METHOD OF DIAGNOSIS - Provided are methods, kits and arrays for use in determining whether a scar of interest is keloid or non-keloid in nature. These determine keloid or non-keloid nature based on comparison of gene expression in the scar of interest with expression in a control sample. If expression of at least one gene, selected from the group of genes set out in Table 1, is decreased in a sample representative of gene expression in the scar of interest compared to expression of the same gene (or genes) in the control sample this indicates that the scar of interest comprises a keloid.12-10-2009
20090305278SEQUENCE DETERMINATION IN CONFINED REGIONS - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system.12-10-2009
20090305273NANONOZZLE DEVICE ARRAYS: THEIR PREPARATION AND USE FOR MACROMOLECULAR ANALYSIS - Constricted nanochannel devices suitable for use in analysis of macromolecular structure, including DNA sequencing, are disclosed. Also disclosed are methods for fabricating such devices and for analyzing macro-molecules using such devices.12-10-2009
20090305276Method for Predicting Skin Sensitizing Activity of Compounds - The present invention provides methods for predicting the in vivo skin sensitizing activity of chemical compounds using a combination of mammalian cell models with multiple endpoint analysis, time and concentration response curves. The methods allow the determination of a predicted in vivo sensitization value of a compound—for example, a EC3 LLNA value, a GPMT value or a IVTI value—without the use of animals, with a high degree of accuracy. The methods involve detecting expression levels of genes implicated in skin sensitization, combining expression level data with concentration response data, conducting a computational analysis, and comparing test compound data to a database of known skin sensitizers.12-10-2009
20090305275DNAs AND PROTEINS OR PEPTIDES SPECIFIC TO BACTERIA OF THE SPECIES NEISSERIA MENINGITIDIS, PROCESS FOR OBTAINING THEM AND THEIR BIOLOGICAL USES - The DNA of the invention are characterised in that they concern the whole or pan of genes, with their reading frame, to be found in 12-10-2009
20090305274Method for determining azole resistance in candida glabrata - There is disclosed a method for determining azole resistance in 12-10-2009
20090305277GENE EXPRESSION MARKERS FOR PREDICTION OF PATIENT RESPONSE TO CHEMOTHERAPY - The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.12-10-2009
20090305271In Vitro Assay Based on Camp Levels Modulated by Gi-Coupled Receptors - The present invention relates to a reliable and effective in vitro assay based on cAMP levels modulated by Gi-coupled receptors expressed in a selected cell for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor.12-10-2009
20090305269PCR SCREENING METHOD - A tooling system (12-10-2009
20090305268METHOD OF DETERMINING AN AMOUNT OF FATTY ACID CONTENTS IN BOVINE INTRAMUSCULAR FAT ON THE BASIS OF GENOTYPE OF FATTY ACID SYNTHASE GENE AND METHOD OF DETERMINING GOODNESS OF EATING QUALITY OF BEEF ON THE BASIS OF THE RESULTS THEREOF - The present invention has an object to provide a method of determining fatty acid composition in intramuscular fat on the basis of bovine genotype, in particular a method of simply determining an amount of an oleic acid content with a high degree of accuracy, and a method of objectively determining the goodness of eating quality of beef on the basis of the results of the determination. The present invention provides a method of determining an amount of fatty acid content in bovine intramuscular fat on the basis of the genotype of fatty acid synthase determined by determining base <1> and/or base <2> described below, and a method of determining whether cattles are those from which beef with an excellent eating quality is obtained on the basis of the results thereof.12-10-2009
20090305267MICROBIAL MARKERS OF INFLAMMATORY BOWEL DISEASE - The present invention relates to bacterial serine protease autotransporter (SPATE) and Antigen 43 (Ag43) and their various uses relating to inflammatory bowel disease (IBD), specifically in the diagnosis of IBD and the screening of potential agent for treating IBD. The invention also relates to methods for cultivating and identifying enteric microbes.12-10-2009
20090305257BIOMARKERS DOWNREGULATED IN PROSTATE CANCER - Biomarkers are identified by analyzing gene expression data using support vector machines (SVM), recursive feature elimination (RFE) and/or linear ridge regression classifiers to rank genes according to their ability to separate prostate cancer from normal tissue. Proteins expressed by identified genes are detected in patient samples to screen, predict and monitor prostate cancer.12-10-2009
20090305263PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 43 to 45 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.12-10-2009
20090305262PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 56 to 58 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.12-10-2009
20090305261PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 65 to 67 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.12-10-2009
20090305260PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 59 to 61 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.12-10-2009
20090305259Early Diagnosis of Congenital Abnormalities in the Offspring of Diabetic Mothers - The present invention relates to the identification of a series of biomarkers, the detection of which is prognostic for women at risk of becoming hyperglycemic during pregnancy and/or fetuses at risk of developing congenital anomalies as a result of maternal hyperglycemia.12-10-2009
20090305258METHODS FOR THE DIAGNOSIS OF PROLIFERATIVE AND/OR CONFORMATIONAL DISEASES - The present invention discloses methods to diagnose and/or to make prognostic predictions and/or to monitor the efficacy of a therapy of a proliferative or conformational disease, or to establish the state of ageing in a subject. Kit for performing such methods are also disclosed.12-10-2009
20090305256DNA methylation biomarkers for lung cancer - The present invention relates to the identification of novel DNA biomarkers and the use of the aberrant methylation patterns of the biomarkers to diagnose a disease or a condition (e.g., a cancer) associated therewith. In particular, the present invention relates to the use of the novel DNA biomarkers to diagnose lung cancers, e.g., squamous cell carcinomas and adenocarcinomas.12-10-2009
20090305255 Substrate Protein for M-Phase Kinase and use Thereof - An isolated protein of (a) a protein having an amino acid sequence of SEQ ID No. 2; (b) a protein having an amino acid sequence partially different from the amino acid sequence of SEQ ID No. 2 that is a substrate of M-period kinase and has nucleic acid-methylating activity suppressed by phosphorylation; (c) a protein having the amino acid sequence of SEQ ID No. 2 that is phosphorylated by M-period kinase; or (d) a protein having an amino acid sequence partially different from the amino acid sequence of SEQ ID No. 2 that is phosphorylated by M-period kinase.12-10-2009
20090305253Methods and Compositions Related to the Modulation of Riboswitches - Disclosed herein are methods and compositions related to the detection of conformational changes and interactions with trigger molecules in riboswitches.12-10-2009
20090305252Methods and species-specific primers for detection and quantification of Streptococcus mutans and Streptococcus sanguinis in mixed bacterial samples - Dental caries is a polymicrobial infectious disease. Of the hundreds of bacteria present in the biofilms coating teeth, the 12-10-2009
20090305250DETERMINATION OF THE BIOLOGICAL FUNCTION OF A TARGET GENE IN A CELL - Disclosed herein is a method to determine the biological function(s) of a target gene in a cell, the steps of which involve separately culturing a first population and a second population of the cell under same culturing conditions, the first population of the cell differing from the second population of the cell in that the first population of the cell has accepted the introduction of a methylated polynucleotide; comparing the first population and the second population of the cell to determine which biological difference(s) is/are present therebetween; and determining which biological function(s) the target gene is associated with based on the determined biological difference(s) between the first population and the second population of the cell.12-10-2009
20090305248METHODS FOR INCREASING ACCURACY OF NUCLEIC ACID SEQUENCING - The invention provides methods for improving the fidelity of a sequencing-by-synthesis reaction by resequencing at least a portion of a nucleic acid template.12-10-2009
20090305265INTERLEUKIN-33 (IL-33) FOR THE DIAGNOSIS AND PROGNOSIS OF CARDIOVASCULAR DISEASE - The present invention includes methods for the use of interleukin-33 (IL-33) in the diagnosis of cardiovascular conditions including acute coronary syndrome (ACS), myocardial infarction, and/or heart failure, angina, cardiac hypertrophy, arteriosclerosis, myocarditis, pancarditis, endocarditis, stroke and/or pulmonary embolism and the determination of the severity of such conditions (prognosis).12-10-2009
20090305249METHOD OF DETECTING CYP2A6 GENE VARIANTS - The present invention relates to methods for amplifying various regions of the CYP2A6 gene. Methods are provided for amplifying one or more fragments of the CYP2A6 gene in a single tube. The methods can identify mutations, deletion, duplication, and/or rearrangement in a sample containing the CYP2A6 gene.12-10-2009
20090305264COOPERATIVE PROBES AND METHODS OF USING THEM - The present invention provides inter alia, cooperative probe assays for analyzing and identifying biological substances.12-10-2009
20090305247NANOPARTICLE AND METHODS THEREFOR - There is provided an electroactive nanoparticle, which may be used as a label in electrochemical detection assays. The nanoparticle comprises a transition metal oxide and a capping agent, the capping agent comprising a ligand group and a functional group. The capping agent is coordinated to a transition metal centre in the transition metal oxide via the ligand group. Also provided are methods relating to preparation of the nanoparticle and detection of an analyte molecule in a sample using electrochemical methods.12-10-2009
20090305246SCHIZOPHRENIA ASSOCIATED GENES AND MARKERS - The invention discloses schizophrenia-associated polymorphism located on chromosome 6q23 within the human Abelson Helper Integration Site 1 gene (AHI1), or a genomic region linked to the AHI1 gene that includes the C6orf217 gene. The invention further discloses systems and methods for diagnosing schizophrenia or predisposition to schizophrenia.12-10-2009
20090305244Selection, Propagation and Use of Mosaic Aneuploid Stem Cells - The distribution of cell karyotypes within a population of cells can determine the phenotype and ability of stem cells to differentiate into desired cell types, to function normally, as well as represent risk for adverse events like cancer. Therefore, determination of the aneuploid mosaic status of a cell population is useful in identifying and/or maintaining desirable traits and eliminating undesirable traits in stem cells, and for defining them at the level of their chromosomal complement.12-10-2009
20090305242SKIN AGING MARKER AND TECHNIQUE FOR USE THEREOF - It is an object of the present invention to find substances that can be used as skin aging markers, and the present invention provides a method for determining the degree of skin aging, including measurement of expression of secretory proteins and/or intracellular proteins and/or their genes in skin cells and/or skin tissues, wherein the secretory proteins and/or intracellular proteins change their expression with aging of skin. The present invention also provides a kit for determining the degree of skin aging and a method for identifying substances effective in the prevention of skin aging.12-10-2009
20090305239Methods and compositions for determing a level of biologically active serum paraoxonase - A method of determining a level of biologically active PON enzyme is provided. The method comprising determining lactonase activity of the PON enzyme, the lactonase activity being indicative of the level of biologically active PON enzyme. Also provided are novel compounds which may be used for measuring a lactonase activity of an enzyme.12-10-2009
20090305238Microarray Microcard - A fluid processing device is provided that comprises a substrate including a surface and a fluid processing pathway at least partially formed in or on the surface. The fluid processing pathway can comprise a channel, a reaction region in fluid communication with the channel, a microarray in fluid communication with the channel, and optionally a deformable valve. The microarray can comprise binding and/or detection sites, and each site can comprise a binding moiety. A method and a system using the fluid processing device, are also provided.12-10-2009
20090305237QUANTIFICATION OF NUCLEIC ACIDS AND PROTEINS USING OLIGONUCLEOTIDE MASS TAGS - The invention provides a method for detecting and quantifying the amount of target molecules, such as nucleic acids or proteins in a sample. The target molecules are first recognized and bounded by target-specific probes, generally nucleic acids or proteins that bind specifically to the targets, each of which is labeled with a short single-stranded nucleic acid probe, either DNA or RNA, with distinct molecular weight. This label is called an oligonucleotide mass tag. One or several standard oligonucleotide sequences can be designed with similar sequence but distinct molecular weight to those oligonucleotide mass tags. Then the oligonucleotide mass tags associated with bounded probes and the standard sequences are co-amplified using a pair of common primers. The presence and/or amount of each oligonucleotide mass tag, which corresponds to the amount of corresponding target molecule, is determined by a primer extension reaction and quantification of the primer extension product.12-10-2009
20090305234Specific DNAS for Epigenetic Characterisation of Cells and Tissues - The present invention provides methods, nucleic acids and molecular markers for the characterization of cells, tissues and heterogeneous mixtures of cells. Specifically, it describes particular genes and genomic regions in which DNA methylation patterns are a consistent and characteristic property of different cell types, states and stages of differentiation. The invention is useful in determining the identity, composition, quality and potency of cells and cell populations. Furthermore, the invention will be useful in monitoring the differentiation of cells.12-10-2009
20090305233Methods and Reagents for Polynucleotide Assembly - The present invention provides methods, compositions, and kits for polynucleotide assembly.12-10-2009
20090305241DNA demethylases and uses thereof - Polypeptides with DNA demethylase activity as well as methods of their use are provided.12-10-2009
20100015610DIAGNOSTIC SCREENING METHODS FOR DISORDERS OF THE ENDOPLASMIC RETICULUM-TO-GOLGI TRAFFICKING OF PROTEINS - The invention relates to methods of diagnosing Cranio-lenticulo-sutural dysplasia and other disorders that occur as a result of defective endoplasmic reticulum-to-Golgi trafficking using immunofluorescence based screening tests using antibodies against protein disulfide isomerase.01-21-2010
20090117563Identification of TRPML3 (MCOLN3) as a Salty Taste Receptor and Use in Assays for Identifying Taste (Salty) Modulators and/or Therapeutics that Modulate Sodium Transport, Absorption or Excretion and/or Aldosterone and/or Vasopressin Production or Release - This invention relates to the elucidation that TRPML3 is involved in salty taste perception in primates including humans and likely other mammals (given the significance of sodium and other ions to physiological functions and conditions this phenotype is likely strongly conserved in different animals). The invention also relates to the discovery that the TRPML3 gene also modulates one or more of sodium metabolism, sodium excretion, blood pressure, fluid retention, cardiac function and urinary functions such as urine production and excretion. The invention also relates to transgenic animals that have been engineered to express or knock out TRPML3 expression and assays using TRPML3 expressing animals, cells and isolated ion channel polypeptides for identifying compounds that modulate TRPML3-associated functions including salty taste, sodium metabolism, sodium excretion, blood pressure, fluid retention, cardiac function and urinary functions such as urine production and excretion.05-07-2009
20090104612DETECTION OF BLOOD GROUP GENES - Disclosed herein are nucleic acid molecules which permit the accurate and direct determination of blood groups based on the presence of certain genes. A method of determining blood groups is also provided.04-23-2009
20100099111ANTIBODIES AGAINST A PROTEIN ENTITLED 161P2F10B - Antibodies and methods of using same against products of the gene designated 161P2F10B and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.04-22-2010
20090286234IL10 SNP ASSOCIATED WITH ACUTE REJECTION - The present invention concerns a method for the prediction of acute renal transplant rejection by detecting a poly-morphism in the promoter region of the IL 10 gene, optionally in combination with polymorphisms of the MDR1 and IMPDH2 genes which were found to be associated with this disease.11-19-2009
20100279294METHODS OF DETECTING AND GENOTYPING ESCHERICHIA COLI O157:H7 - A method for detecting and genotyping 11-04-2010
20090092994Reagents, methods and kits for classification of fungi and direction of anti-fungal therapy - Provided herein are methods, kits and compositions to classify fungi. Methods are provided for classification of fungi according to established phenotypes, for example, antimicrobial susceptibility profiles. More specifically, the invention provides methods for the use of PNA probes in diagnostic applications, which will aid in the direction of appropriate therapy against fungi.04-09-2009
20090092992Novel human dickkopf-related protein and nucleic molecules and uses therefor - Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.04-09-2009
20090092991Assays, methods and systems for predicting follicular lymphoma outcome - Assays, kits, methods and systems for predicting outcome in patients with follicular lymphoma based upon measurement of one or more phenomenologically competitive or synergistic gene pairs or a set of classifier genes are provided.04-09-2009
20090092974Micrornas differentially expressed in leukemia and uses thereof - The present invention concerns methods and compositions for identifying a miRNA profile for acute myeloid leukemia (AML), and using the profile in assessing the condition of a patient.04-09-2009
20090092973Grading of Breast Cancer - Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer.04-09-2009
20090092990PRIMERS AND METHODS FOR THE DETECTION AND DISCRIMINATION OF NUCLEIC ACIDS - The present invention provides novel primers and methods for the detection of specific nucleic acid sequences. The primers and methods of the invention are useful in a wide variety of molecular biology applications and are particularly useful in allele specific PCR.04-09-2009
20090092988Modulating Gene Expression with agRNA and Gapmers Targeting Antisense Transcripts - Gene expression is selectively modulated in the genome of a mammalian cell determined to be in need thereof by determining the presence of an encoded antisense transcript overlapping a promoter of the target gene; contacting the transcript with an agRNA or gapmer complementary to a portion of the transcript upstream relative to the transcription start site of the gene; and detecting a resultant modulation of expression of the target gene.04-09-2009
20090092987Polymorphic Nucleic Acids Associated With Colorectal Cancer And Uses Thereof - The present invention provides compositions and methods for research, diagnostic, drug screening, and therapeutic applications related to colorectal cancer and related conditions. In particular, the present invention provides genetic variations in or associated with one or more of the STK38L, GPR45, TGFBRAP1, PADI3, IBRDC1, and/or GRK5 genes as being associated with such conditions.04-09-2009
20090092986Fluorescent Nucleobase Conjugates Having Anionic Linkers - Provided are nucleotide-dye conjugates and related compounds in which a dye is linked to a nucleobase directly or indirectly by an anionic linker. The anionic character of the linker is provided by one or more anionic moieties which are present in the linker, such as phosphate, phosphonate, sulfonate, and carboxylate groups. When the dye is a provided as a donor/acceptor dye pair, the anionic linker can be located between the donor and the acceptor, or between the nucleobase and either the donor or acceptor, or both. In one embodiment, conjugates of the invention provide enhanced electrophoretic mobility characteristics to sequencing fragments, e.g., for dideoxy sequencing using labeled terminators.04-09-2009
20090092985Screening tools for discovery of novel anabolic agents - The disclosure provides nucleic acids including the polynucleotide sequence of the human MAFbx core promoter involved in muscle specific expression. Also provided are reporters operably linked to a polynucleotide sequence including MAFbx transcription regulatory sequences, and constructs including polynucleotides that encode reporters and other polynucleotide sequences operably linked to the MAFbx core transcription regulatory sequence. Systems for identifying agents that inhibit muscle loss and/or increase muscle mass or tone are also provided.04-09-2009
20090092982METHODS AND COMPOSITIONS FOR INCREASING BIOLOGICAL MOLECULE STABILITY - The present invention relates to methods and compositions for enhancing folding and stability of biological molecules. In particular, the present invention relates to methods and compositions for identifying biological molecules with enhanced stability. The present invention further relates to host cells that confer enhanced stability to biological molecules expressed therein.04-09-2009
20090092981TETRAHYDROPYRAN NUCLEIC ACID ANALOGS - The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, tetrahydropyran nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.04-09-2009
20090092979METHODS FOR ISOLATING LONG FRAGMENT RNA FROM FIXED SAMPLES - The present invention relates to methods for the extraction of long fragment RNA from fixed tissue specimens. In particular, the present invention relates to methods for the extraction of RNA from formalin-fixed paraffin-embedded tissue specimens for use in biologic applications, including assays based on oligonucleotide hybridization.04-09-2009
20090092978ASSOCIATION OF UQCRC1SNPs WITH FAT DEPOSITION AND FATTY ACID COMPOSITION - The present invention relates to the identification of single nucleotide polymorphisms (SNPs) in a ubiquinol-cytochrome c reductase core protein I (UQCRC1) gene and its associations association with fat deposition and fatty acid composition. The invention further encompasses methods and systems, including network-based processes, to manage the SNP data, haplotype data and other data relating to specific animals and herds of animals, veterinarian care, diagnostic and quality control data and management of livestock which, based on genotyping, have predictable meat quality traits, husbandry conditions, animal welfare, food safety information, audit of existing processes and data from field locations.04-09-2009
20090092977MASS SPECTROMETRIC METHODS FOR DETECTING MUTATIONS IN A TARGET NUCLEIC ACID - Fast and highly accurate mass spectrometry-based processes for detecting particular nucleic acid molecules and mutations in the molecules are provided.04-09-2009
20090092972Method of evaluating drug sensitivity by analyzing girk channel genes - A method of evaluating drug sensitivity or disease vulnerability, includes linking a gene polymorphism in a GIRK channel gene or a haplotype comprising the gene polymorphism to individual drug sensitivity or individual disease vulnerability.04-09-2009
20090092971Method for Detecting p53 Dysfunction, Method for Molecular Diagnosis of Cancer and Method for Evaluating Compound Effective in Treating Cancer - The present invention relates to methods for detecting a dysfunctional cancer suppressing gene, particularly p53. In other aspects, the invention provides methods for diagnosing cell proliferative disorders such as cancer by measuring expression of a predetermined target gene. Methods of evaluating the efficacy of a test compound to treat a cell proliferative disorder are also included. Such methods generally rely on the expression levels of a predetermined or targeted gene.04-09-2009
20090092970COMPOSITION AND METHOD FOR NUCLEIC ACID SEQUENCING - The present invention provides compositions and methods for detecting incorporation of a labeled nucleotide triphosphate onto the growing end of a primer nucleic acid molecule. The method is used, for example, to genotype and sequence a nucleic acid. In a preferred embodiment, the method described herein detects individual NTP molecules.04-09-2009
20090092968SCREENING METHOD FOR MYCOBACTERIA IN METAL REMOVAL FLUID SYSTEMS - One embodiment of the invention includes a method for testing a fluid for contamination by a mycobacterial organism. A plurality of individual standardized samples may be acquired from a plurality of predetermined sampling points and pooled into a pooled sample. The pooled sample may be analyzed using a polymerase chain reaction technique and the results compared against a pool concern level which is calculated from an individual concern level that governs each individual standardized sample.04-09-2009
20090092989MICROFLUIDIC PLATFORMS FOR MULTI-TARGET DETECTION - Disclosed are example methods and devices for detecting one or more targets. An example method includes placing a sample including a first target with in a microfluidic device and hybridizing a plurality of copies of the first target with a plurality of nanostructures. The example method includes applying an electric current to the plurality of nanostructures and using an electric field created by the electric current to move the plurality of nanostructures. In addition, the plurality of nanostructures are sorted and evaluated to determine at least one of a presence, an absence, or a quantity of the first target.04-09-2009
20090305272METHOD OF CHARACTERIZING ENDOGENOUS POLYNUCLEOTIDE-POLYPEPTIDE INTERACTIONS - A method for characterizing an endogenous polypeptide includes introducing epitope tag-encoding polynucleotide into an endogenous locus of a somatic cell by homogenous recombination mediated knock-in so that an epitope tagged endogenous polypeptide is expressed by the cell, and characterizing the epitope tagged endogenous polypeptide using an immunoassay.12-10-2009
20090111093Methods and compositions for pre-symptomatic or post-symptomatic diagnosis of alzheimer's disease and other neurodegenerative disorders - Methods, compositions and apparatus (e.g., test kits, test systems, reagents, related computer software, calculators, etc.) for pre-symptomatic or post-symptomatic diagnosis of Alzheimer's Disease or other disorders associated with the formation of β-amyloid deposits (e.g., plaques) and/or β-amyloid fibrils. Also, methods, compositions and apparatus assessing the efficacy of treatments for such disorders. Sample cells, tissue or body fluid are obtained from a human or animal subject and analyzed to determine whether or to what extent certain mitochondrial DNA control region (mtDNA CR). Significantly elevated numbers of these mtDNA CR mutations may indicate that the subject suffers from, or is at increased risk for development of, Alzheimer's Disease or other disorders associated with the formation of β-amyloid deposits (e.g., plaques) and/or β-amyloid fibrils. A significant decrease in the numbers of these mtDNA CR mutations during treatment for the disorder may indicate that the treatment is effective.04-30-2009
20110039263PLANTS HAVING ALTERED AGRONOMIC CHARACTERISTICS UNDER NITROGEN LIMITING CONDITIONS AND RELATED CONSTRUCTS AND METHODS INVOLVING GENES ENCODING LNT2 POLYPEPTIDES AND HOMOLOGS THEREOF - Isolated polynucleotides and polypeptides and recombinant DNA constructs particularly useful for altering agronomic characteristics of plants under nitrogen limiting conditions, compositions (such as plants or seeds) comprising these recombinant DNA constructs, and methods utilizing these recombinant DNA constructs. The recombinant DNA construct comprises a polynucleotide operably linked to a promoter functional in a plant, wherein said polynucleotide encodes an LNT2 polypeptide.02-17-2011
20110039261MOBILE RAPID TEST SYSTEM FOR NUCLEIC ACID ANALYSIS - A mobile rapid test system for nucleic acid analysis. A method comprising the steps of amplification of the nucleic acids by means of rapid-PCR technology, conversion of a double-stranded amplification product into a single-stranded DNA fragment, hybridization with a labeled probe and detection of the nucleic acids on a lateral-flow test strip. A device comprising a reaction cavity which preferably consists of a thin film, inlet and outlet openings for the reaction cavity, one or more heatable sample blocks which are connected to miniaturized cooling bodies and a window for reading off the result. The lateral-flow test strip is a component of the mobile rapid test system. Operation of the instrument system requires no external power source, but only batteries or a rechargeable battery.02-17-2011
20100136561Genetic Markers for Weight Management and Methods of Use Thereof - This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subject's metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subject's metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subject's responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information.06-03-2010
20110059448COMPOSITIONS AND METHODS FOR DETERMINING CANCER STEM CELL SELF-RENEWAL POTENTIAL - In alternative embodiments, the invention provides compositions and methods for determining the self-renewal potential of a cancer stem cell (CSC) through analysis of the cross-talk between cell self-renewal pathways leading to deregulation and enhanced self-renewal of the CSC, or for predicting the drugability (susceptibility to a drug) of a CSC, and/or for predicting the progression of a cancer that corresponds to the CSC, the method comprising detecting and quantifying in CSCs one or more B-cell lymphoma-2 (Bcl-2) family protein isoform(s) or transcripts (mRNAs, messages) encoding one or more Bcl-2 family protein(s) or protein isoform(s) thereof. In alternative embodiments, the invention provides compositions and methods to determine and measure the levels of Wnt, glycogen synthase kinase-3 beta (GSK-3 beta), glycogen synthase kinase-3 alpha (GSK-3 alpha), and/or Sonic Hedgehog Homolog (SHH or Shh) family proteins and alternatively spliced transcripts (mRNAs), and Wnt, GSK3beta, GSK3alpha and/or Shh family protein and alternatively spliced transcript ratios in cancer cells, e.g., stem cells, e.g., CSCs, for diagnostic, drug discovery and prognostic purposes.03-10-2011
20110059445MUCOSAL GENE SIGNATURES - Infliximab (IFX) is an effective treatment for Crohn's disease (CD) and ulcerative colitis (UC) not responding to standard therapy. Thirty percent to forty percent of patients however do not improve and the response is often incomplete. We identified mucosal gene signatures predictive of response to EFX using high-density oligonucleotide arrays. Eight UC patients and twelve CD patients showed healing. In UC, only one probe set was differentially expressed in responders compared with non-responders, i.e., IL-13R(alpha)2. At PAM analysis, two probe sets, representing IL-13Ralpha2 and IL-I 1, separated IBD responders from non-responders with an overall misclassification error rate of 0.046 (2/43), with 100% sensitivity and 91.3% specificity. The IL-13R(alpha)2 probe set was a top-ranked probe set in all our analyses using both LIMMA and PAM strategies. Our gene array studies of mucosal biopsies identified IL-13R(alpha)2 in IBD as a predictor of response or non-response to IFX.03-10-2011
20110059441METHOF OF PRODUCING BIOACTIVE PAPER - The present disclosure relates to methods for attaching bioactive agents to paper products by contacting the paper with a solution comprising colloidal support particles where said colloidal support particles are associated with bioactive agents. In specific embodiment of the disclosure, the colloidal support particles are functionalized poly(N-isopropylacrylamide) microgels. The disclosure further covers the bioactive paper produced by this method as well as uses thereof, in particular for pathogen detection.03-10-2011
20110059435 Methods for Beaming - Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutations in DNA isolated from plasma of cancer patients.03-10-2011
20110059434P13k pathway mutations in cancer - Given the important role of protein kinases in pathways affecting cellular growth and invasion, we have analyzed 340 serine/threonine kinases for genetic mutations in colorectal cancers. Mutations in eight genes were identified, including three members of the phosphatidylinositol-3-kinase (PI3K) pathway; the alterations in the latter genes each occurred in different tumors and did not overlap with mutations in PIK3CA or other non-serine-threonine kinase (STK) members of the PI3K pathway, suggesting that mutations in any of these genes had equivalent tumorigenic effects. These data demonstrate that the PI3K pathway is a major target for mutational activation in colorectal cancers and provide new opportunities for therapeutic intervention.03-10-2011
20110014625System and Method for Determining the Health of a Subject Using Polymorphic Risk Markers - A system and method for predicting the health of a subject comprising obtaining nucleic acid sequence data about the subject. Identifying at least one polymorphic risk marker associated with a change in promoter methylation of a gene associated with lung cancer; and predicting the health of the subject from a presence of at least one polymorphic risk marker identified and kits associated therewith.01-20-2011
20110014624Methods For Identifying Cells Suitable For Large-Scale Production of Recombinant Proteins - The present invention provides methods of identifying a clonal population of cells suitable for large-scale production of a protein of interest. The invention further provides methods for high-throughput screening for genetic rearrangements in the gene encoding the protein of interest, whereby the absence of a deletion in the gene encoding the protein of interest indicates that the cell is suitable for large-scale production of the protein of interest.01-20-2011
20110014622GENETIC REFERENCE MATERIALS - The invention provides a genetic reference standard with at least one human genetic reference sequence (having a human DNA sequence containing at least one genetic variant whose presence in the DNA of a human subject is indicative of a pathological condition, a predisposition to a pathological condition, or a predisposition to an adverse reaction to external stimuli, or is indicative of a patient's likely response to a therapeutic intervention, i.e. a variant used in pharmacogenomic analysis) cloned into a non-mammalian animal cell line. There are also provided such reference standards where the human DNA is targeted to specific location in the host genome, using homologous recombination. The invention further provides a method of detecting a genetic variant using such reference standards.01-20-2011
20110014619REACTION TREATMENT APPARATUS AND REACTION TREATMENT METHOD - Provided is a reaction treatment apparatus in which, in a case of mixing a plurality of solutions in a microchip used in a biochemical reaction system, an electric field generation area for changing solute concentration distribution in the solutions is provided in a solution upstream fluid path. Diffusion between the solutions is accelerated by bringing an area with a high solute concentration into contact with another solution. This may shorten a time required for mixing the solutions.01-20-2011
20110014618DETECTION OF NUCLEIC ACIDS AND PROTEINS - The invention generally relates to methods for detecting a target nucleic acid and a target protein in a single assay.01-20-2011
20110014617Methods and Systems for Detecting Nucleic Acids - Methods and kits for detecting a target nucleic acid in a sample are described. In some embodiments, the sample to be analyzed includes a primer which hybridizes to at least a portion of the target nucleic acid, a probe having a first region which hybridizes to at least a portion of the target nucleic acid and a second region having a detectable label, a polymerase which extends the hybridized primer and an enzyme comprising nuclease activity that can cleave the hybridized hybridization probe to thereby release a labeled probe fragment. In some embodiments, the sample can then be contacted with a solid support comprising surface bound capture probes which can hybridize to the labeled probe fragment(s). These capture probes more readily bind to the probe fragment(s) than to the intact hybridization probe. The label can then be detected on the support surface. In this manner, improved discrimination between the probe fragments and the intact hybridization probes can be achieved.01-20-2011
20110014616Rapid screening of biologically active nucleases and isolation of nuclease-modified cells - Disclosed herein are methods and compositions for rapidly identifying active nucleases and cells having nuclease-mediated genomic modifications.01-20-2011
20110014615METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCERS BY tRNA-DIHYDROURIDINE SYNTHASE ACTIVITY OF URLC8 - The present invention features a method for determining t-RNA dihydrouridine-synthase activity of a polypeptide and screening for modulators of t-RNA dihydrouridine-synthase activity. The present invention further provides methods or pharmaceutical compositions for preventing and/or treating non-small cell lung cancer (NSCLC) using such modulators. Furthermore, the present invention provides methods for diagnosing non-small cell lung cancer (NSCLC) using the t-RNA dihydrouridine-synthase activity of IMS-E21 (URLC8) protein as an index. The present invention further provides methods for predicting and prognosing lung squamous-cell carcinoma (SCC).01-20-2011
20110014614Method of profiling gene expression in a subject having an infectious disease - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.01-20-2011
20110014613Genotyping for Risk of Atherosclerosis - The invention provides a kits, compositions and methods useful for determining atherosclerotic risk in a subject. In one aspect, the invention provides kit comprising a solid support comprising a capture probe set comprising a plurality of probes selected from (a) a probe selective for PTGS1, (b) a probe selective for PTGS2, (c) a probe selective for NOS3, (d) a probe selective for SERPINE1, (e) a probe selective for F5, (f) a probe selective for MTHFR, (g) a probe selective for ALOX5AP, (h) a probe selective for CETP, (i) a probe selective for APOE, (j) a probe selective for F2, (k) a probe selective for ACE, (l) a probe selective for LTA and (m) a probe selective for LPL.01-20-2011
20110014612POLYMERASE COMPOSITIONS & METHODS - Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.01-20-2011
20110014611DESIGN AND SYNTHESIS OF CLEAVABLE FLUORESCENT NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCES BY SYNTHESIS - This invention provides novel azido linkers for deoxynucleotide analogues having a detectable marker attached thereto.01-20-2011
20110014609NUCLEIC ACID SIGNAL ENHANCEMENT USING NANOPARTICLE-BASED HYBRIDIZATION - A method of enhancing signal detection through use of nanoparticle-conjugated nucleic acid probes is provided. Following chromosomal FISH hybridization of a target sequence with a genomic probe linked to a flag sequence, the flag sequence is hybridized to an anti-flag sequence conjugated to a nanoparticle. The enhanced fluorescent probe is then visualized using microscopy.01-20-2011
20110014608SCREENING FOR CD93 (C1qRp)-ASSOCIATED POLYMORPHISM(S) IN THE DIAGNOSIS, PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES - This invention is directed to a marker gene for autoimmune disease. Specifically, the invention is directed to the use of a polymorph of CD93 in methods and compositions for the detection, prognosis and therapy of Type I Diabetes and systemic lupus erythematosus (SLE).01-20-2011
20110014606Assays - A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative of the presence and/or amount of the target molecules, a micro fluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the micro fluidic network.01-20-2011
20110014604METHODS FOR SEQUENCE DETERMINATION - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system.01-20-2011
20110014603TARGETS FOR USE IN DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCER - Provided herein are targets that can be used for the diagnosis, prognosis and therapy of a variety of cancers.01-20-2011
20110014602Diagnostic composition for hepatocellular carcinoma, a diagnostic kit comprising it and diagnostic methods of hepatocellular carcinoma - In the present invention, it is confirmed that cystatin B (cystatin B, CSTB) can be used as a diagnostic marker for hepatocellular carcinoma. Accordingly, the invention relates to a method for early diagnosing hepatocellular carcinoma using the cystatin B as a diagnostic marker for hepatocellular carcinoma, a method for determining the progression or prognosis of hepatocellular carcinoma according to the CSTB expression level, and a method for applying to the prevention or treatment of hepatocellular carcinoma by adjusting the cystatin B expression.01-20-2011
20090298086PLANT FARNESYLTRANSFERASES - This invention relates to an isolated nucleic acid fragment encoding a farnesyltransferase subunit. The invention also relates to the construction of a chimeric gene encoding all or a portion of the farnesyltransferase subunit, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the farnesyltransferase subunit in a transformed host cell.12-03-2009
20090298080METHODS AND REAGENTS FOR DETECTING CpG METHYLATION WITH A METHYL CpG BINDING PROTEIN (MBP) - The present invention provides a simple and sensitive technology for the detection of CpG methylation in DNA without chemical modification of sample DNA by bisulfite treatment or PCR amplification. Signal generation is based on an Abscription (Abortive Transcription) technology in which DNA signal generators called Abortive Promoter Cassettes (APCs) are bound to target mCpG sites via mCpG target specific probes based on methyl binding polypeptides or methyl binding domains thereof. RNA polymerase produces uniform, short RNA molecules from synthetic promoters in APCs as signals of the presence of methylated CpGs. Detection of CpG methylation and hypermethylation of DNA targets such as CpG islands provides a convenient means for detecting and monitoring cancer in a subject.12-03-2009
20090298078METHOD FOR THE DETECTION OF AN ACTIVATION OF THE IMMUNE SYSTEM OR THE EXTENT OF CELL DEATH - The present invention relates to a method for the detection of an activation of the immune system, preferably in the sense of an NET formation, or the extent of cell death in a non-tumorous tissue or in a body fluid, wherein free DNA is measured in a sample from an individual. Furthermore, the invention relates to a method for the production of a kit for the detection of an activation of the immune system or the extent of cell death in an individual, comprising the packaging of a fluorescent dye and a DNA standard in at least one container.12-03-2009
20090298075COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING - Compositions and methods for nucleic acid sequencing include template constructs that comprise double stranded portions in a partially or completely contiguous constructs, to provide for redundant sequence determination through one or both of sequencing sense and antisense strands, and iteratively sequencing the entire construct multiple times. Additional sequence components are also optionally included within such template constructs. Methods are also provided for the use and preparation of these constructs as well as sequencing compositions for their application.12-03-2009
20090298068METHOD AND TEST KIT FOR THE DIAGNOSIS AND/OR MAKING PREDICTIONS ABOUT AND/OR FOR THE ASSESSMENT OF THE EFFICACY OF THERAPEUTIC AGENTS FOR THE TREATMENT OF OVARIAN CANCER AND METHOD OF PLANNING A REGIMEN FOR THE TREATMENT OF OVARIAN CANCER - The invention relates to a method and a test kit for diagnosing ovarian cancer and/or making predictions in case of ovarian cancer as well as a method for estimating the effectiveness of therapeutic agents during the treatment of ovarian cancer, the promoter hypermethylation of the TUSC3 marker in a biological sample that is to be analyzed, preferably in a tissue sample or biological liquid that is to be analyzed, being measured. The result of said method can be used for planning an ovarian cancer treatment.12-03-2009
20090298052Diagnosing or Predicting the Course of Breast Cancer - A method of diagnosing the presence or predicting the course of breast cancer by measuring the expression of a combination of Marker genes comprising a tissue-specific gene and a non-tissue specific gene in a cell or tissue sample derived from a patient. In one aspect of the invention, the genes are mammaglobin and CK19. Kits, nucleic acid primers and probes and controls are provided.12-03-2009
20090291440METHOD FOR SYNTHESIZING NUCLEIC ACID USING DNA POLYMERASE BETA AND SINGLE MOLECULE SEQUENCING METHOD - The present invention provides a nucleic acid synthesis method capable of continuously carrying out an extension reaction and a single molecule sequencing method capable of obtaining base information accurately at high speed. A method for synthesizing a nucleic acid, including the steps of: forming a complex of a target nucleic acid hybridized to a primer oligonucleotide and a DNA polymerase β; allowing the DNA polymerase β to incorporate a fluorescently-labeled dNTP so that the fluorescently-labeled dNTP is bound to the 3′ end of the primer oligonucleotide; and allowing the DNA polymerase β to continuously incorporate fluorescently-labeled dNTP to extend a nucleic acid complementary to the target nucleic acid from the 3′ end of the bound fluorescently-labeled dNTP. A method for sequencing a single nucleic acid molecule, including the steps of said method for synthesizing a nucleic acid, wherein fluorescence emitted from each of the fluorescently-labeled dNTP incorporated into the DNA polymerase β is sequentially detected to carry out the sequencing of the target nucleic acid.11-26-2009
20090023141METHOD FOR DETECTING BACTERIA OF THE GENUS MYCOBACTERIUM (ACID-FAST BACTERIA) AND KIT FOR THE SAME - An object of the present invention is to provide an oligonucleotide for rapidly and conveniently detecting bacteria of the genus 01-22-2009
20090286254GENE SILENCING - Methods are disclosed for screening for the occurrence of gene silencing (e.g., post transcriptional gene silencing) in an organism. Also provided are methods for isolating silencing agents so identified.11-19-2009
20090286251Enzyme Reagents for Amplification of Polynucleotides in the Presence of Inhibitors - Compositions and methods are provided for amplifying polynucletoides from samples containing inhibitors that normally inhibit amplification using an enzyme blend containing a plurality of polymerases. The ability to amplify polynucleotides efficiently in the presence of inhibitors allows the enzyme reagent to be used in both routine amplification and real-time amplification from inhibitor-containing samples.11-19-2009
20090286236Method for detecting cell proliferative disorders - The present invention relates to the detection of a cell proliferative disorder associated with alterations of microsatellite DNA in a sample. The microsatellite DNA can be contained within any of a variety of samples, such as urine, sputum, bile, stool, cervical tissue, saliva, tears, or cerebral spinal fluid. The invention is a method to detect an allelic imbalance by assaying microsatellite DNA. Allelic imbalance is detected by observing an abnormality in an allele, such as an increase or decrease in microsatellite DNA which is at or corresponds to an allele. An increase can be detected as the appearance of a new allele. In practicing the invention, DNA amplification methods, particularly polymerase chain reactions, are useful for amplifying the DNA. DNA analysis methods can be used to detect such a decrease or increase. The invention is also a method to detect genetic instability of microsatellite DNA. Genetic instability is detected by observing an amplification or deletion of the small, tandem repeat DNA sequences in the microsatellite DNA which is at or corresponds to an allele. The invention is also a kit for practicing these methods.11-19-2009
20090286242MicroRNA Expression Profiling and Uses Thereof - Provided are methods and reagents for obtaining microRNA expression profiles in selected cell populations or sub-populations, such as stem cell or progenitor cell populations, and using such microRNA expression profiles for cell characterization, isolation/purification, and/or reinforcement of cell fate specification, both in research & development, and in therapeutic applications. Also provided are methods of identifying and isolating mammary progenitor cells using miRNA sensor constructs.11-19-2009
20090269739Kit for detection of telomerase reverse transcriptase nucleic acids - The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.10-29-2009
20090275041NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 193P1E1B USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 0193P1E1B (also designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 193P1E1B can be used in active or passive immunization.11-05-2009
20090275018Detection of hepatotoxic cyanobacteria - The present invention relates to methods and kits for the detection of toxic cyanobacteria, in particular of hepatotoxin-producing cyanobacteria.11-05-2009
20090275021NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS - Novel splice variants, amino acid sequences and nucleotide sequences thereof, and methods of using same.11-05-2009
20090269775PROGNOSTIC MARKERS FOR CLASSIFYING COLORECTAL CARCINOMA ON THE BASIS OF EXPRESSION PROFILES OF BIOLOGICAL SAMPLES - The invention relates to the use of gene expression profiles for predicting the probability of recurrence or metastases to develop in remote organs of patients from which a primary colon carcinoma has been removed.10-29-2009
20090269774EVALUATION OF EOSINOPHILIC ESOPHAGITIS - A method to evaluate eosinophilic esophagitis based on information in an eosinophilic esophagitis transcriptome.10-29-2009
20090269773METHODS OF DETERMINING THE HEALTH STATUS OF AN INDIVIDUAL - Methods of determining health status based on analysis of single cells in a sample or set of samples from an individual are described.10-29-2009
20090269772SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST - Systems, methods, and apparatus for searching for a combination of compounds of therapeutic interest are provided. Cell-based assays are performed, each cell-based assay exposing a different sample of cells to a different compound in a plurality of compounds. From the cell-based assays, a subset of the tested compounds is selected. For each respective compound in the subset, a molecular abundance profile from cells exposed to the respective compound is measured. Targets of transcription factors and post-translational modulators of transcription factor activity are inferred from the molecular abundance profile data using information theoretic measures. This data is used to construct an interaction network. Variances in edges in the interaction network are used to determine the drug activity profile of compounds in the subset of compounds. The drug activity profiles are used to form a filter set of compound combinations from the subset of compounds.10-29-2009
20090269771METHOD OF SEQUENCING AND MAPPING TARGET NUCLEIC ACIDS - The present teachings pertain to methods, compositions, reaction mixtures, and kits for mapping a low complexity sequence to a locus in a genome. In some embodiments, the low complexity sequence can be used to determine the methylation profile of a target nucleic acid. A strand-replacing reaction results in a product containing a first strand and a second strand, which can be connected together with a stem-loop adapter to form a single strand. A sequencing reaction can compare the two strands of the product, allowing the experimentalist to both map the sequence to a locus in a reference genome, as well as ascertain the methylation profile of the original target nucleic acid.10-29-2009
20090269769Drug Discovery Methods Involving A Preclinical, In Vitro Isolated Gastrointestinal Epithelial Stem Cell-Like Progenitor Cell System - The described invention relate to systems comprising isolated human gastrointestinal segment-specific epithelial stem cell-like progenitor cells and uses thereof in drug discovery.10-29-2009
20090269768DETECTION OF HIGH GRADE DYSPLASIA IN CERVICAL CELLS - Methods of using probes and probe sets for the detection of high grade dysplasia and carcinoma in cervical cells are described. Methods of the invention include hybridizing one or more chromosomal probes to a biological sample obtained from a subject and detecting the hybridization pattern of the chromosomal probes to the sample to determine whether the subject has high grade dysplasia or carcinoma. Methods of the invention also include preliminary screening the cells for a marker associated with a risk for cancer, and preferably involves screening for HPV infected cells by in situ hybridization using an HPV probe mixture.10-29-2009
20090269764COMPOSITIONS AND METHODS FOR DETECTION OF PROPIONIBACTERIUM ACNES NUCLEIC ACID - Methods for amplifying and detecting 10-29-2009
20090269762Cotton event PV-GHGT07(1445) and compositions and methods for detection thereof - The present invention provides DNA compositions and assays for detecting the presence of the DNA compositions in PV-GHGT07(1445) cotton event based on the DNA sequence of the recombinant construct inserted into the cotton genome and of the genomic sequences flanking the insertion site. Kits and conditions useful in conducting the assays are provided.10-29-2009
20090269760ENRICHMENT METHODS FOR THE DETECTION OF PATHOGENS AND OTHER MICROBES - The present invention provides novel enrichment, testing and detection methods for detection of pathogens or other microbes in a food, water, wastewater, industrial, pharmaceutical, botanical, environmental samples and other types of samples analyzed by enrichment-detection methods. In preferred aspects, a sample is obtained at a first location and is diluted (e.g., in the case of a solid or semi-solid sample or liquid) at the first location at a ratio of about 1:0 (wt./vol.) to 1:2 (wt./vol.), or greater, preferably at a ratio of about 1:0.1 (wt./vol.) or greater, or more preferably, at a ratio of about 1:2 (wt./vol.) or greater. The diluted sample is incubated at an optimal temperature in an incubator and either tested locally, or sent in a shipping incubator to a second location that is a remote test location. The incubated sample is received and tested at the second location by assaying the sample, or a portion thereof, with an assay suitable to detect the pathogen or other microbe. In alternate embodiments, no dilution at the first location is required, and optionally minimal additions to adjust intrinsic deficiencies may be made, but the sample is nonetheless incubated during transit to the test location.10-29-2009
20090269767MICROFLUIDIC CHIP DEVICES AND THEIR USE - A microfluidic chip device (MCD) and its use for performing miniaturized assays on magnetic microbeads (MMs) are described. The MCD is particularly useful for carrying out miniaturized transcript analysis by aiding affinity capturing (TRAC) assays, including PCR. The MCD comprises at least one reaction chamber with sealable liquid connections and at least one fluidic pillar filter in each chamber. The fluidic pillar filter comprises rods with spacings allowing MMs to pass. The sealable liquid connections feed liquid to the reaction chamber, wherein air bubbles are removed. The liquid stream contacts the MMs, which are manipulated with a magnetic rod. The liquid connections enable trapping of the MMs behind the pillar filters or in the channel, while the liquid is changed.10-29-2009
20090269765Compositions And Methods For Detection Of Small Molecules Using Dyes Derivatized with Analyte Responsive Receptors in a Chemiluminescent Assay - Compositions, methods, and systems for detecting small molecules using chemiluminescent signaling assay technology are provided. One system provided herein comprises a chromophore; an oxalate ester, a peroxide, and a modulating agent, wherein the modulating agent will perturb a chemiluminescent signal generated by an interaction among the chromophore, the oxalate ester, and a peroxide; and the perturbation will occur in response to an analyte. One method provided herein comprises combining a chromophore, an oxalate ester, a peroxide, and a modulating agent, wherein: the modulating agent will perturb a chemiluminescent signal generate by an interaction among the chromophore, the oxalate ester, and a peroxide; and the perturbation will occur in response to an analyte. Another method provides a calorimetric or fluorometric signal response in the presence of an analyte.10-29-2009
20090269758Diagnostic methods and kits for functional disorders - The present invention relates to methods for the diagnosis of functional disorders in humans. A method of the invention, in certain embodiments, comprises the detection of one or more polymorphisms in mitochondrial DNA of a human. The current invention further provides kits for use in a method of the invention.10-29-2009
20090269757DIAGNOSIS KITS AND METHOD FOR DETECTING CANCER USING POLYMORPHIC MINISATELLITE - The present invention relates to a kit and a method for diagnosing cancer using polymorphic minisatellites (MS), more specifically, relates to a primer set for detecting polymorphic minisatellites MUC2-MS6 or MUC2-MS7 in the MUC2 gene, a DNA typing kit comprising said primer set, and a kit and a method for diagnosing cancer using a primer set for detecting polymorphic minisatellites MUC2-MS6, MUC2-MS7 or hTERT-VNTR 2-2. According to the present invention, DNA typing of MUC2-MS6 and MUC2-MS7 can effectively achieve the parentage identification, kinship identification or medicolegal examination, because the polymorphic minisatellites MUC2-MS6 and MUC2-MS7 are inherited through meiosis according to Mendelian genetics. In addition, the polymorphic minisatellites MUC2-MS6, MUC2-MS7 and hTERT-VNTR 2-2 can be used to predict and diagnose various cancers; such as gastric cancer, colon cancer, rectal cancer and prostate cancer etc.10-29-2009
20090269756PRIMER SET FOR AMPLIFYING CYP2C19 GENE, REAGENT FOR AMPLIFYING CYP2C19 GENE CONTAINING THE SAME, AND THE USES THEREOF - Primer sets for amplifying target regions containing sites to be detected in the CYP2C19 gene by a gene amplification method are provided, wherein the primer sets can amplify the regions specifically. Two pairs of primer sets are used including forward primers consisting of the base sequences of SEQ ID NOs: 12 and 32 as well as reverse primers consisting of the base sequences of SEQ ID NOs: 22 and 48, respectively. The use of these primer sets makes it possible to amplify two target regions including parts where two types of polymorphisms (CYP2C19*2 and CYP2C19*3) of the CYP2C19 gene are generated, respectively, in the same reaction solution at the same time.10-29-2009
20090269755MEANS AND METHOD FOR INDUCING EXON-SKIPPING - In the present invention means and method are provided for optimising exon-skipping using exon-internal AON. We show that skipping efficiencies are improved by targeting putative splicing regulatory sequences (ESEs) within an exon. Such double targeting may be particularly useful for exons with which efficient skipping was difficult to obtain prior to the invention.10-29-2009
20090269754METHOD OF PRODUCING AMPLIFICATION PRODUCT BY PCR AND USAGE THEREOF - A method of producing a PCR amplification product is provided that suppresses an effect of precipitate, turbidity, or the like derived from a whole blood sample on a detection in the detection of an amplified nucleic acid by an optical unit. The amplification product complementary to a target nucleic acid in the whole blood sample is produced by PCR in a condition where a ratio of the whole blood sample in a PCR reaction solution is in the range of 0.1 to 0.9% by volume or 0.01 to 1.8 g/L in term of hemoglobin content. When the PCR is carried out with such conditions, even with an untreated whole blood sample, a monitoring of the amplification product by the optical unit can be done while suppressing the effect of the precipitate or the turbidity.10-29-2009
20090269753GENOTYPING FOR SRC-1 PREDICTS FOR BONE LOSS - Osteoporosis is a common skeletal disease characterized by loss of bone mineral density (BMD) and increased risk of fracture. Osteoporosis most commonly occurs in postmenopausal women due to estrogen deficiency. We identified 3 genetic variants in steroid receptor coactivator 1 (SRC-1) that are significantly associated with a decrease in BMD in women. We characterized a functional variant in exon 18 of SRC-1 that is associated with increased loss of bone mineral density in women who received tamoxifen for treatment or prevention of breast cancer. In vitro experiments show that this variant decreases estrogen receptor alpha response (ER-alpha) to hormone, suggesting an attenuated response to endogenous and exogenous hormones in the bone of these women, and therefore a need for additional bone protective measures.10-29-2009
20090269752METHOD FOR SELECTING NUCLEIC ACIDS THAT BOND WITH HIGH-AFFINITY TO A TARGET - The invention relates to a method for selecting nucleic acids that bond with high affinity to a target molecule from a mixture of nucleic acids, comprising the following steps: a) loading a column with the target molecules whereby the target molecules are immobilized in said column, b) feeding the mixture of nucleic acids into a first end of the column, to create a defined volumetric flow of medium through the column, running from the first end to the second end of said column, c) immobilizing the nucleic acids to the target molecule wherein an affinity of the nucleic acids to the target molecule decreases as the distance from the first end of the column increases, d) stopping the volumetric flow of medium through the column after a defined period of time, e) cutting the column into column segments, and allocating a routing co-ordinate to each segment, and f) identifying and collecting nucleic acids that bond with a high affinity to the target molecule by desorbing the immobilized nucleic acids from at least one segment in a non-specific manner and extracting the nucleic acids, wherein the routing co-ordinate allocated a segment in step e) is allocated to the nucleic acids desorbed from that segment.10-29-2009
20090269751DOT1 HISTONE METHYLTRANSFERASES AS A TARGET FOR IDENTIFYING THERAPEUTIC AGENTS FOR LEUKEMIA - The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.10-29-2009
20090269750MARKER AND METHOD FOR CANCER DIAGNOSIS - The present invention relates to a diagnostic cancer marker using variation of a granulocyte colony stimulating factor (G-CSF) gene and a method for preparing the same, and more specifically, relates to a method for diagnosing cancer and/or assessing the state of cancer progression using an oligonucleotide having the 3′-terminal end of exon 2 region linked to the 5′-terminal end of exon 4 region of a G-CSF gene as a diagnostic cancer marker. According to the present invention, cancer can be quickly and exactly diagnosed using variation in a G-CSF gene expression.10-29-2009
20090269749METHOD FOR HIGH-THROUGHPUT AFLP-BASED POLYMORPHISM DETECTION - The invention relates to a method for the high throughput discovery, detection and genotyping of one or more genetic markers in one or more samples, comprising the steps of restriction endonuclease digest of DNA, adaptor-ligation, optional pre-amplification, selective amplification, pooling of the amplified products, sequencing the libraries with sufficient redundancy, clustering followed by identification of the genetic markers within the library and/or between libraries and determination of (co-) dominant genotypes of the genetic markers.10-29-2009
20090269748IDENTIFICATION OF SUBSTANCES THAT INHIBIT NEMO OLIGOMERIZATION - The present invention provides methods for screening for substances which inhibit the oligomerization of NEMO and/or IKK-related complexes and/or signaling pathways based on the interference with NEMO oligomerization10-29-2009
20090269747Marker Genes Based on Amiodarone Treatment for Screening of Drug Inducing Toxicity and Screening Method Therefor - The present invention relates to a marker gene for screening of drug candidates inducing pulmonary toxicity and a screening method using the same, more precisely a marker gene up- or down regulated by amiodarone which is a drug inducing pulmonary toxicity and a method for screening drug candidates inducing pulmonary toxicity using the same. The marker gene of the present invention can be effectively used for monitoring and identifying drugs or chemical having high risk of inducing pulmonary toxicity and can be used as an effective tool for examining the mechanism of amiodarone which causes pulmonary toxicity and side effects.10-29-2009
20090269746MICROSEQUENCER-WHOLE GENOME SEQUENCER - The method and apparatus are disclosed to support speedy sequencing of genomes of individuals. The method comprises random digestion of a stretch of DNA; adaptor ligation of adaptor DNA fragments to DNA segments produced in random digestion, each said adaptor DNA fragment containing a sequence which is complementary to a single DNA primer; PCR amplification of the ligated segments produced in adaptor ligation, utilizing a single DNA primer; distributing the ligated segments into one or more pre-defined isolated locations of a sequencing apparatus, each said location containing DNA fragments placed there for capturing a unique kind of digested DNA segments; capturing at each location a unique kind of amplified DNA segments by hybridization with the DNA fragments, dislodging captured DNA segments from DNA fragments; adding DNA sequencing reaction components into the locations; performing sequencing reactions at each location; separating the products of the sequencing reactions in the sequencing apparatus; and determining the sequences of DNA segments captured at individual locations of the sequencing apparatus. The apparatus comprises one or more isolated locations, each location has a reservoir containing DNA fragments placed there for capturing a unique kind of DNA segments from a DNA solution after dispensing the DNA solution into the reservoir; one or more channels performing DNA separation according to size, said channels being associated with one or more reservoirs; one or more gates controlling the flow of substances in the reservoirs; an optical system which induces fluorescence excitation in, and detects fluorescence emission in the channels; and a computer to produce DNA sequence data.10-29-2009
20090269745RNA EXTRACTION METHOD AND RNA DETECTION METHOD - The present invention provides a method for inactivating RNase which generally presents in a sample such as biological sample (especially an excrement sample), or in a sample such as a living body-derived sample (especially an excrement-derived sample) obtained by separation of an RNA-including body therefrom or the like; a method for extracting and detecting RNA from the sample. An RNA extraction method, comprising the steps of: obtaining a mixture under a heating condition, said mixture comprising: a sample comprising an RNA-including body and RNase, and an alkaline treating reagent comprising at least a reducing agent, and having pH of 8.1 or higher, and conducting inactivation of the RNase and extraction of RNA from the RNA-including body by keeping the mixture under the heating condition. An RNA detection method, comprising conducting RNA amplification reaction by mixing a treated sample liquid comprising RNA extracted by the extraction method and an amplification reaction solution.10-29-2009
20090269744CANCER DETECTION METHOD - The present application concerns methods and compositions which can be used to detect cancer in mammals, in particular in humans. It notably describes serum markers of cancers and their uses in diagnosis methods. It also concerns tools and/or kits which can be used to implement these methods (reagents, probes, primers, antibodies, chips, cells, etc.), their preparation and their uses. The invention can be used to detect the presence or the progression of a cancer, particularly breast cancer, including at an early stage.10-29-2009
20090269743DNA Collection Sticker and Method for Isolating DNA From the Sticker - The present invention relates a sticker for DNA collection and a method for isolating DNAs using the same. Particularly, the sticker for DNA collection is covered with a paint solution comprising EDTA, Tris, SDS and peyonine to isolate keratins exclusively when attached onto human skin and detached. Further, the specific sticker for DNA collection separates DNAs efficiently to amplify genes by using a PCR technique. Therefore, the present invention can be applied to identify a real child and investigate a crime with a fingerprint and to screen genetic diseases.10-29-2009
20090269740Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.10-29-2009
20090269737Integrated non-homogeneous nucleic acid amplification and detection - The present invention relates to an integrated method of amplifying and analyzing target nucleic acids, in which immobilized or immobilizable oligonucleotide capture probes are provided and a nucleic acid containing sample to be analyzed is added together with a reagent mixture, which mixture contains all reagents needed for amplification and subsequent analysis of said target nucleic acids. In the method amplification of the target nucleic acids, hybridization of said amplified target nucleic acids to the capture probes and separating the hybrids formed from un-reacted components, as well as the detection and measuring of the amount of labeled, hybridized target nucleic acids by means of a detectable signal, is performed in one reaction chamber. Further provided are reagent mixtures and kits for use in such methods.10-29-2009
20090269736Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients - Aspects of the present invention provide compositions and methods for prognosis of, and/or predicting the estrogen treatment outcome of breast cell proliferative disorder patients, and in particular of patients with breast carcinoma. In preferred embodiments, this is achieved, at least in part, by determining the expression level of PITX2, and/or the genetic or the epigenetic modifications of the genomic DNA associated with the gene PITX2. Additional aspects of the invention provide novel sequences, oligomers (e.g., oligonucleotides or peptide nucleic acid (PNA)-oligomers), and antibodies, which have substantial utility in the described inventive methods and compositions.10-29-2009
20090269759UNNATURAL POLYMERASE SUBSTRATES THAT CAN SUSTAIN ENZYMATIC SYNTHESIS OF DOUBLE STRANDED NUCLEIC ACIDS FROM A NUCLEIC ACID TEMPLATE AND METHODS OF USE - Nucleotide analogs that can sustain the enzymatic synthesis of double-stranded nucleic acid from a nucleic template are described. The nucleotide analogs include: (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil and their analogs; (ii) a label attached to the base or analog of the base via a cleavable linker; (iii) a deoxyribose; and (iv) one or more phosphate groups. The linker and/or the label inhibits template directed polymerase incorporation of a further nucleotide substrate onto an extended primer strand. In addition, cleavage of the linker leaves a residue attached to the base which is not present in the natural nucleotide and which does not inhibit extension of the primer strand. The nucleotide analogs can therefore be used as reversible terminators in sequencing by synthesis methods without blocking the 3′ hydroxyl group. Methods of sequencing DNA using the substrates are also described.10-29-2009
20090269738Method of Screening for the Presence of a Genetic Defect Associated With Deep Venous Thrombosis - The present invention relates to a method for screening an individual for the presence in his/her genome of a genetic marker that is indicative of an increased risk of deep venous thrombosis, wherein the genetic marker is haplotype 2 of the fibrinogen γ gene (FGG-H2) as given in FIG. 10-29-2009
20090269741Method for assessing traits selected from longissimus dorsi peak force, intramuscular fat, retail beef yield and net feed intake in bovine animals - A method for assessing a trait in a bovine animal selected from the group consisting of longissimus dorsi peak force, intramuscular fat, retail beef yield and net feed intake, comprising the steps of: (1) providing a nucleic acid from the bovine animal or carcass; (2) assaying for the occurrence of a single nucleotide polymorphism (SNP), wherein the identification of said nucleotide occurrence as set forth herein is associated with variation in longissimus dorsi peak force, intramuscular fat deposition, retail beef yield or net feed intake.10-29-2009
20090269742SUBSTRATE FOR IMMOBILIZING BIOPOLYMER AND METHOD OF IMMOBILIZING BIOPOLYMER BY USING THE SAME - [Problems] To immobilize a chain-type biopolymer in an elongated state at a predetermined position on a substrate.10-29-2009
20090186343METHODS FOR PREPARING MODIFIED BIOMOLECULES, MODIFIED BIOMOLECULES AND METHODS FOR USING SAME - A novel and efficient single pot synthetic schemes are disclosed for preparing modified nucleotides, nucleotide analogs, nucleotide polyphosphates, and nucleotide polyphosphate analogs. The novel method is used to prepare nucleotides, nucleotide analogs, nucleotide polyphosphates, and nucleotide polyphosphate analogs having non-persistent or persistent and non-persistent modifications. Novel biomolecular reactions are also disclosed using the novel modified biomolecules disclosed herein.07-23-2009
20090087856METHOD FOR ADMINISTERING ANTICOAGULATION THERAPY - The present invention provides a method for use in treating a patient with an anticoagulant to optimize drug therapy and/or to prevent an adverse drug response. More particularly, the present invention relates to a method and system for use in treating a patient with Coumadin® or a substance containing warfarin. Methods of the present invention utilize variables that include the patient's CYP4F2 genotype.04-02-2009
20090075286Detection of Polyketide Synthetase Gene Expression in Karenia Brevis - The present invention concerns an assay for the detection of polyketide synthetase (PKS) mRNA from the red tide dinoflagellate 03-19-2009
20090075275NUCLEIC ACID PROBE-IMMOBILIZED SUBSTRATE AND METHOD OF DETECTING THE PRESENCE OF TARGET NUCLEIC ACID BY USING THE SAME - The invention provides a nucleic acid probe-immobilized substrate comprising a substrate and a nucleic acid probe containing a nucleotide sequence complementary to a target sequence and immobilized via a spacer onto the substrate, wherein upon hybridization, with the nucleic acid probe, of a target nucleic acid partially containing the target sequence, the spacer satisfies the relationship:03-19-2009
20090075266MULTIPLE ANALYTE DIAGNOSTIC READOUT - The invention provides methods for assessing clinical status through the creation of a diagnostic readout based upon the analysis of multiple biomarkers. According to the invention, an algorithm is provided that allows the use of multiple biomarker thresholds from a patient sample to be used in order to increase the sensitivity and specificity of a diagnostic procedure.03-19-2009
20090068664AMPLIFICATION METHODS AND COMPOSITIONS - The present invention provides methods and routines for developing and optimizing nucleic acid detection assays for use in basic research, clinical research, and for the development of clinical detection assays. In particular, the present invention provides methods for designing oligonucleotide primers to be used in multiplex amplification reactions. The present invention also provides methods to optimize multiplex amplification reactions.03-12-2009
20090233279Methods and Compositions for Predicting Death from Cancer and Prostate Cancer Survival Using Gene Expression Signatures - The emerging concept of cancer stem cells suggests that activation in transformed cells of “sternness” genetic pathways (e.g., normal stem cells' self-renewal pathways) may contribute to the survival life cycle of cancer stem cells, and to tumor progression and metastasis of the malignancy. Thus, activation of “sternness” genes in cancer cells may be associated with aggressive clinical behavior and increased likelihood of therapy failure. General methods and kits associated with prediction of clinical outcome for a disease state of a subject based on gene expression analysis are described. The invention includes determining expression of at least three genes selected from the group consisting of GBX2, MKI67, CCNB1, BUB1, KNTC2, USP22, HCFC1, RNF2, ANK3, FGFR2, and CES1, and mouse homologs thereof.09-17-2009
20090202990METHODS FOR THE SELECTION OF APTAMERS - The present invention generally relates to methods for selecting aptamers. More specifically, the invention provides methods for the selection of at least one aptamer for use in combination with another epitope binding agent such as another aptamer, an antibody, or a double stranded nucleic acid. The invention also encompasses methods for simultaneously selecting at least two aptamers that each recognize distinct epitopes on a target molecule.08-13-2009
20090117571IMPEDANCE SPECTROSCOPY OF BIOMOLECULES USING FUNCTIONALIZED NANOPARTICLES - A biosensor system includes a functionalized interdigitated electrode, functionalized nanoparticles, a current/voltage signal generator, and a circuit analyzer. The interdigitated electrode can be functionalized by coating an exposed surface with first biomolecular probes. The nanoparticles are functionalized by coating an outer surface with second biomolecular probes. A signal generator provides a signal (e.g., an alternating current or voltage) having a selected range of frequencies. A circuit analyzer analyzes electrical parameters of the circuit as the signal is applied. Sensitivity is increased by the presence of functionalized nanoparticles in the system. An analytic method includes measuring changes in electrical parameters of the circuit over the range of frequencies. Using these measurements, the biosensor system can determine whether a target biomolecule is bound. The biosensor system can also identify a biomolecule by comparing the detected signal or “electro-fingerprint” with a reference set of signals over the frequency range.05-07-2009
20080305477Novel Iminecalixarene Derivatives and Aminocalixarene Derivatives, Method of Preparation Thereof, and Self-Assembled Monolayer Prepared by the Method, Fixing Method of Oligo-Dna By Using the Self-Assembled Monolayer, and Oligo-Dna Chip Prepared By the Method - The present invention relates to novel iminecalixarene derivatives, method of preparation thereof, and self-assembled monolayer prepared by the method, fixing method of oligo-DNA by using the self-assembled monolayer, and oligo-DNA chip prepared by the method. Also, the present invention relates to novel aminocalixarene derivatives, method of preparation thereof, and self-assembled monolayer prepared by the method, fixing method of oligo-DNA wherein the oligo-DNA is voluntarily fixed by molecular recognition on said self-assembled monolayer in a liquid phase, and oligo-DNA chip prepared by the method.12-11-2008
20080305478Processes Using Dual Specificity Oligonucleotide and Dual Specificity Oligonucleotide - The present invention relates to various processes by a template-dependent extension reaction using a dual specificity oligonucleotide and a dual specificity oligonucleotide composed of three different Tm portions therefor. Demonstrated in the present invention are the features of the dual specificity oligonucleotide, which are high hybridization specificity and mismatch tolerance.12-11-2008
20100035243Ultra-sensitive detection of analytes - The present invention relates to screening methods, compositions, and kits for detecting for the presence or absence of one or more target analytes, e.g. biomolecules, in a sample. In particular, the present invention relates to methods that utilize nanoparticle probes in an in-solution homogeneous assay system for high-sensitivity detection of target proteins or nucleic acids based on flow analysis of single particles.02-11-2010
20110020832METHOD FOR DETECTING CANCER CELL CAUSED BY HPV, METHOD FOR DETERMINING WHETHER OR NOT TISSUE IS AT STAGE OF HIGH-GRADE DYSPLASIA OR MORE SEVERE STAGE, AND PRIMER SET AND KIT USED THEREFOR - Provided are a primer set, a method and a kit therefor, which can easily perform with high accuracy the detection of a cancer cell caused by HPV and the determination of whether or not a tissue is a tissue with high-grade dysplasia or in a more severe phase. As a primer set, used is a primer set consisting of a first primer which hybridizes with a nucleic acid consisting of a nucleotide sequence in which cytosine present in a site other than a CpG site is converted into another base in a nucleotide sequence having a CpG site in L1 region or L2 region of HPV and a second primer which hybridizes with a nucleic acid consisting of a nucleotide sequence in which cytosine is converted into another base in a nucleotide sequence having a CpG site in LCR or E6 region of HPV.01-27-2011
20110020830DESIGN FOR RAPIDLY CLONING ONE OR MORE POLYPEPTIDE CHAINS INTO AN EXPRESSION SYSTEM - The present invention provides methods and compositions for the generation and identification of expression constructs that can be used to express sufficient levels of a polypeptide of interest. The compositions include a population of expression vectors, wherein members of the population have a type IIS restriction enzyme recognition site adjacent to a regulatory sequence, and wherein the regulatory element is distinct in at least two members of the population of expression vectors. In various embodiments, the expression vectors further comprise a polynucleotide sequence encoding a polypeptide of interest, wherein the polynucleotide encoding the polypeptide, the polynucleotide of the regulatory sequence, or both, are distinct in at least two members of the population. The compositions are useful for identifying a combination of coding sequences and/or regulatory elements useful for the heterologous expression of the polypeptide of interest.01-27-2011
20110020829RAPID ASSAY FOR DETECTING ATAXIA-TELANGIECTASIA HOMOZYGOTES AND HETEROZYGOTES - The present disclosure relates to methods for performing an assay to identify ataxia-telangiectasia homozygotes or heterozygotes. Some embodiments include the use of a rapid flow cytometry-based ataxiatelangiectasia (ATM) kinase assay that measures ATM-dependent phosphorylation of SMC1 following DNA damage.01-27-2011
20110020824METHODS AND COMPOSITIONS FOR QUANTITATIVE AMPLIFICATION AND DETECTION OVER A WIDE DYNAMIC RANGE - Disclosed are compositions and methods for making differentiable amplicon species at unequal ratios using a single amplification system in a single vessel. The number of differentiable amplicons and their ratios to one another are chosen to span the required linear dynamic range for the amplification reaction and to accommodate limitations of the measuring system used to determine the amount of amplicon generated. Unequal amounts of distinguishable amplicon species are generated by providing unequal amounts of one or more amplification reaction components (e.g., distinguishable amplification oligomers, natural and unnatural NTP in an NTP mix, or the like). The amount of target nucleic acid present in a test sample is determined using the linear detection range generated from detection of one or more amplicon species having an amount within the dynamic range of detection.01-27-2011
20110020822MOLECULAR DETECTION OF CHROMOSOME ABERRATIONS - The invention relates to the field of cytogenetics and the application of genetic diagnostic techniques in pathology and hematology. Specifically, the invention relates to nucleic acid probes that can be used in hybridization techniques for the detection of chromosomal aberrations and other gene rearrangements such as immunoglobulin and T-cell receptor gene rearrangements. The probes provided by the invention are a distinct and balanced set of probes of comparable size, each preferably being from 1 to 100 kb, or smaller, and flanking a potential breakpoint in a chromosome.01-27-2011
20110020821METHOD FOR DETECTION OF MICROORGANISM AND KIT FOR DETECTION OF MICROORGANISM - According to the following steps, live cells, injured cells, VNC cells and dead cells of a microorganism in a test sample are detected by flow cytometry: 01-27-2011
20110020820METHOD FOR DETECTION OF MICROORGANISM AND KIT FOR DETECTION OF MICROORGANISM - A kit is disclosed for preparing a measurement sample for detecting live cells, injured cells, VNC cells and dead microorganism cells in a test sample by the following steps: 01-27-2011
20110020819ISOTHERMAL DETECTION METHODS AND USES THEREOF - The present disclosure relates to methods and probes for rapid, single temperature (isothermal) detection of specific nucleic acid sequences. The methods and probes provide a simple method for detecting bioagents including bacteria and viruses, and the detection of specific genetic markers on any nucleic sequence.01-27-2011
20110020818REACTOR FOR THE QUANTITATIVE ANALYSIS OF NECLEIC ACIDS - A reactor for the quantitative analysis of target nucleic acids using an evanescent wave detection technique and a method of use thereof is provided. The reactor includes a substrate with a cavity, a buffer layer arranged over the substrate; a cover plate arranged over the buffer layer, and inlet and outlet ports. The reactor is thermally and chemically stable for PCR processing and suitable for an evanescent wave detection technique.01-27-2011
20110020817De novo synthesized plasmid, methods of making and use thereof - The invention relates to a de novo synthesized plasmid. The plasmid comprises relevant sequences for plasmid replication and plasmid selection. The methods of making and use of the plasmid are disclosed. The plasmid can be used to make other plasmids. These plasmids and their host cells can be used for biomedical applications.01-27-2011
20110020816Precursor miRNA loop-modulated target regulation - By modifying nucleotides from either or both the stem and loop of precursor-miRNA, greater specificity is achieved as to the mRNAs targeted. The improved efficiency in target regulation can be either mediated by direct base-pairings between targets and precursor miRNAs or indirectly by energy constraints on the availability of such base-pairings. It is found that pri- and pre-miRNA are active in the absence of functional mature miRNA, so pri- or pre-miRNA or truncated portion thereof, but not as mature miRNA, can be used as RNAi agents by themselves. Furthermore, besides the seed sequence of the stem of the pre-miRNA and 3′-extensions thereof to provide greater complementarity to the target mRNA, nucleotides in the loop can affect the activity and specificity of the precursor-miRNA and the processing and binding to target mRNA. By using mutated sequences in the natural pri- or pre-miRNA or modified mimetics, one can screen for target mRNA, target a unique mRNA or a group of mRNAs for regulation, and modulate cell properties with greater specificity and investigate cellular activity as to phenotype and response to external stimuli in the presence or absence of at least partial target protein expression.01-27-2011
20110020815METHODS FOR GENOMIC ANALYSIS - The present invention relates to methods for identifying variations that occur in the human genome and relating these variations to the genetic basis of disease and drug response. In particular, the present invention relates to identifying individual SNPs, determining SNP haplotype blocks and patterns, and, further, using the SNP haplotype blocks and patterns to dissect the genetic bases of disease and drug response. The methods of the present invention are useful in whole genome analysis.01-27-2011
20110020813ADVANCED PATHOGEN DETECTION AND SCREENING - Disclosed is a rapid, dual purpose, PCR-based method for identifying two or more pathogens, including 01-27-2011
20110020812METHODS OF USING FET LABELED OLIGONUCLEOTIDES THAT INCLUDE A 3'-5' EXONUCLEASE RESISTANT QUENCHER DOMAIN AND COMPOSITIONS FOR PRACTICING THE SAME - Methods and compositions are provided for detecting a primer extension product in a reaction mixture. In the subject methods, a primer extension reaction is conducted in the presence of a polymerase having 3′→5′ exonuclease activity and at least one FET labeled oligonucleotide probe that includes a 3′→5′ exonuclease resistant quencher domain. Also provided are systems and kits for practicing the subject methods. The subject invention finds use in a variety of different applications, and are particularly suited for use in high fidelity PCR based reactions, including SNP detection applications, allelic variation detection applications, and the like.01-27-2011
20090253131HYBRID FUSION REPORTER AND USES THEREOF - The invention provides vectors encoding hybrid fusion proteins and vector sets encoding different hybrid fusion proteins useful, for instance, in protein complementation assays.10-08-2009
20110020811HOST CELLS COMPRISING ALPHA 1,2 MANNOSIDASE AND CULTURE METHODS THEREOF - Improved host cells and culture methods involving overexpression of MAN1C1 activity to improve protein production are provided.01-27-2011
20110020810TRPC6 INVOLVED IN GLOMERULONEPHRITIS - Focal and segmental glomerulosclerosis (FSGS) is a kidney disorder of unknown etiology and up to 20% of patients on dialysis have this diagnosis. A large family with hereditary FSGS carries a missense mutation in the TRPC6 gene on chromosome 11q, encoding the ion channel protein Transient Receptor Potential Cation Channel 6. The missense mutation is a P112Q substitution, which occurs in a highly conserved region of the protein, enhances TRPC6-mediated calcium signals in response to agonists such as angiotensin II, and alters the intracellular distribution of TRPC6 protein. Previous work has emphasized the importance of cytoskeletal and structural proteins in proteinuric kidney diseases. Our findings suggest a novel mechanism for glomerular disease pathogenesis.01-27-2011
20110020808BIOMARKERS FOR DIAGNOSING SCHIZOPHRENIA AND BIPOLAR DISORDER - The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease.01-27-2011
20110020807Methylated CpG Island Amplification (MCA) - The present invention provides a method for identifying a methylated CpG containing nucleic acid by contacting a nucleic acid with a methylation sensitive restriction endonuclease that cleaves unmethylated PcG sites and contacting the sample with an isoschizomer of the methylation sensitive restriction endonuclease, which cleaves both methylated and unmethylated CpG sites. The method also includes amplification of the CpG-containing nucleic acid using CpG-specific oligonucleotide primers. A method is also provided for detecting an age associated disorder by identification of a methylated CpG containing nucleic acid. A method is further provided for evaluating the responses of a cell to an agent. A kit is useful for detection of a CpG containing nucleic acid is also provided. Nucleic acid sequences encoding novel methylated clones.01-27-2011
20110020806Rapid DNA Sequencing by Peroxidative Reaction - Disclosed is a method of polynucleic acid (e.g., DNA) sequencing which is based on the generation of pyrophosphate (PPi) that occurs when a complementary base is incorporated into a growing DNA strand being synthesized on a template. The method utilizes a cascade of enzymatic reactions catalyzed by hypoxanthine-phosphoribosyl transferase, xanthine oxidase, and peroxidase in addition to DNA polymerase and apyrase. The last chemical step in the cascade of reactions is the oxidation of a material such as an electrode or luminol by hydrogen peroxide. This generates a detectable electrical or optical signal. This method is independent of luciferase, does not require dATP analogue, and is intended to improve precision and sensitivity of DNA sequencing, and to lessen the unsynchronized polymerization.01-27-2011
20110020805MUTATIONAL ANALYSIS OF CHRONIC MYELOPROLIFERATIVE DISORDERS - The invention relates to molecular assays, reagents and kit for the mutational analysis, for diagnostic and prognostic purposes, of chronic myeloproliferative disorders, a group of neoplastic pathologies of the haemopoietic system. The invention relates to the identification of nucleic acid probes labelled with fluorochrome, allowing a quantitative assessment, in a specific and sensitive way, of mutation of MPL gene sequence and quantification of the mutated alleles of the MPL gene in Genomic DNA samples from patients with chronic myeloproliferative syndrome.01-27-2011
20110020802NUCLEIC ACIDS, METHODS AND KITS FOR THE DIAGNOSIS OF DYT6 PRIMARY TORSION DYSTONIA - The invention relates generally to the THAP1 gene and mutations in this gene, as well as the THAP1 protein and mutations in this protein, that are associated with dystonia. The invention relates to the identification, isolation, cloning and characterization of the DNA sequence corresponding to the wild type and mutant THAP1 genes, as well as isolation and characterization of their transcripts and gene products. The invention further relates to methods and kits useful for detecting mutations in THAP1 that are associated with dystonia, as well as to methods and kits useful for diagnosing dystonia. The present invention also relates to therapies for treating dystonia, including gene therapeutics and protein/antibody based therapeutics.01-27-2011
20110020801Carboxylesterase-1 Polymorphisms and Methods of Use Therefor - Methods and kits are provided for detecting polymorphisms in carboxylesterase-1 (CES1). Several single nucleotide polymorphisms (SNPs) in CES1 in humans, and methods for detecting the same, are provided (e.g., Gly143Glu, 12754T>del). Results indicate that the Gly143Glu (9486G>A) polymorphism has an allelic frequency of 1.5% in the Caucasian population. Polymorphisms of the present invention may alter the function of the carboxylesterase-1 enzyme (hCES1). Thus, the methods and kits of the present invention may be used to personalize a therapy and/or avoid adverse consequences of altered metabolism of a therapeutic or compound (e.g., enalapril, methylphenidate, etc.) which may result due to a CES1 polymorphism. In addition, recombinant cells lines overexpressing wild-type CES1 or expressing CES1 mutants are provided. Such cell lines may be used to assess the effects of candidate compounds on CES1, and the action of CES1 on these candidate compounds.01-27-2011
20110020800Characterization of BBK07 antigen of Borrelia burgdorferi and methods of use - In this application is described the characterization 01-27-2011
20110020799Screening method for damaged DNA repairing substance - Provided are a novel screening method for a substance that potentiates damaged DNA repair capability, based on a test with DNA repair as an index with improved sensitivity as a simplified version of the currently available unscheduled DNA synthesis (UDS) assay based on 01-27-2011
20110020798Novel italy, LOR-2, strife, trash, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor - Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST proteins, the invention further provides isolated ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST fusion proteins, antigenic peptides and anti-ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST antibodies. The invention also provides ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.01-27-2011
20110020797Methods For Identifying Patients With An Increased Likelihood Of Responding To DPP-IV Inhibitors - The invention provides novel in vitro diagnostic methods for identifying patients who may have an increased likelihood of responding to DPP-IV inhibitor therapy. The invention also provides novel polynucleotides associated with increased responsiveness of a patient to DPP-IV inhibition. Polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides, which comprise at least one polymorphic locus per fragment, are also provided. Allele-specific primers and probes which hybridize to these polymorphic regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis.01-27-2011
20110020795ANALYZING THE FMR1 GENE - A method of predicting a degree of risk of early ovarian aging of a young female. The method includes analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele; determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat numbers for both of the first and second alleles are within the normal range, then the female is at minimal risk for early ovarian aging. If the triple CGG repeat number for one of the first and second alleles is outside of the normal range and the other one of the first and second alleles is within the normal range, then the first and second alleles are heterozygous and the female is at increased risk for early ovarian aging. If the triple CGG repeat numbers for both of the first and second alleles are outside of the normal range, then the first and second alleles are homozygous and the female is also at an increased risk for early ovarian aging.01-27-2011
20110020794METHOD FOR THE DETECTION OF DIAGNOSTIC RNA - Methods for the direct detection of diagnostic target RNA have been developed, which obviate the need for time consuming RNA purification and isolation procedures.01-27-2011
20110020793Molecular counting by color-coded micelles - The invention provides a method of determining ratios of target DNA molecules in a sample. A digital readout of the target DNA molecules is provided by converting ratios of target DNA molecules into equivalent ratios of amplifiable tags, which are, in turn, converted into ratios of color-coded micelles in an emulsion reaction. The micelles may be detected and counted by various methods, including by flow cytometers or slide-based imaging devices. The invention is useful for detection of relative expression levels of selected genes, gene copy number polymorphisms, allelic imbalance, relative levels of iRNAs, and related phenomena of scientific and medical interest.01-27-2011
20110020792DETECTION OF UTERINE LEIOMYOSARCOMA USING LMP2 - This invention provides a method for detecting the presence of uterine leiomyosarcoma using the transcription or expression level of LMP2 and/or cyclin E in uterine smooth muscle tissue as an indicator and a method for detecting uterine leiomyosarcoma using LMP2 and/or cyclin E as a marker.01-27-2011
20090233271Species-Specific And Quantitative Detection Of CNS Tissue In Meat And Meat Products - The present invention concerns a method for the species-specific and quantitative detection of CNS tissue in meat and meat products of the ruminant species bovine, ovine and caprine or porcine by a real-time PCR method, using glial fibrillary acidic protein (GFAP) messenger (m)-RNA. The method is very reliable and can be easily conducted even in heat-treated samples.09-17-2009
20090239237METHOD FOR THE IDENTIFICATION OF A RISK FOR A THROMBOGENIC DISORDER BY DETERMINING THE TAFl-lle347 POLYMORPHISM - The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.09-24-2009
20090239222COMPOSITION FOR NUCLEIC-ACID TRANSFECTION - To provide a nucleic-acid-transfecting composition which exhibits low cytotoxicity, which facilitates a nucleic acid transfection into cells, and which improves expression of the nucleic acid in the cells.09-24-2009
20110045486Susceptibility Gene For Alzheimer's Disease - The invention relates to genetic screens for susceptibility to Alzheimer's disease. In particular, the invention provides genetic screens based on genotyping of the p21E2c31 A/T polymorphism and/or the p21E3+20 C/T polymorphism in the p21cip 1 gene.02-24-2011
20110045476INFLAMMATORY BOWEL DISEASE PROGNOSTICS - The methods and systems of the present invention are useful in the diagnosis of inflammatory bowel disease (IBD) and in the prognosis of IBD progression and disease complications. With the present invention, it is possible to predict outcome of disease and patients who will have a particular risk of disease complications and/or progression to surgery.02-24-2011
20110045462DIGITAL ANALYSIS OF GENE EXPRESSION - The disclosure provides methods and compositions useful for high throughput sequencing of nucleic acid sequences associated with gene expression, nucleic acid-polypeptide interactions, and/or chromosomal interactions.02-24-2011
20090035766Methods for Analyzing High Dimension Data for Classifying, Diagnosing, Prognosticating, and/or Predicting Diseases and Other Biological States - A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.02-05-2009
20090035765Polynucleotides and methods for making plants resistant to fungal pathogens - This invention relates to polynucleotide sequences encoding a gene that can confer resistance to the plant pathogen 02-05-2009
20090035757SUBSTRACTIVE SINGLE LABEL COMPARATIVE HYBRIDIZATION - Provided are methods of determining differences between nucleic acids in a test sample and a reference sample. In certain embodiments the methods are used for detecting and mapping chromosomal or genetic abnormalities associated with various diseases or with predisposition to various diseases, or to detecting the phenomena of large scale copy number variants. In particular, provided are advanced methods of performing array-based comparative hybridization that allow reproducibility between samples and enhanced sensitivity by using the same detectable label for both test sample and reference sample nucleic acids. Invention methods are useful for the detection or diagnosis of particular disease conditions such as cancer, and detecting predisposition to cancer based on detection of chromosomal or genetic abnormalities and gene expression level. Invention methods are also useful for the detection or diagnosis of hereditary genetic disorders or predisposition thereto, especially in prenatal samples. Moreover, invention methods are also useful for the detection or diagnosis of de novo genetic aberrations associated with post-natal developmental abnormalities.02-05-2009
20090233309BIOLOGICAL SPECIMEN COLLECTION/TRANSPORT COMPOSITIONS AND METHODS - Disclosed are compositions for collecting, storing, and transporting populations of nucleic acids from biological specimens, and clinical, forensic, or environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. In particular embodiments, the invention provides a single, one-step, sample collection/transport/storage formulation containing a known quantity of a non-genomic, nucleic acid carrier molecule that serves as an internal reference control to monitor the fidelity of the collection/transportation medium, and measure the integrity of nucleic acids subsequently isolated and purified from the processed sample.09-17-2009
20090233306Biomarkers for Inflammatory Bowel Disease and Irritable Bowel Syndrome - The present invention provides compositions and their use in diagnosing and/or distinguishing inflammatory bowel disease and irritable bowel syndrome.09-17-2009
20090233304Biomarkers for Inflammatory Bowel Disease and Irritable Bowel Syndrome - The present invention provides compositions and their use in diagnosing and/or distinguishing inflammatory bowel disease and irritable bowel syndrome.09-17-2009
20090233302LABELED REACTANTS AND THEIR USES - Labeled reactant compositions, and particularly labeled nucleic acid reaction compositions, that include structural components that maintain potentially damaging labeling components sufficiently distal from the reactant portion of the molecule such that damaging effects of the label group on other reaction components, such as enzymes, are reduced, minimized and/or eliminated.09-17-2009
20090233300Markers for Diagnosis of Pulmonary Inflammation and Methods Related Thereto - The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.09-17-2009
20090233299Physiogenomic Method for Predicting Statin Injury to Muscle and Muscle Side Effects - The present invention relates to the use of genetic variants of associated marker genes to predict an individual's susceptibility to muscular injury and muscular side effects in response to statin therapy. The present invention further relates to analytical assays and computational methods using the novel marker gene set. The present invention has utility for personalized medical treatment, drug safety, statin compliance, and prophylaxis of muscle side effect.09-17-2009
20090233298FIG4 GENE MUTATIONS IN NEURODEGENERATION - The present invention relates to neurological disease, in particular to mutations in the FIG4 gene. The present invention also provides assays for the detection of variant FIG4 alleles, and assays for detecting FIG4 polymorphisms and mutations associated with disease states such as ALS.09-17-2009
20090233297MICRORNA MARKERS FOR RECURRENCE OF COLORECTAL CANCER - The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as colorectal cancer, and using the profile in the diagnosis and/or prognosis of a patient for a condition, such as colorectal cancer and colorectal cancer recurrence or response to therapy.09-17-2009
20090233296Thiamin production by fermentation - The present invention provides a method for producing thiamin products using a microorganism containing a mutation that causes it to overproduce and release thiamin products into the medium. Biologically pure cultures of the microorganisms and isolated polynucleotides containing the mutations are also provided. In addition, methods for detecting a pathogenic microorganism in a clinical sample, assays for identifying an antibiotic, as well as, antibiotics identified by such assays are provided.09-17-2009
20090233273Transgenic aloe plants for production of proteins and related methods - The present inventions provide transgenic aloe plants and recombinant constructs for transforming aloe plants, aspects of which, may be applied to other monocots. The recombinant constructs may include one or more DNA sequences encoding mammalian proteins and at least one promoter capable of directing the expression of recombinant proteins in an aloe plant. The present inventions also provide methods for constructing and reproducing a transgenic aloe plant. The present inventions include methods for transfection of an aloe plant with several genes of interest simultaneously. The aloe plant production methods of the inventions may provide the potential to inexpensively and more safely mass-produce some biologically active compounds including biopharmaceuticals for disease therapy, diagnosis and prevention, and is more accessible to the less affluent countries. The aloe plant production methods may also produce proteins for cosmetics.09-17-2009
20090233292Method and kit for identification of genetic polymorphisms - Provided herein are primer sets, kits, and methods for identifying mtDNA polymorphisms in a sample. In one embodiment, the primer sets, kits and methods are directed to identifying global haplogroups (“Global”). In another embodiment, the primer sets, kits, and methods are directed to identifying specific European haplogroups (“European”).09-17-2009
20090233287PRODUCTION OF COMPOUNDS IN A RECOMBINANT HOST - The present invention provides a recombinant 09-17-2009
20090233286Methods of diagnosis and prognosis of pancreatic cancer - Disclosed herein are methods of diagnosing pancreatic cancer in a subject. Also provided are methods of monitoring the efficacy of a therapeutic treatment of pancreatic cancer as well as methods of determining the likelihood that a subject having pancreatic cancer will survive, and methods of determining the suitability of a subject having pancreatic cancer for surgical resection therapy.09-17-2009
20090233285SPECIFIC METHOD OF PROSTATE CANCER DETECTION BASED ON PCA3 GENE, AND KITS THEREFOR - The present invention relates, in general, to prostate cancer. More specifically, the present invention relates to a method to diagnose prostate cancer in a patient by detecting a PCA3 sequence, and more particularly a PCA3 RNA, the PCA3 sequence detected in a sample from the patient being specifically associated with prostate cancer. In a particular embodiment the method and kit enables an amplification of a PCA3 RNA through an exon-exon junction of a spliced PCA3 mRNA. The invention also relates to methods and kits to detect such an amplified PCA3 RNA, using a probe which spans the amplified exon-exon junction. In particular the methods and kits are designed to detect a PCA3 RNA which lacks one intron or more, and in particular case is intron-less. The invention further relates to a method of detecting PCA3 RNA expressed in non-prostate tissue or cells of the urinary tract, that comprises PCA3 intron 3.09-17-2009
20090233284METHOD FOR THE SIMULTANEOUS DETECTION OF MUTATIONS OCCURRING IN RELATED GENOMES, EXPLOITING MOBILITY VARIATIONS IN 2-D ELECTROPHORESIS OF DNA DUPLEXES UNDERGOING DIFFERENTIAL HELIX-COIL TRANSITION IN A DENATURING GRADIENT - A method for the simultaneous mutation detection exploiting the variable electrophoretic mobility of related DNA samples, caused by the differential onset of helix-coil transition in denaturing gradients, comprises the following subsequent steps: a) preparation of DNA samples; b) fragmentation of the samples through a first restriction; c) terminal labeling of the fragments of each genome with a different fluorochrome; d) mixing the samples; e) carrying out a simultaneous second restriction, converting each long duplex into a set of shorter fragments with two of them labeled at only one of their ends e) carrying out a 2D separation of the mixed digestion products in order to obtain: a first dimension consisting of a standard 20 polyacrylamide gel; and a second dimension against a denaturing gradient; f) spotting, picking of singly labeled spots and sequencing of their DNA.09-17-2009
20090233295TRIM59 DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE - Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of TRIM59 in the test cell sample or fluid sample as compared to the level of expression of TRIM59 in a control cell sample or fluid sample isolated from a normal subject.09-17-2009
20090233280METHOD OF ACQUIRING INFORMATION REGARDING BASE SEQUENCE AND INFORMATION READING DEVICE FOR THE SAME - Information regarding a base sequence of a target nucleic acid is acquired by preparing a sample comprising the target nucleic acid hybridized with a primer or a sample comprising the target nucleic acid containing a promoter sequence, a polymerase, a nucleotide derivative having an electrochemically convertible moiety; allowing the three components to coexist in a solvent; and detecting whether the nucleotide derivative is introduced into the primer or a transcription product of the target nucleic acid or not using an electrochemical reaction.09-17-2009
20090233278Branched-chain amino acid aminotransferase gene and use thereof - The present invention relates to a branched-chain amino acid aminotransferase gene and a use thereof, particularly, to a brewery yeast for producing alcoholic drinks with enhanced flavor, to alcoholic drinks produced with said yeast and to a method for producing said drinks. More particularly, the present invention relates to a yeast whose capacity of producing amyl alcohol and/or isobutanol and/or isoamyl acetate that contribute to the product flavor is controlled by controlling the expression levels of BAT1 and BAT2 genes coding for brewery yeast branched-chain amino acid aminotransferases Bat1p and Bat2p, respectively, particularly nonScBAT1 or nonScBAT2 gene specific to lager brewing yeast, and to a method for producing alcoholic drinks using said yeast.09-17-2009
20090233277PRIMER GENERATION ROLLING CIRCLE AMPLIFICATION - A method of amplifying a nucleic acid is provided which comprises: generating a first nucleic acid primer from a first nucleic acid sequence; combining the first nucleic acid primer with a first polymerase and a first circular nucleic acid probe, wherein the first circular nucleic acid probe contains at least one antisense sequence to a second nucleic acid sequence and at least one antisense sequence to the first nucleic acid primer; producing at least one repeat of a sequence copy of the first circular nucleic acid probe by rolling circle amplification using the first polymerase, wherein the sequence copy contains at least the second nucleic acid sequence; generating a second nucleic acid primer from the second nucleic acid sequence; combining the second nucleic acid primer with a second polymerase and a second circular nucleic acid probe, where the second circular nucleic acid probe contains at least one antisense sequence to the second nucleic acid primer; and producing at least one repeat of a sequence copy of the second circular nucleic acid probe by rolling circle amplification using the second polymerase. The method may be employed to detect molecules of interest such as nucleic acid sequences, DNA methylation, single nucleotide polymorphisms (SNP), proteins and posttranslational modifications. Furthermore, a ribbon probe is provided that comprises a circular nucleic acid probe and a nucleic acid lock probe, wherein: the nucleic acid lock probe contains at least a cleavable linker, and the circular nucleic acid probe and the lock probe are unable to dissociate without cleaving the cleavable linker.09-17-2009
20090233276Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions - This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.09-17-2009
20090233274DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING - The present invention provides novel target proteins and target genes for drug discovery, and the means that enable the development of novel drugs using the same. More particularly, the present invention provides NCS proteins and genes thereof; screening methods for drug (for example, anti-central nervous disease drug); agents for regulating disease (for example, central nervous disease); production methods of a drug derivative; a complex comprising a drug and NCS protein, and a method of producing the complex; a kits comprising a drug or a salt thereof; determination methods for the onset or risk of onset of a specified disease, determination methods for susceptibility to a drug, and determination kits used for the determination methods; and the like.09-17-2009
20090233272Multiplexed Nucleic Acid Analysis with High Specificity - A test kit and method includes amplification and extension primers that are selected to allow multiplex PCR and extension at increased specificity. Preferably, the extension primers include a tag that hybridizes with a capture probe on a biochip, wherein the tag is distinct from the target nucleic acid sequence to be analyzed. Further preferred kits include a biochip and various instructions.09-17-2009
20090233281DIAGNOSTIC MARKER FOR ALLERGY - The present invention provides a test system that specifically detects allergy, a test system that highly sensitively reflects aggravation of allergy and the like.09-17-2009
20090233294UHRF1 DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE - Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of UHRF1 in the test cell sample or fluid sample as compared to the level of expression of UHRF1 in a control cell sample or fluid sample isolated from a normal subject.09-17-2009
20090233301In Vitro System for Assessing Immune Activity Using Pig Immune Cells - An in vitro system in which immune cells of a non-immunized pig are used for assessing immunoactivity of a substance.09-17-2009
20090233270Secreted and cytoplasmic tumor endothelial markers - To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed many differentially expressed genes, including a large nujber of genes that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions fo the liver. Theses results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic. 09-17-2009
20100015627SELECTION METHOD - The current invention comprises a method for the selection of a mammalian cell by transfecting a mammalian cell with a nucleic acid comprising a part of a nucleic acid encoding a polypeptide that catalyzes an α1,6-glycosidic bond formation between fucose and an asparagine-linked N-acetylglucosamine and cultivating the transfected mammalian cell in the presence of Lens culinaris agglutinin (LCA) and selecting a mammalian cell viable under these conditions.01-21-2010
20090047684Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan - The present invention includes gene and protein expression profiles indicative of whether a cancer patient is likely to respond to treatment with irinotecan. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and/or protein expression profiles and assays for identifying the presence of a gene and/or protein expression profile in a patient sample.02-19-2009
20090047679METHOD AND SYSTEM FOR ANALYZING REACTIONS USING AN INFORMATION SYSTEM - A method and system for determining the quantity of an analyte initially present in a chemical and or biological reaction as well as a computer implemented method and system to automate portions of the analysis comprising mathematical or graphical analysis of an amplification reaction.02-19-2009
20090047678ACCELERATED CASCADE AMPLIFICATION (ACA) OF NUCLEIC ACIDS COMPRISING STRAND AND SEQUENCE SPECIFIC DNA NICKING - Particular aspects provide nucleic acid amplification and detection methods comprising: providing a reaction mixture containing a target nucleic acid with an amplifiable target sequence, forward and reverse external nick-directing primers (ND-primers), at least one internal ND-primer, a strand-displacing DNA polymerase, a nick-directing endonuclease for strand-specific cleavage of ND-primer-extension products, and deoxynucleoside 5′-triphosphates; and incubating the reaction mixture with reagents, and under conditions suitable to provide for amplification of the amplifiable target sequence, wherein the amplification comprises primer extension, by least one internal ND-primer, of an external ND-primer extension product comprising the amplifiable target sequence or a portion thereof but lacking the respective external ND-primer sequence or a portion thereof. Preferably, amplification comprises using a plurality of internal ND-primers, extension of one internal ND-primer extension product by a different internal ND-primer, and amplification is isothermal and synergistic with respect to the number of primers employed. Amplification and detection kits are provided.02-19-2009
20090047677METHODS FOR GENERATING A DISTRIBUTION OF OPTIMAL SOLUTIONS TO NONDETERMINISTIC POLYNOMIAL OPTIMIZATION PROBLEMS - The present invention overcomes problems in prior art DNA-based computing methods for solving non-deterministic polynomial optimization problems, by providing methods that derive the most probable answers in a statistically significant manner that makes the methods scalable with increases in the number of data inputs, and thus makes the methods practical.02-19-2009
20090047676System and method for obtaining and maintaining high-resistance seals in patch clamp recordings - The invention provides a system, system components, and a method for rapidly obtaining and stably maintaining a cell in optimal contact with the cell-contacting surface of a sensor in a cell-based biosensor. In one aspect, the system maximizes the seal between a whole cell and the cell-contact surface of a patch clamp micropipette, maximizing the efficiency of a whole cell patch clamp recording.02-19-2009
20090047675Compositions and methods for indentifying transforming and tumor suppressor genes - Provided herein are nucleic acids, proteins, vectors, cells, kits, devices and methods useful for identifying regulatable proteins that are able to complement components of cellular signaling pathways. Also provided are compositions and methods using these complementing genes directly as markers for cancer diagnosis or prognosis and as targets for anti-neoplastic therapeutics. Further provided are methods for using changes caused by expression of the complementing genes to indirectly identify associated genes to be used as markers for cancer diagnosis or prognosis and as targets for anti-neoplastic therapeutics.02-19-2009
20090047672Telomerase RNA Subunit and Methods of Use Thereof - The present invention provides a novel telomere associated RNA (hTERC-2) that mediates the DNA repair function of telomerase.02-19-2009
20090047671SPECIFIC AND UNIVERSAL PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL PATHOGENS AND ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR ROUTINE DIAGNOSIS IN MICROBIOLOGY LABORATORIES - The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens 02-19-2009
20090047670HYBRIDIZATION-BASED BIOSENSOR CONTAINING HAIRPIN PROBES AND USE THEREOF - A sensor chip that includes: a fluorescence quenching surface; a nucleic acid probe that contains first and second ends with the first end bound to the fluorescence quenching surface, and is characterized by being able to self-anneal into a hairpin conformation; and a first fluorophore bound to the second end of the first nucleic acid molecule. When the first nucleic acid molecule is in the hairpin conformation, the fluorescence quenching surface substantially quenches fluorescent emissions by the first fluorophore; and when the first nucleic acid molecule is in a non-hairpin conformation, fluorescent emissions by the fluorophore are substantially free of quenching by the fluorescence quenching surface. Various nucleic acid probes, methods of making the sensor chip, biological sensor devices that contain the sensor chip, and their methods of use are also disclosed.02-19-2009
20090047669DNA recombination junction detection - The present invention provides methods, compositions and kits for detecting the presence or absence of an integrated insertion polynucleotide.02-19-2009
20090047666Methods and nucleic acids for the analysis of colon proliferative disorders - The invention provides methods, nucleic acids and kits for detecting colon cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients.02-19-2009
20090203020BOVINE POLYMORPHISMS AND METHODS OF PREDICTING BOVINE TRAITS - Methods of predicting the phenotype of a trait in a bovine subject are provided. The methods include obtaining information about polynucleotide sequences specifically regarding the identity of the nucleotides present at one or more identified single nucleotide polymorphisms and using this information to make predictions regarding the trait in the subject. Also provided are kits for and methods of determining the nucleotide present in a bovine subject at a position in which a single nucleotide polymorphism is correlated with a trait.08-13-2009
20090233293TTK DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE - Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of TTK in the test cell sample or fluid sample as compared to the level of expression of TTK in a control cell sample or fluid sample isolated from a normal subject.09-17-2009
20090253125Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof - Novel denaturant-stable, protease resistant, homo-oligomeric proteins, also referred to herein as stable proteins (SPs), having chaperone-like activity; methods of production and purification of SPs; nucleic acids encoding SPs; methods of isolating nucleic acids encoding SPs; antibodies recognizing SPs; the use of SPs for stabilizing, refolding, repairing, preventing aggregation and de-aggregating macromolecules such as proteins; fusion proteins including SPs; nucleic acid constructs encoding the fusion proteins; and their uses in a variety of methods and applications. 10-08-2009
20090258345PROTEIN ASSOCIATED WITH COLORECTAL CANCER, POLYNUCLEOTIDE INCLUDING SINGLE-NUCLEOTIDE POLYMORPHISM ASSOCIATED WITH COLORECTAL CANCER, MICROARRAY AND DIAGNOSTIC KIT INCLUDING THE SAME, AND METHOD OF DIAGNOSING COLORECTAL CANCER USING THE SAME - Provided are an isolated nucleolar protein having an amino acid sequence of NCBI GenBank Accession No. XP_033371, a method of diagnosing colorectal cancer in an individual, including measuring an expression level of a protein having an amino acid sequence of NCBI GenBank Accession No. XP_033371 in the individual, and a polynucleotide for diagnosis or treatment of colorectal cancer including at least 10 contiguous nucleotides of a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NOS: 1-5 and including a nucleotide at position 101 of the nucleotide sequence, or a complementary polynucleotide thereof.10-15-2009
20090263817METHODS FOR DIAGNOSING AND TREATING SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE AND COMPOSITIONS THEREOF - The present invention is directed to novel methods for diagnosis and prognosis of Systemic lupus erythematosus by identifying differentially expressed genes. Moreover, the present invention is also directed to methods that can be used to screen test compounds and therapies for the ability to inhibit systemic lupus erythematosus. Additionally, methods and molecule targets (genes and their products) for therapeutic intervention in systemic lupus erythematosus are described.10-22-2009
20090275043Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus - Polymorphisms in the gene TCF7L2 are shown by association analysis to be a susceptibility gene for type II diabetes. Methods of diagnosis of susceptibility to diabetes, of decreased susceptibility to diabetes and protection against diabetes, are described, as are methods of treatment for type II diabetes.11-05-2009
20090291448Prognostic and Predictive Gene Signature for Non-Small Cell Lung Cancer and Adjuvant Chemotherapy - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application.11-26-2009
20100062430METHOD AND KIT FOR MOLECULAR CHROMOSOMAL QUANTIFICATION - Diagnosis of chromosomal abnormalities or genetic disorders is performed using at least two marker sequences, wherein one marker sequence is a sequence known to be present on the chromosome or in the gene of interest, another marker sequence is a sequence known to be present on an autosomal chromosome, and the marker sequences are partially homologous. A kit for performing this diagnosis is also claimed.03-11-2010
20100003679ASSESSMENT OF CELLULAR COMPOSITION AND FRACTIONAL VIABILITY AND USES THEREOF - A method of assessing cellular composition and fractional viability that can be predictive of post-transplant cell potency and transplantation outcome, comprises identifying cellular composition and assessing cellular viability. This has particular importance in the field of tissue and cell transplantation, cell therapy and regenerative medicine, providing a method for tissue and cell characterization, viability and potency testing, that could be useful for the definition of product release criteria for research and clinical applications.01-07-2010
20100068701CHROMOSOME LABELING METHOD - A method of sample analysis is provided. In certain embodiments, the method may involve a) contacting a genomic sample comprising a test chromosome with a plurality of sets of labeled oligonucleotide probes under in situ hybridization conditions to produce a contacted sample having an oligonucleotide binding pattern; b) imaging the contacted sample to provide an image showing the oligonucleotide binding pattern; and c) analyzing the oligonucleotide binding pattern to identify a chromosomal rearrangement in the test chromosome relative to a reference chromosome.03-18-2010
20090029380HUMAN MutY - A human mutY polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating diseases associated with a mutation in this gene. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.01-29-2009
20090023138ORAL CANCER MARKERS AND THEIR DETECTION - Methods of detecting progression from precancer to cancer are provided utilizing toluidine blue staining as well as detecting allelic variation at microsatellite loci. An allelic variation in one or more locus is indicative of a progression from precancer to cancer.01-22-2009
20090181392Transgenic Zebrafish Models for Neurodegenerative Diseases - The present invention relates to zebrafish models for neurodegenerative disorders that allow screening of compounds for their ability to protect and/or regenerate neurons in vivo in a whole vertebrate organism. The present invention also provides methods of identifying gene targets for neuroprotective compounds, compounds that regenerate neurons and compounds that promote neurogenesis.07-16-2009
20090035755Yeast Strain And Screening Method For Identifying Inhibitors Of The Expression Of The Hexose Transporter Genes By A Positive Phenotype - The present invention provides screening procedures for identifying inhibitors of components of regulatory networks by a positive phenotype and modified yeast cell lines suitable for said screening. The screening procedures are especially suited to screen for substances that re-sensitize resistant pathogenic microorganisms or tumor cells by suspending the expression of resistance-relevant genes. The invention further provides methods for constructing said cell lines and their use in screening systems.02-05-2009
20090011424Cancer-suppressing agents - It is an object of the present invention to provide a cancer-suppressing agent comprising a novel cancer-suppressing gene based on the discovery of such cancer-suppressing gene. The present invention provides a cancer-suppressing agent which comprises NR1I2 gene or a homologous gene thereof; and a cancer-suppressing agent which comprises NR1I2 protein or a homologous protein thereof.01-08-2009
20090011423GENES FOR PROGNOSIS OF CANCER - To provide a novel method for determining the risk of lymph node metastasis of breast cancer uses as an index the difference in the expression levels of marker genes between metastatic breast cancer tissue (or cell) and non-metastatic breast cancer tissue (or cell). The method involves (01-08-2009
20090011421SUSCEPTIBILITY TO BONE DAMAGE - In one aspect, the present invention provides methods for determining susceptibility to bone damage in a subject. In some embodiments, the methods comprise screening for polymorphisms in the MTHFR and collagen Iα1 genes that are associated with susceptibility to bone damage. In some embodiments, the methods comprise screening for elevated levels of homocysteine in a subject, wherein elevated levels of homocysteine are associated with an increased risk of bone damage. The methods of the invention may be used in predicting the response of a patient to treatment. Also provided are methods for prevention or reducing the risk of bone damage in a subject.01-08-2009
20090011420SPARSELY CROSS-LINKED NANOGELS: A NOVEL POLYMER STRUCTURE FOR MICROCHANNEL DNA SEQUENCING - The present invention is generally directed to novel polymeric materials for use in the electrophoretic separation of nucleic acids. In particular, the novel polymer materials are sparsely crosslinked nanogels, dissolved in an aqueous buffer to form solutions with moderate to high viscosity. The present invention further provides methods for generating such novel polymers, and related methods of their use.01-08-2009
20090011419PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof.01-08-2009
20090011417Testing Device - The invention provides, in different aspects, a system, sample preparation device, sample processing cartridge, kit, methods of use, business methods, and computer program product.01-08-2009
20090011416Random array DNA analysis by hybridization - The invention relates to methods and devices for analyzing single molecules, i.e. nucleic acids. Such single molecules may be derived from natural samples, such as cells, tissues, soil, air and water without separating or enriching individual components. In certain aspects of the invention, the methods and devices are useful in performing nucleic acid sequence analysis by probe hybridization.01-08-2009
20090011414HUMAN AUTISM SUSCEPTIBILITY GENE ENCODING A KINASE AND USES THEREOF - The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the MARK1 gene on chromosome 1 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the MARKI gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of Asperger syndrome, pervasive developmental disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases including schizophrenia.01-08-2009
20090011413Method for screening colon cancer cells and gene set used for examination of colon cancer - Colon cancer cells in a sample are screened by analyzing the amount of expression of at least 2 or more genes or products thereof selected from the group of genes listed in Tables 1 and 30. As compared to conventional method, patients having colon cancer can be detected with higher accuracy. Colon cancer cells in stool are also screened by analyzing expression of genes selected from the group of genes listed in Table 37.01-08-2009
20090011412HIP1 cancer markers - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, HIP01-08-2009
20090011411Method for Detecting and Quantifying Endogenous Wheat Dna Sequence - It is an object of the present invention to provide partial sequences of endogenous wheat DNA (genome) which are single copies and which allow wheat to be specifically detected without cross-reacting with other plants in PCR, and to provide primers for amplifying these partial sequences, along with a good method for detecting and quantifying endogenous DNA using these primers. The present invention provides, in a method for detecting or quantifying an endogenous wheat DNA sequence in a test sample by means of a polymerase chain reaction, a method comprising a step of using a nucleic acid in the test sample or a nucleic acid extracted from the test sample as a template to amplify the nucleic acid of a region comprising at least 80% or more of a nucleotide sequence represented by one of SEQ ID NO:1 through SEQ ID NO:7 using a primer pair capable of amplifying that region, and a step of detecting or quantifying the amplified nucleic acid.01-08-2009
20090011410METHOD FOR TAILORING ADMINISTRATION OF DRUGS BY QUANTITATION OF MRNA - The present invention discloses a method for tailoring drug protocols to individual patients based on the levels of marker mRNA measured in leukocytes after stimulation of whole blood of the patient with candidate drugs. A method of measuring a patient's responsiveness to a drug is disclosed that includes exposing whole blood of the patient to the drug for 7 hours or less; after the exposure, measuring the amount of an mRNA associated with an effect of the drug in blood cells; and identifying responsiveness to the drug based on the results of the measurement, wherein a change in the amount of the mRNA indicates the patient's responsiveness to the drug. The amount of mRNA measured in the blood cells may be compared with the level of mRNA present in the cells before exposure or with the level of mRNA present in cells exposed for the same amount of time to a control vehicle. Marker mRNAs useful in the present invention include mRNAs encoding the gene product of the p21, BAX, PUMA, NOXA, and IL-2 genes. The method may be employed for patients with, among other conditions, cancer or diseases or conditions requiring immunosuppression.01-08-2009
20090011409Antibodies Against Cells of Fetal Origin - This invention relates to antibodies that specific bind to fetal CD36+ cells in preference to binding to maternal CD36+ cells and methods for using these antibodies to detect and separate fetal cells from adult biological fluids including maternal peripheral blood.01-08-2009
20090011408Methods for detection of a target nucleic acid by forming a cleavage structure using a reverse transcriptase - The invention relates to and methods for generating a signal indicative of the presence of a target nucleic acid in a sample. The compositions and methods include a reverse transcriptase, a nuclease, an upstream primer and downstream probe.01-08-2009
20090011407Polymorphic Cd24 Genotypes that are Predictive of Multiple Sclerosis Risk and Progression - An image data correction apparatus has a motion information acquisition section, a correction section, and a composition section. The motion information acquisition section acquires motion information indicating spatial distribution of the magnitude of motion, in actual space, of a to-be-imaged portion of a subject. Based on the motion information, the correction section performs correction, which is different from correction in a second region, in a first region of image data collected by a scan by magnetic resonance imaging. The composition section composes individual image data of the first region and the second region that are corrected by the correction section.01-08-2009
20090011405Modulating Screening Thresholds for N-Hybrid Screening - The present invention provides improved N-hybrid assays. In particular, the present invention provides an improved reverse N-hybrid assay comprising modulating the amount of a substrate of a reporter gene and/or the amount of a reporter gene thereby enhancing cell death in the absence of a peptide inhibitor of a DNA-protein or protein-protein interaction and/or enhancing cell survival in the presence of a peptide inhibitor of a DNA-protein or protein-protein interaction. Furthermore, the present invention provides an improved forward N-hybrid assay comprising modulating the amount of a reporter gene thereby enhancing cell death in the absence of a heterologous peptide or protein capable of binding to the DNA or protein in a cell and enhancing cell survival in the presence of a heterologous peptide or protein capable of binding to the DNA or protein in a cell.01-08-2009
20090317818RESTRICTION ENDONUCLEASE ENHANCED POLYMORPHIC SEQUENCE DETECTION - Provided in part herein is an improved method for the detection of specific polymorphic alleles in a mixed DNA population. The method comprises enriching the relative percentage of a given polymorphic allele that is exponentially amplifiable by PCR. Provided also are methods for selectively enriching target nucleic acid, for example, fetal nucleic acid in a maternal sample. In the case of detecting fetal nucleic acid in a maternal sample, a restriction enzyme is introduced that can discriminate between the alleles of a polymorphic site. In some embodiments, the maternal allele is digested and nucleic acid comprising the paternal allele is relatively enriched.12-24-2009
20090176233Screening assays for polymerase enhancement - Methods of screening for and selecting for improved polymerases suitable for single molecule sequencing are provided.07-09-2009
20080280286Compositions and Methods for Gene Expression - The invention provides nucleotide sequences that mediate one or more functions of IKKα, kits and methods for using these sequences to identify therapeutic compounds that alter IKKα related pathology.11-13-2008
20090203015MULTIPLEX ASSAYS FOR HORMONAL AND GROWTH FACTOR RECEPTORS, AND USES THEREOF - The present invention provides compositions and methods for simultaneously detecting mRNA expression levels of hormonal receptors, particularly both estrogen receptor (ER) and progesterone receptor (PR), optionally in combination with growth factor receptors, particularly epidermal growth factor receptor ERBB2 (Her-2), and further optionally in combination with control genes, such as the housekeeping genes NUP214 and/or PPIG. Exemplary embodiments of the invention are useful for determining hormonal receptor and/or growth factor receptor status, particular both ER and PR status and optionally also ERBB2 status, such as for assessing or treating breast cancer.08-13-2009
20100086910Surface-modified single-walled carbon nanotubes and methods of detecting a chemical compound using same - A method for surface modification of single walled carbon nanotubes. In one embodiment, the method includes the steps of providing a detergent solution, adding a plurality of single walled carbon nanotubes into the detergent solution, performing a first sonication to disperse the single walled carbon nanotubes in the detergent solution, and performing a second sonication after the first sonication to make detergent encased single walled carbon nanotubes. At least one of the plurality of single walled carbon nanotubes is at least partially wrapped by one or more detergent molecules to make it a detergent encased single walled carbon nanotube. In one embodiment, the detergent comprises SDS, PSS or a combination of them.04-08-2010
20100086915DETECTION OF ESR1 AMPLIFICATION IN BREAST CANCER - The present invention relates to an in-vitro method of identifying a tumor resulting from a proliferative breast disease as responsive to anti-estrogen treatment. Further, the invention relates to an in-vitro method of identifying a candidate patient with a proliferative breast disease as suitable for anti-estrogen treatment. In a further aspect, the invention provides an in-vitro method of identifying an individual with a non-cancerous proliferative breast disease who is at risk of developing breast cancer. The invention also provides kits for performing the above methods.04-08-2010
20100086916OLIGONUCLEOTIDE PROBES AND USES THEREOF - The present invention provides a dually labeled oligonucleotide probe, methods of preparing and using the same. The subject probes are particularly useful for high-sensitive nucleic acid detection via hybridization assays including but not limited to template-directed polymerization reactions.04-08-2010
20100086917Isolated polynucleotides, nucleic acid constructs, methods and kits for localization of rna and/or polypeptides within living cells - An isolated polynucleotide comprising a first nucleic acid sequence which comprises two functionally compatible recognition sites for a site-specific recombination enzyme and a second nucleic acid sequence encoding a protein binding-RNA sequence is provided. Also provided are nucleic acid constructs, methods and kits for localization of an mRNA and/or a polypeptide encoded by a given gene-of-interest within living cells.04-08-2010
20100086918Methods for High Sensitivity Detection of Genetic Polymorphisms - Multiplex PCR-based methods for detecting a variant polynucleotide having a nucleotide sequence differing from the wild-type nucleotide sequence of a nucleic acid molecule, wherein the variant polynucleotide is in a sample containing an excess of the wild-type nucleic acid molecule. The methods are particularly useful for detection of deletions from, or translocations and inversions in, genomic DNA. The susceptibility to, diagnosis of, and progression of a disease clinically related to the occurrence of such polymorphisms in an individual may also be confirmed and monitored using the multiplex PCR-based methods or by detecting RNA fusion transcripts in a sample that correspond to previously identified deletions, translocations or inversions in genomic DNA.04-08-2010
20100086919Devices and methods for immunoglobulin production - The present invention relates to devices and methods that are useful for screening and isolating cells that express a desired immunoglobulin. The present invention further relates to devices and methods that are useful in producing monoclonal antibodies from non-immortal cells (such as B cells) or immortalized cells (such as hybridoma cells). The devices and methods disclosed herein significantly improve the efficiency for monoclonal antibody production.04-08-2010
20100086920METHOD TO ASSESS CANCER SUSCEPTIBILITY AND DIFFERENTIAL DIAGNOSIS OF METASTASES OF UNKNOWN PRIMARY TUMORS - This invention discloses using SPR technology to simultaneously and quantitatively measure the concentrations of different tumor markers in a serum sample, which can be used to screen for and determine susceptibility to cancer as well as for the differential diagnosis of metastases from an unknown primary tumor. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of monoclonal antibodies used for cancer susceptibility assessment and for differential diagnosis of metastases from an unknown primary tumor.04-08-2010
20100086922Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment - Disclosed herein are chromosomal loci associated with clinical outcome to treatment for multiple myeloma. Genome-wide changes observed in myeloma relate to prognosis and treatment response to a proteasome inhibitor. Compositions and methods are provided to assess DNA copy number at corresponding to markers of loci and genes found thereon which are amplified or deleted, overexpressed or underexpressed in myeloma tumors to predict response to treatment, time-to-progression and survival upon treatment.04-08-2010
20100086923USE OF ACETALS FOR ISOLATION OF NUCLEIC ACIDS - The invention provides the use of water-miscible liquid cyclic acetals for adsorbing a nucleic acid to a solid phase such as a substrate with a silica surface. To this end, the invention also provides compositions comprising said acetals. Methods are disclosed and claimed to purify nucleic acids from samples, as well as kits useful for performing these methods. The nucleic acids purified by a method of the invention are suited for assays aiming at the detection of a target nucleic acid.04-08-2010
20100086924USE OF TDE FOR ISOLATION OF NUCLEIC ACIDS - The invention provides the use of tetraethylene glycol dimethyl ether for adsorbing nucleic acids to solid phases such as those with silica surfaces. To this end, the invention also provides compositions comprising TDE. Methods are disclosed and claimed to purify nucleic acids from samples, as well as kits useful for performing these methods. Particularly, the invention encompasses methods for the purification of nucleic acids with low molecular weight. The nucleic acids purified by a method of the invention are suited for assays aiming at the detection of a target nucleic acid.04-08-2010
20100086925MICROFLUIDIC STRUCTURE FOR MULTI-ASSAY AND MICROFLUIDIC DEVICE COMPRISING THE SAME - Exemplary embodiments relate to a microfluidic structure including: a plurality of sample chambers; a reaction chamber in which at least two types of materials, which respectively specifically react with at least two types of target materials, are immobilized; a detection chamber connected to the reaction chamber; a path connecting the chambers; and a valve for opening and closing the path, and a microfluidic device including the microfluidic structure. Since at least two types of materials specifically binding to target materials are immobilized in a reaction chamber of the microfluidic structure, space may be efficiently used and the target materials may be assayed in a one-step test. An internal space of the microfluidic device using the microfluidic structure, the amount of samples, and costs for manufacturing the microfluidic device may be reduced, and internal quality control may be efficiently performed using the microfluidic structure as a control for the operations.04-08-2010
20100086929DETECTION OF ANALYTES - A kit and article of manufacture for detecting an analyte is disclosed. The kit comprises: 04-08-2010
20100086931METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING DECREASE IN GENE EXPRESSION LEVEL AS INDEX - An object of the present invention is to provide a method, a probe, a primer, an antibody, a reagent, and a kit for assaying an action of a pladienolide derivative to a living subject. According to the present invention, there is provided a method for assaying an action of the pladienolide derivative using a decrease in gene expression level as an index.04-08-2010
20100086933SENSOR FOR DETECTING AN ANALYTE - The present invention relates to a sensor for detecting an analyte, to a sensor array, and to a method of detecting an analyte using the sensor of the invention.04-08-2010
20090325184Compositions and Methods for Clonal Amplification and Analysis of Polynucleotides - Compositions and methods of use are disclosed for clonally amplifying and analyzing one or more polynucleotides.12-31-2009
20100075329METHODS FOR PREDICTING PRODUCTION OF ACTIVATING SIGNALS BY CROSS-LINKED BINDING PROTEINS - The present invention provides human binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL21R), and uses therefore. The invention further provides methods to predict whether the binding proteins of the invention may take on agonistic activities in vivo and produce a cytokine storm. In addition, the invention provides methods for determining whether an anti-IL21R binding protein is a neutralizing anti-IL21R binding protein, based on the identification of several IL21-responsive genes. The binding proteins can act as, e.g., antagonists of IL21R activity, thereby modulating immune responses in general, and those mediated by IL21R in particular.03-25-2010
20080318244Large-scale parallel nucleic acid analysis method - It is intended to provide a technique for amplifying, individually and in parallel, nucleic acids contained in a mixture of plural kinds of nucleic acid samples. The present invention provides a nucleic acid analysis method comprising amplification means, whereby amplification reaction is performed in a reaction solution comprising a homogeneous solvent and comprising at least plural template nucleic acids and solid phase carriers comprising one or more kinds of amplification probes immobilized on the surface, to prevent amplified products attributed to two or more template nucleic acids from being replicated in one solid phase carrier. According to the present invention, plural kinds of analyte nucleic acid samples in a mixed state can be amplified individually and in parallel. This method achieves one solid phase carrier-one nucleic acid. Therefore, a higher density of solid phase carriers with obtained amplified products is easily achieved, leading to improved throughput of amplified product analysis. Reactions in all the amplification reaction steps are performed under homogeneous solvent conditions. Therefore, the method of the present invention is performed by convenient procedures and as such, is suitable to automation.12-25-2008
20080318220METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF ALZHEIMER'S DISEASE - The present invention relates to a method for the diagnosis and/or prognosis of Alzheimer's disease by means of determining the ZMIZ1 gene expression level in a biological sample and comparing said level with a reference value, in which the alteration of said level is indicative of Alzheimer's disease.12-25-2008
20080318214Genome Analysis Method - This invention makes it possible to perform analysis for estimating the characteristics of a population using sample data. By obtaining sample data, embedding genetic (statistical) knowledge in a first and second state variable that have duality, and having the first and second state variables converge to the original value, the characteristics of the population of the sample data are estimated, and the estimated results of the characteristics of the population are output. By doing so, it is possible to perform analysis for estimating characteristics of a population using sample data.12-25-2008
20080299582Culture System for Rapid Expansion of Human Embryonic Stem Cells - This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of feeder cells (such as mouse embryonic fibroblasts) to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by components added to the culture environment that support rapid proliferation without differentiation. Effective features are a suitable support structure for the cells, and an effective medium that can be added fresh to the culture without being preconditioned by another cell type. Culturing human embryonic stem cells in fresh medium according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.12-04-2008
20090203018NUCLEIC ACID DETECTION ASSAYS EMPLOYING BLOCKER OLIGONUCLEOTIDES - The present invention provides methods, compositions, and kits for detecting the presence or absence of target sequences in a sample, where the sample also contains interfering sequences that are similar or identical to the target sequences. In particular, the present invention provides blocker oligonucleotides that at least partially inhibit the formation of invasive cleavage structures with the interfering sequences but do not substantially inhibit the formation of invasive cleavage structures with the target sequences.08-13-2009
20090208962MARKERS FOR BREAST CANCER - Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described.08-20-2009
20110027795CELL PROCESSING AND/OR ENRICHMENT METHODS - The present invention relates to methods of processing and/or enriching cells from a pregnant female. More particularly the invention provides methods for processing and/or enriching fetal cells from a pregnant female. The enriched fetal cells can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing.02-03-2011
20110027791METHOD FOR GENERATING SINGLE-STRANDED DNA MOLECULES REPRESENTATIVE OF A DNA SAMPLE - A method for generating a population of single stranded DNA molecules representative of a DNA sample, including digesting the DNA sample with a Type I restriction endonuclease; subjecting the DNA fragments to melt conditions to produce a melt-generated mixture of forward and reverse single stranded DNA fragments; contacting the mixture of forward and reverse single strand DNA fragments with a solid support having immobilized thereon the complement of either the forward or reverse strand, wherein the solid phase hybridizations are favored over self-annealing of the melt-generated single stranded DNA molecules; and releasing the captured forward or reverse single strand DNA fragments from the complement immobilized to the solid support to generate a population of single stranded DNA molecules representative of the DNA sample.02-03-2011
20100021914OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY - The present invention describes oligonucleotides that bind to microRNA target sites in target RNAs, such as mRNAs. The oligonucleotides of the invention may mediate RNase H degradation of the target RNA, mediate RNAi of the target RNA or prevent microRNA regulation of the target RNA. The oligonucleotides of the invention are useful e.g. as research tools for studying microRNA:mRNA interactions and for therapeutic development. The present invention also describes methods of identifying microRNA target sites, methods of validating microRNA target sites, methods of identifying oligonucleotides of the invention and methods of modulating the activity of a target RNA using the oligonucleotides of the invention.01-28-2010
20080241846Genetic polymorphisms associated with coronary events and drung response, methods of detection and uses thereof - The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.10-02-2008
20080286765Human Obesity Susceptibility Gene Encoding a Taste Receptor and Uses Thereof - The present invention discloses the identification of a human obesity susceptibility gene, which can be used for the diagnosis, prevention and treatment of obesity and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the TAS1R1 gene on chromosome 1 and certain alleles thereof are related to susceptibility to obesity and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the TAS1R1 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of coronary heart disease and metabolic disorders, including hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes and dyslipidemia.11-20-2008
20110033860Method For Searching Target Base Sequence Of Rna Interference, Method For Designing Base Sequence Of Polynucleotide For Causing Rna Interference, Method For Producing Double-Stranded Polynucleotide, Method For Inhibiting Gene Expression, Base Sequence Processing Apparatus, Program For Running Base Sequence Processing Method On Computer, Recording Medium, And Base Sequence Processing System - In the present invention, a sequence segment conforming to the following rules (a) to (d) is searched from the base sequences of a target gene of RNA interference and, based on the search results, siRNA capable of causing RNAi is designed, synthesized: 02-10-2011
20090011415REGULATION OF NEURONAL EXPRESSION OF APOLIPOPROTEIN E - The present invention provides nucleic acids comprising a nucleotide sequence encoding an apolipoprotein E (apoE) splice variant, e.g., an unprocessed apoE, that retains intron 3; and vectors and host cells comprising same. The present invention further provides screening methods to identify agents that inhibit cleavage of intron-3 from the apoE splice variant. The present invention further provides methods of treating apoE-related neurological disorders, involving administering an agent that inhibits removal of intron-3 from a precursor apoE mRNA.01-08-2009
20090042188Agent for Differentiating Hematopoietic Stem Cell Into Natural Killer Cell Comprising Vdup1 Protein or Gene Encoding the Same, and a Method of Differentiating Hematopoietic Stem Cell Into Natural Killer Cell Using Thereof - The present invention is related to an agent for differentiating hematopoietic stem cell into natural killer cell comprising VDUP1 protein or gene encoding the same, and a method of differentiating hematopoietic stem cell into natural killer cell using thereof. The present invention reveals for the first time that the VDUP1 gene is a critical factor for the regulation of differentiation of natural killer cell by generating a mouse deficient in VDUP1 gene, which confirms that VDUP1 gene is required for NK maturation. Thus, through the regulation of VDUP1 gene, the modulation of NK cells that have ability to kill cancer cells is possible and can be utilized for cell therapeutics.02-12-2009
20090047668Novel method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same - A method for achieving site specific integration of a desired DNA at a target site in a mammalian cell via homologous recombination is described. This method provides for the reproducible selection of cell lines wherein a desired DNA is integrated at a predetermined transcriptionally active site previously marked with a marker plasmid. The method is particularly suitable for the production of mammalian cell lines which secrete mammalian proteins at high levels, in particular immunoglobulins. Novel vectors and vector combinations for use in the subject cloning method are also provided.02-19-2009
20090053718NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs - The invention relates to ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNAs and their target mRNAs, as well as small interfering RNAs (siRNAs). The invention furthermore relates to oligonucleotide probes for detection and analysis of other non-coding RNAs, mRNAs, mRNA splice variants, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g. alterations associated with human disease, such as cancer.02-26-2009
20090081655Multiplex Real-time Quantitative PCR - Disclosed are compositions and methods for analyzing multiple nucleic acids using PCR.03-26-2009
20090098550MRI CONTRAST AGENTS AND HIGH-THROUGHPUT SCREENING BY MRI - The present invention provides an MRI contrast agent, comprising: MRI contrast agent particles, and oligonucleotides, attached to the particles.04-16-2009
20090104601GENETIC DIAGNOSIS USING MULTIPLE SEQUENCE VARIANT ANALYSIS - The present invention is in the field of nucleic acid-based genetic analysis. More particularly, it discloses novel insights into the overall structure of genetic variation in all living species. The structure can be revealed with the use of any data set of genetic variants from a particular locus. The invention is useful to define the subset of variations that are most suited as genetic markers to search for correlations with certain phenotypic traits. Additionally, the insights are useful for the development of algorithms and computer programs that convert genotype data into the constituent haplotypes that are laborious and costly to derive in an experimental way. The invention is useful in areas such as (i) genome-wide association studies, (ii) clinical in vitro diagnosis, (iii) plant and animal breeding, (iv) the identification of micro-organisms.04-23-2009
20090162842Circulating mRNA as diagnostic markers - Methods and kits are provided for diagnosing, monitoring, or predicting the conditions of pre-eclampsia, fetal chromosomal aneuploidy, and pre-term labor in a pregnant woman, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more mRNA species encoding human chorionic gonadotropin β subunit (hCG-β), human placental lactogen (hPL), human corticotropin releasing hormone (hCRH), KiSS-1 metastasis-suppressor (KISS1), tissue factor pathway inhibitor 2 (TPFI2), placenta-specific 1 (PLAC1), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and comparing the amount of the mRNA species with a standard control.06-25-2009
20080293061PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof.11-27-2008
20090305292DNA POLYMERASE - The present invention relates to DNA polymerases. In particular the invention relates to a method for the generation of DNA polymerases exhibiting a relaxed substrate specificity. Uses of mutant polymerases produced using the methods of the invention are also described.12-10-2009
20090170098ANTIBODIES TO CELL-CYCLE REGULATORY PROTEIN P16, AND USES RELATED THERETO - The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins. The present invention is directed to a kit for detecting the level of cyclin-dependent kinase inhibitor p16 gene expression comprising antibodies directed to a p16 protein.07-02-2009
20100124745Methods ofr the detection of gene trannscripts in blood and uses thereof - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.05-20-2010
20110045483Diagnostic Screens for Alzheimer's Disease - The present invention relates diagnostic screens for Alzheimer's disease, and in particular to diagnostic tests based on screening for the presence of cellular changes that occur early in the pathology of Alzheimer's disease.02-24-2011
20100099081Method for Typing HLA Alleles - The present invention relates to the typing of HLA alleles. The sequence of exon 2 and exon 3 of the alleles HLA-B*3913, HLA-B*1406 and HLA-B*51 new and of exon 2 of the alleles HLA-DRB1*0820, HLA-DRB1*04 new and HLA-DRB4*01 new are disclosed. The present invention relates to methods for typing of said alleles. According to a preferred embodiment, said typing comprises the following steps: i) amplifying a relevant fragment of said alleles using at least one suitable pair of primers; ii) hybridizing the amplification product of step i) to at least one probe that specifically hybridizes to a target region comprising one or more polymorphic nucleotides in said relevant fragment; iii) determining from the result of step ii) the absence or presence of said alleles in the sample. The present invention further provides primers and probes to be used in said methods for typing. A diagnostic kit comprising said primers and probes is also part of the present invention.04-22-2010
20110091891PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof.04-21-2011
20100159453GENES INVOLVED IN INTESTINAL INFLAMMATORY DISEASES AND USE THEREOF - The invention concerns genes involved in inflammatory and/or immune diseases and some cancers, in particular intestinal cryptogenic inflammatory diseases, and proteins coded by said genes. The invention also concerns methods for diagnosing inflammatory diseases.06-24-2010
20110111396BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS - Provided herein are the biomarkers for monitoring the treatment by quinazolinone compounds. For example, the use of SPARC, p21, and cyclin D1 mRNA levels as biomarkers to predict whether a quinazolinone compound is likely to be successful in treating certain types of cancer, such as NHL is provided. Further, the expression of these genes can be used to monitor progress of treatment effectiveness and patient compliance in cancer patients that are receiving treatment with quinazolinone compounds.05-12-2011
20100028874HEPATITIS C VIRUS INFECTION BIOMARKERS - A signature set of genes associated with hepatitis C virus infection is described.02-04-2010
20090130688Method for Accessing Microbial Diversity - A method of interfering with quorum sensing regulation of genes to promote cell growth is disclosed. The method of is aimed at accessing microbial biodiversity. The method involves obtaining an environmental sample comprising at least one novel (uncultivated in the laboratory) microorganism, contacting the environmental sample with an effective amount of an agent or combination of agents which interferes with the quorum sensing regulation of genes, growing the treated sample in a culture medium containing the quorum sensing signal disrupting agent or agents, and analyzing the colonies of microorganisms grown to demonstrate genetic novelty.05-21-2009
20080299548Gene Expressed Specifically in Es Cells and utilization of the Same - The present invention relates to an ES cell detection marker containing a polynucleotide derived from any one of ECAT15-1 gene, ECAT15-2 gene, ECAT16 gene, Rnf17 gene and LOC380905(TDRD4) gene.12-04-2008
20100167277Fret sequencing by DNA scanning proteins - This patent describes a novel method for DNA sequencing. A DNA hybrid is created such that one strand contains nucleotides (A, G, C, T/U) bound to different FRET acceptor fluorophores that emits a distinct, differentiable wavelength. A DNA scanning protein carrying a FRET donor fluorophore is also added. A laser with a wavelength that excites the donor molecule irradiates the reaction. As the protein complex passes over a nucleotide on the DNA strand, a FRET reaction occurs between the donor and acceptor fluorophores. The acceptor fluorophore will emit a distinct wavelength which is detected and correlated to a specific nucleotide. As the DNA scanning protein moves along the DNA molecule the entire sequence of nucleotides can be determined by correlating the wavelengths emitted with the specific nucleotide associated with it.07-01-2010
20090208944ASSESSING OUTCOMES FOR BREAST CANCER PATIENTS TREATED WITH TAMOXIFEN - This document provides methods and materials related to assessing the likely outcome for mammals (e.g., humans) with cancer (e.g., breast cancer). For example, methods and materials that involve assessing a breast cancer patient's cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) genotype to determine the likelihood of the beast cancer patient to experience breast cancer relapse or death are provided. Methods and materials that involve assessing the likelihood that a breast cancer patient being treated with tamoxifen will experience side effects such as hot flashes also are provided.08-20-2009
20080274469C-Kit Oncogene Mutations in Melanoma - The present invention provides methods of detecting c-KIT-dependent-melanoma for diagnostic and prognostic purposes. The invention further provides methods of treating such melanoma by inhibiting c-KIT.11-06-2008
20100240039FHL1 MUTATIONS ASSOCIATED WITH NOVEL X-LINKED MUSCULAR MYOPATHIES - Four and a Half LIM domains protein 1 (FHL-1) mutations at positions 128 or 224 that are associated with X-linked muscular myopathy, methods of screening subjects to identify those susceptible to muscular myopathy including muscular dystrophy and cardiomyopathy and kits.09-23-2010
20090061444PHYTOCHROME-BASED FLUOROPHORES - Genetically-engineered fluorophore molecules with increased fluorescence are provided. These fluorophores are derived from the domains of phytochromes, and in particular bacterial phytochromes. Methods for generating these fluorophores and various applications of these fluorophores are also provided.03-05-2009
20100035245Analyte test system using non-enzymatic analyte recognition elements - An analyte test element for the qualitative and/or quantitative determination of at least one analyte in a physiological or aqueous sample fluid having a first surface (02-11-2010
20100035254COMPOSITION AND METHOD FOR NUCLEIC ACID SEQUENCING - The present invention provides compositions and methods for detecting incorporation of a labeled nucleotide triphosphate onto the growing end of a primer nucleic acid molecule. The method is used, for example, to genotype and sequence a nucleic acid. In a preferred embodiment, the method described herein detects individual NTP molecules.02-11-2010
20090186342Methods of producing competitive aptamer fret reagents and assays - Methods are described for the production and use of fluorescence resonance energy transfer (FRET)-based competitive displacement aptamer assay formats. The assay schemes involve FRET in which the analyte (target) is quencher (Q)-labeled and previously bound by a fluorophore (F)-labeled aptamer such that when unlabeled analyte is added to the system and excited by specific wavelengths of light, the fluorescence intensity of the system changes in proportion to the amount of unlabeled analyte added. Alternatively, the aptamer can be Q-labeled and previously bound to an F-labeled analyte so that when unlabeled analyte enters the system, the fluorescence intensity also changes in proportion to the amount of unlabeled analyte. The F or Q is covalently linked to nucleotide triphosphates (NTPs), which are incorporated into the aptamer by various nucleic acid polymerases, such as Taq or Deep Vent Exo07-23-2009
20100240031Method of Predicting Metastatic Potential Prognosis or Overall Survival of Cancer Patients - A method of predicting metastatic potential, prognosis or overall survival of cancer patients is provided. The method utilizes reliable markers, HIF-1α, TWIST or Snail, to predict the probability of the metastatic potential, prognosis situation or overall survival of cancer patients. Moreover, the method provided by the present invention can reach relatively higher predictability of metastatic potential, prognosis situation or overall survival as compared with the current markers.09-23-2010
20090042200CELLOMICS SYSTEM - In labeling a cell, and separating and collecting the cell according to a degree of the labeling using a cell separator, effects on the cell is minimized and the use of the collected cell is facilitated, thereby, when labeling a cell, the cell is labeled in the state where interaction of each cell is retained. In the labeling, a specific labeling material present on a surface of a target cell is taken in the cell via a transporter, and the cell is dispersed one by one to separate the same with a cell separator. Immediately after the separation, the cell is put in a solution not containing the specific labeling substance to remove the specific labeling substance taken in the cell. This series of steps is continuously conducted with a cell separation chip.02-12-2009
20110039275 Method for Predicting a Clinical Response of a Patient Suffering from or at Risk of Developing Cancer Towards a Given Mode of Treatment - The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing cancer, preferably colorectal cancer, towards a given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the expression level of at least SPON-2, and optionally determining the expression level of SPON-1, in said sample; c) comparing the expression level or expression levels determined in (b) with one or several reference expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient or implementing therapeutic regimen in said subject from the outcome of the comparison in step (C).02-17-2011
20110129818ASSAY FOR CARDIAC TROPONIN-T (cTnT) - The present disclosure describes immunoassays for detecting cardiac troponin-T (cTnT) in a test sample, and in particular immunoassays and kits for detecting cTnT in a test sample suspected of containing substances that may interfere with the determination of cTnT, such as heterophilic endogenous antibodies and autoantibodies to cTnT. The methods use more than one capture phase antibody and more than one detection antibody to improve specificity, and provide for the use of humanized immunoreagents to overcome heterophilic antibody interferences.06-02-2011
20110033854METHODS AND COMPOSITIONS FOR LONG FRAGMENT READ SEQUENCING - The present invention is directed to methods and compositions for long fragment read sequencing. The present invention encompasses methods and compositions for preparing long fragments of genomic DNA, for processing genomic DNA for long fragment read sequencing methods, as well as software and algorithms for processing and analyzing sequence data.02-10-2011
20110117568Method for Amplifying Target Nucleic Acid Sequence, Method for Detecting Mutation Using the Same, and Reagent Used for the Same - The present invention provides a method for detecting a mutation capable of detecting a mutation with high sensitivity and high reliability in one reaction system. Using primers (Xmt) and (Xwt), a target nucleic acid sequence whose objective base to be detected is a mutant-type is amplified with amplification efficiency higher than a target nucleic acid sequence whose objective base to be detected is a normal-type. The (Xmt) is a primer that is complementary to a region including a mutant-type base in the template nucleic acid and has a base complementary to a mutant-type base at a 3′ region, and the (Xwt) is a primer that is complementary to a region including a normal-type base in the template nucleic acid and has a base complementary to a normal-type base at a 3′ region. It is preferable that amplification efficiency by the (Xmt) with reference to a mutant-type template nucleic acid is higher than that by the (Xwt) with reference to a normal-type template nucleic acid. Then, a signal value that shows a molten state of a hybridization product between the thus obtained amplification product and the probe is measured, and the presence or absence of the mutation of the objective base site is determined from a change in the signal value accompanying a change in the temperature.05-19-2011
20110081651EGFR AND KRAS MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and KRAS and methods of detecting such mutations as well as prognostic methods for identifying tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein and/or a mutated KRAS gene or mutated KRAS protein in a tumor sample.04-07-2011
20080268432Method for detection of staphylococcus epidermidis - A method for detecting the bacteria 10-30-2008
20080227100METHOD FOR ESTIMATING hERG INHIBITION OF DRUG CANDIDATES USING MULTIVARIATE PROPERTY AND PHARMACOPHORE SAR - The present invention provides a computational model and methods of use thereof for predicting whether a compound is likely to inhibit K09-18-2008
20100240060Detection and Diagnosis of Smoking Related Cancers - Gene probes for specific regions of chromosome 3 (3p21.3) and chromosome 10 (10q22) have been found to be tools for the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, as well as determine a patients susceptibility to the development of smoking related cancers.09-23-2010
20090275034TEMPERATURE CONTROL SYSTEM - Single molecule technologies generally require sensitive optical detection and the ability to operate at multiple temperatures simultaneously in different parts of the instrument. The system for controlling the temperature of a microfluidic device and methods for controlling the temperature of sequencing reactions includes a chamber for receiving a microfluidic device, a heating control device in fluid communication with the chamber for delivering a heated fluid to the chamber to heat the microfluidic device, and a cooling control device in liquid communication with the chamber for delivering a cooled fluid to the chamber to cool the microfluidic device. A temperature control unit in liquid communication with a cooling element and/or a heating element are used to regulate temperature of sequencing substrates and objective lenses for optical detection of sequencing reactions.11-05-2009
20100196900METHOD OF DETECTING CANINE EXERCISE-INDUCED COLLAPSE - The present invention relates to diagnosing Canine Exercise-Induced Collapse (EIC). 08-05-2010
20110039265Method of detecting tumor-associated DNA in plasma or serum - This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in human or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such a oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humane and other animals.02-17-2011
20110091890TRICHOPLUSIA NI CELL LINE AND METHODS OF USE - An isolated cell from the cell line identified as TnT4. This cell may be infected with a baculovirus expression vector which may carry a heterologous nucleotide that encodes a polypeptide, such as a membrane protein, e.g., human neurotensin receptor 1. Also included is a method for using this cell line to produce a polypeptide, such as a membrane protein; and a method for identifying a cell-of-interest which expresses a protein-of-interest.04-21-2011
20090098565MeCP2E1 gene - The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.04-16-2009
20090098549SELEX AND PHOTOSELEX - The present disclosure describes improved SELEX methods for generating nucleic acid ligands that are capable of binding to target molecules and improved photoSELEX methods for generating photoreactive nucleic acid ligands that are capable of both binding and covalently crosslinking to target molecules. The disclosure further describes nucleic acid libraries having expanded physical and chemical properties and their use in SELEX and photoSELEX; methods for increasing the crosslinking efficiencies of photoaptamers; methods for producing photoaptamers having selective modifications that enhance functionality and minimize non-specific photoreactions; and methods for generating truncated nucleic acid ligands from nucleic acid ligands of longer length. The disclosure further describes aptamers and photoaptamers obtained by using any of the foregoing.04-16-2009
20090098546Methods of Screening for LTRPC7 Modulators - The present invention relates to the identification and isolation of a novel family of ATP regulated calcium transmembrane channel polypeptides designated herein as “LTRPC7” (Long Transient Receptor Potential Channel). Channels comprising these polypeptides close in response to concentrations of cytoplasmic ATP in the millimolar range, are subject to inhibition by high intracellular levels of calcium and/or magnesium, and do not respond to depletion or reduction in intracellular calcium stores. The invention further relates to the methods of utilizing LTRPC7 for binding, and the methods for modulating LTRPC7 activity and for measuring LTRPC2 permeability. The invention further relates to the methods of modulating expression of LTRPC7.04-16-2009
20090098542Gene Methylation in Colon Cancer Diagnosis - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with colon cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of colon cancer.04-16-2009
20090098535UPREGULATION OF RACK-1 IN MELANOMA AND ITS USE AS A MARKER - The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocytic cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocytic cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocytic cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein.04-16-2009
20110129817BLOOD TRANSCRIPTIONAL SIGNATURE OF ACTIVE VERSUS LATENT MYCOBACTERIUM TUBERCULOSIS INFECTION - The present invention includes methods, systems and kits for distinguishing between active and latent 06-02-2011
20090291441POLYPEPTIDE, NUCLEIC ACID MOLECULE ENCODING IT AND THEIR USES - A polypeptide containing epitope of the amino acid sequence shown in SEQ ID NO:3 is provided, which is selected from the amino acid sequence of SEQ ID NO:3 and amino acids at 16-32 positions, amino acids at 1-30 positions, amino acids at 50-80 positions and amino acids at 17-200 positions of the amino acid sequence shown in SEQ ID NO:3. The nucleic acid molecule encoding the polypeptide, recombinant vectors and host cells comprising the nucleic acid molecule are also provided. The polypeptide and the nucleic acid molecule encoding it can be used for preparing reagents, kits or devices for diagnosing the diseases characterized by EECP expression and pharmaceutical compositions for preventing or treating the diseases characterized by EECP expression by increasing or inhibiting EECP expression and/or activity.11-26-2009
20080299567PRIMER AND PROBE SEQUENCES FOR DETECTING CHLAMYDIA TRACHOMATIS - The present invention relates to primers and probes that can be used in various assays to detect a new strain of 12-04-2008
20090136957Methods and compositions for regulating cell cycle progression via the miR-106B family - In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one microRNA-specific inhibitor of at least one miR-106b family member. In another aspect a method is provided for accelerating proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one miR-106b family member.05-28-2009
20090023139Method For Site-Specifically Introducing Non-Natural Amino Acid Into Protien Using Mitochondrial Protein and Method For Effectively Preparing Trna - This invention is intended to provide a protein synthesis system used for producing a tryptophan analogue-containing non-natural-amino-acid-containing protein that satisfies the following conditions: (i) tRNA that transfers a non-natural amino acid is not recognized by an endogenous aminoacyl tRNA synthetase (aaRS); (ii) it is recognized selectively by aaRS exclusive for a non-natural amino acid; and (iii) endogenous tRNA is not recognized by aaRS exclusive for a non-natural amino acid. In the eukaryotic organism-derived cell-free protein synthesis system, a yeast mitochondrial tryptophanyl tRNA synthetase is used in combination with mitochondrial tRNA01-22-2009
20090117538Methods for Obtaining Gene Tags - The present invention provides methods for providing as tags the nucleotide sequences at the 5′ end of mRNA. The method of the present invention comprises the step of synthesizing cDNA using, as a template, mRNA whose CAP structure is linked with a IIs linker having a type IIs endonuclease recognition sequence. Tags including the nucleotide sequence from the 5′ end of mRNA are generated by reacting the type IIs endonuclease to cDNA. Tags can be generated from all mRNA, independently of their nucleotide sequences. Methods for identifying transcriptional start sites and primers for full-length cDNA synthesis are provided based on the nucleotide sequence information of tags of the present invention.05-07-2009
20100028867LRRTM1 Compositions and Methods of Their Use for the Diagnosis and Treatment of Cancer - Microarray analysis, confirmed by RT-PCR, demonstrated that mRNA from certain cancer tissues, for example, ovarian cancer tissue, pancreatic cancer tissue, and colorectal cancer tissue, hybridizes specifically and preferentially to LRRTM1. LRRTM1 is a leucine-rich repeat transmembrane protein overexpressed on the surface of cancer cells compared to normal tissues and thus provides a therapeutic target for treating cancer. Modulators of LRRTM1, highly expressed in cancerous as compared to normal tissues, are provided for the diagnosis and treatment of proliferative disorders such as cancer. The invention further provides methods of treating cancer with therapeutic agents directed toward LRRTM1.02-04-2010
20090061446METHOD FOR QUICKLY IDENTIFYING PATHOGENIC BACTERIA RESPONSIBLE FOR INFECTION - A system rapidly detects and identifies pathogenic bacteria responsible for infection (particularly septicemia), and selects an appropriate antimicrobial drug. A method according to the present invention for detecting and identifying pathogenic bacteria includes performing gene amplification such as real-time PCR, and analyzing the combination of the melting temperatures (Tm values) determined by gene amplification product melting curve analysis or the difference between the Tm values. Specifically, real-time PCR is performed using 4 to 16 primer sets including 1 to 7 primer sets for the 16S ribosomal RNA of bacteria, 1 to 6 primer sets for the 18S ribosomal RNA of fungi, and one primer set respectively for the spa gene and the mecA gene specific to MRSA, and the combination of the Tm values of the amplification product or the combination of the differences between the Tm values is compared with a database to identify pathogenic bacteria responsible for septicemia. Pathogenic bacteria responsible for infection (particularly septicemia) can be rapidly detected and identified using the method according to the invention so that a rapid septicemia diagnosis method and evidence-based medicine in septicemia treatment are implemented.03-05-2009
20100248235BIOMARKERS FOR AUTISM SPECTRUM DISORDERS - Methods of determining the risk of ASD in an individual are provided which comprise identifying the presence of one or more genomic mutations in one or more of the genes, PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1.09-30-2010
20090203002MESENCHYMAL STEM CELLS AS A VEHICLE FOR ION CHANNEL TRANSFER IN SYNCYTIAL STRUCTURES - The present invention provides a method of selectively amplifying fetal DNA sequences from a mixed, fetal-maternal source. This method utilizes differential methylation to allow for the selective amplification of trophoblast/fetal specific sequences from DNA mixtures that contain a high proportion of non-trophoblast/fetal DNA. The invention also provides methods of using the amplified fetal DNA sequences for aneuploidy detection.08-13-2009
20100184081GENETIC MARKERS FOR OBESITY - The present invention is directed to new genetic variants or polymorphisms at the perilipin locus (PLIN) including PLIN1: 6209T (allele 1)>C (allele 2); PLIN3 10171 (allele 1) A >T (allele 2); PLIN4: 11482G (allele 1)>A (allele 2); PLIN5: 13041A (allele 1)>G (allele 2) and PLIN6: 14995A (allele 1)>T (allele 2), and their use in diagnostic and prognostic applications for obesity and obesity-related diseases, such as metabolic syndrome and cardiovascular disease.07-22-2010
20090029386KIT FOR ENUMERATING MAMMALIAN CELL MICRONUCLEI WITH AN EMPHASIS ON DIFFERENTIALLY STAINING MICRONUCLEI AND THE CHROMATIN OF DEAD AND DYING CELLS - The present invention relates a method for the enumeration of mammalian cell micronuclei, while distinguishing micronuclei from the chromatin of dead and dying cells. The method utilizes differential staining of chromatin from dead and dying cells, to distinguish the chromatin from micronuclei and nuclei that can be detected based upon fluorescent emission and light scatter following exposure to an excitatory light source. Counting of micronuclei events relative to the number of nuclei can be used to assess the DNA-damaging potential of a chemical agent, the DNA-damaging potential of a physical agent, the effects of an agent which can modify endogenously-induced DNA damage, and the effects of an agent which can modify exogenously-induced DNA damage. Kits for practicing the invention are also disclosed.01-29-2009
20090208956PRIMER SET FOR AMPLIFYING CYP2C9 GENE, REAGENT FOR AMPLIFYING CYP2C9 GENE CONTAINING THE SAME, AND THE USES THEREOF - A primer set for amplifying a region including a site to be detected of CT2C9*3 in the C-YT2C9 gene by a gene amplification method is provided, wherein the primer set can amplify the region specifically. A pair of primer set is used including a forward primer consisting of the base sequence of SEQ ID NO: 4 as well as a reverse primer consisting of the base sequence of SEQ ID NO: 17. The use of this primer set makes it possible to specifically and efficiently amplify a target region including the site where a polymorphism, CYP2C9*3, of the CYP2C9 gene is generated.08-20-2009
20090035763Methods for Detecting Progression of Low Grade Cervical Dysplasia and for Detecting Adenocarcinomas - The invention provides methods for identifying conditions of low grade cervical dysplasia and assessing the progressive potential of individual lesions to develop into high grade cervical dysplasia and cervical squamous cell cancer as well as cervical adenocarcinoma.02-05-2009
20090176224Udder Health Characteristics - The invention relates to a method for determining udder health characteristics in bovine subjects, wherein udder health characteristics comprise sub-clinical and clinical mastitis. In particular, the method of the invention involves identification of genetic markers and/or Quantitative Trait Locus (QTL) for the determination of udder health characteristics in a bovine subject. The determination of udder health characteristics involves resolution of the specific microsatellite status. Furthermore, the invention relates to a diagnostic kit for detection of genetic marker(s) associated with udder health. The method and kit of the present invention can be applied for selection of bovine subjects for breeding purposes. Thus, the invention provides a method of genetically selecting bovine subjects with udder health characteristics that will yield cows less prone to mastitis.07-09-2009
20080274455Use Of Genes As Molecular Markers In Diagnosis Of Schizophrenia And Diagnostic Kit For The Same - Drug-naive and drug-free schizophrenic PBL were screened to identify additional markers that are differentially expressed compared to healthy individuals using microarray and quantitative real-time PCR (QRT-PCR) techniques. Genes for dopamine D11-06-2008
20100055687Mutations in the BCR-ABL tyrosine kinase associated with resistance to ST1-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.03-04-2010
20090155807C-MET MUTATIONS IN LUNG CANCER - The invention provides methods and compositions useful for detecting mutations in c-met in lung cancer cells.06-18-2009
20100221730Methods for assessing SPARC Resistance, Disease Progression, and Treatment Efficacy in Ovarian Cancer - The invention provides methods for predicting whether an ovarian cancer patient's tumor will be resistant to chemotherapy. The invention also provides methods for monitoring the effectiveness of treatment, particularly a chemotherapeutic treatment, in a patient treated for ovarian cancer. The invention further provides methods for treating ovarian cancer, by reducing chemotherapeutic drug resistance in said cells. In addition, the invention provides methods of screening compounds to identify tumor cell growth inhibitors in tumor cells resistant to conventional chemotherapeutic treatment regimes.09-02-2010
20090117559Methods for Determining Probability of an Adverse or Favorable Reaction to a Niacin Receptor Agonist - The present invention relates generally to a GPR109A niacin receptor. The present invention relates more particularly to assessing a GPR109A polymorphism in an individual, wherein the GPR109A polymorphism is indicative of the subject's risk for an adverse reaction to the administration of a GPR109A receptor agonist, wherein the adverse reaction is associated with stimulation of MAP kinase activity by the GPR109A receptor agonist. More specifically, the present invention relates to assessing a GPR109A polymorphism in an individual and determining the level of risk for the subject for experiencing an adverse reaction, wherein the subject's GPR109A zygosity is predictive of the risk for a cutaneous flushing response that can be experienced following administration of a GPR109A receptor agonist.05-07-2009
20100221711Respiratory Syncytial Virus (RSV) Viral Load Detection Assay - The invention concerns a method for the extraction of nucleic acids from biological samples e.g. tissue material or sputum derived from human or animal species and the quantitative detection thereafter of said nucleic acids e.g. in terms of viral load, more specifically RSV viral load detection.09-02-2010
20080293051 PROXIMITY LIGATION ASSAY - The present invention relates to compositions and methods for sensitive, rapid and convenient assays to detect and/or quantify one or more target using ribonucleic acid as probes, wherein the method includes binding a first and a second ribonucleic acid probe, each of which binds specifically to the target, wherein the first and second probes each comprise a ribonucleic acid tail; ligating the first and second ribonucleic acids tails thereby producing a ligated ribonucleic acid template; and performing amplification of the ribonucleic acid template across the first and second ribonucleic acids.11-27-2008
20090035754Methods and compositions for detecting steroids - The present invention provides for methods and systems for detecting steroids. Examples of such steroids include estrogen, progesterone, androgen, testosterone, and derivatives and analogs thereof. Systems useful for carrying out the method include tripartite constructs including a DNA-binding domain, a ligand binding domain, and an activation domain. The present invention provides numerous improvements over previous diagnostic systems for detection of steroids, such advantages include that the method allows for detection of steroid analogs and derivatives, whose structures may not yet be known, the method is generally applicable to a wide variety of organisms, and numerous ligand binding domains may be used in conjunction with the present system.02-05-2009
20110111408METHODS AND COMPOSITION FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES - The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof.05-12-2011
20090155788GENE EXPRESSION MARKERS FOR INFLAMMATORY BOWEL DISEASE - The present invention provides for a method of detecting the presence of inflammatory bowel disease in gastrointestinal tissues or cells of a mammal by detecting decreased expression of Indian Hedgehog (Ihh) and/or increased expression of Defensin A5 (DefA5) and/or Defensin A6 (DefA6) in the tissues or cells of the mammal relative to a control.06-18-2009
20100009353Dye Compounds and the Use of their Labelled Conjugates - Novel rhodamine dye compounds, labelled conjugates comprising the dyes are described, together with methods for their use. The dyes and labelled conjugates are useful as molecular probes in a variety of applications, such as in assays involving staining of cells, protein binding, and analysis of nucleic acids, such as hybridization assays and nucleic acid sequencing.01-14-2010
20100323361METHODS, SYSTEMS AND KITS FOR DETECTING PROTEIN-NUCLEIC ACID INTERACTIONS - Methods, systems and kits for detecting protein-nucleic acid interactions, in particular, detecting the genomic location to near-base pair resolution at which a particular protein (e.g., transcription factor) binds includes combining steps of a convention chromatin immunoprecipitation (ChIP) assay with use of an exonuclease that digests DNA strands in the 5′-3′ or 3′-5′ direction until it reaches a bound protein including a protein crosslinked to DNA. A significant improvement of the resolution and dynamic range of the ChIP assay will increase one's ability to determine with confidence where a particular protein is binding in the genome. Importantly, proteins that inefficiently crosslink to DNA (either intrinsically or due to indirect crosslinking via another protein) and thus are very difficult to detect, are expected to be significantly detected by the kits and methods described herein. Inasmuch as most aspects of infectious diseases, inborn diseases, and cancers are rooted in the mis-expression of genes, having a better measure of the binding of proteins to genes or promoter regions will greatly enhance the ability of investigators to understand the driving molecular mechanisms behind these human maladies.12-23-2010
20090148836Method for Rapid Detection and Identification of Bioagents - Method for detecting and identifying unknown bioagents, including bacteria, viruses and the like, by a combination of nucleic acid amplification and molecular weight determination using primers which hybridize to conserved sequence regions of nucleic acids derived from a bioagent and which bracket variable sequence regions that uniquely identify the bioagent. The result is a “base composition signature” (BCS) which is then matched against a database of base composition signatures, by which the bioagent is identified.06-11-2009
20110123980SEQUENCE-SPECIFIC DETECTION OF NUCLEOTIDE SEQUENCES - A method for detecting the presence of a target nucleotide sequence in a sample of DNA is described herein in which a test sample comprising single stranded DNA is exposed to a DNA probe and a nicking endonuclease under conditions that would permit sequence-specific hybridization of the probe to a complementary target sequence. The probe comprises a sequence complementary to the target sequence to be detected and this sequence also includes a recognition sequence for the nicking endonuclease. If the sample contains the target sequence, the probe hybridizes to the target and is cleaved by the nicking endonuclease, which leaves the target intact. Observing the presence of probe cleaved by the nicking endonuclease indicates the presence of the target nucleotide sequence in the sample of DNA.05-26-2011
20100330551Novel Restriction Endonucleases, DNA Encoding These Endonucleases and Methods for Identifying New Endonucleases with the Same or Varied Specificity - Specified restriction endonucleases have been characterized for the first time by their amino acid and DNA sequences. These sequences and those with at least 90% identity thereto have been used as probes in sequence similarity analyses to identify sequence matches in a sequence database that corresponds to novel restriction endonucleases or isoschizomers. The sequence similarity analyses includes selecting a positive sequence match from any sequence producing an expectation value of less than or equal to e-02.12-30-2010
20100267039METHOD OF DIFFERENTIATING COCCIDIOIDES SPECIES - The invention pertains to methods and kits useful in the identification of and differentiation between 10-21-2010
20100267045CUDR AS BIOMARKER FOR CANCER PROGRESSION AND THERAPEUTIC RESPONSE - Disclosed is a novel human gene designated CUDR. Provides is also a CUDR gene as a biomarker in the diagnosis of human cancers and a cancer therapy.10-21-2010
20100267037GENOTOXICITY AS A BIOMARKER FOR INFLAMMATION - The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation. The method can be adapted for quantitatively monitoring the efficacy of treatment of inflammatory disease in a subject. Markers of DNA damage include single- and/or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitric oxide oxidative activity (protein nitrosylation in leukocytes). The inflammatory disease can be inflammatory bowel disease (ulcerative colitis or Crohn's disease). The invention may also be used for detection of other types of inflammatory disease, such as non-immune intestinal inflammatory disease (diverticulitis, pseudomembranous colitis), autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, uveitis, vasculitis), or non-immune lung diseases (asthma, chronic obstructive lung disease, and interstitial pneumonitis). This unexpected discovery of markers of genotoxicity present in circulating leukocytes enables detection of inflammation occurring at a localized site with a relatively simple and minimally invasive assay using peripheral blood.10-21-2010
20100267031Method of Screening for RAGE-Amyloid-Beta Peptide Interaction Inhibiting Materials - Provided are a system and a method of screening for RAGE-amyloid beta peptide interaction inhibiting materials using a Transwell plate and a RAGE-expressing cell line.10-21-2010
20100267016TRANSGENIC MICROBIAL POLYHYDROXYALKANOATE PRODUCERS - Transgenic microbial strains are provided which contain the genes required for PHA formation integrated on the chromosome. The strains are advantageous in PHA production processes, because (1) no plasmids need to be maintained, generally obviating the required use of antibiotics or other stabilizing pressures, and (2) no plasmid loss occurs, thereby stabilizing the number of gene copies per cell throughout the fermentation process, resulting in homogeneous PHA product formation throughout the production process. Genes are integrated using standard techniques, preferably transposon mutagenesis. In a preferred embodiment wherein multiple genes are incorporated, these are incorporated as an operon. Sequences are used to stabilize mRNA, to induce expression as a function of culture conditions (such as phosphate concentration), temperature, and stress, and to aid in selection, through the incorporation of selection markers such as markers conferring antibiotic resistance.10-21-2010
20090208952UTILITY OF RET MUTANT IN DIAGNOSIS AND TREATMENT OF MELANOMA - The invention relates to a method of detecting a RET mutant in a melanoma cell. Also disclosed is a method of modulating the activity of a RET mutant in a melanoma cell with an agent that interferes with the activity of the RET mutant.08-20-2009
20090258369OVER-EXPRESSION AND MUTATION OF A TYROSINE KINASE RECEPTOR FGFR4 IN TUMORS - This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR4 variants, which are linked to increased risk of tumor metastasis. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.10-15-2009
20100143912SPECIFIC N-TERMINAL LABELING OF PEPTIDES AND PROTEINS IN COMPLEX MIXTURES - This invention provides general methods for selective labeling of proteins on their N-termini with synthetic peptides. The methods of this invention can be applied to the global proteomic profiling of complex mixtures of proteins and polypeptides.06-10-2010
20100047771MARKERS FOR THE DIAGNOSIS OF LUNG CANCER - Disclosed is a diagnostic marker specific for lung cancer. Also, the present invention relates to a composition and a kit, comprising an agent measuring the presence of the marker, and a method of diagnosing lung cancer using the composition or kit.02-25-2010
20090220980USE OF METHYLATION STATUS OF MINT LOCI AND TUMOR-RELATED GENES AS A MARKER FOR MELANOMA AND BREAST CANCER - The invention relates to a method of detecting melanoma or breast cancer using DNA methylation in MINT17, MINT31, or the promoter region of WIF1, TFPI2, RASSF1A, SOCS1, GATA4, or RARβ2 as a biomarker. Also disclosed are methods of using the biomarker for determining the cancer status and predicting the outcome of the cancer.09-03-2009
20080268436Schizophrenia, Schizoaffective Disorder and Bipolar Disorder Susceptibility Gene Mutation and Applications to Their Diagnosis and Treatment - The present invention provides the identification of a number of SNPs that are associated schizophrenia, schizoaffective disorder, bipolar disorder and related mental disorders which were found to be strongly linked to individuals with the disease. The invention provides SNP locations on human chromosome 6, as well as methods of making PCR primers and assays for detecting the SNPs in tested individuals.10-30-2008
20110097713Compositions and methods for pharmacogenomic screening of CYP2C9 and VKORC1 - Compositions and methods for determining an optimal dose of a medication for a subject are described that include determining the subject's genotype for the CYP2C9 and VKORC1 genes and determining the dose of the medication based on the genotype. Articles of manufacture also are provided that include polynucleotides for genotyping.04-28-2011
20100196907MARKERS TO PREDICT AND MONITOR RESPONSE TO AURORA KINASE B INHIBITOR THERAPY - The present invention relates to identifying the presence or absence of one or more copy number gains in the ABCB1 gene, the ABCB4 gene or combinations thereof, identifying patients eligible to receive Aurora kinase inhibitor therapy, either as monotherapy or as part of combination therapy, and monitoring patients' response to such therapy.08-05-2010
20110003306IDENTIFICATION OF ANTIBIOTIC RESISTANCE USING LABELLED ANTIBIOTICS - Subject of the present invention is a method for detection of an antibiotic resistance in a micro-organism comprising the steps of exposing suspected micro-organism to a labelled (fluorescent) antibiotic and observing the differences between it and a non-resistant micro-organism of the same type.01-06-2011
20090305251BRCA1/BRCA2 SCREENING PANEL - A method for analyzing a biological sample is performed by analyzing a biological sample for the presence of one or more mutations or polymorphisms in the BCRA1 and/or BCRA2 genes.12-10-2009
20100233703EMX2 IN CANCER DIAGNOSIS AND PROGNOSIS - The present invention provides methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. The methods generally involve determining a normalized expression level of an EMX2 gene product, which correlates with prognosis and likelihood of survival.09-16-2010
20100021884mRNA Ratios in Urinary Sediments and/or Urine as a Prognostic and/or Theranostic Marker for Prostate Cancer - Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and PSA expression in a urine sample and (b) correlating the value of the PCA3/PSA ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of PSA in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of PSA; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.01-28-2010
20080293057DETECTION OF UNSPECIFIED GENETICALLY MODIFIED ORGANISM (GMO) ON MICRO-ARRAYS - The present invention is related to a method, kit and computer program for detecting the presence in a sample of an unspecified Genetically Modified Organism (GMO).11-27-2008
20100248229INVITRO HUMAN EMBRYONIC MODEL AND A METHOD THEREOF - The present invention relates to the field of stem cells particularly development of a novel human embryonic model using human embryoid bodies obtained from the human embryonic stem cell. The novel human embryonic model disclosed thus can provide a screening assay for determining the toxic activity of the compound and/or drug.09-30-2010
20090181384Prognosis prediction for colorectal cancer - This invention relates to prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for colorectal cancer. Specifically, this invention relates to the use of genetic markers for the prediction of the prognosis of cancer, such as colorectal cancer, based on signatures of genetic markers. In various aspects, the invention relates to a method of predicting the likelihood of long-term survival of a cancer patient, a method of determining a treatment regime for a cancer patient, a method of preparing a treatment modality for a cancer patient, among other methods as well as kits and devices for carrying out these methods.07-16-2009
20090042204ACNE LESION BIOMARKERS AND MODULATORS THEREOF - The present invention relates to acne lesions biomarkers/genes expression products pattern and particularly inflammatory acne lesions biomarkers and their uses, modulators thereof and the use of modulators for acne treatment or associated disorders. Invention also concerns in vitro diagnostic methods.02-12-2009
20090136925IDENTIFICATION OF TERPENOID-BIOSYNTHESIS RELATED REGULATORY PROTEIN-REGULATORY REGION ASSOCIATIONS - Materials and methods for identifying terpenoid regulatory region-regulatory protein associations are disclosed. Materials and methods for modulating expression of a sequence interest are also disclosed.05-28-2009
20090317807Primers for Use in Detecting Metallo-Beta-Lactamases - Oliognucleotide primers are provided that are specific for nucleic acid characteristic of certain beta-lactamases. The primers can be employed in methods to identify nucleic acid characteristic of family-specific beta-lactamase enzymes in samples, and particularly, in clinical isolates of Gram-negative bacteria.12-24-2009
20090176217NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS - Novel splice variants, amino acid sequences and nucleotide sequences thereof, and methods of using same.07-09-2009
20100047783SMALL MOLECULE MODULATORS OF P53 FAMILY SIGNALING - This invention relates to methods for identifying compound capable of activating p53-responsive transcriptional activity in a p53-deficient tumor cell and the use of these compounds.02-25-2010
20090203032SPECIES-SPECIFIC PRIMER SETS AND IDENTIFICATION OF SPECIES-SPECIFIC DNA SEQUENCES USING GENOME FRAGMENT ENRICHMENT - Targeted sequencing of genetic regions that differ between two DNA preparations uses genomic fragment enrichment. This method can be used to study genetic variation among closely related species and microbial communities, particularly for identifying sources of fecal pollution.08-13-2009
20090176228LUNG CANCER MARKERS, AND USES THEREOF - Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.07-09-2009
20090233283STABLE COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION AND SEQUENCING - The present invention is directed to compositions comprising mixtures of reagents, including thermostable enzymes (e.g., thermostable DNA polymerases), buffers, cofactors and other components, suitable for immediate use in nucleic acid amplification or sequencing techniques without dilution or addition of further components. The compositions contain no stabilizing agents (e.g., glycerol or serum albumin) and unexpectedly maintain activity for extended periods of time upon storage at temperatures above freezing. These compositions are useful, alone or in the form of kits, for nucleic acid amplification (e.g., by the Polymerase Chain Reaction) and sequencing (e.g., by dideoxy or “Sanger” sequencing), or for any procedure utilizing thermostable DNA polymerases in a variety of medical, forensic and agricultural applications. In particular, the compositions and methods are useful for amplifying and sequencing nucleic acid molecules that are larger than about 7 kilobases in size.09-17-2009
20080280298SATB1: A DETERMINANT OF MORPHOGENESIS AND TUMOR METASTASIS - It is proposed that cancer cells express SATB1, and that SATB1 acts as a determinant for the acquisition of metastatic activity by controlling expression of a specific set of genes that promote metastatic activity. In order for cancer cells to gain the ability to metastasize, SATB1 re-organizes or re-packages genomic sequences in a specific manner to allow a switch in the pattern of gene expression. SATB1 expression was found restricted mainly to aggressive cancer cells where it may regulate the genetic and epigenetic changes that program the steps involved in the metastatic process. The present invention describes reagents and tools to detect the SATB1 protein for use in diagnosis and prognosis of aggressive cancers and therapeutics to inhibit SATB1 protein to deplete its expression in metastatic and aggressive cancers.11-13-2008
20100184054BINDING OF PATHOLOGICAL FORMS OF PRION PROTEINS - A process for the selective binding of an aggregating abnormal form of a protein in the presence of the nonaggregating normal form of the protein, including contacting under selective binding conditions a material containing both the abnormal and normal forms with a binding agent which is a polyionic material having a binding avidity for the aggregating form of the protein as present in the sample.07-22-2010
20090311701Organ-specific gene, method for identifying the same and use thereof - The present invention provides a method of extracting an organ- or tissue-specific highly expressed gene, including:12-17-2009
20110123987METHODS FOR THE DIAGNOSIS OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS - Methods and formulations for diagnosing onocological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.05-26-2011
20090053725Using DNA aptamers and quantum dots for the detection of proteins or other targets - The solutions provided here use DNA aptamers and quantum dots for the detection of bacteria, viruses, proteins or other targets. An example of a method described here comprises: providing a complex of DNA complementary strands, one strand being an aptamer, having one strand covalently linked to a quantum dot, and having the other strand linked to a quencher; and contacting said complex of DNA complementary strands with a microorganism or components thereof, under conditions that permit binding of said aptamer with said microorganism or components thereof. In some examples described here, the methods and systems are extremely simple to use and appear to have several advantages over the traditional ELISA. Since no blocking steps are required and the number of washing steps is reduced, the time required to conduct the test is greatly reduced. In some examples described here, a quantum dot aptamer complex comprises one strand of a duplex DNA molecule linked to the quantum dot by an amide bond. It does not matter if the aptamer or the complimentary strand is attached. However, the strand that is not attached contains a non-radiative quencher. Upon addition of the aptamers' target, the amount of light emitted by the quantum dots increases. In some examples described here, the methods and systems can also be used in reverse, with the aptamers' target immobilized on a microtiter plate. This permits an assay like a competitive immuno-assay.02-26-2009
20100151448Asymmetric PCR Amplification, its Special Primer and Application - The present invention discloses an asymmetric PCR amplification method, its special primer and application, aims to provide a simple, effective PCR amplification for preparation of single-stranded product. The asymmetric PCR primer of the invention comprises some PCR primer pairs, in which an unrelated nucleic acids sequence to target sequence to be detected is added onto 5′-terminal of one primer. The asymmetric PCR amplification provided includes the steps: 1) preparative denaturing; 2) repetitiously denaturing, primers annealing, extending cycles as the first stage of PCR amplification; 3) repetitiously denaturing, primer extending cycles as the second stage of PCR amplification, wherein an unrelated nucleic acids sequence to target sequence to be detected is added onto 5′-terminal of one PCR primer of each pair in extension. With the asymmetric PCR amplification of the invention, high throughput of single-stranded products can be obtained, single PCR amplification or multiple PCR amplification can be carried out. And the method can be widely used in detection of nucleic acids.06-17-2010
20090035777HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION - Nucleic acid sequencing methods and related products are disclosed. Methods for sequencing a target nucleic acid comprise providing a daughter strand produced by a template-directed synthesis, the daughter strand comprising a plurality of subunits coupled in a sequence corresponding to a contiguous nucleotide sequence of all or a portion of the target nucleic acid, wherein the individual subunits comprise a tether, at least one probe or nucleobase residue, and at least one selectively cleavable bond. The selectively cleavable bond(s) is/are cleaved to yield an Xpandomer of a length longer than the plurality of the subunits of the daughter strand, the Xpandomer comprising the tethers and reporter elements for parsing genetic information in a sequence corresponding to the contiguous nucleotide sequence of all or a portion of the target nucleic acid. Reporter elements of the Xpandomer are then detected. Corresponding products, including Xpandomers and oligomeric and monomeric substrate constructs are also disclosed.02-05-2009
20090075276High throughput mutation screening methods and kits using a universalized approach - differential sequence fill-in (dsf)-enabled sequential adapter ligation and amplification - This disclosure teaches high throughput mutation screening methods allowing simultaneous analysis of multiple genetic regions of interest and sensitive detection of very low frequency mutation(s) by the use of a universalized approach. Methods comprise treating RNA:DNA heteroduplexes of interest with a ribonuclease, sequence extension by an RNA-primed DNA polymerase, ligation with a blocking adapter, and differential sequence fill-in followed by single-strand-specific nuclease digestion to permit full-length sequence extension and subsequent ligation with a tagged reporter adapter solely in mutants filled in with a complementary deoxyribonucleotide triphosphate. By forming tagged mutant-dual adapter hybrids or mutant-triple adapter hybrids, the detection and/or quantification of mutants may be directed to the commonly shared tag(s) or flanking adapter sequences for signal detection/enhancement or sequence amplification in all different mutants regardless of the source or the number of mutations involved, thereby avoiding the tremendous effort of multiple target-specific sequence amplifications. Methods may be performed wholly or partially in solution, on solid phase media, in large scale, adapted for automated or semi-automated analysis, and any combinations thereof.03-19-2009
20080286782ANALYSIS OF DNA SAMPLES - The invention provides an improved method for obtaining information about DNA analysis of samples of uncertain origin by establishing the likelihood that they arose in certain manners compared with other possible manners. In this way all of the analysis information is taken into account and likelihood ratios are provided to express the results. The invention is particularly useful in analysing small DNA samples or DNA samples where the contribution from one or more sources is small.11-20-2008
20090087853HERBICIDE TOLERANT COTTON PLANTS AND METHODS FOR PRODUCING AND IDENTIFYING SAME - The invention pertains to transgenic cotton plants, plant material and seeds, characterized by harboring a specific transformation event, particularly by the presence of a gene encoding a protein that confers herbicide tolerance, at a specific location in the cotton genome. The cotton plants of the invention combine the herbicide tolerant phenotype with optimal agronomic performance.04-02-2009
20090087836IL-B30 ANTIBODIES - Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided. 04-02-2009
20100297615EGFR MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.11-25-2010
20100184053IDENTIFICATION AND QUANTIFICATION OF ONCOGENIC HPV NUCLEIC ACIDS BY MEANS OF REAL-TIME PCR ASSAYS - Method for the identification and quantification of oncogenic HPV nucleic acids comprising: a) first line screening by means of 5 independent SYBR Green I Real-time PCR assays to determine the total viral load and to identify the presence of one or more of 13 high risk HPV genotypes in the sample; b) second line assays to be applied to samples positives for: 5 independent TaqMan Real-time PCR assays to determine the presence and the viral load of the most common oncogenic HPV types: HPV types: 16, 18, 31, 45, 33 group (including 33, 52, 58, 67 genotypes).6 independent SYBR Green I RT Real-time PCR assays to determine the presence in the sample of the oncogenic transcripts E6/E7 of HPV types 16, 18, 31, 33, 45, 58.07-22-2010
20090029366METHODS OF IDENTIFYING MODULATORS OF HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED (HCN) CHANNELS - Methods, including high-throughput methods, for identifying modulators of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels.01-29-2009
20090042205FLUORESCENCE DETECTION OF DNA BREAKS USING MOLECULAR OSCILLATORS - A method to detect DNA breaks includes providing a mixture of fluorescence energy transfer molecular oscillators and a DNA sample. The FET oscillator is a synthetic oligonucleotide that has a topoisomerase recognition sequence, a fluorescence donor and a fluorescence acceptor. The synthetic oligonucleotide is bound to a type I topoisomerase capable of binding to the topoisomerase recognition sequence. The mixture is irradiated at a wavelength of the fluorescence donor, and the emission is measured. Another variant of the disclosure is a probe for detecting DNA breaks utilizing a synthetic oligonucleotide comprising a topoisomerase recognition sequence, a fluorescence donor, and a nonradiative fluorescence quencher. Yet another variant of the disclosure is a probe for detecting DNA breaks utilizing a synthetic oligonucleotide comprising a topoisomerase recognition sequence, a fluorescence donor, and a fluorescence acceptor. The mixture is irradiated at a wavelength of the fluorescence donor; and the emission is measured. A method to detect DNA breaks may use these probes in a manner similar to that of the FET oscillator. The FET oscillators and probes are capable of being prepared in a kit formulation.02-12-2009
20110104671METHODS AND COMPOSITIONS FOR ASSESSING RESPONSIVENESS OF B-CELL LYMPHOMA TO TREATMENT WITH ANTI-CD40 ANTIBODIES - The invention provides methods and kits useful for predicting or assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies.05-05-2011
20100068708Methods for Identifying Compounds that Modulate WNT Signaling in Cancer Cells - Provided herein are methods for screening compounds for their ability to modulate Wnt signaling in cancer cells.03-18-2010
20090258366pCryptoRNAi - A vector developed to transform fungi can be used to study the expression of a gene of interest. The vector can provide for the expression of signal proteins in fungi that can be observed and/or monitored. The vector can be used to investigate the effects of RNA interference on a gene of interest in pathogenic fungi. Systems and methods of using the vector are provided.10-15-2009
20100203512METHOD FOR RENAL DISEASE DIAGNOSIS AND PROGNOSIS USING ANNEXIN A1 AND RAB23 AS MARKERS - Use of Annexin A1 or Rab23 as a biomarker for diagnosing kidney disease or assessing efficacy of kidney disease treatment.08-12-2010
20090305236METHODS OF ENRICHING FETAL CELLS - The present invention relates to methods of enriching fetal cells from a pregnant female. The present invention relates to removing, from a sample, cells that comprise at least one MHC molecule. The present invention also relates to methods that rely on using telomerase, mRNA encoding components thereof, as well as telomere length, as markers for fetal cells. Enriched fetal cells can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing.12-10-2009
20100330561Marker Gene For Detection of Tumor Promoter, and Method For Detection of Tumor Promoter - The present invention provides 27 marker genes comprising Orm1, Scarb1, Stmn1, Rad21, Nup54, Jun, Dmp1, Abi1, 6530403A03Rik, Slc2a1, Plf (Plf2, Mrpplf3), Fosl1, Chek1, Pik3r5, JunB, Vegfa, Rif1 (LOC671598), Il1rl1, Phex, Tfrc, Zfhx1b, Rad51ap1, Hells, Mcm3, Orm2, Car13 and Ccnb1, which enables the detection of a tumor promoter in a simple manner and within a short period of time in a test for predicting carcinogenicity as a tumor promoter using a cultured cell. The present invention further provide a tumor promoter detection method using at least one of the marker genes.12-30-2010
20090325175METHODs OF DETECTION AND QUANTIFICATION OF HOST CELL DNA CONTAMINATION OF PURIFIED PROTEINS - The present invention provides a novel robust, sensitive, reproducible, and accurate method of detecting and quantifying host cell genomic DNA contamination utilizing quantitative real time Polymerase Chain Reaction (qPCR), wherein the qPCR primers are complementary to the highly repetitive host cell genomic DNA sequences, e.g., Alu-equivalent sequences. The present invention is particularly useful for determining the levels of residual genomic DNA in biological products to be administered as therapeutics, e.g., therapeutic proteins.12-31-2009
20090239231RNA From Cytology Samples To Diagnose Disease - The invention relates to methods and kits for detecting the likelihood that a subject has cancer, e.g., squamous cell carcinoma, by assaying the expression levels of tumor associated genes. More specifically, the expression levels of nucleic acids or proteins can be assayed in the tumor associated genes, e.g., beta-2 microgobulin (B2M) and cytochrome p450 1B1 (CYP1B1). The expression levels compared to standards can be indicative of the likelihood a subject has squamous cell carcinoma. For example, over-expression of B2M and under-expression of CYP1B1 can be indicative of the likelihood a subject has squamous cell carcinoma. Also, over-expression of B2M and over-expression of CYP1B1 can be indicative of the likelihood a subject has a precancerous squamous cell disorder. The expression levels of B2M and CYP1B1 can also be repeatedly assayed to monitor the progression of a squamous cell neoplasia.09-24-2009
20100203521METHOD FOR BACTERIAL LYSIS - The present invention is directed to a microfluidic device for lysis of cells, such as bacteria and microorganisms. In particular, the present invention relates to microfluidic devices and methods of manufacture of such microfluidic devices comprising a substrate with at least one channel packed with a polymer monolith embedded with carbon particles, for example carbon nanotubes. The microfluidic devices and methods of the present invention are useful for cell lysis of cells within a biological sample, such as a untreated biological sample comprising microorganisms, such as but not limited to gram positive and gram negative bacteria. In some embodiments, the microfluidic devices of the present invention can also optionally comprise other modules enabling further processing of the biological sample, for example isolation, purification and detection of biomolecules released from the lysed cells, such as but not limited to nucleic acids or proteins or peptides from the lysed cells, providing a complete Lab-on-a-Chip analysis system for biomolecules released from difficult to lyse microorganisms in a single step or process. The microfluidic devices of the present invention can also be adapted and are useful to methods to enrich for microorganisms in a biological sample, for example enrich for a desired type of bacteria within a biological sample. The microfluidic devices and methods of the present invention can be adapted to perform highly efficient lysis of microorganisms within a biological sample for diagnostic tests, for example for diagnosis of infectious agents and pathogens, such as bacteria, viruses or parasites.08-12-2010
20080280296METHOD FOR DETECTION OF FOOT-AND-MOUTH DISEASE VIRUS WITH CHROMATOGRAPHIC STRIP TEST - The present invention discloses a method for detection of foot-and-mouth disease virus with chromatographic strip test. Firstly, the nucleic acid sequence of FMDV NSPs is set up, the nucleic acid sequence is amplified by the reverse transcriptase polymerase chain reaction (RT-PCR) method, the recombinant vector is constructed and performed through a prokaryotic system to transform and express the recombinant protein, and the purified recombinant protein is mass produced. Design principles of the method are based on immunoassay and chromatographic analysis. The advantages are easy and simple to handle, no need of elaborate equipment, only one drop of body fluid is required to quickly complete the qualitative test in 10-20 minutes, and operating with a portable POCT (Point of care testing) instrument to complete the quantitative detection within 40-50 minutes.11-13-2008
20100255476Composition For Increasing Microorganism Wall Permeability And Method For Detecting Said Microorganisms On A Membrane - The present invention relates to a composition for permeabilizing microorganism walls, comprising the combination of polyethyleneimine (PEI) with at least one alcohol, and also to a method using said composition for counting and detecting in a targeted manner the microorganisms on a membrane. The invention also relates to a kit and to probes that are suitable for carrying out said method.10-07-2010
20100151451Method for Identifying the Genotype in Position 171 of the Ovine Prion Protein as well as Kits for Implementing said Method - The invention relates a method to identify genotype at position 171 of the ovine PrP, and a method to select an ovine for reproduction.06-17-2010
20080318223LARGE DELETIONS IN HUMAN BRCA1 GENE AND USE THEREOF - Large deletions have been identified in the BRCA1 gene in patients. The large deletions predispose the patients to breast cancer and ovarian cancer. Thus, methods for detecting the genetic variants are provided which can be used in detecting a predisposition to cancer.12-25-2008
20090053726SYSTEMS AND METHODS FOR REAL-TIME PCR - In one aspect, the present invention provides a systems and methods for the real-time amplification and analysis of a sample of DNA.02-26-2009
20110065105Novel transcription factor-based biosensor - The present invention provides for a system comprising a BmoR transcription factor, a σ03-17-2011
20100081139METHOD FOR DETECTION OF PRESENCE OF TARGET POLYNUCLEOTIDE IN SAMPLES - A method for detecting the presence of a target polynucleotide in a sample, including providing a mixture of the sample and target binding agent and measuring a signal from the mixture, where the target binding agent is capable of assuming a first position where the target binding agent is not bound to the target polynucleotide and a second position where the target binding agent is bound to the target polynucleotide, and the intensity of the signal depends on the proportion of target binding agent in the first and second positions. The method is suitable for detecting a PCR product using a homogeneous detection method.04-01-2010
20090035775PCR-BASED DETECTION METHOD FOR CHLAMYDIA TREACHOMATIS - A process for designing of PCR-based detection method for 02-05-2009
20090258357CYTOKINE RECEPTOR COMMON GAMMA CHAIN LIKE - The present invention relates to a novel human gene encoding a polypeptide which is a member of the Cytokine Receptor family. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named Cytokine Receptor Common Gamma Chain Like, or “CRCGCL.” This invention also relates to CRCGCL polypeptides, as well as vectors, host cells, antibodies directed to CRCGCL polypeptides, and the recombinant methods for producing the same. Also provided are diagnostic methods for detecting disorders related to the immune system, and therapeutic methods for treating diagnosing, detecting, and/or preventing such disorders. The invention further relates to screening methods for identifying agonists and antagonists of CRCGCL activity.10-15-2009
20100136562Multivariate Analysis Involving Genetic Polymorphisms Related To Mediators Of Inflammatory Response For Prediction Of Outcome Of Critcally Ill Patients - A method of using genetic polymorphisms related to pro-inflammatory mediators to predict clinical outcome in critically ill patients admitted to an ICU is provided.06-03-2010
20080206773DNA Fingerprinting Using Allelic Specific Oligonucleotide Reversed DOT BLOT (ASO-RDB) Flow Through Hybridization Process and Device - The present invention disclosed the use of single nucleotide polymorphism (SNP) as the detection assay for human identification. Using the reversed dot-blot format and the flow through hybridization process, the process can be more efficient, less expensive and with similar or better power of exclusion in definitive identification. The present method can be applied to any other organisms.08-28-2008
20100159462TUNABLE ELASTOMERIC NANOCHANNELS FOR NANOFLUIDIC MANIPULATION - The invention relates to tunable elastomeric nanochannels for nanofluidic manipulation. In particular, the present invention relates to nanochannels for performing biological assays.06-24-2010
20090142771Methods and Instruments for Processing a Sample in a Multi-Chambered Receptacle - A receptacle having a plurality of interconnected chambers arranged to permit multiple process steps or processes to be performed independently or simultaneously. The receptacles are manufactured to separate liquid from dried reagents and to maintain the stability of the dried reagents. An immiscible liquid, such as an oil, is included to control loading of process materials, facilitate mixing and reconstitution of dried reagents, limit evaporation, control heating of reaction materials, concentrate solid support materials to prevent clogging of fluid connections, provide minimum volumes for fluid transfers, and to prevent process materials from sticking to chamber surfaces. The receptacles can be adapted for use in systems having a processing instrument that includes an actuator system for selectively moving fluid substances between chambers and a detector. The actuator system can be arranged to concentrate an analyte present in a sample. The detector can be used to detect an optical signal emitted by the contents of the receptacle.06-04-2009
20100184033METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY - Aspects of the present invention relate to methods to differentiate pluripotent primordial stem cells, such as human embryonic stem (“hES”) cells, human embryonic germ (“hEG”) cells, human embryo-derived (“hED”) cells and human embryonal carcinoma (“hEC”) cells, to obtain subpopulations of cells from heterogeneous mixtures of cells, wherein the subpopulation of cells possess reduced differentiation potential compared to the original pluripotent stem cells and where the subpopulation is capable of being propagated 20 or more population doublings. This invention also provides novel compositions of such subpopulations of cells and methods to propagate and differentiate said cells.07-22-2010
20090098558DETECTION, IDENTIFICATION AND DIFFERENTIATION OF PROTEUS SPECIES USING THE SPACER REGION - The present invention relates to new nucleic acid sequences derived from the ITS region, between the 16S and 23S ribosomal ribionucleic acid (rRNA) or rRNA genes, to be used for the specific detection and/or identification of 04-16-2009
20110020804PHOTOINDUCED ELECTRON TRANSFER (PET) PRIMER FOR NUCLEIC ACID AMPLIFICATION - This application provides photoinduced electron transfer (PET) nucleic acid molecules that can be used detect and amplify nucleic acid molecules, such as target nucleic acid molecules. These PET tags can be attached to the 5′-end of a target sequence-specific primer, thereby generating a PET primer. In particular examples, a PET tag includes a 5′-labeled nucleotide that can be quenched by at least two consecutive Gs within the tag sequence, and is unquenched when the PET tag hybridizes with its complementary nucleic acid molecule. Also disclosed are methods of using PET primers in nucleic acid amplification, such as real-time PCR.01-27-2011
20090239224Methods for identifying bioagents - The present invention provides methods for rapid forensic analysis of mitochondrial DNA and methods for characterizing heteroplasmy of mitochondrial DNA, which can be used to assess the progression of mitochondrial diseases.09-24-2009
20100297644HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY SPACING - Nucleic acid sequencing methods and related devices, products and kits are disclosed. Methods for sequencing a target nucleic acid comprise providing a daughter strand produced by a template-directed synthesis, the daughter strand comprising a plurality of subunits coupled in a sequence corresponding to a contiguous nucleotide sequence of all or a portion of the target nucleic acid, wherein the individual subunits comprise a probe and a reporter construct. The subunit encodes sequence information in its reporter construct that is less than sequence information in the corresponding portion of the target nucleic acid. The reduced information allows for reduced resolution requirements on the detection system and for increased size of resolvable reporter groups.11-25-2010
20090092995Method for Identifying Within a Mammal a DNA encoding a Physiologically Active Polypeptide - The present inventors found that a physiological effect of a particular DNA can be detected independently within mice into which a pool of various DNAs in various quantities has been introduced. This finding suggests that it is possible to identify a DNA having a particular physiological effect by successively fractionating a pool of various DNAs in various quantities using the particular physiological effect seen within a mammal as an index. Such a method of screening will have the advantage of saving much time and effort as required in conventional screenings such as those utilizing transgenic and knockout mice. Furthermore, the method of screening has the additional advantage of enabling the identification of a DNA having a physiological activity, for example, even when the cells producing a physiologically active substance cannot be maintained in vitro or in immunodeficient animals, or when the cells change their characteristics during passage and stop producing the physiologically active substance.04-09-2009
20090104615PHENOTYPE PREDICTION - Detection of epigenetic alteration, especially methylation, of a gene or a combination of genes, preferably in a perinatal tissue sample such as umbilical cord, for predicting diverse phenotypic characteristics such as propensity for obesity, altered body composition, impaired cognition, low bone mineral content, neuro-behavioural problems and altered cardiovascular structure and function occurring in an individual.04-23-2009
20090181400Method of Detection of Prostate Cancer - The present invention provides methods and kits useful for detecting neplasia by measuring the methylation level of biomarkers, especially the promoter region of GSTP1 for the detection of prostate adenocarcinoma.07-16-2009
20090136954GENETIC MARKERS FOR SCD OR SCA THERAPY SELECTION - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”), or Sudden Cardiac Arrest (“SCA”) risk, are described. Novel genetic markers useful in assessing the risk of SCD, or SCA, and kits containing the same are provided herein. Methods of distinguishing patients having an increased susceptibility to SCD, or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of assessing the need for an Implantable Cardio Defibrillators (“ICD”) in a patient are taught.05-28-2009
20100221709METHODS FOR IDENTIFYING AGENTS THAT MODULATE APOPTOSIS IN CELLS THAT OVER-EXPRESS A BCL-2 FAMILY MEMBER PROTEIN - The present invention provides methods and combinations of methods for identifying agents that modulate the apoptotic state of a cell by binding to the hydrophobic groove of a Bcl-2 family member anti-apoptotic protein. In certain embodiments, the methods generally comprise the use of Bcl-2 family member proteins having one or more mutations in the hydrophobic groove that, relative to a corresponding protein lacking the mutation, affect, e.g., binding of desired agents or in vitro antimycin sensitivity without substantially altering tertiary protein structure. In these embodiments, the methods comprise the identification of agents that exhibit reduced binding affinities and/or other biological activities for the mutant proteins relative to the corresponding Bcl-2 family member lacking the mutation. In other embodiments, the methods generally comprise the detection of the ability of an agent to induce increased glucose uptake or lactate production in proportion to the level of expression of an anti-apoptotic Bcl-2 family member protein.09-02-2010
20090197272VITRO METHOD OF DETECTING AND/OR DIAGNOSING CANCER USING UV LIGHT BASED DNA IMAGE CYTOMETRY - The invention relates to a method of determining in vitro the amount of nuclear DNA within a human or animal cell using UV absorption measurement with UV light. The invention also relates to a method for detecting in vitro cancerous cells in a biological sample relying on the aforementioned principles. The invention also relates to an in vitro method of diagnosing or predicting the likely occurrence of cancer in a human or animal subject.08-06-2009
20090280493Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia - The invention relates to methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of neoplastic disease. Neoplastic disease is often caused by chromosomal rearrangements which lead to over- or underexpression of the rearranged genes. The invention discloses genes which are overexpressed in neoplastic tissue and are useful as diagnostic markers and targets for treatment. Methods are disclosed for predicting, diagnosing and prognosing as well as preventing and treating neoplastic disease.11-12-2009
20090029355Abnormalities of Phosphatase 2A (PP2A) for Diagnosis and Treatment of Alzheimer's Disease - This invention relates to methods of diagnosing Alzheimer's disease and methods of screening for compounds for the treatment or prevention of Alzheimer's disease. The methods are based upon newly discovered differences in protein phosphatase 2A (PP2A) function and related molecular events in Alzheimer's disease cells compared to control cells. In one embodiment, differences in basal PP2A gene expression in Alzheimer's cells are compared to controls. In another embodiment differences in PP2A protein and enzyme activity are compared in test and control cells. In another embodiment differences in response to substances that inhibit PP2A function are compared. Still another embodiment detects differences in the subcellular distribution of phosphorylated Erk1/2, a substrate of PP2A, in normal and Alzheimer's disease cells. The detection of Alzheimer's disease-specific differences in PP2A function and related events in peripheral tissues provides the basis for highly practical and efficient tests and diagnostic test kits for the early diagnosis of Alzheimer's disease, as well as providing a biochemical basis for identifying therapeutic targets for drug development.01-29-2009
20110104665MUTANT SODIUM CHANNEL NAV 1.7 AND METHODS RELATED THERETO - Described are mutant Na05-05-2011
20090075274MULTIPLEXED QUANTITATIVE DETECTION OF PATHOGENS - The invention allows for the quantitative detection of a plurality of pathogens in a single sample. The method includes the amplification of a sample with a plurality of pathogen-specific primer pairs to generate amplicons of distinct sizes from each of the pathogen specific primer pairs. The method further includes the use of a plurality of competitor polynucleotide targets that correspond to each of the pathogen-specific primer pairs. The competitor polynucleotides are added to the reaction mixture at a known concentration to allow for the quantitation of the amount of pathogen in the sample. The method can be used for monitoring pathogen infection in an individual, preferably an immunocompromised individual.03-19-2009
20100009345Compositions and methods comprising a ligand of chemerin R - The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screeing assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.01-14-2010
20090220952Compositions And Methods For Analyzing Protein Interactions - The present invention relates to compositions and methods for analyzing and modulating (e.g., enhancing or inhibiting) protein-protein interactions. In particular, compositions and methods of the present invention find use in identifying, reconstituting and characterizing protein-protein interactions, identifying binding subunits, and drug screening. The methods and compositions of the invention may also be used to identify agents that may agonize or antagonize a protein-protein interaction (e.g., using test compounds).09-03-2009
20090068656Methods of diagnosing osteoarthritis - A method of diagnosing osteoarthritis in a mammal is provided comprising the steps of obtaining a biological sample from the mammal; and quantifying in the sample the expression of at least one chondrocyte-specific gene or gene product, wherein a differential in expression of said gene or gene product in comparison with expression of said gene or gene product in a non-osteoarthritic mammal is indicative of osteoarthritis.03-12-2009
20100003671NUCLEOTIDE PRIMER SET AND NUCLEOTIDE PROBE FOR DETECTING GENOTYPE OF N-ACETYLTRANSFERASE-2 (NAT2) - There is provided a nucleotide primer set for LAMP amplification, used for detecting genotypes of single-nucleotide polymorphisms G590A, G857A and T341C of a NAT2 gene. There is also provided a nucleotide probe for detection of an amplification product amplified with the primer set according to the present invention. There is also provided a method of detecting the genotypes of NAT2 gene single-nucleotide polymorphisms G590A, G857A and T341C by using the primer set according to the present invention.01-07-2010
20090004651Screening methods for compounds that modulate the activity of G-protein coupled receptors - The present invention relates to a screening system for modulators of GPCRs. Further it relates to recombinant vector systems for the heterologous expression of heterodimeric g-protein coupled receptors (GPCRs) in eucaryotic host cells. Preferably the functional expression of engineered GPCRs for the perception of sweet and L-amino acid taste or more preferably the use of said receptors for the identification of functional ligands is also encompassed.01-01-2009
20090111114RNA EXTRACTION METHOD, RNA EXTRACTION REAGENT, AND METHOD FOR ANALYZING BIOLOGICAL MATERIALS - A method to extract RNA with high purity from biological materials containing RNA in a safe, rapid, and simple procedure and a method to analyze it are provided. The procedure includes the steps of mixing a biological material containing RNA with a predetermined concentration of a chaotropic agent and a predetermined concentration of an organic solvent, allowing the mixed solution to contact a nucleic acid-binding solid phase, washing the nucleic-acid binding solid-phase to which RNA is bound, and eluting RNA from the nucleic-acid binding solid-phase having the bound RNA. Furthermore, the obtained RNA is analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) or the like.04-30-2009
20100304384METHOD OF IDENTIFYING COMPOUNDS THAT INDUCE OR INHIBIT ENDOPLASMIC RETICULUM STRESS OR OXIDATIVE STRESS - The present invention generally relates to a method for the identification of compounds for the treatment of neurodegenerative diseases. Said method is based on a cell model for neurodegeneration useful for the identification of potentially useful compounds for the treatment or the prevention of a neurodegenerative disease associated with deficient expression of the DDIT3 gene, also known as CHOP.12-02-2010
20090170109CORN EVENT TC1507 AND METHODS FOR DETECTION THEREOF - The invention provides DNA compositions that relate to transgenic insect resistant maize plants. Also provided are assays for detecting the presence of the maize TC1507 event based on the DNA sequence of the recombinant construct inserted into the maize genome and the DNA sequences flanking the insertion site. Kits and conditions useful in conducting the assays are provided.07-02-2009
20100015619METHOD OF DETECTING GENOMIC ABERRATIONS FOR PRENATAL DIAGNOSIS - This invention relates to assays used to detect and confirm genomic aberrations, such as chromosomes 13, 18, 21, X and Y aneuploidy as well as 22q11.2 deletions, for prenatal diagnosis. For the detection, combined STR markers (all tetra-nucleotide repeats) are employed to cover different chromosome regions. For the confirmation step, individual chromosome specific STR markers (tetra-nucleotide repeats) are utilized. This invention particularly relates to multiplex analysis for the presence or absence of STR markers in genomic DNA isolated from peripheral blood, amniotic fluid, cultured amniocytes, chorionic villi, or fetal cells existing in maternal blood. This invention offers an efficient approach to identify chromosomal abnormalities by using STR markers.01-21-2010
20080206762Method for the Diagnosis of Alzeimer's Disease - The invention relates to a method for the diagnosis and/or prognosis of Alzheimer's disease, consisting in determining the expression level of a gene encoding a lysosomal marker.08-28-2008
20100173313BIOMARKERS OF INFLAMMATION - Methods for the detection of DP07-08-2010
20080318212Orphan Receptor Tyrosine Kinase as a Target in Breast Cancer - Methods and materials relating to the orphan receptor tyrosine kinase (ROR1) are described. ROR1 exhibits restricted tissue expression in normal adult tissue and is overexpressed in certain breast cancer subtypes. ROR1 provides a diagnostic and/or therapeutic target for breast cancers.12-25-2008
20090197250METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE PROGNOSIS OF PROSTATE CELL PROLIFERATIVE DISORDERS - Particular aspects provide novel methods and compositions (e.g., nucleic acids, kits, etc.) having substantial utility for providing a prognosis of prostate cell proliferative disorders. In particular aspects, this is achieved by the analysis of the expression status of a panel of genes, or subsets thereof.08-06-2009
20110104690ENGINEERED NITRILE HYDRATASE-PRODUCING BACTERIUM WITH AMIDASE GENE KOUCKED-OUT, THE CONSTRUCTION AND THE USE THEREOF - An engineered nitrile hydratase-producing bacterium and its construction method as well as its applications, wherein the engineered nitrile hydratase-producing bacterium is a mutant strain of an original nitrile hydratase-producing bacterium strain obtained by knocking-out or inhibiting the amidase gene in the original strain. The construction method of the engineered bacterium is to block the expression of the amidase gene by inserting the large fragment of a recombinant suicide plasmid carrying an amidase gene fragment into a wild-type strain through the homologous recombination between the recombinant suicide plasmid and the amidase gene of the wild-type strain. Compared to the corresponding wild-type bacterium strain, both the cell growth and the nitrile hydratase expression of the engineered nitrile hydratase-producing bacterium according to the invention are increased. In the process of catalyzing the hydration of acrylonitrile to produce acrylamide, the yield of the product, acrylamide, is significantly increased, while the yield of the by-product acrylic acid is significantly decreased. The engineered nitrile hydratase-producing bacterium of the present invention has wide application prospect in the production of acrylamide by microbiological process.05-05-2011
20100311041PCR DIAGNOSTICS OF DERMATOPHYTES AND OTHER PATHOGENIC FUNGI - Dermatophytes which belong to one of the three genera 12-09-2010
20100184079SOYBEAN EVENT 3560.4.3.5 AND COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND DETECTION THEREOF - Compositions and methods related to transgenic glyphosate/ALS inhibitor-tolerant soybean plants are provided. Specifically, soybean plants having a 3560.4.3.5 event which imparts tolerance to glyphosate and at least one ALS-inhibiting herbicide are provided. The soybean plant harboring the 3560.4.3.5 event at the recited chromosomal location comprises genomic/transgene junctions having at least the polynucleotide sequence of SEQ ID NO:10 and/or 11. The characterization of the genomic insertion site of the 3560.4.3.5 event provides for an enhanced breeding efficiency and enables the use of molecular markers to track the transgene insert in the breeding populations and progeny thereof. Various methods and compositions for the identification, detection, and use of the soybean 3560.4.3.5 events are provided.07-22-2010
20080248466Method Of Detecting Mutations In The Gene Encoding Cytochrome P450-2C19 - The present invention describes a method for the simultaneous identification of two or more mutations located in the gene encoding Cytochrome P450-2C19. Multiplex detection is accomplished using multiplexed tagged allele specific primer extension (ASPE) and hybridization of such extended primers to a probe, preferably an addressable anti-tagged support.10-09-2008
20090233289Novel DNA threading intercalators - The invention is directed to a compound having the general formula (1):09-17-2009
20090208954PRIMER SET FOR AMPLIFICATION OF UGT1A1 GENE, REAGENT FOR AMPLIFICATION OF UGT1A1 GENE CONTAINING THE SAME, AND THE USES THEREOF - Primer sets for amplifying target regions containing sites to be detected in the UGT1A1 gene by a gene amplification method are provided, wherein the primer sets can amplify the regions specifically. Three pairs of primer sets are used including forward primers consisting of the base sequences of SEQ ID NOs: 4 or 81, 21, and 42 as well as reverse primers consisting of the base sequences of SEQ ID NOs: 13 or 91, 29 and 48, respectively. The use of these primer sets makes it possible to amplify three target regions including parts where three types of polymorphisms (UGT1A1*6, UGT1A1*27, and UGT1A1*28) of the UGT1A1 gene are generated, respectively, in the same reaction solution at the same time.08-20-2009
20090311672Detection of amplicon contamination during pcr exhibiting two different annealing temperatures - A method to perform PCR reactions with one set of primers comprising sequence elements that are complementary to the target sequence and comprising sequence elements that server as tagging sequences. By conducting amplification reactions at different temperatures, the presence of contaminations arising from amplification products of previous reactions can be determined, improving reliability of the reaction and reducing the need for control reactions and reproduction of reactions.12-17-2009
20090130660Single Nucelotide Polymorphism (SNP) - Association of Type 2 diabetes with single nucleotide polymorphisms and haplotypes are disclosed. Also disclosed are diagnostic applications in identifying those who have Type 2 diabetes or are at risk of developing Type 2 diabetes, and discovery of therapeutic agents and methods of treatment.05-21-2009
20100285472PRIMERS AND PROBES FOR DETECTION OF HIGH RISK GROUP GENO-TYPE HUMAN PAPILLOMAVIRUS DNA, A QUALITATIVE ASSAY METHOD OF THE SAME DNA USING THEM AND A QUALITATIVE ASSAY KIT OF THE SAME DNA - The present invention relates to a method for qualitative assay of high risk group Human Papillomavirus (HPV) DNA by PCR method using primers designed to detect the infection of 13 high risk group HPV which are closely associated with cervical cancer in a simple and precise way, and a kit for qualitative assay of high risk group HPV DNA.11-11-2010
20100184037DEATH ASSOCIATED PROTEIN KINASE 1 (DAPK1) AND USES THEREOF FOR THE TREATMENT OF CHRONIC LYMPOCYTIC LEUKEMIA - A method for determining susceptibility to chronic lymphocytic leukemia in a subject includes determining a loss or reduced expression of death associated protein kinase 1 (DAPK1) or fragments or functional equivalents thereof.07-22-2010
20090104620Simplified Method of Determining Predisposition to Scoliosis - The present invention relates to novel genetic markers associated with scoliosis, risk of developing scoliosis and risk of scoliosis curve progression, and simplified methods and materials for determining whether a human subject has scoliosis, is at risk of developing scoliosis or is at risk of scoliosis curve progression.04-23-2009
20100047780TARGET AND METHOD FOR INHIBITION OF BACTERIAL RNA POLYMERASE - Target and method for inhibition of bacterial RNA polymerase disclosed are targets and methods for specific binding and inhibition of RNAP from bacterial species.02-25-2010
20110117553Methods for PCR and HLA typing using raw blood - Provided are methods for amplifying a gene or RNA or sets thereof of interest using a tandem PCR process. The primers in the first PCR or set of PCR reactions are locus-specific. The primers in the second PCR or set of PCR reactions are specific for a sub-sequence of the locus-specific primers and completely consumed during the secondary PCR amplification. For RNA amplification, the first PCR is reverse transcription and the resulting cDNA(s) provide a template for cRNA synthesis, endpoint PCR or real time PCR. Also provided is a method of allelotyping a gene or set thereof by amplifying the gene(s) using tandem PCR on DNA or RNA comprising the sample, hybridizing the resulting amplicon or sets thereof to probes with sequences of gene-associated allele variations. A detectable signal indicating hybridization corresponds to an allelotype of the gene or a set of allelotypes for the set of genes.05-19-2011
20100196913Mutant AOX1 Promoters08-05-2010
20080286778Method for Investigating Cytosine Methylations in Dna - The invention relates to a method for sensitively and specifically detecting cytosine methylations. For this purpose, DNA is first analysed by reacting with the aid of a methylation specific restriction enzyme. In such a way, the background DNA is removed from a reaction preparation. At a next step, a specific conversion of a non-methylated cytosine is carried out, while a methylated cytosine remains unchanged. The converted DNA can be analysed according to different methods, in particular by means of real time PCR method.11-20-2008
20100285468DETECTION AND/OR QUANTIFICATION OF NUCLEIC ACIDS - The present invention provides compositions, methods, and kits for nucleic acids analyses. In particular, melting analyses are used to detect the presence or absence and to quantify nucleic acids.11-11-2010
20100151479SENSING APPARATUS AND METHOD - A sensing apparatus comprising an ion sensitive field effect transistor arranged to generate an electrical output signal in response to localised fluctuations of ionic charge at or adjacent the surface of the transistor, and means for detecting the electrical output signal from the ion sensitive field effect transistor, the localised fluctuations of ionic charge indicating events occurring during a chemical reaction.06-17-2010
20090017456DETECTION, IDENTIFICATION AND DIFFERENTIATION OF EUBACTERIAL TAXA USING A HYBRIDIZATION ASSAY - The present invention relates to a method for the specific detection and/or identification of 01-15-2009
20100304380Quantitative DNA Methylation Imaging of Cells and Tissues - The invention is a method using immunofluorescence, high-resolution imaging, and 3D image analysis to quantify spatial distribution of methylcytosine (MeC) in global DNA in individual cell nuclei, for the characterization of cells and tissues based on their nuclear MeC distribution patterns. The invented method is intended for basic research, clinical diagnostics and prognostics, pharmacology and toxicology, and molecular and cell-based therapy.12-02-2010
20110117549METHOD FOR DETECTING NUCLEIC ACID, AND DEVICE OR KIT - The present invention has its object to provide a method and a device or kit for detecting a nucleic acid, which enable simple and precise visual detection of a nucleic acid amplified by a nucleic acid amplification method, without necessity of a special device.05-19-2011
20090068641Highly conserved genes and their use to generate probes and primers for detection of microorganisms - Four highly conserved genes, encoding translation elongation factor Tu, translation elongation factor G, the catalytic subunit of proton-translocating ATPase and the RecA recombinase, are used to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes and amplification primers to rapidly detect and identify algal, archaeal, bacterial, fungal and parasitical pathogens from clinical specimens for diagnosis. The detection of associated antimicrobial agents resistance and toxin genes are also under the scope of the present invention.03-12-2009
20100240044Micro Chip - Instant invention is about a micro chip comprising plurality of layers of LTCC wherein a reaction chamber is formed in plurality of top layers to load samples. A heater embedded in at least one of the layers below the reaction chamber and a temperature sensor is embedded in at least one of the layers between the heater and the reaction chamber for analyzing the sample. The temperature sensor can be placed outside the chip to measure the chip temperature.09-23-2010
20090170097GENE EXPRESSION IN BIOLOGICAL CONDITIONS - The present invention relates to a method of predicting the prognosis of a biological condition in animal tissue, wherein the expression of genes is examined and correlated to standards. The invention further relates to the treatment of the biological condition and an assay for predicting the prognosis. In particular, the invention concerns gene expression in epithelial tissue, such as urinary bladder under both normal and abnormal conditions.07-02-2009
20100099082Allele Detection - Method for simultaneously determining alleles present in a set of loci from at least one nucleic acid sample comprising the steps: a) providing said at least one sample, b) subjecting said sample to a nucleic acid amplification reaction using a primer pair simultaneously primer pairs specific and optimized for each of the loci of a set of at least three loci selected from the group consisting of D2S1360, D7S1517, D8S1132, D9S1118, D10S2325, D11S554, D12S1064, D12S391, D17S1290, D19S253, MYCLl, P450CYP19 and SE-33, and c) evaluating the length and optionally the relative quantity of amplification products obtained from step b) or from the analysis of one or two of the above loci to determine and/or optionally quantify the alleles present at each of the loci analyzed in the set within said sample.04-22-2010
20100086911PREVENTIVE/THERAPEUTIC AGENT FOR CANCER - Identification of a novel target molecule for preventing/treating cancer and a preventive/remedy agent for cancer which targets the molecule, specifically, an agent for promoting the apoptosis in cancer cells and/or inhibiting the growth of cancer cells and a preventive/remedy agent for cancer, which comprise an antibody against a protein including the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10; an antisense polynucleotide of the protein (preferably, siRNA against mRNA of the protein); and a substance controlling the expression and/or activity of the protein, are provided by the present invention. A method of screening for a substance that promotes apoptosis in cancer cells and/or inhibits the growth of cancer cells and a preventive/remedy substance for cancer, in which the method comprises using a protein (preferably a cell producing the protein), an antibody against the protein, or a polynucleotide encoding the protein, is also provided by the present invention.04-08-2010
20080274458NUCLEIC ACID QUANTITATION METHODS - The invention relates to a method of determining the amount of a target nucleic acid sequence in a sample, the method comprising: obtaining multiple distinguishable amplicons of the target nucleic acid sequence, each comprising a distinguishing tag and a target portion; amplifying the amplicons in a single reaction volume; and detecting nucleic acids amplified from the amplicons. Detection of the distinguishable amplicons can be varied in each of the steps of the method, which expands the dynamic range of the nucleic acid quantification methods and improves the reliability and accuracy of the methods.11-06-2008
20080268428Chromosome 5 Genetic Variants Related to Dyslexia - An isolated polynucleotide or genetic material from human Chromosome 5 that indicates the presence of dyslexia or a predisposition to develop dyslexia in the individual from whom which the sample was obtained. A method of diagnosing dyslexia or a predisposition to develop dyslexia.10-30-2008
20090148846Modified Oligonucleotides and Applications Thereof - Disclosed, among other things, are primers containing certain modified nucleobases in the 3′ terminal region of the primers that provide reduced formation of primer-dimers during amplification reactions, and various methods of use thereof.06-11-2009
20090117548ANALYSIS OF HIV-1 CORECEPTOR USE IN THE CLINICAL CARE OF HIV-1 INFECTED PATIENTS - A change in viral tropism occurs in many HIV positive individuals over time and can be indicated by a change in coreceptor usage from CCR5 to CXCR4. The change in coreceptor usage to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus can be shifted back to CCR5-mediated entry after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CXCR4 specific strains. The diagnostic methods can be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time. 05-07-2009
20090130656NEISSERIA GONORRHOEAE DETECTION - A method for determining whether a human individual is or has been infected with 05-21-2009
20090162840Methods and compositions for use in analyte detection using proximity probes - Methods and compositions for detecting an analyte in a sample are provided. In practicing the subject methods, a sample is combined with at least a pair of proximity probes that each include an analyte binding domain and a nucleic acid domain. The resultant mixture is then contacted with a pair of asymmetric nucleic acid connectors. Proximity dependent connector mediated interaction between the nucleic acid domains of the proximity probes is then detected to determine the presence of the analyte in the sample. Also provided are kits and systems for practicing the subject methods.06-25-2009
20100136527Dominant B Cell Epitopes and Methods of Making and Using Thereof - Disclosed are methods for obtaining at least one epitope suitable for detecting the presence of an antibody against a tumor associated antigen of a cancer in a sample. Kits, assays, and substrates employing the epitopes of the present invention are disclosed. Also disclosed are epitopes of NY-ESO-1 and XAGE-1b and methods of using thereof.06-03-2010
20100136529Rare cell analysis using sample splitting and DNA tags - The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves labeling regions of genomic DNA in each cell in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the invention involves quantifying labeled DNA polymorphisms from each cell in the mixed sample.06-03-2010
20090298054Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders - The present application provides methods and nucleic acids for the detection and differentiation of breast cell proliferative disorders. This is achieved by the analysis of the methylation of a panel of genes, or subsets thereof. The invention may be used for the detection and/or differentiation of a variety of tissue types including breast cancer and benign breast disorders as well as other cancers and tissue types.12-03-2009
20090298053Use of novel biomarkers for detection of testicular carcinoma in situ and derived cancers in human samples - The present invention relates to methods and kits for identification of testicular carcinoma in situ (CIS), gonadoblastoma (a CIS-like pre-cancerous lesion found in dysgenetic gonads) and CIS-derived cancers based on at least one of the biomarkers included in the invention. It also relates to diagnosis of a subject's status of the testicular carcinoma in situ and the derived cancers based on the measurement of a relative abundance of one of the biomarkers.12-03-2009
20090298074Modulators of ELOVL5 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of ELOVL5 and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described.12-03-2009
20100035268MATERIALS AND METHODS FOR SINGLE MOLECULE NUCLEIC ACID SEQUENCING - Provided herein are methods and compositions for real time single molecule sequencing of short nucleotide sequences using nucleotide fluorescent semiconductor nanocrystals-conjugated nucleotide primers.02-11-2010
20100035266Methods for Assessing Risk of Alzheimer's Disease in a Patient - Disclosed are methods for diagnosis or prognosis of Alzheimer's disease in a patient. The methods may include assessing whether a patient has Alzheimer's disease or assessing a patient's risk for developing Alzheimer's disease. The methods typically include determining, either directly or indirectly, whether the patient has mutations, such as single nucleotide polymorphisms, in a plurality of genes that encode gene products that function in steroid biosynthesis.02-11-2010
20100035264METHODS AND VECTORS FOR PRODUCING TRANSGENIC PLANTS - Methods of, and compositions for, assembling one or more transcription units in a genome without a linked selectable marker or other unwanted transcription unit are provided. Also provided methods of, and compositions for, assembling one or more transcription units in a genome with a reduced frequency of vector backbone.02-11-2010
20100035260Compositions, devices, systems, for using a Nanopore - The invention herein disclosed provides for devices and methods that can detect and control an individual polymer in a mixture is acted upon by another compound, for example, an enzyme, in a nanopore in the absence of requiring a terminating nucleotide. The devices and methods are also used to determine rapidly (˜>50 Hz) the nucleotide base sequence of a polynucleotide under feedback control or using signals generated by the interactions between the polynucleotide and the nanopore. The invention is of particular use in the fields of drug discovery, molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof.02-11-2010
20100035258ASSAY AND METHOD - The present invention relates to a method and assay useful for determining the sensitivity of the cells of a subject to genetic damage from electromagnetic radiation. The assay may comprise a substrate suitable for mounting a sample of lymphocytes from a subject and an electromagnetic radiation source.02-11-2010
20100035256ENDURACIDIN BIOSYNTHETIC GENE CLUSTER FROM STREPTOMYCES FUNGICIDICUS - This disclosure describes the molecular cloning of an enduracidin biosynthetic gene cluster from 02-11-2010
20100035255METHOD AND KIT FOR ASSESSING RISK OF GOUT AND HYPERURICEMIA - A method for assessing a risk of suffering from a gout of a subject is provided. The method includes steps of obtaining a nucleotide sample from the subject; determining a genetic polymorphism of one of a Urate transporter 1 (URAT1) gene and an alpha-kinase 1 (ALPK1) gene in the nucleotide sample, wherein the genetic polymorphism is associated with an occurrence of the gout; and comparing the genetic polymorphism with a predetermined genetic polymorphism so as to assess the risk of suffering from the gout of the subject.02-11-2010
20100035247Heterogeneous Assay of Analytes in Solution Using Polymers - The invention relates to methods and systems for identifying, quantitating and/or analyzing analytes from samples. The analytes may be organic or inorganic in nature and include but are not limited to pathogens such as viruses.02-11-2010
20100035251BioMarkers for the Progression of Alzheimer's Disease - The genetic polymorphism LRRK2 (leucine-rich repeat kinase 2)-T1602S is significantly associated with conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD), with the patients with TT genotype being at greater risk to progress to Alzheimer's disease. The LRRK2-T2352 also showed a trend for conversion to Alzheimer's disease, with the patients with CC genotype tending to progress to Alzheimer's disease. Similar to the APOE-E4 allele, in the presence of a BuChE-K variant, LRRK2-T1602S and LRRK2-T2352 showed a greater association with the rate of conversion from mild cognitive impairment to Alzheimer's disease. In another study with placebo-treated Alzheimer's disease patients, LRRK2-T1602S and LRRK2-T2352 showed a same trend of association. The Alzheimer's disease patients with TT genotype of LRRK2-T1602S or CC genotype of LRRK2-T2352 tended to decline faster on cognitive performance over 6 months, especially in the presence of a BuChE-K variant. The association between the two common LRRK2 polymorphisms and Alzheimer's disease progression shows that LRRK2 may play a role in Alzheimer's disease pathogenesis, especially disease progression, and that polymorphisms of LRRK2 can be used as biomrkers of this progression.02-11-2010
20100035248SURFACE-BASED NUCLEIC ACID ASSAYS EMPLOYING MORPHOLINOS - The sequence determination, detection, and quantification of nucleic acid molecules through sequence-specific binding (hybridization) on a solid support, specifically when Morpholinos are used as the surface-immobilized probe species in surface-based nucleic acid assays, and the assays as disclosed herein.02-11-2010
20100035240METHODS AND KIT FOR THE PROGNOSIS OF BREAST CANCER - The present invention relates to a method and kit, including parts thereof, for the prognosis of breast cancer. In particular, the method involves identifying a gene expression pattern, or molecular signature, that indicates the likelihood of survival of a patient with breast cancer, and/or likelihood of recurrence of the disease in a patient being treated, or having been treated, for breast cancer, and the likelihood of a patient having a metastatic form of cancer. Six molecular signatures, comprising twelve groups/sets of molecular markers have been identified, which have relevance in determining the prognosis of a given breast cancer. Each molecular signature comprises a plurality of genetic markers whose expression, either high or low in respect of normal tissue, is indicative of a given outcome, such as survival or recurrence.02-11-2010
20100035238Anti-freeze protein enhanced nucleic acid amplification - Methods and compositions are provided for enhanced signal intensity and storage stability of standard nucleic acid amplification buffers, real-time PCR buffers or both. Buffers in accordance with the present invention include anti-freeze protein(s) (AFPs), optionally with a carrier protein, such as BSA.02-11-2010
20100035253Methods And Compositions For Incorporating Nucleotides - The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.02-11-2010
20100209926METHODS FOR DETECTING NEUTRALIZING ANTIBODIES FOR BONE MORPHOGENETIC PROTEINS - The present invention relates to methods of detecting neutralizing antibodies for bone morphogenetic proteins (BMP). More particularly, it relates to a highly specific, robust, rapid and accurate cell-based assay for detecting the presence of anti-BMP neutralizing antibodies.08-19-2010
20100209925HYBRIDIZATION METHOD AND APPARATUS - A target nucleic acid contained in a sample solution is hybridized with a probe nucleic acid capable of binding specifically to the target nucleic acid and immobilized on a substrate. The process includes hybridizing the target nucleic acid with the probe nucleic acid, collecting the sample solution that has undergone the hybridization, amplifying the target nucleic acid contained in the collected sample solution, and hybridizing the amplified nucleic acid with the probe nucleic acid.08-19-2010
20100209924Nuclear localization of Src-family tyrosine kinases is required for growth factor-induced euchromatinization - A method for quantitatively evaluating chromatin structural changes using pixel imaging of the nucleus is provided. Pixel imaging of the nucleus can include capturing one or more images of a nucleus of one or more nucleic acid stain treated cells. The stain intensity can be measured by quantitating the intensity. The mean and/or standard deviation of stain intensity per pixel can be used to determine chromatin condensation levels or chromatin structural change.08-19-2010
20100028878Modulators of UDP-glucose ceramide glucosyltransferase for treating acne or hyperkeratinization - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of UDP-glucose ceramide glucosyltransferase (UGCG), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperkeratinization; methods for the in vitro diagnosis or prognosis of these pathologies are also described.02-04-2010
20100209923Probe for diagnosis of marfan syndrome and a method for screening using the probe - The purpose of this invention is to provide a probe for diagnosis of Marfan syndrome, which enables early diagnosis of Marfan syndrome, and to provide a method for screening using said probe. The invention is a probe for a Marfan Syndrome characterized by using a nucleic acid comprising following (a) or (b); 08-19-2010
20090208953NEUROFIBROMIN PATHWAY MODULATORS - The present invention encompasses methods for treating neurofibromatosis and methods for screening for modulators of the neurofibromin pathway.08-20-2009
20100209922METHOD OF DETERMINING THE NUCLEOTIDE SEQUENCE OF OLIGONUCLEOTIDES AND DNA MOLECULES - The present invention relates to a novel method for analyzing nucleic acid sequences based on real-time detection of DNA polymerase-catalyzed incorporation of each of the four nucleotide bases, supplied individually and serially in a microfluidic system, to a reaction cell containing a template system comprising a DNA fragment of unknown sequence and an oligonucleotide primer. Incorporation of a nucleotide base into the template system can be detected by any of a variety of methods including but not limited to fluorescence and chemiluminescence detection. Alternatively, microcalorimetic detection of the heat generated by the incorporation of a nucleotide into the extending template system using thermopile, thermistor and refractive index measurements can be used to detect extension reactions.08-19-2010
20100209921Digital Amplification - The identification of pre-defined mutations expected to be present in a minor fraction of a cell population is important for a variety of basic research and clinical applications. The exponential, analog nature of the polymerase chain reaction is transformed into a linear, digital signal suitable for this purpose. Single molecules can be isolated by dilution and individually amplified; each product is then separately analyzed for the presence of pre-defined mutations. The process provides a reliable and quantitative measure of the proportion of variant sequences within a DNA sample.08-19-2010
20100209920Gene Expression Profiling in Biopsied Tumor Tissues - The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.08-19-2010
20100209919POLYNUCLEOTIDE MARKERS - The invention relates to polynucleotides that are closely linked to the bolting gene or B gene within the sugar beet genome and can be used for the development of molecular markers. The invention further relates to molecular markers and kits comprising said markers that can be used for mapping, identification and isolation of the bolting gene or S gene in the sugar beet genome and to discriminate between the annual and bienniai genotype or between different haplotypes within plant groupings of sugar beet plants exhibiting a biennial genotype. The invention also relates to assays and methods of breeding sugar beet plants involving said markers.08-19-2010
20100209917POLYMORPHIC LENGTH OF FOXE1 ALANINE STRETCH AND GENETIC SUSCEPTIBILITY TO THYROID DYSGENESIS - The present invention concerns a method for diagnosis an increased likelihood of developing a thyroid dysgenesis (TD) for an individual, wherein said method comprises determining the length of the polyalanine repeat of the protein encoded by at least one allele of the FOXE1 (Forkhead box E1) gene in a tissue sample obtained from said individual; and a kit for diagnosis an increased likelihood of developing a thyroid dysgenesis (TD) in an individual comprising at least one nucleic acid probe or oligonucleotide which can be used in such a method.08-19-2010
20100028900SCREENING METHODS AND SEQUENCES RELATING THERETO - Disclosed are screening methods and sequences related thereto. Disclosed are methods for detecting mutations in the MYH gene of an individual. Also disclosed are methods of genotyping and methods of predicting for an individual the likelihood of developing certain cancers, such as colorectal cancer.02-04-2010
20100028883METHOD FOR EVALUATION OF TISSUE PRESERVATION SOLUTION - The present invention provides a method for evaluating preservative effect of a tissue preservation solution, comprising immersing a mammalian tissue introduced with a luminescence or fluorescence labeling gene in the tissue preservation solution, measuring a luminescence or fluorescence level by the labeling gene in the tissue after immersion, and evaluating the preservative effect of the tissue preservation solution based on the luminescence or fluorescence level.02-04-2010
20100209916Apparatus, System, And Method Using Immiscible-Fluid-Discrete-Volumes - Various embodiments of the teachings relate to a system or method for sample preparation or analysis in biochemical or molecular biology procedures. The sample preparation can involve small volume processed in discrete portions or segments or slugs, herein referred to as discrete volumes. A molecular biology procedure can be nucleic acid analysis. Nucleic acid analysis can be an integrated DNA amplification/DNA sequencing procedure.08-19-2010
20100028886METHODS OF DETERMINING PROPERTIES OF MOLECULES - This disclosure features, inter alia, methods for determining at least one property of a nucleic acid. The methods include: (a) fixing the nucleic acid on a planar surface; (b) digesting the nucleic acid into fragments with at least one enzyme; (c) imaging the nucleic acid; and (d) analyzing the imaged nucleic acid to determine the property of the nucleic acid, wherein no internal nucleic acid standard is added during the method.02-04-2010
20100028881EXTRACELLULAR AND MEMBRANE-ASSOCIATED PROSTATE CANCER MARKERS - This document relates to methods and materials involved in identifying, assessing, and monitoring prostate cancer in male mammals. For example, this document provides arrays for detecting polypeptides or nucleic acids that can be used to identify prostate cancer in male mammals. In addition, methods and materials for assessing and monitoring prostate cancer in mammals are provided herein.02-04-2010
20090191556Method - The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described.07-30-2009
20100209915Gene Expression Profiling for Identification, Monitoring, and Treatment of Ocular Disease - A method is provided in various embodiments for determining a profile data set for a subject with ocular disease or conditions related to ocular disease based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least one constituent from Tables 1-5, 7-9, and 11-13. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.08-19-2010
20100209914METHODS, SYSTEMS, AND KITS FOR EVALUATING MULTIPLE SCLEROSIS - The present invention provides a method for evaluating multiple sclerosis (MS), or excluding MS as a diagnosis for a patient The method comprises determining a gene expression profile for a sample from such a patient. The gene expression profile, which contains gene expression values for a plurality of genes that are differentially expressed in white blood cells of MS patients, is compared to an MS-profile and/or a non-MS profile, and classified. The invention also provides a method for monitoring treatment of an MS patient Pre-treatment and post-treatment gene expression profiles contain gene expression values for a plurality of genes that are differentially expressed upon treatment of MS patients. The expression profiles may then be compared, to identify differences between pre-treatment and post-treatment gene expression. These differences are indicative of the patient's response to treatment The invention further provides kits and systems for performing the methods of the invention.08-19-2010
20090280483Methods for Screening Interleukin-6 (IL-6) Signal Transduction Inhibitors - The present invention provides methods for screening compounds which inhibit activation of a member of the IL-6 signaling pathways, comprising: (a) a positive screening step using a cell capable of being killed by IL-6 stimulation to select compounds which inhibit death of the cell when it is stimulated by IL-6; and then (b) a biochemical screening step to further select compounds which inhibit activation of a member of the IL-6 signaling pathways by a biochemical means from the compounds selected in step (a). The present invention also provides compounds which inhibit activation of a member of the IL-6 signaling pathways identified using said methods.11-12-2009
20100209912METHOD FOR THE TREATMENT OF A SAMPLE CONTAINING BIOMOLECULES - The invention generally provides a method for the sample preparation for a subsequent preparation, processing or analysis method of a sample containing an at least one species of nucleic acid and/or one species of protein, whereby the method comprises the following steps: A) providing a sample which contains at least one species of a nucleic acid and/or of a protein, B) contacting the sample with a fluid or solid composition to produce a fluid sample preparation, whereby the composition contains at least a nitrogenous compound, which is selected from the group consisting of a) polyamines, b) amino acids, and oligo- and polypeptides, c) nitrogenous heterocyclic compounds, including homo- oder heteropolymers, which comprise these nitrogenous compounds, d) amines of the type R08-19-2010
20100209911Microsatellite maker combination and method for identifying Lanyu pig breed - The present invention provides a microsatellite marker combination for identifying Lanyu pig breed, and the identification method thereof. The identification method comprises the following steps: (a) providing a genomic DNA sample obtained from a pig; (b) identifying the polymorphism of microsatellite markers of said genomic DNA sample; and (c) analyzing the results obtained from step (b) to determine the phylogenetic relationship between said pig and Lanyu pig.08-19-2010
20100209910Methods and systems for identifying polynucleotide sequences with translational self-cleavage activity - Provided herein are methods and systems for identifying 2A-like sequences with translational self-cleavage activity in an insect expression system.08-19-2010
20100209909ASSAYS BASED ON DETECTION OF PHOTOBLEACHING REACTION PRODUCTS FROM DYE CATALYTIC COMPLEX - The present invention relates to the methods for assaying an analyte comprising a nucleic acid analog binding substrate in a sample, comprising reacting a catalytic complex comprising a nucleic acid analog, a nucleic acid analog specific binding substrate and a light reactive dye with a light stimulus, and detecting the presence or absence or amount of a reaction product of the catalytic complex and light stimulus. The present invention also relates to a method of assaying a nucleic acid analyte in a sample using an analyte-specific reporter complex. The present invention also relates to a method of assaying an analyte in a sample using a reporter molecule.08-19-2010
20100209908SYSTEM AND METHOD FOR NUCLEOTIDE SEQUENCE PROFILING FOR SAMPLE IDENTIFICATION - The invention includes a method of sample profiling for identification. The method includes the steps of performing less than four nucleotide-specific chemical cleavage reactions to obtain nucleotide sequence fragments, performing size separation on the fragments, detecting the fragments' separation, generating a profile based on the detection, and comparing the profile to a data base to identify the sample.08-19-2010
20100209907ISOLATED MAMMALIAN MONOCYTE CELL GENES; RELATED REAGENTS - Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.08-19-2010
20100209906Methods and compositions for detecting colon cancers - This application describes methods and compositions for detecting and treating vimentin-associated neoplasia. Differential methylation of the vimentin nucleotide sequences has been observed in vimentin-associated neoplasia such as colon neoplasia.08-19-2010
20090208939Identification of Molecular Diagnostic Markers for Endometriosis in Blood Lymphocytes - The invention comprises a method of identifying or predicting the predisposition to endometriosis in a female subject comprising determining the level of gene expression of at least one differentially-expressed gene or protein or peptide of peripheral blood leukocytes in a sample of peripheral blood leukocytes or peripheral blood in a subject to provide a first value, determining the level of gene expression of the at least one differentially-expressed gene or protein or peptide of said leukocytes in a control or reference standard to provide a second value, and comparing whether there is a difference between the first value and second value.08-20-2009
20090203009Novel method for high-throughput integrated chemical and biochemical reactions - The present invention relates to methods for monitoring in a high through-put fashion a multitude of molecular reaction processes, using a substrate, said substrate comprising a plurality of micro-channels, wherein each micro-channel has inlet and outlet open ends on opposing sides of said substrate, and wherein said micro-channels comprise at least one first reaction component, comprising the steps of: (a) contacting said micro-channels of said solid substrate with a sample, said contacting being via said inlet open ends, wherein said sample comprises an analyte, under conditions that allow said analyte to be specifically retained within said micro-channels by said first reaction component; (b) optionally removing excess of sample via said outlet open ends; (c) contacting the retained analyte with at least one second reaction component, said second reaction component being different from said first reaction component as defined in step (a), under conditions that allow a molecular reaction to take place, said reaction producing a signal; (d) detecting said signal and reading-out reaction results; (e) removing second reaction components via said outlet open ends; (f) repeating steps (c) to (e) at least once, wherein said at least one second reaction component as defined in (c) may be changed in composition; and, final detecting and reading-out of reaction results. The present invention also relates to the uses thereof as well as to microarrays and kits for performing said methods of the invention.08-13-2009
20100105064METHOD OF SCREENING TEST SUBSTANCES FOR TREATING OR PREVENTING A DISEASE MEDIATED BY PLASMA CELLS - The present invention relates to a method of screening a compound for potential effectiveness in treating or preventing a mammalian disease mediated by plasma cells or a mammalian disease caused by virus infection of mammalian cells. Compounds are tested for their ability to inhibit IRE1-mediated processing of untranslatable XBP-1 mRNA into translatable XBP-1 mRNA. Drugs that are useful in treating or preventing a mammalian disease mediated by plasma cells and a method for detecting XBP-1 activity in living cells are also described.04-29-2010
20090098567COLLECTION DEVICE - A cap which can form an essentially leak-proof seal with an open-ended vessel capable of receiving and holding fluid specimens or other materials for analysis. To minimize potentially contaminating contact between a fluid sample present in the vessel and humans or the environment, the present invention features a cap having a frangible seal which is penetrable by a plastic pipette tip or other fluid transfer device. The cap further includes a filter for limiting dissemination of an aerosol or bubbles once the frangible seal has been pierced. The filter is positioned between the frangible seal and a retaining structure. The retaining structure is positioned on the cap above the filter and may be used to contain the filter within the cap. The material of the retaining structure may be penetrable by a fluid transfer device.04-16-2009
20090098566METHOD OF SYNTHESIZING NUCLEIC ACID - The present invention relates to an oligonucleotide having a novel structure and a method of synthesizing nucleic acid by using the same as a primer. This oligonucleotide is provided at the 5′-side of the primer with a nucleotide sequence substantially the same as a region synthesized with this primer as the origin of synthesis. The present invention realizes synthesis of nucleic acid based on an isothermal reaction with a simple constitution of reagents. Further, the present invention provides a method of synthesizing highly specific nucleic acid on the basis of this method of synthesizing nucleic acid.04-16-2009
20090098563Diagnosis of (a risk of) disease and monitoring of therapy - Provided are methods for typing a sample of an individual suffering from, or at risk of suffering from, a disease and a method for monitoring treatment of an individual suffering from a disease comprising determining whether a sample from the individual comprises an expression product of AC133 in an amount that is indicative for the disease or for the treatment thereof. That amount may be quantified and compared with a reference value. In one aspect, the amount is compared with an amount of the expression product present in a sample that was obtained from the individual before treatment. Use of a nucleic acid molecule comprising at least part of a sequence of AC133, or an analogue thereof, for monitoring a treatment of an individual suffering from a disease is also provided, as well as a diagnostic kit comprising such nucleic acid molecule.04-16-2009
20090098560PURIFICATION METHOD AND KITS - A method for separating nucleic acid from a liquid sample, said method comprising the steps of causing a liquid sample containing or suspected of containing said nucleic acid to flow along a bibulous membrane, for example of a conventional lateral flow device, so that nucleic acid is distributed along the length of the membrane. The nucleic acid may be detected on the membrane.04-16-2009
20090098547Methods for Identifying DNA Copy Number Changes Using Hidden Markov Model Based Estimations - Methods for estimating genomic copy number and loss of heterozygosity using Hidden Markov Model based estimation are disclosed.04-16-2009
20090098561Higher-order cellular information processing devices - The invention provides various signal processing devices for integrating two or more biological signals (e.g., the presence, absence or concentration of specific ligands, etc.) to generate a status output, or a response that modulates one or more biological activities based on the status of the biological signals. The various described signal processing/integration mechanisms may be combined with one another to provide the device with more flexibility in integrating high-order cellular information. The signal processing devices of the invention have many uses in various biological systems, including gene expression control or ligand-concentration sensing.04-16-2009
20090098548MODULATORS OF ENZYMATIC NUCLEIC ACID ELEMENTS MOBILIZATION - The present invention discloses a nucleic acid cleavage assay for members of the transposase/integrase superfamily. A method of using the assay to screen for modulators of the nucleic acid cleavage activity is also disclosed. The present invention further provides a method for screening for modulators of binding of a transposase/integrase to its corresponding recognition sequence. In addition, the present invention provides a method of identifying a modulator for a particular transposase/integrase such as HIV integrase based on modulators of other members of the transposase/integrase superfamily. Also disclosed are Tn5 transposase inhibitors and HIV integration inhibitors.04-16-2009
20090098551METHODS AND PRODUCTS RELATED TO GENOTYPING AND DNA ANALYSIS - The invention encompasses methods and products related to genotyping. The method of genotyping of the invention is based on the use of single nucleotide polymorphisms (SNPs) to perform high throughput genome scans. The high throughput method can be performed by hybridizing SNP allele-specific oligonucleotides and a reduced complexity genome (RCG). The invention also relates to methods of preparing the SNP specific oligonucleotides and RCGs, methods of fingerprinting, determining allele frequency for a SNP, characterizing tumors, generating a genomic classification code for a genome, identifying previously unknown SNPs, and related compositions and kits.04-16-2009
20090098562Methods for identifying stem cells based on nuclear morphotypes - Methods for identifying stem cells and other cells specific to embryogenesis and carcinogenesis, classifying tissue samples, diagnosing precancerous and cancerous or atherosclerotic lesions, testing the value of anticancer agents, discovering macromolecules specifically expressed in particular cell types, using stem cells in restorative tissue therapy as well as methods for preparing tissue samples so heteromorphic nuclear morphotypes remain intact are disclosed.04-16-2009
20090098559FORENSIC SWAB AND KIT - The present invention relates to a high sensitivity crime scene swab device for maximal recovery of trace forensic DNA evidence left at a crime scene for DNA PCR analysis. More particularly, DNA recovery is obtained from fingerprints lifted from surfaces at the crime scene. The invention also relates to a high sensitivity method for DNA analysis of trace DNA obtained by generating small tandem repeat (STR) profiles using a polymerase chain reaction protocol.04-16-2009
20090098554Method and composition for cancer diagnosis and treatment - Methods and compositions for inhibiting the onset of cancer, and cancer diagnosis and treatment are provided. The treatment method comprises inhibiting the level or function of transcriptional positive factor 4 (PC4). Also provided are methods of screening for cancer inhibition agents based on inhibition of PC4 expression or function.04-16-2009
20090098552METHODS AND COMPOSITIONS FOR ANALYZING AHASL GENES - The invention relates to methods and compositions for analyzing plant acetohydroxy acid synthase large subunit (AHASL) genes. In particular, the invention relates to methods for the detection of wild-type AHASL alleles and mutant AHASL alleles that encode imidazolinone-tolerant AHASL proteins. The methods involve the use of PCR amplification and novel compositions comprising allele-specific and gene-specific primers to detect the presence of mutant and/or wild-type alleles present at the individual AHASL genes of a plant. Specifically, the methods and compositions are useful for analyzing the three AHASL genes of 04-16-2009
20090098553Urine gene expression ratios for detection of cancer - This invention relates to methods for determining the presence of cancer in a subject based on the analysis of the expression levels of an under-expressed tumour marker (TM) and at least one other TM. Specifically, this invention relates to the determination of a cancer, particularly bladder cancer, by performing ratio, regression or classification analysis of the expression levels of at least one under-expressed TM, particularly an under-expressed bladder TM (BTM), and at least one over-expressed TM, particularly an over-expressed BTM. In various aspects, the invention telates to kits and devices for carrying out these methods.04-16-2009
20090098544MARKER MOLECULES ASSOCIATED WITH LUNG TUMORS - The present invention relates to nucleic acids and polypeptides associated with lung cancer. The invention is more specifically related to a nucleic acids and the polypeptides transcribed thereof, the expression of which is significantly altered in association with lung cancer. The invention relates to a series of differentially spliced transcripts of the gene disclosed herein, that are associated with tumors of the respiratory tract. Furthermore the present invention provides a method for early diagnosis, prognosis and monitoring of the disease course and for therapy and vaccination of cell proliferative disorders such as e.g. lung tumors.04-16-2009
20090098543GENE METHYLATION IN LUNG CANCER DIAGNOSIS - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with lung cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of lung cancer.04-16-2009
20090098541Devices and processes for analysing individual cells - A device for individually analysing cells of interest, comprising (a) a channel for receiving the contents of a cell of interest, wherein the channel has an input end and an output end, and (b) a cell trapping site in proximity to the input end of the channel, wherein (i) the input end of the channel is adapted such that an intact cell of interest cannot enter the channel; and (ii) the channel contains one or more analytical components for analysing the contents of the cell of interest. In use, a cell is applied to the device, where it is trapped by the cell trapping means. The cell cannot enter the channel intact, but its contents can be released in situ to enter the channel's input end. The contents can then move down the channel, towards the output end, and they encounter the immobilised reagents, thereby permitting analysis of the cell contents.04-16-2009
20090098540RECIRCULATING MICROFLUIDIC DEVICE AND METHODS OF USE - The present invention relates to a microfluidic test device for detecting or quantifying an analyte in a test sample. The device includes a non-absorbent substrate having at least one microchannel imbedded in the substrate, a non-specific capture device, and one or more stationary mixing structures extending into the at least one microchannel. The present invention also relates to relates to various methods of using the microfluidic test device to detect or quantify an analyte in a test sample. The present invention also relates to a microfluidic device that includes a non-absorbent substrate having at least one microchannel imbedded in the substrate and one or more stationary mixing structures extending into the at least one microchannel.04-16-2009
20090098534Full Karyotype Single Cell Chromosome Analysis - A full set of 24 chromosome-specific probes to analyze single cells or cell organelles to test for abnormalities is described. When used in an assay based on sequential hybridization, the full set is comprised of three subsets of chromosome-specific probes with each set comprised of 8 different probes. Also described are assays using a set of probes to analyze single cells and cellular organelles to accurately determine the number and type of targeted human chromosomes in various types of cells and cell organelles, such as tumor cells, interphase cells and first polar bodies biopsied from non-inseminated oocytes. Methods of selection or generation of suitable probes and hybridization protocols are described, as are preferred probes for frill set of 24 chromosome-specific probes to target all 24 human chromosomes are described in the Tables.04-16-2009
20090098537Biomarker for Sensitivity to mTOR Inhibitor Therapy in Kidney Cancer - The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits adapted for performing such methods. For example a correlation between VHL loss and mTOR inhibitor sensitivity in human kidney cancer cells is disclosed, indicating that VHL loss confers autonomous and angiogenic competitive advantages to such cells.04-16-2009
20090098533Methods and kits for investigating cancer - The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and breast cancer. The invention further relates to genes that are differentially expressed in breast tissue of breast cancer patients versus those of normal “healthy” tissue. Differentially expressed genes for the identification of patients which are likely to respond to chemotherapy are also provided.04-16-2009
20090098538Prognostic and diagnostic method for disease therapy - The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian, bladder, lymphoma, mesothelioma, medullablastoma, glioma, and AML. Identification of therapy-resistant patients early in their treatment regimen can lead to a change in therapy in order to achieve a more successful outcome. One embodiment of the present invention is directed to a method for diagnosing cancer or predicting cancer-therapy outcome by detecting the expression levels of multiple markers in the same cell at the same time, and scoring their expression as being above a certain threshold, wherein the markers are from a particular pathway related to cancer, with the score being indicative or a cancer diagnosis or a prognosis for cancer-therapy failure. This method can be used to diagnose cancer or predict cancer-therapy outcomes for a variety of cancers. The markers can come from any pathway involved in the regulation of cancer, including specifically the PcG pathway and the “stemness” pathway. The markers can be mRNA, microRNA, DNA, or protein.04-16-2009
20090186356DEVICE AND SUBSTANCE FOR THE IMMOBILIZATION OF MESENCHYMAL STEM CELLS (MSCs) - The invention relates to a device comprising at least one surface which comes into contact with biological tissue and/or liquid, which is at least partially coated with a substance which mediates the binding of mesenchymal stem cells (MSCs), a method for the binding and/or isolation of MSCs from biological tissue and/or liquid, a nucleic acid molecule which selectively and highly specifically binds to MSCs, the use of the nucleic acid molecule for the binding and/or isolation of MSCs from biological tissue and/or liquid, as well as a method for the production of a device mentioned at the outset.07-23-2009
20090233282PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof.09-17-2009
20090176229Methods and compositions for the identification of insect repellent compounds - Methods for identifying a candidate compound with an ability to modulate cation transport through a transient receptor potential (TRP) channel in a cell are disclosed. The methods can include (a) providing a cell expressing a recombinant nucleic acid sequence encoding an transient receptor potential (TRP) channel gene product or a functional fragment or derivative thereof; (b) contacting the cell with the candidate compound; (c) comparing cation transport in the cell in the absence of the candidate compound with cation transport in the cell in the presence of the candidate compound; and (d) identifying a candidate compound through the comparing step that modulates cation transport in the cell through the transient receptor potential (TRP) channel. Also disclosed are nucleic acid and amino acid sequences for insect TRP channel gene products, antibodies that bind to the disclosed TRP channels, and recombinant host cells the include the disclosed biosequences.07-09-2009
20090220947Biomarkers for toxic algae - The present invention is directed toward biomarkers that identify characteristics of algae. The invention is further directed toward biomarkers that serve to identify algae species and strains of algae species as well as detect the presence of algal toxins. Additional embodiments feature methods utilizing algal biomarkers and polypeptides that can serve as biomarkers.09-03-2009
20090162861METHOD FOR SUPPRESSING A FRET SIGNAL, FRET SIGNAL SUPPRESSOR AGENTS AND USE IN A METHOD FOR MULTIPLEXING BIOLOGICAL EVENTS - The invention relates to a method for suppressing the FRET emitted by a reaction medium containing a pair of fluorescent FRET partner conjugates specific for a biological event, characterized in that a FRET signal killer which does not disturb said biological event is introduced into this medium.06-25-2009
20090162860Method of nucleic acid sequence detection and nucleic acid sequence detection substrate - According to an aspect of the present invention, a pair of oligonucleotide strands are anchored onto the surface of a substrate by immobilizing one of the ends thereof onto the substrate. Each of the immobilized oligonucleotide strands is bound to a target nucleic acid sequence (single-stranded) having complementary sequences thereto to form a cross-linked structure on the substrate, thereby forming a finely reticulated space. Ligands are captured by this reticulated space through physical adsorption and caused to color with active substances reactive to the ligands. As a result of this, the present invention is capable of highly sensitively detecting even an exceedingly small concentration of a particular target nucleic acid sequence to be detected, at low cost and for a short time.06-25-2009
20090162850NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 125P5C8 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.06-25-2009
20090092969DETECTION OF ATYPICAL PNEUMONIA - Disclosed herein are methods and compositions for detecting one or more pathogens that cause atypical pneumonia. Detectable pathogens include 04-09-2009
20090280484METHODS FOR GENE MAPPING AND HAPLOTYPING - The present invention is directed to methods for providing a definitive haplotype of a subject. The haplotype information generated by the methods described herein is more accurate than that provided by prior art methods that only give an inferred haplotype. Accordingly, in one aspect the present invention provides a method for determining a definitive haplotype of a subject the method including the steps of providing a substantially isolated haploid element from the subject, and obtaining nucleotide sequence information from the haploid element. Applicants propose that the use of a substantially isolated haploid element eliminates the problem of incorrect or misleading inferences concerning the phase of two or more loci within a haplotype, and allows for revelation of two or more participatory genes within a haplotype, uncomplicated by differences in modes of inheritance. The guarantee of strictly cis-phase associations is provided in the present methods by the use of a substantially isolated haploid element as starting material for sequence analysis.11-12-2009
20100112582GENE ENCODING LABYRINTHIN, A MARKER FOR CANCER - A cDNA molecule that encodes a protein designated Labyrinthin (Lab) isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab), or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells.05-06-2010
20080311577Method for the Identification of Sulfo-Oxidizing Bacteria and for the Monitoring of Elemental Sulfur in the Environment - A method is described for the identification of sulfooxidizing bacteria comprising the extraction of the DNA from environmental samples and the subsequent identification of at least one fragment of the Thio 16S gene or SoxB gene present in these bacteria. The method can be used for determining the level of elemental sulfur in samples of soil.12-18-2008
20080311576Replication competent hepatitis C virus and methods of use - The present invention provides a replication competent hepatitis C virus that includes a heterologous polynucleotide. The invention also includes methods for modifying a hepatitis C virus polynucleotide, selecting a replication competent hepatitis C virus polynucleotide, detecting a replication competent hepatitis C virus polynucleotide, and identifying a compound that inhibits replication of a hepatitis C virus polynucleotide.12-18-2008
20080311574Novel Missense Mutations and Single Nucleotide Polymorphisms in the Rabphillin-3A-Like Gene and Uses Thereof - The invention relates to methods and compositions of matter for determining or predicting aggressiveness of a subject's tumor, for determining a subject's predisposition to cancer, for diagnosing cancer in a subject, and for selecting a therapy for a subject with cancer. Also provided are methods and compositions of matter for determining a Rabphillin-3A-Like gene genotype in a subject and for characterizing a Rabphillin-3A-Like gene in a subject.12-18-2008
20090305254Method and Apparatus for Assaying Test Substance in Sample - Disclosed are a method for assaying a target substance in a sample and an apparatus for the method. The method can specifically assay the target substance in the sample without using any antibody against the target substance. The assaying method includes simultaneously or successively bringing a labeled aptamer, the target substance in the sample and a solid phase into contact together, and then measuring the label of the aptamer which has not been bound on the solid phase. The labeled aptamer has a property of binding to the target substance. The solid phase carries an oligonucleotide immobilized on it in an excess amount relative to the target substance. The oligonucleotide is hybridizable with the labeled aptamer when the labeled aptamer is in a state that it is not bound to the target substance, but is not hybridizable with the labeled aptamer when the labeled aptamer is in a state that it is bound to the target substance.12-10-2009
20090203026Methods and compositions for targeting secretory lysosomes - This invention relates to methods and compositions for targeting proteins to secretory lysosomes. The invention further provides methods of use in drug screening assays, and methods of purifying secretory lysosomes.08-13-2009
20100184070Methods and Devices for Diagnosis of Appendicitis - A method is provided for diagnosing appendicitis in a patient that includes identifying at least one symptom of appendicitis in the patient and identifying the presence of at least one molecule differentially associated with appendicitis in a fluid or tissue sample of said patient. MRP-8/14 and haptoglobin are examples of molecules differentially associated with appendicitis. Devices and kits for performing the appendicitis assays of this invention are also provided. In one embodiment, the device is in a flow-through immunoassay format for testing blood samples. Further, methods for screening for molecules differentially associated with appendicitis are provided that include the use of samples from patients being operated on for suspected appendicitis.07-22-2010
20090197257PAIRED-END READS IN SEQUENCING BY SYNTHESIS - The disclosure provides methods of generating paired reads in sequencing-by-synthesis process, particularly, in systems with relatively short read lengths (e.g., 15-35 bases), such as for example, in single molecule sequencing by synthesis. Several implementations of the methods are provided. Of particular advantage are the methods that permit re-sequencing of the template, which yields lower error rates. The invention further provides methods of using paired reads, for example, for positioning them over repeats or for assembly into large sequences, including whole genome assembly.08-06-2009
20080311566Method for Quantification of Methylated Dna - The present invention relates to a method for the quantification of methylated cytosines in DNA. In the first step of the invention unmethylated cytosines in the DNA to be analysed are chemically converted into uracil while 5-methylcytosines remain unchanged. In a second step the converted DNA is amplified methylation specifically in a real time PCR using a methylation specific probe. Finally the amount of uniformly methylated DNA is calculated by combining criteria derived from the shape of the real time curve and from the signal intensity. The method is preferably used for diagnosis and/or prognosis of adverse events for individuals, for distinguishing cell types and tissues, or for investigating cell differentiation.12-18-2008
20080311569METHOD FOR QUANTITATIVE MEASUREMENT OF GENE EXPRESSION FOR INDENTIFYING INDIVIDUALS AT RISK FOR BRONCHOGENIC CARCINOMA - A method measure expression of multiple target genes in a progenitor cell for bronchogenic carcinoma comprising the use of reverse transcription-polymerase chain reaction (RT-PCR) to allow simultaneous expression measurement of the multiple target genes is disclosed.12-18-2008
20080311567Tumor Markers for Use in the Diagnosis of Colorectal Carcinomas and/or Metastases Originating Therefrom - The invention relates to a method (i) for detecting a carcinoma, especially an adenocarcinoma, preferably a gastrointestinal carcinoma and more preferably a colorectal carcinoma, (ii) for predicting metastases, preferably liver metastases, depending on a primary colon carcinoma and/or (iii) for predicting the response of metastases to a 5-fluorouracil-containing chemotherapy. The inventive method comprises determining a gene expression profile of 120 marker genes or a selection thereof.12-18-2008
20100068702Method for Detecting Disease-Related Marker Using Gastric Mucosal Lavage Fluid - The invention relates to a sample containing a gastric mucosa lavage fluid collected from a subject who has received a gastric mucus removal treatment and a method for detecting a disease-related marker using the same. By using the sample of the invention, the disease-related marker can be detected conveniently, less invasively, highly sensitively and highly accurately.03-18-2010
20080311565Methods and Kits for Detecting Germ Cell Genomic Instability - Disclosed are methods for detecting microsatellite instability in the germ line of males, methods of assessing risk for developing testicular cancer, methods of evaluating the microsatellite stability of putative cancer or precancerous cells or a tumor, methods for evaluating germ cells for exposure to mutagens, and kits for use in the methods of the invention.12-18-2008
20090181387Method for Analysing Nucleic Acids - Method of analyzing nucleic acids comprising the steps of nucleic acid fractionation, adaptor binding and nucleic acid amplification, and an in vitro transcription step. The invention has application in the field of genomic analysis of organisms by the use of DNA microarrays.07-16-2009
20090170077Method for detecting recombinant event - Methods relating to isolating and amplifying chimeric nucleic acid molecules are provided. The methods of the invention are useful for detecting chromosome translocation events associated with diseases or conditions, such as cancer.07-02-2009
20090170112Loci Associated Charcoal Rot Drought Complex Tolerance in Soybean - The invention relates to methods and compositions for identifying soybean plants that are tolerant, have improved tolerance or are susceptible to Charcoal Rot Drought Complex. The methods use molecular genetic markers to identify, select and/or construct tolerant plants or identify and counter-select susceptible plants. Soybean plants that display tolerance or improved tolerance to Charcoal Rot Drought Complex that are generated by the methods of the invention are also a feature of the invention.07-02-2009
20090162841Method of selecting a desired protein from a library - Described is an improved method of selecting a member of a specific binding pair (sbp) having a desired specify, preferably an antibody, from a library expressing said member of a sbp, preferably a phage-display antibody library.06-25-2009
20090317800REPORTER VECTOR FOR USE IN EVALUATION OF CYP1A2 INDUCTION - A reporter vector which can evaluate the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 and a method for evaluation of the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 by using the reporter vector. A reporter system which can evaluate the ability of a drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 is completed by constructing a reporter vector having a reporter gene linked to the 3′ end of a region between CYP1A1 and CYP1A2 or a reporter vector having different reporter genes linked to the both ends of the region, respectively, so as to sandwich the region, and a reporter vector having a deletion mutation in the region, and confirming that the expression of a reporter molecule is increased by the drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 in the reporter system using the reporter vector.12-24-2009
20100035242Methods and nucleic acids for the detection of metastasis of colon cell proliferative disorders - The invention provides methods, nucleic acids and kits for detecting metastasis of colon cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of metastasis of colon cell proliferative disorders, thereby enabling the improved diagnosis and treatment of patients.02-11-2010
20090081677METHOD FOR GENDER IDENTIFICATION OF EAGLES WITH PROBE-BASED REAL-TIME PCR AND THE SEQUENCES USED FOR GENDER IDENTIFICATION OF EAGLES - A method for gender identification of eagles includes: providing a DNA of an eagle; performing a probe-based real-time PCR using the DNA as a template, a universal primer pair P2/P8 as a primer pair and a first probe and a second probe as probes, wherein the 5′ ends of the first probe and the second probe are labeled with a first fluorescent dye and a second fluorescent dye, respectively, and the first probe is a sequence with about 15-38 nucleotides in length of SEQ ID No. 1 and the second probe is a sequence with about 15-44 nucleotides in length of SEQ ID No. 2; and analyzing a result of the PCR, wherein if the result is positive for both the first and the second fluorescent dye, the eagle is a female, and if the result is positive for only the first fluorescent dye, the eagle is a male.03-26-2009
20100112567RANDOM ACCESS SYSTEM AND METHOD FOR POLYMERASE CHAIN REACTION TESTING - A random access, high-throughput system and method for preparing a biological sample for polymerase chain reaction (PCR) testing are disclosed. The system includes a nucleic acid isolation/purification apparatus and a PCR apparatus. The nucleic acid isolation/purification apparatus magnetically captures nucleic acid (NA) solids from the biological sample and then suspends the NA in elution buffer solution. The PCR testing apparatus provides multiple cycles of the denaturing, annealing, and elongating thermal cycles. More particularly, the PCR testing apparatus includes a multi-vessel thermal cycler array that has a plurality of single-vessel thermal cyclers that is each individually-thermally-controllable so that adjacent single-vessel thermal cyclers can be heated or cooled to different temperatures corresponding to the different thermal cycles of the respective PCR testing process.05-06-2010
20100112565Methods, kits, and reaction mixtures for high resolution melt genotyping - Various methods are described that provide for high resolution melt (HRM) genotyping. Some embodiments comprise providing a locus specific primer, and two allele specific primers each comprising at least one single nucleotide polymorphism (SNP) allele-hybridizable sequence, wherein at least one of the allele specific primers also comprises at least one nucleotide alteration. In some embodiments, a nucleic acid is provided comprising a SNP base located within 1-20 bases of its 3′ end. Some embodiments comprise hybridizing the locus specific primer and at least one of the allele specific primers to the nucleic acid, amplifying the hybridized nucleic acid using pyrophosphorolysis activated polymerization (PAP) PCR, and determining the melting temperature (Tm) of the resulting amplicons, for example, using HRM. In some embodiments, reaction mixtures and kits for HRM genotyping are provided. The reaction mixtures and kits can each comprise a locus specific primer, one or more allele specific primers each comprising at least one SNP allele-hybridizable sequence, and a PAP PCR enzyme, wherein at least one of the allele specific primers also comprises a nucleotide alteration, for example, a tail.05-06-2010
20100112585Method for Enriching Methylated CpG Sequences - Compositions and methods are provided for facilitating the enrichment of single-stranded DNA containing methylated CpG in a mixture containing methylated and unmethylated DNA. The compositions relate to methylation-binding protein domains that selectively bind to methylated single strand DNA. In embodiments of the invention, the methylated DNA is eluted in 0.4M-0.6M NaCl while the unmethylated single strand DNA is eluted in less than 0.4M salt. The ability to readily enrich for methylated DNA permits high throughput sequencing of the methylated DNA and identification of abnormal methylation patterns associated with disease.05-06-2010
20100112583BLOOD DIAGNOSIS METHOD FOR DIALYSIS PATIENT AND DIALYSIS MACHINE - Provided is a blood diagnosis method and a dialysis machine, using a diagnostic marker which is versatile and which can contribute to the improvements in dialysis treatment and the evaluation of clinical effects, 05-06-2010
20100112584CYANINE COMPOUNDS AND THEIR USE IN STAINING BIOLOGICAL SAMPLES - Cyanine compounds having the general formula I for staining biological samples, wherein R05-06-2010
20100112578Test chip, detection apparatus, and method for detecting analyte - A test chip for detecting an analyte modified with a modulator releasing electrons upon photoexcitation, comprising: semiconductor electrode part including a metal layer formed on a semiconductor layer; a probe immobilized on the metal layer, the probe trapping the analyte; and a counter electrode part including a conductive layer. A detection apparatus and a method for detecting an analyte are also disclosed.05-06-2010
20100112566VIPR1S as Modifiers of the E2F/RB Pathway and Methods of Use - Human VIPR1 genes are identified as modulators of the E2F/RB pathway, and thus are therapeutic targets for disorders associated with defective E2F/RB function. Methods for identifying modulators of E2F/RB, comprising screening for agents that modulate the activity of VIPR1 are provided.05-06-2010
20100112575Noninvasive Diagnosis of Fetal Aneuploidy by Sequencing - Disclosed is a method to achieve digital quantification of DNA (i.e., counting differences between identical sequences) using direct shotgun sequencing followed by mapping to the chromosome of origin and enumeration of fragments per chromosome. The preferred method uses massively parallel sequencing, which can produce tens of millions of short sequence tags in a single run and enabling a sampling that can be statistically evaluated. By counting the number of sequence tags mapped to a predefined window in each chromosome, the over- or under-representation of any chromosome in maternal plasma DNA contributed by an aneuploid fetus can be detected. This method does not require the differentiation of fetal versus maternal DNA. The median count of autosomal values is used as a normalization constant to account for differences in total number of sequence tags is used for comparison between samples and between chromosomes.05-06-2010
20100112556METHOD FOR SAMPLE ANALYSIS USING Q PROBES - A method of sample analysis is provided. In certain embodiments, the method may comprise: a) contacting a plurality of Q probes with a nucleic acid sample comprising a target polynucleotide under hybridization conditions to form a plurality of flap endonuclease substrates each comprising a Q probe and a site in the target polynucleotide; b) contacting the plurality of flap endonuclease substrates with a flap endonuclease under cleavage conditions to produce cleavage products, in which each of the Q probes of the flap endonuclease substrates is cleaved to produce cleavage products that include at least a first fragment that is hybridized with a site in the target polynucleotide and a second fragment that is linear and free in solution; and c) detecting at least one of the cleavage products.05-06-2010
20100112562Mutation Implicated in Abnormality of Cardiac Sodium Channel Function - A novel mutation in the SCN5A gene is associated with loss of cardiac sodium channel function. Analysis of the novel mutation provides an early diagnosis of subjects with cardiac diseases or disorders caused by loss of cardiac sodium channel function, particularly Brugada syndrome. Diagnostic methods include analyzing the sequences of the SCN5A gene or protein of an individual to be tested and comparing them with the sequences of the native, nonvariant SCN5A gene or protein. Pre-symptomatic diagnosis of these syndromes will enable practitioners to treat these disorders using existing medical therapy, e.g., using sodium channel blockers or through electrical stimulation.05-06-2010
20100112558Probe Bead Synthesis and Use - The present invention relates to the field of methods and devices of miniaturized synthesis. More specifically, the present invention relates to the parallel synthesis of large number of different types of molecules and oligomers, such as oligonucleotides (oligos), peptides, lipids, carbohydrates, small ligand molecules, and other organic and inorganic molecules as probes for multiplexing assays. The probes may be synthesized from and/or attached to nanobeads to microbeads. The present invention provides for assays of multiplexing large scale biology, such as analysis of genomic DNAs and RNAs and proteomic proteins or peptides performed simultaneously on the synthetic beads.05-06-2010
20100112553LUCIFERASE GENE OPTIMIZED FOR USE IN IMAGING OF INTRACELLULAR LUMINESCENCE - The present invention provides a gene construct encoding pH insensitive luciferase for visualizing intracellular information, wherein an intracellular expression activity is higher compared with a gene construct of luciferase derived from a firefly. 05-06-2010
20090311706QUANTITATIVE ANALYSIS OF IN VIVO MUTATION AT THE PIG-A LOCUS - The invention relates to methods and kits for the quantitative analysis of in vivo mutation frequencies of the Pig-A gene in individuals exposed to a genotoxicant, particularly using peripheral blood samples of vertebrates.12-17-2009
20090311704COMPOSITIONS AND METHODS FOR DIAGNOSIS OF AUTOPHAGIC VACUOLAR MYOPATHY - Transmembrane V-ATPase proton pump complexes regulate pH of extracellular space or intracellular compartments of cells. V-ATPase complexes are ubiquitous in cells across species. A human orthologue of yeast vma21, LOC203547 (VMA21), is likely involved in the assembly of the V-ATPase. Hypomorphic mutations of VMA21 are identified from XMEA patients. Methods to diagnose and/or distinguish between different forms of vacuolar or vacuolated myopathy in an individual or patient are provided based either on the sequence of the VMA21 gene and/or the level and/or activity of the V-ATPase complex. Compositions of the present invention may comprise DNA, RNA, or protein molecules corresponding to all or a portion of VMA21 and including one or more of the mutations in VMA21 identified. Cultured cells or cell lines having one or more mutations in the VMA21 gene derived from patients having a form of vacuolar or vacuolated myopathy are provided.12-17-2009
20090311703METHODS FOR IDENTIFYING FACTORS FOR DIFFERENTIATING DEFINITIVE ENDODERM - Disclosed herein are methods of identifying one or more differentiation factors that are useful for differentiating cells in a cell population comprising definitive endoderm cells into cells which are capable of forming tissues and/or organs that are derived from the gut tube.12-17-2009
20100035239Compositions for use in identification of bacteria - The present invention provides oligonucleotide primers and compositions and kits containing the same for rapid identification of bacteria by amplification of a segment of bacterial nucleic acid followed by molecular mass analysis.02-11-2010
20090042184Method Of Diagnosing Cancer And Reagents Therefor - The present invention provides methods for diagnosis and monitoring the efficacy of treatment of a cancer. More particularly, the methods of the invention comprise detecting an enhanced degree of chromatin modification within Chromosome 2 of the human genome from about map position 2q14.1 to about map position 2q14.3 in a sample derived from a subject. The methods include detecting an enhanced level of methylation, or detecting an enhanced level of modification of a histone positioned within the chromatin within the region of about 2q14.1 to 2q14.3 of Chromosome 2. The methods also include detecting a modulated level of expression of a gene within the region of about 2q14.1 to 2q14.3 of Chromosome 2. The gene may be selected from the group consisting of DEAD box polypeptide 18 (DDX18), translin (TSN), v-ral simian leukaemia viral oncogene homolog B (RALB), secretin recepto (SCTR), engrailed homolog 1 (EN1), macrophage receptor with collagenous structure (MARCO), protein tyrosine phosphatase non-receptor type 4 (PTPN4), insulin induced gene 2 (INSIG2), inhibin beta B (INHBB), GLI-Kruppel family member 2 (GLI2), FLJ10996, STEAP3, diazepam binding inhibitor (DBI), MGC10993, erythrocyte membrane protein band 4.1 like 5 (EPB41L5), FLJ14816, transcription factor CP2-like 1 (TFCP2L1).02-12-2009
20100196915Method of Detecting Oncogenesis of Hematopoietic Cells - Disclosed in a method of detecting cancer using IL-27 receptors. IL27R is a cytokine receptor identified as a novel oncogene from an acute myeloid leukemia patient. It induces cancer-like properties when expressed in cells and can activate a protein that causes various myeloid cell disorders. The data show cytokine receptors play unappreciated roles in mediating activation of signaling pathways in circulatory system cancers. Also method of screening for novel oncogenes using a functional, approach is disclosed using cytokine-dependent cells to screen for transforming events.08-05-2010
20080268434Temperature Control of Reaction Vessel, System with Reaction Vessel, Software Product for System and Use of System - The invention relates to a method for rapid thermal control of a reaction volume (10-30-2008
20090148853BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA - Provided herein are the biomarkers for monitoring the treatment by immunomodulatory compounds. The use of biomarkers such as SPARC, p21, and cyclin D1 mRNA or protein levels as biomarkers to predict whether an immunomodulatory compound is likely to be successful in treating certain types of cancer, such as NHL, is also provided. Further, the expression of these genes or proteins can be used to monitor progress of treatment effectiveness and patient compliance in cancer patients that are receiving treatment with immunomodulatory compounds.06-11-2009
20090148845ENZYME MEASUREMENT ASSAY USING A MODIFIED SUBSTRATE COMPRISING A SUBSTRATE ATTACHED TO A MACROMOLECULE VIA A SPACER - The invention provides novel reagents and methodologies for detecting free versus bound compounds. It is particularly useful to detect thrombin when it is not bound to A2M in the presence of thrombin bound to A2M by using a modified substrate that is sterically hindered from reacting with the bound thrombin.06-11-2009
20090148854NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 184P1E2 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.06-11-2009
20080311587Use of Genetic Information to Detect a Predisposition for Bone Density Conditions - The invention relates to kits and methods for assessing susceptibility of a human to an undesirable bone density condition, such as osteopenia and osteoporosis, and advising appropriate interventions. The methods involve contemporaneously assessing occurrence in the human's genome of a plurality of polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated with bone density regulation and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kits for performing the methods.12-18-2008
20080311585System and method for multiplex liquid handling - The present invention generally relates to microfabricated devices for carrying out and controlling chemical reactions and analysis. In particular, the present invention provides systems, methods, devices and computer software products related to multiplex liquid handling systems utilizing lab cards related to biological assays.12-18-2008
20080311584Methods for Detection of Mutations in Myostatin Variants - Methods for detecting allelic variants of the myostatin (growth and differentiation factor-8) gene are provided. Specifically provided are methods of identifying subjects having or having a predisposition for increased muscle mass as compared to subjects having wild-type myostatin. Increased muscle mass is particularly desirable for identification of animals used to produce food products, including bovine, porcine, ovine, avian and piscine species.12-18-2008
20080311575Modulation of Muci-Dependent Anti-Estrogen Resistance - The present invention provides methods for identification and use of compounds that modulate the association of MUC1 with estrogen receptors and thereby antagonize MUC1-related resistance to anti-estrogen treatment.12-18-2008
20090053723Peripherin and Neurofilament Light Protein Splice Variants in Amyotrophic Lateral Sclerosis (ALS) - Nucleotide sequences encoding novel splice variants of peripherin and neurofilament light protein, proteins encoded by the novel splice variants and antibodies thereto are disclosed. In addition, methods are described for detecting ALS in a subject suspected of having ALS, comprising detecting the presence or absence of the novel splice variants or resulting proteins or a change in the amount of the novel splice variants or resulting proteins; wherein the presence or change in the amount of the nucleotide sequence is indicative of ALS.02-26-2009
20080311571Nucleic Acid Fragments for Detecting Nucleic Acid and Method for Detecting Nucleic Acid - A nucleic acid fragment set according to the present invention comprises a plural number of nucleic acid fragments capable of individually hybridizing with a plural number of target sequences, in which each nucleic acid fragment has a region ligatable with each other and the affinity between such ligatable regions is adjusted to a higher level than the affinity between the target sequence and the nucleic acid fragment. The nucleic acid fragment according to the present invention is for use in a nucleic acid fragment kit. The nucleic acid fragment of the present invention can be used as a probe for detecting nucleic acid or a competitor for detecting nucleic acid. According to the present invention, human leukocyte antigen (HLA) genes, T-cell receptor genes, red blood cell group determining genes, and Rh antigen genes, and the like can be detected at a high accuracy level.12-18-2008
20090092975SELECTABLE MARKER - A nucleic acid sequence encoding a decarboxylation enzyme E.G. PAD1 is used as a selectable marker in a recombinant organism. A weak acid is used as the selecting agent.04-09-2009
20090087855MARKERS OF ALTERATIONS IN THE Y CHROMOSOME AND USES THEREFOR - Novel sequence tagged sites (STSs), probes and primers useful, e.g., for detecting the presence or absence of an STS in a sample, and methods of using these STSs, probes and primers, e.g., in methods of detecting alterations in the Y chromosome are disclosed. These compositions are also useful in methods of diagnosing or aiding in the diagnosis and/or cause of reduced sperm count and in methods of predicting or aiding in the prediction of the likelihood of success of infertility treatments.04-02-2009
20100311061REAL-TIME SEQUENCING METHODS AND SYSTEMS - The present invention is generally directed to compositions, methods, and systems for performing single-molecule, real-time analysis of a variety of different biological reactions. The ability to analyze such reactions provides an opportunity to study those reactions as well as to potentially identify factors and/or approaches for impacting such reactions, e.g., to either enhance or inhibit such reactions. In certain preferred embodiments, RNA templates are used in single-molecule real-time sequencing reactions.12-09-2010
20090081689Reagents and methods to enrich rare cells from body fluids - The present invention relates to compositions and methods for separating cells. The present invention utilizes a combination of techniques to deplete non-nucleated and nucleated cells in a biological sample. The use of this invention assists in reducing the complexity of a biological sample such as peripheral blood, and help in the diagnosis and prognosis of many conditions. The invention includes solutions and methods to selectively deplete red and white blood cells from a blood sample. The preferred sample is blood, effusion, or aspirate samples containing one or more cell types that can be enriched from such a sample. The present invention provides methods for identifying target cells, nucleic acids or chromosome quantification.03-26-2009
20090068671Binding method and apparatus for sorting objects - The present invention relates to a method and apparatus of sorting objects including, providing a sample having wanted objects and unwanted objects; coating a surface of a sample holder with an antibody; placing an eluted sample on the sample holder; binding an antigen in the wanted objects with the antibody on the surface of the sample holder to sort the objects into wanted objects and unwanted objects; separating the wanted objects; and performing PCR-based STR analysis on the wanted objects. In one embodiment, holographic optical trapping is used to further sort the wanted objects. In other embodiments, the wanted objects are sperm and the antibody is a human sperm specific antibody, and the PCR is single cell PCR-based STR analysis. In still other embodiments, the binding is direct or indirect, ligands are used to bind to object-specific organomolecules, and protein A or protein G are used to bind the antibody.03-12-2009
20090142765METHOD AND APPARATUS FOR RAPIDLY COUNTING AND IDENTIFYING BIOLOGICAL PARTICLES IN A FLOW STREAM - A method for increasing the throughput, or the precision, or both the precision and the throughput, of a flow cytometer, or of a hematology analyzer employing a flow cytometer, and for further reducing the complexity of such a cytometer or analyzer, by utilizing the technique of laser rastering in combination with a lysis-free single-dilution method. Laser rastering involves sweeping a laser beam across a flowing sample stream in a hematology analyzer. A lysis-free single-dilution method involves performing all the flow cytometer measurements on a sample using a single aliquot, a single lysis-free reagent solution, a single dilution, and a single pass of said dilution through the measurement apparatus. An apparatus suitable for carrying out the method of this invention comprises an optical module comprising a source of light, a scanning device, a lens or system of lenses, a flowcell, detectors, and filters; and an electronic module comprising preamplifiers, analog signal conditioning elements, analog-to-digital converters, field-programmable gate arrays, digital signal processing elements, and data storage elements.06-04-2009
20090142762Method of Screening for Binding Interaction Using Sets of Microparticles and Unique Probes - The present invention relates to methods for screening for binding interactions using multiple sets of microparticles, wherein said set has the same identifiable characteristic and wherein one of more sets comprise subsets of microparticles and said subset presents at least one unique probe that acts as a binding partner for a target molecule in a biological sample. In particular, the invention provides for methods of detecting tissue-typing antigens in donor tissue or recipient tissue using these multiple sets of microparticles.06-04-2009
20090142750Method of detecting and identifying gram-negative obligative anaerobic bacterium - There is provided a method of detecting potentially beer-spoiling obligatory anaerobic gram-negative bacteria, and a method of simultaneously detecting and distinguishing different beer-spoilage microorganisms including such bacteria.06-04-2009
20090068651Method for the detection of the antibiotic resistance spectrum of mycobacterium species - Method for the detection of the antibiotic resistance spectrum of 03-12-2009
20090148855NUCLEIC ACID ENCODING OR TARGETING SODIUM CHANNEL SCN3A ALPHA SUBUNITS - The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.06-11-2009
20090148849ONE-STEP TARGET DETECTION ASSAY - The present invention provides nucleic acid amplification, detection, and genotyping techniques. In one embodiment, the present invention provides a method for amplifying and detecting a target nucleic acid sequence by providing a first primer pair comprising: a first primer comprising a target specific sequence, a tag sequence 5′ of the target specific sequence, and a blocker between the target specific sequence and the tag sequence, and a second primer comprising a target specific sequence; providing a reporter attached to either the second primer or to a dNTP; providing a capture complex comprising an anti-tag sequence attached to a solid support; combining the first primer pair, the capture complex, the reporter, and a sample comprising a target nucleic acid sequence under conditions suitable for amplification of the target nucleic acid sequence and hybridization of the amplified target nucleic acid sequence to the capture complex; and detecting the amplified target nucleic acid sequence.06-11-2009
20090148847RAPID MAGNETIC FLOW ASSAYS - Disclosed is an improvement in methods for nucleic acid and immunological bioassays. The methods comprise a step for “sweeping” paramagnetic bead: target molecule complexes so as to capture them with an affinity capture agent on a test pad by moving a magnetic force field from outside to inside the test pad area so as to bring into contact the paramagnetic complexes with the capture agent, while sweeping any unbound paramagnetic material off the test pad by moving the magnetic field from inside to outside the test pad area. Surprisingly, the paramagnetic complexes are rapidly affinity-extracted from the moving magnetic field.06-11-2009
20090148850Methods for identifying modulators of P2RY14 - Methods for identifying modulators of P2RY14 are described. The methods are particularly useful for identifying agents that are useful for treating metabolic syndrome.06-11-2009
20090148843Means and Methods for the Prediction of Joint Destruction - The present invention relates to a method of diagnosing and/or predicting joint destruction, early joint destruction and/or accelerated joint destruction in particular, in rheumatoid arthritis, comprising determining in a sample obtained from an individual the presence of at least one nucleic acid sequence encoding an IL-4 receptor (IL-4R) which contains a mutation in position 465 of the nucleotide sequence of the wild-type IL4R as shown in SEQ ID NO: 1, whereby at said position the nucleotide A is replaced or a nucleic acid sequence encoding an IL-4 receptor (IL-4R), said IL-4R comprising at position 75 as shown in SEQ ID NO: 2 a valine instead of an isoleucine. Furthermore, the invention provides for a method of diagnosing and/or predicting early joint destruction and/or accelerated joint destruction comprising determining in a sample obtained from an individual the presence of an encoded IL-4 receptor (IL-4R) which comprises at the homologous position 75 of IL-4 receptor as depicted in SEQ ID NO: 2 a mutation, said mutation comprising the exchange from an isoleucine to a valine. In addition, the present invention relates to a use of specific probes and/or primers for the preparation of a diagnostic composition for diagnosing and/or predicting early joint destruction and/or accelerated joint destruction in particular in rheumatoid arthritis.06-11-2009
20090148840Method for detecting colon cancer markers - A method of detecting a tumor marker for the diagnosis of large bowel cancer and adenomatous polyposis coli comprising the steps of a) collecting and freezing feces, b) homogenizing the frozen feces in the presence of an RNAase inhibitor and preparing a suspension, c) extracting RNA from the obtained sample from which RNA is extracted, d) obtaining cDNA by reverse transcribing the extracted RNA, e) amplifying the obtained cDNA, and f) detecting the amplified cDNA, characterized in that the tumor marker is one or more tumor markers selected from the group consisting of COX-2, SNAIL and MMP-7 (with the proviso that a case where only COX-2 or MMP-7 is selected is excluded).06-11-2009
20090148839METHOD FOR EVALUATING CELL POPULATIONS - The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.06-11-2009
20090148837Method for Rapid Detection and Identification of Bioagents - Method for detecting and identifying unknown bioagents, including bacteria, viruses and the like, by a combination of nucleic acid amplification and molecular weight determination using primers which hybridize to conserved sequence regions of nucleic acids derived from a bioagent and which bracket variable sequence regions that uniquely identify the bioagent. The result is a “base composition signature” (BCS) which is then matched against a database of base composition signatures, by which the bioagent is identified.06-11-2009
20090148835METHOD FOR IDENTIFYING THE ORIGIN OF A COMPOUND BIOLOGICAL PRODUCT - The present invention relates to an identification method. In particular, a method for identifying the origin of a compound biological product, including the batch of origin, but also in some cases the actual biological sources of a compound biological product.06-11-2009
20090148833DEVICES FOR GENERATING DETECTABLE POLYMERS - This document provides systems, devices, and methods involved in generating detectable polymers. For example, diagnostic systems, diagnostic devices, primer systems, and collections of primer systems are provided.06-11-2009
20090148848PITX2 Polynucleotide, Polypeptide and Methods of Use Therefor - A novel T-type calcium channel (CACNA1G) is provided, as are polynucleotides encoding the same. CACNA1G has been implicated in cellular proliferative disorders. More specifically, it has been observed that the methylation state of specific regions within CpG islands associated with the CACNA1G gene correlates with a number of cancerous phenotypes involving a variety of tissue and cell types. Also provided are methods for detecting cellular proliferative disorders by determining the methylation state of genes or regulatory regions associated therewith, including CACNA06-11-2009
20090148841MULTIPLEXED GENOMIC GAIN AND LOSS ASSAYS - Encoded bead multiplex assays for chromosomal gains and losses are provided that provide the benefits of complex, large template DNA sources, such as BAC DNA, as the probe material without bead networking or other assay performance problems. Reagents for assaying DNA are described herein which include a plurality of encoded particles having attached amplicons amplified from a template DNA sequence. Each individual attached amplicon includes a nucleic acid sequence identical to a random portion of the template DNA sequence, wherein the amplicons together represent substantially the entire template DNA and wherein the nucleic acid sequence identical to a random portion of the template DNA sequence of each individual amplicon is shorter than the entire template DNA.06-11-2009
20080299581Screening for expressible transfectants in a eukaryotic system - The present invention relates to the field of molecular cloning and to the field of expression cloning in higher, eukaryotic cells. In particular, the present invention relates to a method for fast and reliable identification of vectors and vector DNA which will be capable of providing a desired expression product if a eukaryotic host cell is transfected with the vector DNA.12-04-2008
20100015630Light Emission Modifiers and Their Uses in Nucleic Acid Detection, Amplification and Analysis - The present invention relates to methods and reagents for modifying the emission of light from labeled nucleic acids for the purpose of real time detection, analysis, and quantitation of nucleic acid sequences, e.g., using singly labeled probes. These methods and reagents exploit advantageous properties of thiazine dyes and diazine dyes. Furthermore, the use of these light emission modifiers in background reduction, nucleic acid duplex stabilization and other uses is also described. Related kits, reaction mixtures and integrated systems are described.01-21-2010
20090142759qPCR array with IN SITU primer synthesis - Application of in situ oligonucleotide synthesis, using a maskless photolithographic oligonucleotide synthesis apparatus or by other means, for direct fabrication of polymerase chain reaction (PCR) primers in situ in PCR reaction wells. The synthesized oligonucleotides contain an enzymatically degradable linker sequence and a specific primer sequence. The method may be used for manufacturing of quantitative PCR (qPCR) arrays containing a plurality of independent qPCR assays while eliminating the need for presynthesized primer libraries.06-04-2009
20080274472Novel kinases and uses thereof - Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.11-06-2008
20090123926Method for the diagnosis of genetic diseases by molecular combing and diagnostic kit - The invention concerns a method for detecting or locating one or several genes of one or several specific A DNA sequence or one or several molecules reacting with DNA on a B DNA characterised in that it consists in: (a) fixing and combing a certain amount of said B DNA on a combing surface; (b) reacting the product of the B combing with one or several probes, linked with the gene(s) or specific A DNA sequences, or with the molecules capable of reacting with DNA; (c) extracting information corresponding to at least one of the following categories: (1) the position of the probes. (2) the distance between the probes, (3) the size of the probes (the total sum of sizes for quantifying the number of hybridised probes) for determining therefrom the presence, the location and/or the amount of genes or specific A DNA sequences. This method can be used in particular for the diagnosis of genetic diseases.05-14-2009
20090123935Measurement of a population of nucleic acids, in particular by real time PCR - The invention relates to a method for measuring the amount of nucleic acids of a target sequence in a sample of interest. The method comprises several steps, and in particular subjecting the sample of interest to an amplification treatment, in the presence of at least one nucleic acids label specific for said target sequence; measuring a physical quantity representative of the evolution of the label; calculating a parameter F05-14-2009
20100267042Antigen-Presenting Cell Populations And Their Use As Reagents For Enhancing Or Reducing Immune Tolerance - The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.10-21-2010
20100267044GENETICALLY ENGINEERED BIOLOGICAL INDICATOR - The disclosed technology relates to a genetically engineered biological indicator, comprising: at least one test organism and at least one reporter gene suitable for producing an indicator enzyme, the reporter gene being taken up by the test organism; and at least one repressor gene that inhibits expression of the reporter gene until the reporter gene is exposed to at least one inducer. A process and an apparatus for using the biological indicator are disclosed.10-21-2010
20100267043System and method for identification of individual samples from a multiplex mixture - An embodiment of an identifier element for identifying an origin of a template nucleic acid molecule is described that comprises a nucleic acid element comprising a sequence composition that enables detection of an introduced error in sequence data generated from the nucleic acid element and correction of the introduced error, where the nucleic acid element is constructed to couple with the end of a template nucleic acid molecule and identifies an origin of the template nucleic acid molecule.10-21-2010
20100267040MN/CA IX and Cancer Prognosis - Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary of the types of preneoplastic/neoplastic diseases subject to the prognostic methods of this invention are those of gastric mucosa, gallbladder, biliary ducts, and ductal cells of duodenal glands. An exemplary prognostic method comprises comparing the level of MN gene expression product in a tissue sample from the affected subject, with the average MN gene expression product level found in analogous preneoplastic/neoplastic tissue samples; an above average MN gene expression product level indicates poorer prognosis for the subject. MN gene expression products useful in the prognostic methods include MN protein, MN polypeptide, and/or MN nucleic acids.10-21-2010
20100267038POLYNUCLEOTIDES FOR THE AMPLIFICATION AND DETECTION OF CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE - Polynucleotides useful for detecting 10-21-2010
20100267036POLYMORPHISM IDENTIFICATION METHOD - The present invention is to provide a method for identifying a polymorphism. The method includes performing a nucleic acid chain extension reaction and identifying the polymorphism of the nucleic acid contained in the test nucleic acid sample. The extension reaction is conducted with use of a nucleic acid in a test nucleic acid sample as a template, a type I detection primer which hybridizes with a region including the polymorphic site of a nucleic acid whose polymorphic site nucleotide sequence consisting of a first nucleotide sequence, and a polymerase. The reaction is conducted with the presence of an inhibitory oligonucleotide, which hybridizes with the type I detection primer. The region of the type I detection primer to hybridize with the inhibitory oligonucleotide is located on the 5′ side of the polymorphism detection site of the type I detection primer to hybridize with the polymorphic site.10-21-2010
20100267035METHODS OF IDENTIFYING COMPOUNDS THAT TARGET tRNA SPLICING ENDONUCLEASE AND USES OF SAID COMPOUNDS AS ANTI-PROLIFERATIVE AGENTS - The present invention relates to a method for screening and identifying compounds that modulate the activity tRNA splicing endonuclease. In particular, the invention provides assays for the identification of compounds that inhibit animalia tRNA splicing endonuclease. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for treating and/or preventing cancer.10-21-2010
20100267034MARKERS FOR PRENATAL DIAGNOSIS AND MONITORING - Methods and kits are provided for diagnosing, monitoring, or predicting preeclaimpsia in a pregnant woman, trisomy 18 and trisomy 21 in a fetus, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more RNA species derived from a set of genetic loci and comparing the amount of the RNA species with a standard control.10-21-2010
20100267033Methods and Compositions For Detecting Autoimmune Disorders - The invention provides methods and compositions useful for detecting autoimmune disorders.10-21-2010
20100267032Prediction of Likelihood of Cancer Recurrence - The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.10-21-2010
20100267030SYSTEMS AND METHODS FOR MEASURING TRANSLATION ACTIVITY IN VIABLE CELLS - Systems for measuring protein translation and methods for measuring overall translation activity in viable cells or subcellular compartments is disclosed. The methods identify general ribosomal activity, if desired at sub-cellular resolution, thereby providing a signal indicating the rate of any of the steps of protein synthesis selected from initiation, elongation, termination or recycling. The translation system can be used to identify translation modulators in high-throughput-screening (HTS).10-21-2010
20100267029METHOD OF IDENTIFYING THE PLANT SPECIES OF THE GENUS UNCARIA - The present invention provides a method of identifying the plant species of the genus 10-21-2010
20100267028Tgfbr1 HAPLOINSUFFICIENCY MODIFIES RISK FOR CANCER - The present invention provides methods for assessing a genetic susceptibility to cancer in a subject which includes measuring allele specific expression or presence of at-risk haplotypes of TGFBR1, where a difference in expression or the presence of at-risk haplotypes is indicative of a cancer or susceptibility to a cancer. Methods to screen for agents that modify expression of TGRBR1 are also provided.10-21-2010
20100267027HER-2 BINDING ANTAGONISTS - There is disclosed a a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 with an affinity binding constant of at least 1010-21-2010
20100267026METHODS AND APPARATUS FOR CHARACTERIZING POLYNUCLEOTIDES - Systems and methods for analysis of polymers, e.g., polynucleotides, are provided. The systems are capable of analyzing a polymer at a specified rate. One such analysis system includes a structure having a nanopore aperture and a molecular motor, e.g., a polymerase, adjacent the nanopore aperture.10-21-2010
20100267025METHODS AND COMPOSITIONS FOR THE ASSESSMENT OF CARDIOVASCULAR FUNCTION AND DISORDERS - The present invention provides methods for the assessment of risk of developing acute coronary syndrome (ACS) in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's risk of developing ACS. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided.10-21-2010
20100267022MONOCYTE-DERIVED NUCLEIC ACIDS AND RELATED COMPOSITIONS AND METHODS - Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.10-21-2010
20100267020GENETIC RISK FACTOR FOR NEURODEGENERATIVE DISEASE - The present invention relates to single base polymorphisms in the glycogen synthase kinase 3 beta and risk for developing neurodegenerative disease.10-21-2010
20100267019Identification And Use Of Genes Encoding Amatoxin And Phallotoxin - The present invention relates to compositions and methods comprising genes and peptides associated with cyclic peptide toxins and toxin production in mushrooms. In particular, the present invention relates to using genes and proteins from 10-21-2010
20100267017MONITORING REAL-TIME PCR WITH LABEL FREE INTRINSIC IMAGING - The invention provides a method for the detection of nucleic acid the method comprising carrying out a PCR reaction in a microfluidic device wherein the sample shuttles within the microfluidic channel and the amount of nucleic acid is determined based on the UV absorption of the nucleic acid.10-21-2010
20100267013METHODS TO INCREASE NUCLEOTIDE SIGNALS BY RAMAN SCATTERING - The methods and apparatus disclosed herein concern nucleic acid sequencing by enhanced Raman spectroscopy. In certain embodiments of the invention, nucleotides are covalently attached to Raman labels before incorporation into a nucleic acid. In other embodiments, unlabeled nucleic acids are used. Exonuclease treatment of the nucleic acid results in the release of labeled or unlabeled nucleotides that are detected by Raman spectroscopy. In alternative embodiments of the invention, nucleotides released from a nucleic acid by exonuclease treatment are covalently cross-linked to nanoparticles and detected by surface enhanced Raman spectroscopy (SERS), surface enhanced resonance Raman spectroscopy (SERRS) and/or coherent anti-Stokes Raman spectroscopy (CARS). Other embodiments of the invention concern apparatus for nucleic acid sequencing.10-21-2010
20100267012Highly conserved genes and their use to generate probes and primers for detection of microorganisms - Compositions and methods for the detection of vancomycin-resistant pathogens using primers and/or probes to the vanA and vanB genes.10-21-2010
20100267011Method and apparatus for detecting nucleic acids using bead and nanopore - There are provided a method and apparatus for detecting nucleic acid using bead and nanopore, and more specifically, a method and apparatus capable of detecting nucleic acid fragments of 70 bps to 300 bps in length by a nanopore detection unit with nanopores of 20 to 120 nm in diameter by attaching a bead to a nucleic acid probe and then detecting the bead attached to nucleic acid not nucleic acid itself. Accordingly, the present invention can detect the nucleic acid fragments using the nanopore detection unit with nanopores of 20 to 120 nm in diameter, even in case where Polymerase Chain Reaction (PCR) products are given as the sample, particularly the PCR products are the nucleic acid fragments of 70 to 300 bps in length.10-21-2010
20100248252METHODS FOR ANALYSIS OF MOLECULAR EVENTS - Methods and compositions are provided for detecting the presence of nucleic acid sequence variants in a subpopulation of nucleic acid molecules in a biological sample. These methods are particularly useful for identifying individuals with mutations indicative of cancer.09-30-2010
20080318237METHODS OF DIAGNOSING ENDOMETRIOSIS - The present invention provides biomarkers for the diagnosis and prognosis of endometriosis. Generally, the methods of this invention find use in diagnosing or for providing a prognosis for endometriosis by detecting the expression levels of biomarkers, which are differentially expressed (up- or down-regulated) in endometrial cells from a patient with endometriosis. Similarly, these markers can be used to diagnose reduced fertility in a patient with endometriosis or to provide a prognosis for a fertility trial in a patient suffering from endometriosis. The present invention also provides methods of identifying a compound for treating or preventing endometriosis. Finally, the present invention provides kits for the diagnosis or prognosis of endometriosis.12-25-2008
20080318229Method for Diagnosing Neuro-Degenerative Disease - A method for the diagnosis of Alzheimer's Disease (AD) or Parkinson's Disease (PD), comprises measuring the level of expression of one or more AD markers (Table 1) or PD markers (Table 2) in a sample of platelets isolated from a person suspected of having AD or PD, and determining whether the levels of expression are altered compared to a control.12-25-2008
20090142761METHODS AND KITS FOR METHYLATION DETECTION - Ligation-based methods and kits are disclosed for determining the degree of methylation of one or more target nucleotides. In certain embodiments, the methylation status of one or more target nucleotides is determined by generating misligation products. In certain embodiments, at least one target nucleotide is amplified prior to the ligation reaction. In certain embodiments, at least one ligation product, at least one ligation product surrogate, at least one misligation product, at least one misligation product surrogate, or combinations thereof are amplified. In certain embodiments, one or more ligation probes comprise at least one nucleotide analog, at least one Modification, at least one mismatched nucleotide, or combinations thereof.06-04-2009
20080305476Immunoassay Methods - The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.12-11-2008
20100261185LABELED ENZYME COMPOSITIONS, METHODS AND SYSTEMS - Disclosed herein are conjugates comprising a biomolecule linked to a label that have biological activity and are useful in a wide variety of biological applications. For example, provided herein are labeled polymerase conjugates including a polymerase linked to one or more labels, wherein the conjugate has polymerase activity. Such conjugates can exhibit enhanced biological activity and/or superior detectability as compared to conventional labeled polymerases. Also disclosed herein are improved methods for preparing such conjugates, and methods and systems for using such conjugates in biological applications such as nucleotide incorporation, primer extension and single molecule sequencing.10-14-2010
20100015618DNA FRAGMENT USED AS ATTACHED TO 5' END OF PRIMER USED IN NUCLEIC ACID AMPLIFICATION REACTION AND USE OF DNA FRAGMENT - A method is provided which enables quick, convenient, inexpensive, and high sensitivity confirmation of nucleic acid amplification after a nucleic acid amplification reaction. The DNA fragment in accordance with the present invention is a single-stranded DNA fragment containing a hairpin structure which in turn contains a bulge, wherein the DNA fragment is used as being attached to the 5′ end of a primer used in nucleic acid amplification. The nucleic acid amplification confirmation method in accordance with the present invention quantifies a hairpin primer containing the DNA fragment at its 5′ end by using bulge-binding fluorescent molecules after carrying out PCR or like nucleic acid amplification reaction using the hairpin primer. SNPs are detected quickly and conveniently at low cost and with high sensitivity by applying the nucleic acid amplification confirmation method, for example, to allele specific PCR.01-21-2010
20080286766Comparing Method for Expression Amount of the Same Gene from Different Sources by Base Sequence Measurement - The present invention relates to an analysis method used to quantitatively compare the expression levels of the same gene from different sources. The method of the present invention can be used to quantitatively compare the gene expression level difference of the same gene of tissues or cells from different sources, making use of the quantitative characteristics of bioluminescent assay and the principle of adding different deoxyribonucleic acids (dNTP) one by one. The concrete steps are: reverse transcript the messenger ribonucleic acids (mRNA) from different sources into cDNA, and label a segment of source specific sequence in cDNA from each source; mix the labeled cDNA of different sources into one tube and use it as the substrate of polymerase chain reaction (PCR); PCR amplification is performed using the same common primer and a gene-specific primer; Detect the base sequence by bioluminescent assay, wherein the base type represents the different gene source, and the signal intensity of each base represents the gene expression level from each source. This method has a significant meaning for the screening of disease-related genes, clinical early diagnosis and the preparation of specific medicine for the treatment of disease.11-20-2008
20100261178High Throughput Assays for Inhibitors and Activators of PAQR Receptors - The subject invention provides methods of screening compounds or ligands that interact with human and/or non-human PAQR receptors or fungal osmotin receptors. These methods utilize a colorimetric assay to ascertain whether a compound binds to and activates a PAQR receptor or the osmotin receptor.10-14-2010
20080280293Method of Examining Inflammatory Disease and Method of Screening Remedy for Imflammatory Disease - A gene polymorphism on a Toll-like receptor gene is analyzed and an inflammatory disease is examined based on the results of the analysis. A remedy for an inflammatory disease is screened by selecting a substance capable of altering the interaction between Toll-like receptor and galectin-2.11-13-2008
20080268458Method of Preparing Nucleic Acids for Detection - A method is provided for preparing a test sample for detecting a predetermined target nucleic acid. The method includes the steps of providing a test probe comprising an oligonucleotide attached to a nanoparticle and providing a hybridization unit containing the test sample and the test probe, wherein said hybridization unit further includes a target sample substrate and a distribution manifold coupled to a first side of the substrate. The method further includes the steps of clamping a processing fluids manifold to the distribution manifold of the hybridization unit, denaturing the test sample and preparing the test sample for detecting the predetermined target nucleic acid by pumping a plurality of processing fluids between the processing fluids source manifold and distribution manifold to hybridize the test probe and predetermined target nucleic acid to the target sample substrate, to wash the hybridized sample and to amplify a detectable parameter of the hybridized sample.10-30-2008
20080268456METHOD FOR DETECTING AND QUANTITATING MULTIPLE-SUBCELLULAR COMPONENTS - A method for detecting and quantitating multiple and unique fluorescent signals from a cell sample is provided. The method combines immunohistochemistry and a fluorescent-labeled in situ hybridization techniques. The method is useful for identifying specific subcellular components of cells such as chromosomes and proteins.10-30-2008
20080268454Compositions, methods and systems for inferring bovine breed or trait - Methods, compositions, and systems are provided for managing bovine subjects in order to maximize their individual potential performance and edible meat value, and to maximize profits obtained in marketing the bovine subjects. The methods and systems draw an inference of a trait of a bovine subject by determining the nucleotide occurrence of at least one bovine SNP that is identified herein as being associated with the trait. The inference is used in methods of the present invention to establish the economic value of a bovine subject, to improve profits related to selling beef from a bovine subject; to manage bovine subjects, to sort bovine subjects; to improve the genetics of a bovine population by selecting and breeding of bovine subjects, to clone a bovine subject with a specific trait, to track meat or another commercial product of a bovine subject; and to diagnose a health condition of a bovine subject. Methods are also disclosed for identifying additional SNPs associated with a trait, by using the associated SNPs identified herein.10-30-2008
20100120022Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis - Novel splice variant nucleic acid sequences. The novel splice variants and their nucleic acid sequences according to the present invention may optionally be used for diagnosis of a variant-detectable disease as described herein.05-13-2010
20110065113RECURRENT GENE FUSIONS IN PROSTATE CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for prostate cancer.03-17-2011
20100124741METHODS FOR DETECTING IgH/BCL-1 CHROMOSOMAL TRANSLOCATION - The invention provides methods for detection of Bcl-1 nucleic acid in acellular body fluid. The methods can be used to detect the IgH/Bcl-1 translocations (11;14)(q13;q32) in acellular body fluid. The chromosomal translocation (11;14)(q13;q32) is often associated with mantle cell (centrocytic) lymphoma and occasionally in other B-cell neoplasms, notably myeloma. The invention is useful in the diagnosis of mantle cell lymphoma (MCL) and also for determining the prognosis of the disease.05-20-2010
20080261219Polynucleotide Primers - A polynucleotide primer comprising at least the final six nucleotides of one of the following primer sequences, or a sequence complementary thereto: SEQ. ID NOS. 1 to 18, 21 to 45 or 74 to 77.10-23-2008
20090136932FIBERS WITH ISOLATED BIOMOLECULES AND USES THEREOF - The present invention relates to compositions, methods, and uses for isolated biomolecule-containing fibers. The invention also relates to isolated, elongated biopolymers such as nucleic acids, polypeptides, lipids, and carbohydrates within fibers. The invention relates to methods of detecting and analyzing biomolecules in fibers using light, electrons, and neutrons. The invention further relates to methods of determining the sequence, structure, and properties of isolated, elongated biopolymers fixed within fibers.05-28-2009
20100015599ISOLATED REDUCTIVE DEHALOGENASE GENES - The invention is directed to novel reductive dehalogenase genes encoding for reductive dehalogenases which are capable of dehalogenating halogenated organic compounds and may be useful in the bioremediation of pollutants. In particular, the invention provides an isolated polynucleotide of a novel vinyl chloride dehalogenase gene (bvcA). The novel vinyl chloride dehalogenase gene encodes a reductive dehalogenase that is capable of the complete reduction of vinyl chloride to ethene.01-21-2010
20100015607NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF - The present invention relates to compositions and methods for detection and quantification of individual target molecules in biomolecular samples. In particular, the invention relates to coded, labeled probes that are capable of binding to and identifying target molecules based on the probes' label codes. Methods of making and using such probes are also provided. The probes can be used in diagnostic, prognostic, quality control and screening applications.01-21-2010
20100015625CTIP2 EXPRESSION IN SQUAMOUS CELL CARCINOMA - The present disclosure provides methods of diagnosing and staging squamous cell carcinomas, for instance head and neck (HNSCC), by detecting chicken ovalbumin upstream promoter-transcription factor-interacting protein 2 (CTIP2) expression. For example, it is demonstrated herein that expression of CTIP2 is increased in SCC relative to a corresponding normal sample. Also included are kits for detecting SCC, as well as methods for identifying CTIP2 inhibitors.01-21-2010
20100086935Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles - A method provides an index that is indicative of the state of a subject, as to a biological condition, based on a sample from the subject. An embodiment of this method includes: deriving from the sample a profile data set, the profile data set including a plurality of members, each member being a quantitative measure of the amount of a distinct RNA or protein constituent in a panel of constituents selected so that measurement of the constituents enables evaluation of the biological condition; and in deriving the profile data set, achieving such measure for each constituent under measurement conditions that are substantially repeatable; and applying values from the profile data set to an index function that provides a mapping from an instance of a profile data set into a single-valued measure of biological condition, so as to produce an index pertinent to the biological condition of the subject04-08-2010
20090305286Method for the Identification of Suitable Fragmentation Sites in a Reporter Protein - The invention concerns a combinatorial method for the generation of new split-protein sensors, and its application towards the (β/α)12-10-2009
20090305240METHOD FOR DETECTION OF MICROORGANISM AND KIT FOR DETECTION OF MICROORGANISM - Live cells of a microorganism in a test sample are detected by the following steps: 12-10-2009
20100129796DYE PROBE FLUORESCENCE RESONANCE ENERGY TRANSFER GENOTYPING - An improved method for detecting, identifying and screening single polynucleotide polymorphisms, insertion/deletion loci, and microsatellites is provided. The method includes adding a donor intercalating dye to a sample containing an amplified target nucleic acid sequence, adding a probe containing an acceptor fluorophore to the sample, hybridizing the probe to the target sequence, exciting the donor dye with a specific wavelength of light, monitoring fluorescence from the sample due to FRET energy transfer from the dye to the probe fluorophore associated with one or both of the hybridization of the probe to the target sequence and the dissociation of the probe from the target sequence, and analyzing the sample using a melt-curve analysis to identify at least one single (or multiple) known or unknown nucleotide polymorphism, insertion/deletion loci, or microsatellite therein.05-27-2010
20100099097A Flow Through System, Flow Through Device And A Method Of Performing A Test - The invention relates to a flow through system for quantifying a target component in a liquid. The flow through system comprises a flow-through device comprising a flow path comprising a marker section, a capture section downstream to said marker section, and at least two quantification sections. The marker section comprises a non-immobilized marker. The capture section comprises a capture zone with an immobilized capture agent, and the at least two quantification sections comprise a pre-capture quantification section placed downstream to the marker section and up stream to the capture section, and a post-capture quantification section placed downstream to the capture section. The system further comprises a quantification unit for each of said quantification sections. The quantification unit(s) being arranged to quantify marker containing components and/or particles passing through said respective quantification sections. The invention also relates to a flow through device for such flow through system and a method of determining the amount of target component in a liquid using a flow through system.04-22-2010
20100099104GENETIC TEST FOR THE IDENTIFICATION OF CARRIERS OF COMPLEX VERTEBRAL MALFORMATIONS IN CATTLE - Genetic markets for identifying bovine carriers of complex vertebral malformation (CVM) disease gene are described. The genetic markers, including the microsatellite markers, BM4129, INRAA003, BMS2790, ILSTS029, INRA123, BM220, HUJ246, BMS862, BMS937, BL1048, BMS2095 and BMS1266 and the bovine SLC35A3 gene, are located on bovine chromosome BTA3. The G/T polymorphism at position 559 of the bovine SLC35A3 gene is identified as being causative and diagnostic for CVM in cattle.04-22-2010
20100099102Development of Diagnostic Markers From the Saliva of Head and Neck Cancer Patients - The present invention relates to biomarkers that are useful for the detection of cancer. The invention further relates to biomarkers and methods of using biomarkers for the early detection of head and neck cancer.04-22-2010
20090117573Locus specific amplification using array probes - Methods are provided for multiplexed amplification of selected targets and analysis of the amplified targets. In preferred aspects the amplification and analysis take place on the same solid support and preferably in a localized area such as a bead or a feature of an array. In preferred aspects the analysis is a determination of sequence at one or more locations in the amplified target. The methods may be used for genotyping, sequencing and analysis of copy number.05-07-2009
20090220967Systemic Carnitine Deficiency Gene and Uses Thereof - The gene responsible for systemic carnitine deficiency was found to be the OCTN2 gene involved in the transportation of organic cations. This invention enables tests for this disease by detecting whether or not the OCTN2 gene has a mutation. Furthermore, systemic carnitine deficiency can be treated using the normal OCTN2 gene and its protein.09-03-2009
20100120050Biomarkers For Assessing Altherosclerotic Potential - The invention also provides methods, apparatuses and reagents useful for predicting future atherosclerosis based on expression levels of genes selected from the set of 68 genes with differential expression in response to pioglitazone and rosiglitazone. The invention also discloses reagent sets and biomarkers for predicting progression of atherosclerosis induced by anti-diabetic therapy in a subject. In one particular embodiment the invention provides a method for predict whether a compound will induce atherosclerosis using gene expression data from sub-acute treatments.05-13-2010
20100120043SEQUENTIAL ANALYSIS OF BIOLOGICAL SAMPLES - Methods for detecting a plurality of targets in a biological sample are provided. The method comprises contacting the biological sample with a plurality of target-binding probes simultaneously to form a plurality of target-bound probes and observing the signals from the target-bound probes sequentially. An associated kit and device for detection of the plurality of targets are also provided.05-13-2010
20100120026Particulate Substrates for Improved Recovery of Microbes - Specially modified microbial growth surfaces improve bacterial recovery or counts when testing for the presence or absence of microbial cells or performing microbial enumerations.05-13-2010
20100120041METHODS FOR DETECTING AND TREATING KIDNEY DISEASE - A method is provided for diagnosing and monitoring kidney disease or a predisposition to kidney disease, in a subject comprising detecting pVHL, VEGF-A, CXCR4, integrin β-1, PDGF-A, HIF1α and/or TGFβ in a sample from the subject. Screening methods for test agents for inhibiting kidney disease, and therapeutic applications are also described.05-13-2010
20100120028PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 40 to 42 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.05-13-2010
20100120027PROGNOSTIC TEST FOR EARLY STAGE NON SMALL CELL LUNG CANCER (NSCLC) - The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at chromosome 10q23.3 and centromere 10 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. The chromosome copy number can also be determined using, for example, PCR or array CGH. Assessment of the copy number abnormality patterns with a classifier based on the relative loss of 10q23.3 signals compared to the centromere 10 signals produced statistically significant prognostic classification for NSCLC. The ratio of PTEN/CEP 10 signals, using a cutoff of 0.80, was capable of dividing patients into a group of 41 (≧0.80) in which 33 (80.5%) had the favorable prognosis, and a group of 18 (<0.80) in which 6 (33.3%) had the favorable prognosis (p=0.0008). Median times to recurrence in the former and latter groups were 83.0 and 13.0 months, respectively (p<0.0001).05-13-2010
20100120023Detection of macromolecular complexes with harmonic cantilevers - Method and apparatus which uses harmonic cantilevers, such as used in atomic force microscopy, to detect variations in the attractive and repulsive forces on a solid surface as a result of macromolecular binding, for example, hybridization of a single stranded DNA molecule attached to the surface with another DNA molecule. The complexed macromolecule is less flexible than an uncomplexed molecule. It will typically have more negative charge due to amino acids or DNA monomers. Both stiffness of the surface and the attractive capillary forces will change after binding and may be detected. By scanning the harmonic cantilever across a surface with macromolecules attached in tapping-mode and by recording the signals at the high frequency vibrations provided by harmonic cantilever, complexed molecules on a surface may be identified and quantified.05-13-2010
20100120035METHOD FOR ACCURATE ASSESSMENT OF DNA QUALITY AFTER BISULFITE TREATMENT - The present invention is directed to methods useful for determining DNA quality after bisulfite treatment. The methods include a PCR-based assay, which allows ab-initio assessment of the DNA quality after bisulfite treatment and can help to prevent inaccurate quantitative measurement resulting from poor bisulfite treatment.05-13-2010
20100120037METHOD FOR ISOLATING AND CULTURING UNCULTURABLE MICROORGANISMS - The invention provides a method for isolating and culturing a previously unculturable microorganism, which comprises: (i) collecting a sample from an environmental source; (ii) counting/estimating the number of microorganisms in the sample; (iii) diluting the sample in an appropriate medium; (iv) adding a gelating agent such as to entrap one or more microorganisms within a sphere of the gelating agent; (v) coating the spheres containing the entrapped microorganism(s) with a natural or synthetic polymer to form a polymeric membrane; (vi) incubating the coated spheres in the original environment for an appropriate time; (vii) cutting the spheres and scanning for microorganisms colonies; and (viii) isolating the microorganisms, and repeating steps (iii) to (vii) until a pure clone of said previously unculturable microorganism is obtained.05-13-2010
20100120031SYNTHESIS OF TRANS-TERT-BUTYL-2-AMINOCYCLOPENTYLCARBAMATE - The present invention concerns methods of synthesis of trans-tert-butyl-2-aminocylcopentylcarbamate comprising contacting 6-tosyl-6-azabicyclo[3.1.0]hexane with TMSN05-13-2010
20100120029Mutagenesis of aspergillus fungi and genes essential for growth - The present invention is directed to polynucleotides encoding proteins Essential For the Growth (EFG) of filamentous fungi. The invention also deals with namely polypeptides encoded by said polynucleotides, screening assays for identifying compounds capable of inhibiting said EFG proteins activities, pharmaceutical or phytosanitary compositions comprising such compounds.05-13-2010
20110027784Novel Primers for Identification of Astrocytoma, Its Grades and Glioblastoma Prognosis - The present invention relates to novel primers for identification of astrocytoma, it's grades and glioblastoma prognosis. Further, disclosed is a method of diagnosing the presence of different grades of diffuse astrocytoma and glioblastoma, in a human subject, which involves detection of the expression levels of said genes in tumor tissue samples in comparison to normal brain. Also disclosed is a method of distinguishing between the two types of Glioblastoma—the progressive and de novo types. Also disclosed is a method of prognosis of glioblastoma based on the expression of the gene PBEF1, wherein the higher level of expression of the gene in the tumor sample, indicates poorer survival of the human subject. The disclosed compositions are useful, for example, in the diagnosis, prevention, treatment and/or prognosis of astrocytoma. The invention further provides kits for the detection and prognosis of the said diseases.02-03-2011
20100285451DETECTION OF SUB-CELLULAR COMPARTMENT LOCALIZATION OF A MOLECULE USING A REDUCED AFFINITY ENZYME COMPLEMENTATION REPORTER SYSTEM - Methods and compositions for detecting the sub-cellular localization of a molecule are provided. Aspects of the invention include detecting translocation of a cell-surface receptor to a sub-cellular compartment, e.g., the endosome, using a reduced affinity enzyme complementation reporter system. Also provided are systems and kits for use in practicing embodiments of the methods.11-11-2010
20100285461Methods Of Producing And Sequencing Modified Polynucleotides - The present invention encompasses methods for producing a modified polynucleotide sequence that comprises a (e.g., one or more) phosphorothiolate linkage, methods for determining a polynucleotide sequence comprising a (e.g., one or more) phosphorothiolate linkage, and methods for separating forward and reverse extension products that comprise a (e.g., one or more) phosphorothiolate linkage. The invention also encompasses kits for producing and/or determining the sequence of a modified polynucleotide that comprises a (e.g., one or more) phosphorothiolate linkage.11-11-2010
20100285484APOPTOSIS INDUCING POSITIVE CONTROL FOR EXPRESSION MODULATION EXPERIMENTS - The invention pertains to a method for performing an expression modulating analysis or assay, wherein an apoptosis inducing expression modulating compound targeting a repetitive element present in the untranslated region, in particular the 3′ UTRs of protein coding gene transcripts is introduced into cells to induce apoptosis in the cells as a positive control. Also provided are suitable kits and compositions.11-11-2010
20100184046Methods and systems of using exosomes for determining phenotypes - Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.07-22-2010
20090298058Inhibitors of PGHS-2Transactivator Activity - Prostaglandin-endoperoxide H synthase (PGHS-2) converts arachidonic acid to prostaglandin H12-03-2009
20100081138Nucleotide sequences for the detection of enterohaemorrhagic Escherichia coli (EHEC) - Nucleic sequences of plasmid origin are isolated from bacteria of the enterohaemorrhagic 04-01-2010
20100081135Single nucleotide polymorphisms and use of same predicting male- specific prenatal loss - The present invention is directed to a panel of single nucleotide polymorphisms (SNPs) in specific genes that serve as biomarkers for sex-specific prenatal loss of a conceptus or embryo. There is provided herein methods and reagents for assessing the specific SNPs in those genes. The method useful in applying these SNPs in predicting an increased risk of prenatal loss is also disclosed.04-01-2010
20100081130Multifunctional particles providing cellular uptake and magnetic motor effect - Preparation of novel multifunctional particles and nanomaterials having a useful combination of magnetic and optical properties and biocompatibility. The internalization efficiencies in various in vitro cell studies have been investigated, and the external magnetic motor effect on the floating cells internalized with magnetic nanoparticles were clearly observed, for the first time. The particle surfaces can be derivatized with, for example, DNA or antibodies. The system is stable, versatile, and well-controlled. Novel gene delivery can be achieved using nanoparticles as a carrier.04-01-2010
20090087834Method for characterising polynucleotides - The method of the invention is used to identify specific characteristics of a target polynucleotide in a sample, and comprises the steps of: i) attaching to one end of each target polynucleotide in the sample a polynucleotide signal sequence that is specific for the characteristic under study; ii) contacting the target polynucleotides with a molecule that interacts with the target polynucleotide if the characteristic is present; iii) attaching a polynucleotide adapter sequence to those targets polynucleotides that interact with the molecule of step (ii), the adapter being attached at the end of the target polynucleotide opposite that at which the signal sequence is attached; iv) carrying out a polynucleotide amplification reaction on those target polynucleotides that comprise both the adapter and signal sequence, optionally repeating steps (i) to (iv) for other characteristics; and (v) identifying which signal sequences are present on the amplified products, and in which order, to thereby determine the characteristics of each target polynucleotide.04-02-2009
20090298084GENE AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF IRINOTECAN - The present invention includes gene and protein expression profiles indicative of whether a cancer patient is likely to respond to treatment with irinotecan. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and/or protein expression profiles and assays for identifying the presence of a gene and/or protein expression profile in a patient sample.12-03-2009
20090087858Two-color Real-time/End-point Quantitation of MicroRNAs (miRNAs) - The present invention is directed to methods, reagents, kits, and compositions for detecting target polynucleotide sequences, especially small target polynucleotides such as miRNAs, between two samples. A pair of linker probes can be employed in two different reactions to query a particular species of target polynucleotide. A pair of detector probes, a single forward primer specific for the target polynucleotide, and a reverse primer can be employed in an amplification reaction to query the difference in expression level of the target polynucleotide between the two samples. In some embodiments a plurality of small miRNAs are queried with a plurality of linker probes. The plurality of queried miRNAs can then be decoded in a plurality of amplification reactions.04-02-2009
20090087854METHODS FOR GENETIC ANALYSIS - Methods of treating an individual exhibiting a medical condition are disclosed. The methods involve determining a score of an individual based on the individual's genotypic information, comparing the score to at least one threshold value, wherein the result of the comparison is indicative of a beneficial response to a treatment, and providing a suitable treatment to the individual.04-02-2009
20090087849NUCLEIC ACID-BASED METHODS AND COMPOSITIONS FOR THE DETECTION OF OVARIAN CANCER - Methods and compositions for identifying ovarian cancer in a patient sample are provided. The methods of the invention comprise detecting overexpression or underexpression of at least one nucleic acid biomarker in a body sample, wherein the biomarker is selectively overexpressed or underexpressed in ovarian cancer. The body sample may be, for example, an ovarian tissue sample. The biomarkers of the invention include any nucleic acid molecule that is selectively overexpressed in ovarian cancer, including, for example, MMP-7, PAEP, CA125, HE4, PLAUR, MUC-1, SLPI, SSP1, MSLN, SPON1, interleukin-7, folate receptor 1, claudin 3, inhibin A, inhibin BB, inhibin BA, and PAI-1. Overexpression or underexpression of a biomarker of interest is detected at the nucleic acid level using such methods as real-time PCR and various nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.04-02-2009
20090087847DETERMINING A NUCLEIC ACID SEQUENCE IMBALANCE - Methods, systems, and apparatus are provided for determining whether a nucleic acid sequence imbalance exists within a biological sample. One or more cutoff values for determining an imbalance of, for example, the ratio of the two sequences (or sets of sequences) are chosen. The cutoff value may be determined based at least in part on the percentage of fetal DNA in a sample, such as maternal plasma, containing a background of maternal nucleic acid sequences. The cutoff value may also be determined based on an average concentration of a sequence per reaction. In one aspect, the cutoff value is determined from a proportion of informative wells that are estimated to contain a particular nucleic acid sequence, where the proportion is determined based on the above-mentioned percentage and/or average concentration. The cutoff value may be determined using many different types of methods, such as sequential probability ratio testing (SPRT).04-02-2009
20090087857Molecular Beacons for DNA-Photography - The present invention refers to a detection method for analytes using the principle of black-and-white photography and to reagent kits for performing the method, furthermore applied this new technology to detect a biologically relevant sequence in the nanomolar range (femtomoles) in an application circumventing the necessity of a PCR. There are still numerous ways to optimize this methodology that is suitable for a large variety of applications in the genomic diagnostics and proteomics areas.04-02-2009
20090087850NUCLEIC ACID SEQUENCING METHODS AND SYSTEMS - Sequencing methods that use an exonuclease that comprises template dependent nucleobase binding activity are provided. Related compositions and sequencing systems are also provided.04-02-2009
20090087845Genetic Markers Of True Low Birth Weight - The present application provides for a method of diagnosing TLBW via measurement of expression of various TLBW-related genes. The present application also provides kits for the diagnosis of TLBW in a subject. The present application also provides a method for determining the basis for appropriate therapy for a subject suffering from TLBW.04-02-2009
20090087844METHODS AND COMPOSITIONS FOR CORRELATING GENETIC MARKERS WITH CARDIOVASCULAR DISEASE - The present invention provides methods of identifying a subject having an increased or decreased risk of developing cardiovascular disease, comprising: 04-02-2009
20090087841METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE OF HIV-1 TO PROTEASE INHIBITORS - This invention relates to methods for determining resistance of HIV-I viruses to protease inhibitors (PIs) based on the viral genotypes. The methods generally comprise detecting, in a gene encoding protease of the HIV-I, the presence of a mutation in at least one of codon 22, 69, 74, or 83 alone or in combination with one or more mutations at certain other codons, or, in a gene encoding gag of the HIV-I, the present of a mutation in at least one of codon 418 or 482 alone or in combination with one or more mutations at certain other codons. Combinations of mutations associated with resistance to PIs are also disclosed.04-02-2009
20090087839LONG DISTANCE POLYMERASE CHAIN REACTION-BASED ASSAY FOR DETECTING CHROMOSOMAL REARRANGEMENTS - Methods are presented for determining the presence of an inversion in the factor VIII gene which cause hemophilia A. The methods encompass long distance, multiplex PCR (including overlapping PCR). The use of deaza-dGTP, high levels of DNA polymerases and high levels of DMSO aid in successfully performing the PCR. The use of a novel technique called subcycling PCR can also be applied as part of the methods. The technique allows for the determination of whether a person is homozygous or hemizygous for the inversion and has hemophilia A or whether a person is heterozygous for the inversion and is a carrier. The technique of long distance, multiplex PCR including use of deaza-dGTP, high levels of DNA polymerases and high levels of DMSO are applicable to the determination of the presence of other gross chromosomal aberrations such as deletions/inversions, translocations and inversions. The use of subcycling PCR can achieve efficient and more even amplification than normal two or three temperature PCR and is applicable to long distance, multiplex PCR.04-02-2009
20090087838ANALYTE DETECTION USING AUTOCATALYTIC CHAIN REACTIONS - Compositions and methods for detecting the presence of analytes employing autocatalytic chain reactions (ACR) having super linear kinetics for amplification of signal are disclosed.04-02-2009
20090087837Method Of Detecting Streptococcus Pneumoniae, Primer Set For The Detection And Kit For The Detection - A method of detecting 04-02-2009
20090087835Method of Identifying Hairpin DNA Probes by Partial Fold Analysis - Method of identifying molecular beacons in which a secondary structure prediction algorithm is employed to identify oligonucleotide sequences within a target gene having the requisite hairpin structure. Isolated oligonucleotides, molecular beacons prepared from those oligonucleotides, and their use are also disclosed.04-02-2009
20080268443BROAD-BASED DISEASE ASSOCIATION FROM A GENE TRANSCRIPT TEST - Broad-based disease association gene transcript test and data structure. Disease considerations for this unique test include a custom set of genetic sequences associated in peer-reviewed literature with various known diseases such as Addison's disease, anemia, asthma, atherosclerosis, autism, breast cancer, estrogen metabolism, Grave's disease, hormone replacement therapy, major histocompatibility complex (MHC) genes, longevity, lupus, multiple sclerosis, obesity, osteoarthritis, prostate cancer, and type 2 diabetes. The base dataset may be developed through clinical samples obtained by third-parties. Online access of real-time phenotype/genotype associative testing for physicians and patients may be promoted through an analysis of a customized microarray testing service.10-30-2008
20100196897Method and Device for Non-Invasive Prenatal Diagnosis - Method for non-invasive prenatal diagnosis comprising the following steps: a. obtain a sample of an organic fluid having a high probability of containing foetal cells from a pregnant woman; b. enrich said sample of organic fluid in at least one population of cells comprising at least one type of foetal nucleated cells; c. isolate at least one cell from among said at least one type of foetal nucleated cells; d. perform a genetic analysis on said at least one cell isolated from among said at least one type of foetal nucleated cells in order to highlight at least one genetic characteristic of said at least one foetal nucleated cell suitable for permitting said diagnosis; wherein the step of isolating at least one cell from among said at least one type of foetal nucleated cells is performed by individually selecting single cells in a microfluidic device designed for said purpose.08-05-2010
20100196917CELL ANALYSIS APPARATUS AND CELL ANALYSIS METHOD - A cell analysis apparatus that can accurately distinguish between an aggregating cell and a non-aggregating cell is provided. The cell analysis apparatus (08-05-2010
20100086936HEPATOCYTE PRECURSOR CELL LINES - The present invention is directed to methods for readily generating hepatocyte precursor cell lines that retain hepatocyte-specific functions after extensive in vitro culturing. The methods comprise isolating and culturing hepatocyte precursor cell lines under permissive culture conditions that suppress asymmetric cell kinetics and allow exponential growth of the precursor cells, followed by transferring the hepatocyte precursor cell lines to non-permissive culture conditions that allow expression of asymmetric cell kinetics and induce expression of hepatocyte-specific characteristics.04-08-2010
20100086921GENETIC SUSCEPTIBILITY VARIANTS OF TYPE 2 DIABETES MELLITUS - Association analysis has shown that certain genetic variants are susceptibility variants for Type 2 diabetes. The invention relates to diagnostic applications of such susceptibility variants, including methods of determining increased susceptibility to Type 2 diabetes, as well as methods of determining decreased susceptibility to Type 2 diabetes in an individual. The invention further relates to kits for determining a susceptibility to Type 2 diabetes based on the variants described herein.04-08-2010
20100086914HIGH RESOLUTION, HIGH THROUGHPUT HLA GENOTYPING BY CLONAL SEQUENCING - The invention provides methods and reagent for performing full, multi-locus HLA genotyping for multiple individuals in a single sequencing run using clonal sequencing.04-08-2010
20100086912AZGP Gene Single Nucleotide Polymorphisms (SNPs) - The present invention provides single nucleotide polymorphisms and haplotypes in the AZGP1 gene that can be used for determining the predisposition of an individual to obesity.04-08-2010
20100086926METHOD OF CHARACTERIZING SEQUENCES FROM GENETIC MATERIAL SAMPLES - Among other aspects provided herein is a method describing the use of Single Nucleotide Polymorphism (SNP) genotyping microarrays to resolve whether genetic material (such as genomic DNA) derived from a particular individual is present in a genetic material mixture (such as a complex genomic DNA mixture) is disclosed. Furthermore, it is demonstrated that the identification of the presence of genetic material (such as genomic DNA) of specific individuals within a series of complex genomic mixtures is possible.04-08-2010
20100086909Method for the prediction of individual disease course in sepsis - The invention relates to the use of gene expression profiles, obtained in vitro from a patient sample, for the generation of criteria for the prediction of an individual course of disease in sepsis. The invention is further of use for determining the probability of survival in sepsis, the assessment of the course of disease in sepsis during treatment and for the classification of sepsis patients.04-08-2010
20090305245Method of Examining Zinc-Deficient Taste Disturbance - The present invention provides: a method for testing zinc deficiency dysgeusia, which is characterized in that it comprises correlating the expression levels of a gene encoding a gustatory receptor belonging to the THTR family and a gene encoding a gustatory receptor belonging to the T2R family obtained from a sample derived from the oral cavity of a subject, with a serum zinc level obtained from the sample of the subject; and a kit used for the aforementioned test.12-10-2009
20100099095METHODS FOR DETERMINING PROGNOSES AND THERAPEUTIC INTERVENTIONS FOR OVARIAN CARCINOMAS - Methods for determining the prognosis and therapeutic interventions for cancer and for utilizing the expression of the homeoprotein Six1 to determine the prognosis and therapeutic interventions for cancer, in particular for ovarian carcinomas.04-22-2010
20100099098METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION - Methods of diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection and kits or systems containing the same are also described.04-22-2010
20100081131IDENTIFICATION OF MICROBES USING OLIGONUCLEOTIDE BASED IN SITU HYBRIDIZATION - A method of sample analysis is provided. In certain embodiments, the method may comprise: a) contacting a sample comprising a microbe with a set of at least two labeled oligonucleotides under in situ hybridization conditions to produce a contacted sample, where the labeled oligonucleotides i. hybridize to different RNA molecules of the microbe at sites that are unique to the microbe, ii. provide a predetermined optically detectable signature that identifies the microbe when the labeled oligonucleotides are hybridized to the different RNA molecules of the microbe, and iii. do not hybridize to ribosomal RNA of the microbe; b) reading the contacted sample to detect hybridization of the labeled oligonucleotides; and c) determining the identity of the microbe on the basis of the predetermined optically detectable signal, where the predetermined optically detectable signal indicates the identity of the microbe in the sample.04-01-2010
20100081140CHEMICALLY CLEAVABLE PHOSPHORAMIDITE LINKERS FOR SEQUENCING BY LIGATION - Linkers and methods for determining a nucleotide sequence of a reference oligonucleotide are provided.04-01-2010
20100081134BIO-BARCODE BASED DETECTION OF TARGET ANALYTES - The present invention relates to screening methods, compositions, and kits for detecting for the presence or absence of one or more target analytes, e.g. biomolecules, in a sample. In particular, the present invention relates to a method that utilizes reporter oligonucleotides as biochemical barcodes for detecting multiple protein structures or other target analytes in a solution.04-01-2010
20100081128Self-assembled single molecule arrays and uses thereof - The present invention provides methods of making and using self-assembled arrays of single polynucleotide molecules for carrying out a variety of large-scale genetic measurements, such as gene expression analysis, gene copy number assessment, and the like. Random arrays used in the invention are “self-assembled” in the sense that they are formed by deposition of polynucleotide molecules onto a surface where they become fixed at random locations. The polynucleotide molecules fixed on the surface are then identified by direct sequence determination of component nucleic acids, such as incorporated probe sequences, or by other decoding schemes. Such identification converts a random array of determinable polynucleotides, and their respective probes into an addressable array of probe sequences.04-01-2010
20100081137Click Chemistry for the Production of Reporter Molecules - The present invention relates to methods for producing reporter molecules suitable for the detection of analytes, e.g. nucleic acids. Further, the present invention relates to methods and regions for detecting analytes.04-01-2010
20100081144POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF - This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.04-01-2010
20100081143Preparations, Compositions, and Methods for Nucleic Acid Sequencing - Preparations, compositions and methods of sequencing nucleic acids are provided. The preparations, methods and compositions employ multiple priming sites on a target nucleic acid and typically utilize single molecule sequencing processes to identify sequence portions of the target which are then assembled to obtain the sequence of the target.04-01-2010
20090280486Oligonucleotides for Detecting Nucleic Acids of Pathogen Causing Sexually Transmitted Diseases - The present invention relates to oligonucleotides hybridizable with nucleic acids of pathogens causing sexually transmitted diseases, kits comprising them, and processes for amplifying and detecting viral nucleic acids using them. The present oligonucleotides completely overcome problems of false-negative and false-positive products in detection of pathogens causing sexually transmitted diseases using conventional primers and show dramatic workability in multiplex PCR, enabling to simultaneously detect pathogens causing sexually transmitted diseases in a single PCR reaction.11-12-2009
20100081142BIOMARKERS FOR KIDNEY DISEASES AND METHOD FOR USING SAME - The present invention provides biomarkers for detecting kidney disease, selected from the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof. Moreover, the present invention also provides an assay kit and a method for kidney disease detecting, practically for the kidney disease resulting from acute tubular necrosis.04-01-2010
20090081660Compositions and methods for the diagnosis and treatment of tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.03-26-2009
20090053703SPECIFIC AND UNIVERSAL PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL PATHOGENS AND ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR ROUTINE DIAGNOSIS IN MICROBIOLOGY LABORATORIES - The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens 02-26-2009
20090253127Compositions for Marking Objects with DNA and Methods for Marking and Linking an Object to its Owner - The invention can be summarized as follows. There is provided one or more DNA coating compositions that comprise one or more polymer compounds, water, and optionally one or more non-water polar solvents. The DNA coating composition may also comprise DNA. Also provided are methods and kits for marking objects with a DNA coating composition comprising DNA.10-08-2009
20090087846Method for Detecting Large Mutations and Duplications Using Control Amplification Comparisons to Paralogous Genes - Methods for querying biological samples to detect genetic mutations, particularly insertions and deletions, by co-amplification of a gene of interest in conjunction with a paralogous gene. When the gene of interest and the corresponding paralogous gene are selected from the CYP450 family, the resulting ratios may predict how a particular patient metabolizes certain prescription drugs.04-02-2009
20090286253GENETIC LOCI ASSOCIATED WITH SCLEROTINIA TOLERANCE IN SOYBEAN - The invention relates to methods and compositions for identifying soybean plants that are tolerant, have improved tolerance or are susceptible to 11-19-2009
20090286235Mdr1 Snp in Acute Rejection - The present invention concerns a method for the prediction of acute renal transplant rejection by detecting a polymorphism in exon 26 of the MDR1 gene, optionally in combination with polymorphisms of the IMPDH2 and IL 10 genes which were found to be associated with this disease.11-19-2009
20090208949PHOSPHATIDYLINOSITOL PHOSPHATE KINASE TYPE I GAMMA SPLICE VARIANTS AS BIOMARKERS AND DRUG TARGETS FOR EPITHELIAL CANCERS - The present invention relates generally to the field of phosphatidylinositol based signaling pathways, and more specifically to the use of novel members of these pathways for disease prognosis and treatment. In some aspects, the present invention relates to the use of novel splice variants of type I phosphatidylinositol phosphate kinase γ, named PIPKIγ 700 and PIPKIγ 707, to determine breast cancer and breast cancer prognosis.08-20-2009
20090197267METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS - The present invention provides methods for optimizing clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. The methods of the present invention may further comprise determining the level of at least one long-chain methotrexate polyglutamate (MTXPG) in a sample obtained from the individual. The present invention also provides methods for generating a pharmacogenetic index for predicting clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. In addition, the present invention provides methods for optimizing therapeutic efficacy of chemotherapy in an individual by calculating the level of at least one long-chain MTXPG in a sample obtained from the individual.08-06-2009
20090263819GENE AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF EGFR-TK INHIBITORS - The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample.10-22-2009
20090263820Optimization of Gene Expression Analysis using Immobilized Capture Probes - Disclosed are methods of multiplexed analysis of oligonucleotides in a sample, including: methods of probe and target “engineering”, as well as methods of assay signal analysis relating to the modulation of the probe-target affinity constant, K by a variety of factors including the elastic properties of target strands and layers of immobilized (“grafted”) probes; and assay methodologies relating to: the tuning of assay signal intensities including dynamic range compression and on-chip signal amplification; the combination of hybridization-mediated and elongation-mediated detection for the quantitative determination of abundance of messages displaying a high degree of sequence similarity, including, for example, the simultaneous determination of the relative expression levels, and identification of the specific class of, untranslated AU-rich subsequences located near the 3′ terminus of mRNA; and a new method of subtractive differential gene expression analysis which requires only a single color label.10-22-2009
20090263818Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme - A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan, and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drub reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan.10-22-2009
20090263816LABELLED BEADS - A labelled polymeric bead wherein individual beads comprise a primary particle formed of a synthetic polymeric material, and at least one secondary particle entrapped within the primary particle of the bead and being comprised of a synthetic polymer material incorporating reporter moieties.10-22-2009
20090263812USE OF ID4 FOR DIAGNOSIS AND TREATMENT OF CANCER - The invention relates to a method of determining whether a human subject is suffering from or at risk for developing pancreatic cancer by determining the methylation level of an ID4 gene promoter or the expression level of an ID4 gene in a biological sample from a human subject. Also disclosed are a method of analyzing the methylation level of an ID4 gene promoter or the expression level of an ID4 gene in a pancreatic cancer cell, and a method of inhibiting the methylation of an ID4 gene promoter or enhancing the expression of an ID4 gene by contacting a pancreatic cancer cell with a compound that decreases the methylation level of an ID4 gene promoter or increases the expression level of an ID4 gene in the cell.10-22-2009
20090263807OPTICAL DETECTION FIELD HAVING DIAMOND-LIKE CARBON THIN FILM FORMED THEREIN - An optical detection field, wherein a diamond-like carbon thin film containing therein fluorine is formed on a surface facing an existence region of a substance.10-22-2009
20090263802Methods and compositions for efficient base calling in sequencing reactions - The present invention is directed to methods and compositions for acquiring nucleotide sequence information of target sequences. In particular, the present invention provides methods and compositions for improving the efficiency of sequencing reactions by using fewer labels to distinguish between nucleotides and by detecting nucleotides at multiple detection positions in a target sequence.10-22-2009
20100086930IMPROVED HOMOGENEOUS LUMINESCENCE BIOASSAY - A homogenous bioassay including i) a first group containing a short lifetime fluorescent acceptor capable of energy transfer, and ii) a second group containing a quencher capable of energy transfer from an acceptor, with the first and second groups linked by at least a first linkage. The bioassay measures the acceptor's fluorescence increase resulting from cleavage of the first linkage. The bioassay also includes iii) a third group containing a donor for energy transfer to the acceptor, where the donor is an up-conversion fluorescent compound, a long-lifetime fluorescent compound or an electrogenerated luminescent compound. A conformational or terminal epitope is created on the first group through cleavage of the linkage, and the third group includes a binder with affinity for this conformational or terminal epitope. The acceptor's fluorescence is brought about by exciting the donor. Also disclosed are kits for homogenous bioassays according to the method of the invention.04-08-2010
20090263809Methods for Identification of Bioagents - Methods for detecting and identifying known and unknown bioagents, particularly bacteria, by nucleic acid amplification and amplicon size determination are provided. Nucleic acid amplification utilises multiple primers which hybridize to conserved bioagent ribosomal sequence regions and which bracket variable bioagent ribosomal sequence regions to produce multiple amplicons that uniquely identify the bioagent.10-22-2009
20090263806Method for detecting chikungunya virus - Compositions, methods and kits for detecting Chikungunya viral nucleic acids. Particularly described are methods for detecting very low levels of the viral nucleic acids using nucleic acid amplification.10-22-2009
20090263815CELL CULTURE SYSTEM, PROCESS FOR THE PRODUCTION THEREOF, AND THE USE THEREOF IN PRECLINICAL INVESTIGATION - The invention relates to a cell culture system, in particular for the preclinical testing of active substances, comprising a first and a second compartment which are in communication with one another via a separating layer between the first and the second compartment, the separation layer being permeable for cellularly secreted substances, wherein the first compartment includes a syntopic culture with tissue cells and immune cells and the second compartment includes a culture with blood cells. The invention further relates to a method in this regard and to a kit and uses for the preclinical testing of active substances.10-22-2009
20090263811TARGET BASE DISCRIMINATION METHOD - A target base-specific primer for use in discrimination of the base type of a target base in a nucleic acid in a nucleic acid sample, which is capable of discriminating the target base clearly with less possibility of false positive, and a target base discrimination method using the target base-specific primer, are provided. The target base discrimination method of the present invention uses a target base-specific primer for use in discrimination of the base type of a target base in a nucleic acid having a target nucleotide sequence including the target base in a nucleic acid sample, in the case where a plurality of base types can be enumerated for the target base, wherein the primer has a target base-corresponding base which is a base complementary to a base predicted as the target base, and the base type of a mismatch base is a specific base type when the mismatch base refers to a base adjacent to the 5′ side of the target base-corresponding base, and a mismatch-corresponding base refers to a base adjacent to the 3′ side of the target base in the target nucleotide sequence.10-22-2009
20090263805Methods of identifying point mutations in a genome that affect the risk for or the age of appearance of disease - The invention relates to a method for identifying inherited point mutations in a targeted region of the genome in a large population of individuals and determining which inherited point mutations are deleterious, harmful or beneficial. Deleterious mutations are identified directly by a method of recognition using the set of point mutations observed in a large population of juveniles. Harmful mutations are identified by comparison of the set of point mutation observed in a large set of juveniles and a large set of aged individuals of the same population. Beneficial mutations are similarly identified.10-22-2009
20090263803MIRNAS DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS - The present invention provides diagnostics and/or prognostic methods by identifying miRNAs that are differentially expressed or mis-regulated in various states of diseased, normal, cancerous, and/or abnormal tissues, including but not limited to cervix, skin, colon, breast, bladder, esophagus, liver, ovary, prostate, lung, pancreas, thyroid, kidney, stomach, testicle, uterus, spleen, tongue, brain, thymus, trachea and/or small intestine. In certain apsects, differential miRNA expression is initially determined by comparing miRNA expression between a normal tissue and cancer negative lymph node (LNneg), a normal tissue and a cancer positive lymph node (LNpos), a cancerous tissue and LNneg and/or LNpos, LNneg and LNpos. The methods of the invention are used to identify the presence or absence of non-lymphoid cells from other organs or tissues, and/or metastatic cancer cells present in lymph nodes.10-22-2009
20090263801Phenotype-Genotype Relationship in Age-Related Macular Degeneration - Age-Related Macular Degeneration (AMD) cases possessing the LOC387715 (rs10490924) variant have a higher risk of neovascular AMD. Individuals with AMD who are homozygous for both variants might be at greater risk for earlier onset of neovascular AMD. Determining the presence of this variant indicates which path the disease may take and which nutritional, supplement, or medicaments are appropriate.10-22-2009
20090263800METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION - Methods of diagnosing or monitoring transplant rejection or cytomegalovirus infection in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection or cytomegalovirus infection and kits or systems containing the same are also described.10-22-2009
20090263799ASSAY FOR PROSTATE CANCER - In certain embodiments, a method for detecting a prostate proliferative cell disorder, a prostate cancer or a prostate tumor and/or categorizing Gleason's Sum of the tumors includes performing a digital rectal examination on a subject; obtaining one or more expressed prostatic secretion (EPS) samples from the subject; measuring PSA levels in the EPS; and measuring a biomarker, wherein the biomarker is TMPRSS2:ERG fusion RNA. Optionally, the biomarker may be methylated copies of GSTPI, APC, RARB and/or RASSFI DNA or PCA3 RNA. A kit for performing any of the above embodiments is also contemplated.10-22-2009
20100086913Methods of Identification Using Methylation of CPG - The present invention relates to the materials and methods for the identification of methylated nucleotides in samples of genomic DNA. The present invention also relates to methods of diagnosis of specific conditions by identification of specific methylated nucleotides.04-08-2010
20090263798Method For Identification Of Novel Physical Linkage Of Genomic Sequences - The invention is directed to methods to identify the location in a genome of a nonfixed or multicopy genomic element using microarrays or sequencing.10-22-2009
20090263796METHODS AND COMPOSITIONS FOR DIAGNOSING OR MONITORING AUTOIMMUNE AND CHRONIC INFLAMMATORY DISEASES - Methods of diagnosing or monitoring an autoimmune or chronic inflammatory disease, particularly SLE in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring chronic inflammatory disease, particularly SLE infection and kits or systems containing the same are also described.10-22-2009
20090263797REVERSIBLE DI-NUCLEOTIDE TERMINATOR SEQUENCING - The present teachings provide methods, compositions, and kits for synthesizing and sequencing nucleic acids. In some embodiments, reversible di-nucleotide compounds are employed along with cleaving reactions that remove a label and a blocking moiety. Improved sequencing efficiency is achieved by the rapid polymerase-mediated incorporation of reversible di-nucleotide compounds. In some embodiments, the di-nucleotides do not contain conventional nucleotide triphosphates, but rather employ amino acid phosphoramidate nucleotides (AAPNs).10-22-2009
20090263794High Throughput Flow Through Sample Preparation Using Magnetic Beads - A polymerase chain reaction system for analyzing a sample containing nucleic acid includes providing magnetic beads; providing a flow channel having a polymerase chain reaction chamber, a pre polymerase chain reaction magnet position adjacent the polymerase chain reaction chamber, and a post pre polymerase magnet position adjacent the polymerase chain reaction chamber. The nucleic acid is bound to the magnetic beads. The magnetic beads with the nucleic acid flow to the pre polymerase chain reaction magnet position in the flow channel. The magnetic beads and the nucleic acid are washed with ethanol. The nucleic acid in the polymerase chain reaction chamber is amplified. The magnetic beads and the nucleic acid are separated into a waste stream containing the magnetic beads and a post polymerase chain reaction mix containing the nucleic acid. The reaction mix containing the nucleic acid flows to an analysis unit in the channel for analysis.10-22-2009
20090263795DIAGNOSTIC METHODS INVOLVING DETERMINING GENE COPY NUMBERS AND SNPs IN THE FcyRII/FcyRIII GENE CLUSTER, AND PROBES FOR USE IN SUCH METHODS TO DETECT SUSCEPTIBILITY TO AND TREATMENT EFFICACY IN AUTOIMMUNE DISEASES - The invention relates to diagnostic methods to predict whether a subject is predisposed for acquiring a disease or to predict the therapy responsiveness of an individual patient. Provided is a method for determining whether a subject is predisposed for developing an autoimmune disease, comprising determining in a sample isolated from said subject the amount of intact genes, or gene products thereof, of the FcγRII/FcγRIII gene cluster, said gene cluster comprising the FCGR2C, FCGR3A, FCGR2A and FCGR3B genes encoding an activating FcγR, and FCGR2B encoding an inhibitory Fcγ R; and correlating said amount to the amount observed in a healthy population. Also provided is a method to predict the responsiveness of a subject to therapy with intravenous immunoglobulin (IVIg) therapy or a monospecific biological, such as a humanized or human monoclonal antibody or a chimeric molecule, comprising the C-terminal Fc-tail of IgG.10-22-2009
20090263792ATOPIC DERMATITIS MARKER AND TECHNIQUE OF USING THE SAME - It is an object of the present invention to find substances that can be used as disease markers for atopic dermatitis and the present invention provides a method for determining atopic dermatitis, including measurement of the expression of specific proteins and/or their genes in skin cells and/or skin tissues, wherein the specific proteins change their expression with inflammation caused by atopic dermatitis or change their expression according to the degree of predisposition to atopic dermatitis. The present invention also provides a kit for determining the degree of inflammation of atopic dermatitis or risk of developing atopic dermatitis, as well as a method for determining substances effective in the treatment and/or prevention of atopic dermatitis.10-22-2009
20090263793NOVEL METHOD FOR DIAGNOSING OF MYCOBACTERIUM Tuberculosis - The present invention relates to a method and a kit for detecting 10-22-2009
20090263789Method for Detecting Nucleic Acid Sequences - The invention is directed to a method for detecting a target nucleic acid sequence by non-linear amplification.10-22-2009
20090263790Methods for Identifying Functionally Related Genes and Drug Targets - The identification and evaluation of mRNA and protein targets associated with mRNP complexes and implicated in the expression of proteins involved in common physiological pathways is described. Effective targets are useful for treating a disease, condition or disorder associated with the physiological pathway.10-22-2009
20090263791Chemically Cleavable 3'-O-Allyl-DNTP-Allyl-Fluorophore Fluorescent Nucleotide Analogues and Related Methods - This invention provides a nucleotide analogue comprising (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine and uracil, (ii) a deoxyribose, (iii) an allyl moiety bound to the 3′-oxygen of the deoxyribose and (iv) a fluorophore bound to the base via an allyl linker, and methods of nucleic acid sequencing employing the nucleotide analogue.10-22-2009
20100092947Impdh2 snp associated with acute rejection - The present invention concerns a method for the prediction of acute renal transplant rejection by detecting a polymorphism in intron 7 of the IMPDH2 gene, optionally in combination with polymorphisms of the MDR1 and IL 10 genes which were found to be associated with this disease.04-15-2010
20090220979Methods and Apparatus for Magnetic Separation of Cells - Described here is an automated robotic device that isolates circulating tumor cells (CTCs) or other biological structures with extremely high purity. The device uses powerful magnetic rods covered in removable plastic sleeves. These rods sweep through blood samples, capturing, e.g., cancer cells labeled with antibodies linked to magnetically responsive particles such as superparamagnetic beads. Upon completion of the capturing protocol, the magnetic rods undergo several rounds of washing, thereby removing all contaminating blood cells. The captured target cells are released into a final capture solution by removing the magnetic rods from the sleeves. Additionally, cells captured by this device show no reduced viability when cultured after capture. Cells are captured in a state suitable for genetic analysis. Also disclosed are methods for single cell analysis. Being robotic allows the device to be operated with high throughput.09-03-2009
20090170089METHODS AND COMPOSITIONS FOR DIFFERENTIATING TISSUES OR CELL TYPES USING EPIGENETIC MARKERS - The present invention provides, inter alia, a method for generating a genome-wide epigenomic map, comprising a correlation between methylation variable CpG positions (MVP) and genomic DNA sample types. MVP are those CpG positions that show a variable quantitative level of methylation between sample types. Particular genomic regions of interest (ROI) provide preferred marker sequences that comprise multiple, and preferably proximate MVP, and that have novel utility for distinguishing sample types. The epigenic maps have broad utility, for example, in identifying sample types, or for distinguishing between and among sample types. In a preferred embodiment the epigenomic map is based on methylation variable regions (MVP) within the major histocompatibility complex (MHC), and has utility, for example, in identifying the cell or tissue source of a genomic DNA sample, or for distinguishing one or more particular cell or tissue types among other cell or tissue types. Analysis of epigenetic characteristics of one, or of a set of nucleic acid sequences, in the context of an inventive epigenomic map, allows for the determination of an origin of the nucleic acids.07-02-2009
20090162864BIOLOGICAL SUBSTANCE DETECTION CARTRIDGE,BIOLOGICAL SUBSTANCE DETECTION APPARATUS, AND BIOLOGICAL SUBSTANCE DETECTION METHOD - A biological substance detection cartridge, including: a reaction vessel for reacting a probe with a specific biological substance included in a sample solution, the reaction vessel having a region for fixing the probe for detecting the biological substance; a porous membrane facing the inside of the reaction vessel; a gas-liquid separation membrane superposed with the porous membrane; and a air discharge component which is provided on the opposite side of the gas-liquid separation membrane from the side contacting the porous membrane, and with which the interior can be kept at negative pressure during the reaction between the biological substance and the probe.06-25-2009
20100124750ANALYZING METHODS AND DEVICES FOR BIOLOGICAL REACTIONS BETWEEN A LIQUID PHASE AND A SOLID PHASE - The invention relates to a device for performing immunological, histochemical and cytochemical, molecular biological, enzymological, clinical-chemical and other analyses, wherein the device comprises an object holder having one or more elongate adhesive surfaces and a reagent holder having one or several channels. The object holder is detachably connectable to the reagent holder in such a manner that the elongate adhesive surfaces each face one of the channels and, when reaction partners bound to a solid phase are disposed on the elongate adhesive surfaces and reactants dissolved in liquid are present in the channels, the reaction partners and the reactants are in contact. Means are provided for preventing the liquid from passing from one channel into an adjacent channel. A method for performing a corresponding analysis can be performed with this device, by connecting the object holder to the reagent holder in such a manner that the elongate adhesive surfaces each face a channel, liquid having reactants dissolved therein is introduced into the channels such that the solid phase substrates having reaction partners bound thereto and being disposed on the adhesive surfaces come into contact with the liquid, and the object holder and the reagent holder are moved together in such a manner that the liquid alternately moves into the two longitudinal directions of the channels.05-20-2010
20100124744DETECTION OF TARGET VARIANTS USING A FLUORESCENT LABEL AND A SOLUBLE QUENCHER - Methods, reaction mixtures and systems for detecting the presence or absence of a target nucleic acid variant from a selection of possible variants is described.05-20-2010
20100124742Methods and Compositions to Identify Increased Risk of Breast Cancer by Detection of CPG Island Methylator Phenotype (CIMP) - The present invention is directed to kits and methods for identifying a female subject as having an increased risk of developing breast cancer, comprising detecting a CPG island methylator phenotype (CIMP) in nucleic acid of the subject.05-20-2010
20100099091GENETIC COMPONENT OF COMPLICATIONS IN TYPE 2 DIABETES - The invention provides with means to predict, in subjects affected by type 2 diabetes (T2D), the probability of developing complications related to the disease. The invention involves 1) use of genetic features (SNPs, STRs, or other genomic markers) together with other chromosomal features and phenotypic information to establish a patient profile specifically developed for prediction of complications of T2D 2) use of a set of SNPs allowing to discriminate between individuals according to their descent. A preferred set of genomic markers selected for their association with complications of T2D is provided that can be used with a set of complementary phenotypic markers to evaluate the risk for an individual affected by T2D to develop complications related to the disease and to evaluate the likelihood that an individual affected by T2D type will benefit from treatments reducing the risk of developing such complications.04-22-2010
20100099100'ULTRA-HIGH MULTIPLEX ANALYTICAL SYSTEMS AND METHODS" - Apparatus, systems and methods for use in analyzing discrete reactions at ultra high multiplex with reduced optical noise, and increased system flexibility. Apparatus include substrates having integrated optical components that increase multiplex capability by one or more of increasing density of reaction regions, improving transmission of light to or collection of light from discrete reactions regions. Integrated optical components include reflective optical elements which re-direct illumination light and light emitted from the discrete regions to more efficiently collect emitted light. Particularly preferred applications include single molecule reaction analysis, such as polymerase mediated template dependent nucleic acid synthesis and sequence determination.04-22-2010
20100099085Serum DNA Methylation Screening for Cancer - We disclose a method of screening a mammal for a cancer associated with methylation of promoters of tumor-suppressor genes by collecting a sample of a body fluid or tissue of the mammal containing free DNA; isolating the free DNA from the sample; amplifying at least a portion of the promoter of each of a plurality of turner-suppressor genes associated with the cancer from the free DNA, to yield a plurality of amplified promoters; and quantifying methylation of each of the plurality of amplified promoters, to yield a methylation quantity. The method can have a high sensitivity and high specificity and can thus reduce the proportion of unneeded biopsies. It can also be performed with minimal invasiveness and discomfort to a patient.04-22-2010
20100099092Methods for determination of haplotype dissection - A method for molecular haplotyping of a subject is disclosed. The method comprises: randomly selecting a set of chromosomes in each of a plurality of lyzed diploid cells of the subject, collecting the selected chromosomes from said plurality of cells into a plurality of sample tubes, wherein each sample tube contains chromosomes selected from one or more cells, genotyping genomic DNA in each sample tube, and determining haplotype of the alleles based on allele nucleotide sequence information and corresponding nucleotide signal intensities from genotyping data. Other methods for molecular haplotyping using single cell lysate or single cell microdissection are also disclosed.04-22-2010
20100099090BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO CTLA-4 ANTAGONISTS - CTLA-4 biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an CTLA-4 antagonist, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker s, (b) exposing a biological sample from the mammal to the CTLA-4 antagonist, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.04-22-2010
20100099088RELIABLE DETECTION OF VANCOMYCIN-INTERMEDIATE STAPHYLOCOCCUS AUREUS - The present invention relates to a method for identifying a VISA strain in a sample comprising measuring SAV2095 expression levels, a kit and use of SAV2095 for same. The present invention also relates to a method for facilitating the development of an individualized treatment regimen comprising measuring the expression level of SAV2095. The present invention further relates to a method for monitoring the progression of a vancomycin treatment of an infection comprising measuring the expression level of SAV2095. The present invention also relates to the detection of 04-22-2010
20100099109Methods for Analyzing Drug Response - The present invention provides methods, instruments, reagents, kits and the biology involved in analyzing drug response. An embodiment of the present invention provides an approach for the characterization a plurality of pathways in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states of cellular molecules such as proteins, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Some of these categories include redox potential, ITIM phosphorylation, intracellular pH and other categories allows for characterization of such pathways and cell populations. Also, the present analysis is useful for the analysis of the effect of compounds on potential target cells.04-22-2010
20100099110Allele-Specific Amplification - The present invention includes a method of allele-specific amplification, utilizing an allele-specific oligonucleotide, at least partially complementary to more than one variant of the target sequence, but having a 3′-terminal nucleotide complementary to only one variant of the target sequence and having at least one nucleotide with a base covalently modified at the exocyclic amino group, wherein the allele-specific oligonucleotide is extended by a nucleotide-incorporating biocatalyst predominantly when hybridized to the variant of the target sequence for which it has said complementary 3′-terminal nucleotide.04-22-2010
20100099101METHODS FOR TREATING, DIAGNOSING, AND MONITORING LUPUS - Methods of identifying, diagnosing, and prognosing lupus, including certain subphenotypes of lupus, are provided, as well as methods of treating lupus, including certain subpopulations of patients. Also provided are methods for identifying effective lupus therapeutic agents and predicting responsiveness to lupus therapeutic agents.04-22-2010
20090053702SPECIFIC AND UNIVERSAL PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL PATHOGENS AND ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR ROUTINE DIAGNOSIS IN MICROBIOLOGY LABORATORIES - The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens 02-26-2009
20100081133Methods of Detecting Root Knot Nematodes - The present invention relates to a method of testing a sample for the presence of a 04-01-2010
20090061442Screening assay to identify non-ATP-competitors targeting protein kinase A - Methods for screening compounds for their activity as a protein kinase A modulators are provided. The methods are based on fluorescence polarization of peptide probes to identify drug candidates that act by activating or inhibiting the catalytic function of PKA. In certain embodiments, the methods are adapted for high throughput screening.03-05-2009
20100021902Method for methylation-selective amplification - Aspects of the invention relate to a method for methylation selective amplification. The method comprising a DNA treatment, wherein cytosine is converted to uracil, uracil sulfonate or another base having a different binding behavior than cytosine, while methylated cytosine remains unchanged, and the amplification of treated DNA in the presence of at least one restriction enzyme, said enzyme digesting the amplification product derived either from converted methylated DNA or from converted unmethylated DNA during amplification. Aspects of the invention relate to a kit for performing the inventive method. Aspects of the invention relate also to the use of the inventive methods and kits.01-28-2010
20090053696Biomarker For Heart Failure - The present invention relates, in general, to heart failure, and, in particular, to a method of evaluating heart failure patients by monitoring β-adrenergic receptor kinase (βARK1) levels in lymphocytes from such patients.02-26-2009
20090280476Droplet-based affinity assay device and system - The present invention relates to a droplet-based affinity assay device and system. According to one embodiment, a droplet microactuator is provided and includes an antibody immobilized on a surface. According to another embodiment, a droplet microactuator is provided and includes a droplet on the droplet microactuator, the droplet comprising an antibody.11-12-2009
20090239213Identifying a target polynucleotide - A method for identifying the presence of a single stranded target polynucleotide in a sample comprising the steps of (i) contacting the target polynucleotide, under hybridising conditions, with at least first and second polynucleotide probes, each of which comprise a first region complementary to adjacent non-overlappïng regions of the target polynucleotide; (ii) ligating together those first and second polynucleotides that hybridise to the target polynucleotide; (iii) optionally, amplifying any ligated polynucleotides; and (iv) determining whether the target polynucleotide is present in the original sample, by detecting any ligated polynucleotide, wherein at least one of the first and second polynucleotides comprise a second region having a defined polynucleotide sequence, with each individual nucleotide of the first region being represented by at least two nucleotides on the second region, and the ligated polynucleotide being identified by determining the second region of at least one of the first and second polynucleotide probes.09-24-2009
20100075327INTERMITTENT DETECTION DURING ANALYTICAL REACTIONS - Methods, devices, and systems for performing intermittent detection during analytical reactions are provided. Such methods facilitate collection of reaction data from disparate reaction times. Further, such methods are useful for reducing photo-induced damage of one or more reactants in an illuminated analytical reaction at a given reaction time. In preferred embodiments, the reaction mixture is subjected to at least one illuminated and non-illuminated period and allowed to proceed such that the time in which the reaction mixture is illuminated is less than a photo-induced damage threshold period.03-25-2010
20090170113Non-Invasive Fetal Genetic Screening by Digital Analysis - The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.07-02-2009
20090170102METHODS FOR DETECTING DNA ORIGINATING FROM DIFFERENT INDIVIDUALS - In a first aspect, the present invention features methods for differentiating DNA species originating from different individuals in a biological sample. These methods may be used to differentiate or detect fetal DNA in a maternal sample or to differentiate DNA of an organ donor from DNA of an organ recipient. In preferred embodiments, the DNA species are differentiated by observing epigenetic differences in the DNA species such as differences in DNA methylation. In a second aspect, the present invention features methods of detecting genetic abnormalities in a fetus by detecting fetal DNA in a biological sample obtained from a mother. In a third aspect, the present invention features methods for differentiating DNA species originating from an organ donor from those of an organ recipient. In a fourth aspect, the present invention features kits for differentiating DNA species originating from different individuals in a biological sample.07-02-2009
20090170094FLUORESCENT LABELING SUBSTANCE COMPRISING NANOPARTICLES OR NANORODS - A fluorescent labeling substance that is capable of realizing highly appropriate labeling through enhancing of the luminous efficiency of semiconductor nanoparticles or nanorods. The fluorescent labeling substance can be provided by disposing on a surface of shell of nanorods or nanoparticles having a modification group capable of adsorption with a biosubstance, such as protein, nucleic acid or antibody, a region devoid of the above modification group.07-02-2009
20090170100Biomarkers and detection methods for gastric diseases - The present invention provides a biomarker for detecting gastric diseases, especially gastric cancer selected from: a nucleic acid sequence of GroES, complementary strand, or derivatives thereof or an amino acid sequence of GroES, derivatives, fragments or variants thereof or antibodies against said amino acid sequences or combinations thereof, yet provides a kit for detecting gastric cancer by use of above-mentioned biomarkers and a detection method.07-02-2009
20090170104COMPOSITIONS AND METHODS FOR DETECTING GROUP A STREPTOCOCCI - Compositions, methods and kits for detecting Group A streptococci. Particularly described are oligonucleotides that are useful as amplification primers and hybridization probes for detecting very low levels of Group A streptococci nucleic acids.07-02-2009
20090170085Gene Methylation in Head and Neck Cancer Diagnosis - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with head and neck cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of head and neck cancer.07-02-2009
20090170082GENE METHYLATION IN RENAL CANCER DIAGNOSIS - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with renal cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of renal cancer.07-02-2009
20100099099METHOD AND TEST KIT FOR THE RAPID DETECTION OF SPECIFIC NUCLEIC ACID SEQUENCES, ESPECIALLY FOR DETECTING OF MUTATIONS OR SNPs - A method and a test kit for rapid detection of specific nucleic acid sequences, especially for detection of mutations or single nucleotide polymorphisms (SNPs), in which the detection reaction takes place in two steps. The first step involves the target-specific amplification reaction, coupled with the probe-hybridization reaction using fluorescence-labeled allele-specific amplification primers. In the second step, the fluorescence is detected by means of commercial fluorescence readers. Genotyping is carried out from the ratio of the end-point fluorescence of the samples and negative controls.04-22-2010
20100099105ANTIBODIES HAVING BINDING SPECIFICITY FOR THE EXTRACELLULAR DOMAIN OF A BREAST CANCER RESISTANCE PROTEIN (BCRP) - The present invention includes methods of identifying and/or isolating stem cells based on expression of BCRP. The present invention also describes methods of obtaining and/or using cell populations enriched for stem cells. In addition, methods are provided for diagnosing and/or prognosing leukemia, particularly human acute myelogenous leukemia (AML), through assaying for BCRP expression in leukemic cells.04-22-2010
20100124753SYSTEM AND METHOD FOR IDENTIFYING ERYTHROPOIETIN-RESPONSIVE GENES - The present invention relates to the generation of a population of Epo-responsive marrow derived cells that express Epo-responsive genes and gene products. The present invention also relates to the detection of Epo-responsive genes and gene products as well as to the detection of the administration of Epo, Epo-derivatives and Epo-mimetics in subjects.05-20-2010
20100124743METHOD FOR DIAGNOSIS OF CANCER - Disclosed is a method for diagnosing cancer with high accuracy through quantification of cancer cell-derived DNA, which comprises the steps of: (1) extracting free DNA from a plasma collected from a test subject; (2) quantifying the extracted free DNA and calculating the free DNA content per unit volume of the plasma to obtain a first calculation value; (3) comparing the first calculation value with a second threshold value which is equal to or higher than a first threshold value; and (4) determining that the test subject is highly unlikely affected by cancer if the first calculation value is lower than the first threshold value, determining that the test subject is likely affected by cancer if the first calculation value is equal to or higher than the first threshold value and lower than the second threshold value, or determining that the plasma used for the quantification is contaminated by normal cell-derived DNA if the first calculation value is equal to or higher than the second threshold value.05-20-2010
20100124739Methods and Compositions for Diagnosing Pelvic Floor Dysfunction - The present invention relates to, among other things, methods and compositions for diagnosing and preventing pelvic floor dysfunction, genital prolapse, and similar medical conditions. For example, according to certain embodiments of the present invention, methods of diagnosing genital prolapse and/or pelvic floor dysfunction are provided. Such methods generally comprise (1) collecting a sample of a patient's uterosacral ligament tissue, (2) extracting total genomic DNA from the tissue, (3) amplifying a promoter region operably connected to a nucleic acid sequence encoding lysyl oxidase (LOX), lysyl oxidase like-1 (LOXL1), lysyl oxidase like-2 (LOXL2), lysyl oxidase like-3 (LOXL3), and/or lysyl oxidase like-4 (LOXL4), and (4) determining whether the promoter region comprises methylated CpG islands.05-20-2010
20100124747COMPOSITIONS AND METHODS FOR DIAGNOSIS OR PROGNOSIS OF TESTICULAR CANCER - Provided are compositions and methods for diagnosis or prognosis of testicular or male germ-cell derived cancer, comprising: obtaining sperm DNA from a test subject; determining the methylation status of at least one CpG dinucleotide sequence of at least one gene sequence selected from HRAS, NTF3, MT1A, PAX8, DIRAS3, PLAGL1, SFN, SAT2CHRM1, MEST, RNR1, CYP27B1 and ICAM1; and thereby determining or diagnosing testicular or male germ-cell derived cancer. Provided are compositions and methods for identifying agents that cause testicular or male germ-cell derived cancer, comprising: obtaining human ES-cell derived primordial germ cells; contacting the germ cells or descendants thereof, with a test agent; culturing the contacted cells; determining, using a genomic DNA of the sample, the methylation status of at least one CpG dinucleotide sequence of at least one gene sequence selected from the above group; and identifying at least one test agent that causes testicular or male germ-cell derived cancer.05-20-2010
20100124752Non-Invasive Fetal Genetic Screening by Digital Analysis - The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.05-20-2010
20100124740Somatic transfer of modified genes to predict drug effects - The present invention relates to somatic cell gene transfer methods for mimicking one or more effects of a drug candidate compound. In one aspect, the methods mimic the effect of a drug candidate compound with potential to potentiate or suppress activity of a selected target molecule. In another aspect, the methods provide means of identifying a molecular target for the drug candidate compound. The present methods have a variety of uses including providing identified molecular targets for use in drug screens.05-20-2010
20100273173METHOD FOR AMPLIFYING TARGET NUCLEIC ACID SEQUENCE AND PROBE USED FOR THE SAME - The present invention provides a method for amplifying a target sequence while suppressing inhibition of an amplification reaction in nucleic acid amplification in the presence of the probe. At the time of amplifying the target sequence, as the probe caused to coexist in amplification of the target sequence, a probe having a base sequence in which a melting temperature of the double-stranded nucleic acid is equal to or lower than a reaction temperature of the elongation reaction is used. In the presence of such a probe, for example, annealing of a primer and an elongation reaction from the primer are hardly inhibited by the presence of the probe so that amplification of the target sequence can be conducted sufficiently. Therefore, when a polymorphism of a target site in the target sequence is analyzed by a Tm analysis or the like, high reliability can be achieved.10-28-2010
20100273149PHOTOSYNTHETIC HYDROGEN PRODUCTION FROM THE GREEN ALGA CHLAMYDOMONAS REINHARDTII - The present invention relates generally to hydrogen production for use in fuel cells, foodstuffs and chemical production, and more particularly, to biologically and photosynthetically produced hydrogen. Specifically, disclosed is a method for producing bacteria and green alga that can produce hydrogen in quantities that exceed four hundred percent of the hydrogen produced by green alga in nature; thus, producing organisms which can serve as hydrogen generators for fuel cells, chemical production and numerous other applications.10-28-2010
20090275035PRIMERS FOR HUMAN MITOCHONDRIAL HYPERVARIABLE REGION AND METHOD FOR DETECTING HUMAN DNA BY USING THE PRIMERS - The present invention relates to primer pairs for human mitochondrial hypervariable region and a method for detecting human DNA by using the primer pairs.11-05-2009
20090275032Reprogramming a cell by inducing a pluripotent gene through use of an HDAC modulator - The invention relate to methods, compositions, and kits for reprogramming a cell. In one embodiment, the invention relates to a method comprising inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method comprises inhibiting the activity of an HDAC with an HDAC inhibitor and inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In still another embodiment, the invention relates to a method for reprogramming comprising exposing a cell to more than one agent to inhibit more than ore type of regulatory protein. In yet another embodiment, the invention relates to a reprogrammed cell or an enriched population of reprogrammed cells that can have characteristics of an ES-like cell, which can be re- or trans-differentiated into various differentiated cell types11-05-2009
20090275020Traceability of Cellular Cycle Anomalies Targeting Oncology and Neurodegeneration - The present invention relates to the field of medicine and biology. It concerns a novel test for screening and for therapeutic follow-up in oncology. More particularly, it relates to diagnostic and/or therapeutic tests in oncology and on neurodegenerative diseases. It is a diagnostic test and a prognostic test for various cancers (breast cancer, bladder cancer, ovarian cancer, lung cancer, skin cancer, prostate cancer, colon cancer, liver cancer, gliboblastoma, sarcoma, leukemia, etc.) and therapeutics solutions for specific neurodegenerative diseases. More particularly, the invention concerns the use of the LIV21 protein, LIV21 gene and of derivatives thereof as diagnostic and prognostic markers for cancers. The invention therefore concerns the detection of the LIV21 protein with a kit comprising LIV21-specific antibodies.11-05-2009
20090142770Hair Follicle Pharmacodynamic Assay for Telomerase Activity - The invention is directed to methods for determining the efficacy of treatment with telomerase modulators in mammals by the analysis of the level of telomerase reverse transcriptase activity in mammalian hair follicle cells.06-04-2009
20090142767Method for nucleic acid quantitation - It is intended to provide a novel convenient approach for DNA quantitative analysis that overcomes the disadvantages of conventional formulations. A standard DNA sample is prepared by introducing a single-base substitution into target DNA, and a predetermined amount thereof is mixed with a target DNA sample. The target and standard DNAs are amplified using the same primers designed to amplify a region comprising the single-base substitution site. To a hybridization product of a probe capable of binding to a site immediately before the single-base substitution site, ddATP, ddGTP, ddCTP, and ddTTP are sequentially added one by one to perform a complementary strand synthesis reaction. Luciferase reaction-induced luminescence derived from the formed pyrophosphoric acid is detected. The target DNA is quantitated from the amount of the detected luminescence and the amount of the added standard DNA sample.06-04-2009
20090142755ASSAY FOR DETECTING GENETIC ABNORMALITIES IN GENOMIC NUCLEIC ACIDS - The present invention provides methods of detecting unamplifed genomic nucleic acid anchored to a solid support. The methods are useful for the detecting genetic abnormalities associated with various diseases, diagnosis, and prognosis.06-04-2009
20090142751ANALYZING POLYNUCLEOTIDE SEQUENCES - An apparatus is provided for analysing a polynucleotide. The apparatus includes: a support having an impermeable surface; porous material attached to the impermeable surface; and an array of oligonucleotides with predetermined sequences attached to the porous material. The array includes at least two defined cells, the sequence of the oligonucleotides of a first cell being different from the sequence of the oligonucleotides of a second cell, and the oligonucleotides being shorter than the polynucleotide. 06-04-2009
20080261220Nucleic Acid Detection Assays - The present invention relates to novel methods of producing oligonucleotides. In particular, the present invention provides an efficient, safe, and automated process for the production of large quantities of oligonucleotides.10-23-2008
20080311580Novel genes encoding proteins involved in proanthocyanidin synthesis - This inventions provides an isolated protein or polypeptide having activity in the synthesis of proanthocyanidin (PA) polymer from epicatechin or catechin in plants, and which is not naturally regulated by the TT2 or TT8 regulators, or a fragment comprising at least about 10 contiguous amino acids derived from said protein or polypeptide, particularly TDS1, TDS2, TDS3, TDS4, TDS5, or TDS6 protein, or fragment thereof.12-18-2008
20090004655RNA BIOASSAY - The present invention relates to methods for evaluating the cell damaging potential of an agent by determining the ability of the agent to increase messenger RNA release in cells.01-01-2009
20090004656THERMOSTABLE POLYMERASES HAVING ALTERED FIDELITY AND METHODS OF IDENTIFYING AND USING SAME - The present invention provides a method for identifying a thermostable polymerase having altered fidelity. The method consists of generating a random population of polymerase mutants by mutating at least one amino acid residue of a thermostable polymerase and screening the population for one or more active polymerase mutants by genetic selection. For example, the invention provides a method for identifying a thermostable polymerase having altered fidelity by mutating at least one amino acid residue in an active site O-helix of a thermostable polymerase. The invention also provides thermostable polymerases and nucleic acids encoding thermostable polymerases having altered fidelity, for example, high fidelity polymerases and low fidelity polymerases. The invention additionally provides a method for identifying one or more mutations in a gene by amplifying the gene with a high fidelity polymerase. The invention further provides a method for accurately copying repetitive nucleotide sequences using a high fidelity polymerase mutant. The invention also provides a method for diagnosing a genetic disease using a high fidelity polymerase mutant. The invention further provides a method for randomly mutagenizing a gene by amplifying the gene using a low fidelity polymerase mutant.01-01-2009
20090004646Method for Quantifying Methylated Dna - The inventive method makes it possible to quantify methylated DNA by combining the restricted digestion and real-time PCR. For this purpose, the inventive method consists in isolating the examined DNA from a biological sample, in reacting the isolated AND with a methylation specific restriction enzyme, in amplifying by means of a real-time PCR, wherein the amplified products are formed only when the DNA is precut-off and, afterwards, in calculated the methylated and unmethylated DNA proportion in the initial sample with the aid of a reference measurement. Said method is particularly suitable for diagnosis and prognosis cancer and other diseases associated with a methylation state modification and for predicting the drug effects.01-01-2009
20090280479USE OF FREE CIRCULATING DNA FOR DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER FUNDING - A method of detecting circulating DNA in a body fluid. The method comprises identifying a subject suffering from or at risk for developing cancer, obtaining a body fluid sample from the subject, and determining the sequence integrity of circulating DNA in the sample, wherein the circulating DNA is not purified from the sample.11-12-2009
20080318243DNA measuring system and method - The present invention provides a DNA sequencer using a FET sensor, capable of long-base decoding. Target DNAs are immobilized on the surfaces of spherical fine particles, the fine particles are disposed in the vicinity of metal electrodes each of which is connected electrically to a corresponding one of conductive wirings of the FET sensor and partly has a spherical surface capable of contacting with the fine particles, and the FET sensor detects a change in interfacial potential incident to an extension reaction of DNA molecules containing a hybridization of the target DNA and probe DNA.12-25-2008
20080311562Nucleic Acid Sequencing - A method for determining a target nucleic acid sequence, wherein the target nucleic acid sequence is comprised in a preparation comprising a non-target nucleic acid sequence, the target nucleic acid sequence and the non-target nucleic acid sequence each having a first region of common sequence upstream of a first region of dissimilar sequence upstream of a second region of dissimilar sequence, the method comprising:12-18-2008
20080286770DNA Molecules Encoding L-Glutamate-Gated Chloride Channels From Rhipicephalus Sanguineus - The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode 11-20-2008
20090286239Method of Detecting Individual Encapsulated Influenza Viruses, Primer Set for the Detection and Kit for the Detection - The present invention provides a method of rapidly, simply and accurately detecting capsular serotype 11-19-2009
20090286238Methods to Monitor, Diagnose and Identify Biomarkers for Psychotic Disorders - A stimulated or non-stimulated T-cell sample can be used to diagnose or monitor a psychotic disorder, to identify a biomarker, or as to test a considerate as a potential therapeutic agent.11-19-2009
20090286233Method for Diagnosing Diabetic Retinopathy by Single Nucleotide Polymorphism, DNA Fragment Thereof, and Primer Thereof - Disclosed is a method for diagnosing diabetic retinopathy by a single nucleotide polymorphism of VEGF and its receptor.11-19-2009
20090162844Identification and characterization of racemases, definition of protein signatures, and a test for detecting D-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase - This invention provides identification and characterization of racemases and definition of protein signatures of these racemases. This invention also provides identification of nucleic acid molecules encoding a peptide consisting of a motif characteristic of the protein signatures, and to the peptides consisting of these motifs. Antibodies specific for the peptides and to immune complexes of these antibodies with the peptides are also provided. Further, the invention relates to methods and kits for detecting racemases using the nucleic acid molecules of the invention, as well as the peptides consisting of the motifs and antibodies to these peptides.06-25-2009
20090087842Presynaptic protein cast - The present invention enabled the detection and quantification of CAST, which is localized to synapses and tightly bound to the cytomatrix, and of the mRNA encoding the CAST. Furthermore, it was revealed that CAST functions as a protein scaffold for localizing RIM1 to synapses, contributing as a molecular basis for active zone formation.04-02-2009
20090148838Methods for analysis of gene expression - This invention provides methods, compositions and kits for gene expression analysis and gene expression profiling. The methods of the invention are highly sensitive; have a wide dynamic range; are rapid and inexpensive; have a high throughput; and allow the simultaneous differential analysis of a defined set of genes. The methods, compositions and kits of the invention also provide tools for gene expression data collection and relational data analysis.06-11-2009
20090291432Genetic profiles associated with the 957C>T polymorphism in the DRD2 gene - The present invention relates to a method for profiling an individual or group of individuals with respect to a neurological, psychiatric or psychological condition, phenotype or state, including a sub-threshold neurological, psychiatric or psychological condition, phenotype or state. More particularly, the present invention identifies a genetic profile associated with the 957C>T polymorphysm within the dopamine receptor D2 (DRD2), indicating a predisposition to schizophrenia and other neurological diseases.11-26-2009
20080206777Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors - The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample.08-28-2008
20080206766Compositions and Methods for Detecting And Treating Prostate Disorders - The present invention relates to compositions and methods for the detecting, treating, and empirically investigating cellular proliferation disorders and cellular motility disorders. In particular, the present invention provides compositions and methods for using CXCL chemokines (e.g., CXCL1, CXCL5, CXCL6, CXCL12), CXCL receptors (e.g., CXCR1, CXCR2, CXCR4, CXCR7), and/or pathway related compounds (e.g., NF-kappaB, ERK ½, ELK-1) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy, prostatitis).08-28-2008
20080206772SAMPLE TREATMENT SOLUTION AND REAGENT KIT FOR PREPARING SAMPLE FOR DETECTING DNA METHYLATION - The present invention provides a sample treatment solution for preparing a sample for DNA methylation which can achieve stable detection results in detection of DNA methylation and be easily pretreated, comprising an aqueous solution containing a protease.08-28-2008
20080206765MN Gene and Protein - Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked by organic or inorganic molecules, preferably organic molecules, more preferably proteins/polypeptides that specifically bind to that site. Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Vectors are provided that encode the variable domains of MN-specific antibodies and a flexible linker polypeptide separating those domains. Further vectors are disclosed that encode a cytotoxic protein/polypeptide operatively linked to the MN gene promoter or a MN gene promoter fragment comprising the HIF-1 consensus binding sequence, and which vectors preferably further encode a cytokine. The MN gene promoter is characterized, and the binding site for a repressor of MN transcription is disclosed. Further, the hypoxia inducibility of the MN gene and the uses of such inducibility are disclosed.08-28-2008
20080206755Method for genetic detection using interspersed genetic elements - The way to design a “filled” site (which contains an interspersed element) primer set to target a particular locus is to design one of the two primers such that it encompasses that unique information (e.g., interspersed element+flanking genomic sequence+direct repeat). The way to design an “empty” site primer is to design one of the two primers such that the entire direct repeat sequence in addition to flanking genomic sequence is included on both sides. To improve efficiency, the “empty” site primer designed around the direct repeat should not be too long. This primer design of the present invention allows for the ability to test any type of interspersed genetic element containing characteristic direct repeat sequences (direct repeats). This gives the option of many new polymorphic marker sites because Alu elements are not the only interspersed genetic elements having direct repeats flanking their core sequence.08-28-2008
20080206761Ex Vivo Gene Expression in Whole Blood as a Model of Assessment of Individual Variation to Dietary Supplements - A method is disclosed for individually tailoring the administration of dietary components such as supplements. In the method, whole blood of a mammal is exposed to a dietary component. The level of a marker mRNA linked to a disease state is measured in leukocytes after exposure to the dietary component, and in some cases after further stimulation of the exposed blood cells. By comparing the mRNA level after exposure with the value found in unexposed blood cells, it is possible to determine what the effect of the dietary component will be in the mammal. By screening blood of the mammal against a number of possible dietary components, it is possible to develop an optimized set of dietary components tailored to the specific mammal to treat or prevent a disease state.08-28-2008
20080206763METHODS FOR ISOLATING AND CHARACTERIZING ENDOGENOUS mRNA-PROTEIN (mRNP) COMPLEXES - Cellular mRNA-protein (mRNP) complexes are partitioned in vivo by contacting a biological sample with at least one ligand that specifically binds at least one component of a mRNP complex. Suitable biological samples comprise at least one mRNA-protein (mRNP) complex and include cell cultures, cell extracts, and whole tissue, including tumor tissue. Ligands include antibodies that specifically bind RNA-binding or RNA-associated proteins present in the mRNP complex. The mRNP complex is separated by binding the ligand with a binding molecule specific for the ligand, where the binding molecule is attached to a solid support. The mRNP complex is collected by removing the mRNP complex from the solid support. After collecting the mRNP complex, the mRNA bound within the complex may be characterized and identified. Subsets of the total mRNA population of a cell may accordingly be characterized, and a gene expression profile of the cell obtained.08-28-2008
20080206769Molecular prognostic signature for predicting breast cancer distant metastasis, and uses thereof - The present invention is based on the discovery of a unique 14-gene molecular prognostic signature that is useful for predicting breast cancer metastasis. In particular, the present invention relates to methods and reagents for detecting and profiling the expression levels of these genes, and methods of using the expression level information in predicting risk of breast cancer metastasis.08-28-2008
20080206775Method of Amplifying Nucleic Acids, Reagent Kit for Amplifying Nucleic Acids, Method of Detecting Single Nucleotide Polymorphism, and Reagent Kit for Detecting Single Nucleotide Polymorphism - An object of the present invention is to provide a nucleic acid amplification method for amplifying a desired nucleic acid while suppressing amplification of byproducts in a PCR reaction, a reagent kit used for nucleic acid amplification, a method of detecting single nucleotide polymorphism to detect single nucleotide polymorphism by utilizing that amplification of byproducts is suppressed in a PCR reaction, and a reagent kit used for detecting single nucleotide polymorphism. The method of amplifying nucleic acids by PCR is characterized by admixing in a reaction solution, a homologous recombinant protein which contains at least one of a RecA protein derived from 08-28-2008
20080206767System and method for tracking and controlling infections - The present invention is a system and method for performing real-time infection control over a computer network. The method comprises obtaining a sample of a microorganism at a health care facility, sequencing a first region of a nucleic acid from the microorganism sample, comparing the first sequenced region with historical sequence data stored in a database, determining a measure of phylogenetic relatedness between the microorganism sample and historical samples stored in the database, and providing infection control information based on the phylogenetic relatedness determination to the health care facility, thereby allowing the health care facility to use the infection control information to control or prevent the spread of an infection.08-28-2008
20080206745Nucleic acid extraction solution and use thereof - Disclosed are methods and compositions for extracting nucleic acids from a biological sample. In particular, disclosed is a nucleic acid extraction solution together with methods using such a solution for extracting nucleic acid sequences from biological samples containing cells, cellular debris or both. The nucleic acid extraction solution contains a molecule having the formula R08-28-2008
20080206779Methods and Kits for Multiplex Hybridization Assays - The invention provides a method for genotyping interfering polymorphic loci in a target polynucleotide, such as a strand of genomic DNA, in a multiplex hybridization-based assay. The invention also provides nucleic acid standards for validating the performance of such hybridization-based assays. In one aspect, the method of the invention is carried out by providing for each interfering polymorphic locus one or more probes so that at least one probe is capable of forming a perfectly match duplex at the locus regardless of the characteristic sequence of an adjacent polymorphism.08-28-2008
20080206752Method For the Photochemical Attachment of Biomolecules to a Substrate - Methods and devices for attaching biomolecules to a solid substrate surface for example to the inner surface of a capillary. In particular, the invention relates to compounds and methods for creating patterned arrays of biomolecules inside fused silica capillaries so that a plurality of bioassays can be conducted simultaneously.08-28-2008
20080206760Method for detecting DNA methylation using labelled S-adenosylmethionine analogs - The invention relates to a method for detecting the methylation status in DNA samples. According to the invention, a DNA methyl transferase and a labeled S-adenosylmethionine derivative allow a detectable label to be covalently bonded to the DNA, in accordance with the respective methylation status of the DNA sample.08-28-2008
20080206744Functional Genomics and Gene Trapping in Haploid or Hypodiploid Cells - The present invention provides methods and compositions for performing functional genomics and gene trapping using haploid cells, including haploid or hypodiploid vertebrate cells. The present invention further provides methods for identifying genes involved in cellular signaling pathways.08-28-2008
20080206771Method For Recovering Nucleic Acid From A Mixed Cell Suspension, Without Centrifugation - A method for selectively recovering nucleic acid from a first cell type in a sample containing cells of at least a first cell type and a second cell type, and a cell suspension medium comprising extracellular impurities, is provided. The method entails combining the sample with particles responsive to a magnetic field in a vessel, the magnetic particles having the ability to sequester the cells from the cell suspension medium upon application of a magnetic field; exposing the vessel to a magnetic field for a time sufficient to cause sequestration of the cells by the particles; removing the impurities-containing cell suspension medium from the vessel while retaining the cells; lysing selectively cells of the first cell type; and isolating the nucleic acid from the lysed cells. Methods for recovering nucleic acid from the second cell type are also provided.08-28-2008
20080206758POLYNUCLEIC ACID-ATTACHED PARTICLES AND THEIR USE IN GENOMIC ANALYSIS - Disclosed are methods for preparing particle-linked polynucleotides, and using the particle linked polynucleotides in genomic analysis. The particles as disclosed are characterized as having a size variance of less than 2%.08-28-2008
20100099107METHOD FOR IDENTIFYING AN INTESTINAL PHENOTYPE - The present invention relates to a method for identifying cells having a predisposition to develop an intestinal phenotype, wherein the cells are characterized by the loss of expression of the RUNX3 gene and the expression of one or more intestinal marker genes. In particular, the invention is directed to the identification of cells, which exhibit an intestinal phenotype representing a precursor of gastric cancer. Furthermore, the invention discloses a method for identifying a compound inhibiting the development of an intestinal phenotype in cells having a predisposition to develop an intestinal phenotype. Finally, the invention also relates to kits of parts for performing these methods.04-22-2010
20090148842Preparation of templates for methylation analysis - The invention relates to a method of preparing and using a library of template polynucleotides suitable for use as templates in solid-phase nucleic acid amplification and sequencing reactions to determine the methylation status of the cytosine bases in the library. In particular, the invention relates to a method of preparing and analysing a library of template polynucleotides suitable for methylation analysis.06-11-2009
20090275033Uses of BNIPXL-Beta in premature canities - The present invention concerns the use of a polypeptide comprising a sequence having at least 90% identity with all or part of BNIPXLβ, for cosmetic or therapeutic applications, in the treatment or prevention of premature canities in humans, said portion comprising at least 30 amino acids, as well as the use, for the same purpose, of a molecule comprising a RNAi sequence having at least 90% identity with all or part of the cDNA sequence of BNIPXLβ, said part comprising at least 18 nucleotides.11-05-2009
20090275045METHOD FOR DETECTING MAMMARY CANCER CELLS - The present invention provides a novel method for detecting mammary cancer cells which uses, as an index, an expression level of a specific gene in human mammary cancer tissue (or cells). The method is characterized by including (1) measuring an expression level of a gene having a specific nucleotide sequence in human mammary cancer tissue (or cells), (2) measuring an expression level of the gene in human normal mammary gland tissue (or cells), and (3) detecting mammary cancer cells on the basis of the difference between measurement values obtained in (1) and (2).11-05-2009
20100273170METHOD AND DEVICE FOR PREPARING BIOLOGICAL SAMPLES FOR ANALYSIS - The invention relates to a method for preparing biological samples for analysis, comprising the following steps: (a) the biological sample is placed on a two-dimensional support; (b) application of a protein-precipitating or denaturing first solution L10-28-2010
20090104621METHOD FOR DETECTING A TARGET NUCLEIC ACID SEQUENCE - A method of detecting a target nucleic acid sequence comprising providing a stem-and-loop structured nucleic acid for measurement wherein the nucleic acid comprises complementary sequence portions located at both terminals and a target sequence portion therebetween as well as a double-stranded portion formed by hybridization of the complementary sequence portions located at both terminals and a remaining looped single-stranded portion, providing a probe nucleic acid having a sequence complementary to the target sequence portion wherein one end of the probe nucleic acid being immobilized to a solid substrate surface, reacting the nucleic acid for measurement with the probe nucleic acid to specifically hybridize the target sequence portion of the nucleic acid for measurement to the probe nucleic acid, and detecting presence or absence of the nucleic acid for measurement hybridized to the probe nucleic acid.04-23-2009
20100273151GENOME-WIDE ANALYSIS OF PALINDROME FORMATION AND DNA METHYLATION - The present disclosure provides methods for detecting the genome-wide presence of methylated DNA and palindrome formation. The present disclosure also provides methods for specific enrichment of methylated DNA or DNA having a DNA palindrome. These methods have demonstrated that somatic palindromes and methylated DNA occur frequently and are widespread in human cancers. Individual tumor types have a characteristic non-random distribution of palindromes in their genome and a small subset of the palindromic loci are associate with gene amplification. The disclosed method can be used to define the plurality of genomic DNA palindromes and regions having methylated DNA associated with various tumor types and can provide methods for the classification of tumors, and the diagnosis, early detection of cancer as well as the monitoring of disease recurrence and assessment of residual disease.10-28-2010
20090104618Psoriasin Expression By Breast Epithelial Cells - The invention features methods of diagnosing high grade ductal carcinoma in situ (DCIS) These methods involve measuring: (1) the level of HID-5 in a body fluid (e.g., blood or urine) of a subject suspected of having, or at risk of having, high grade DCIS; or (2) the level of HID-5 gene expression in breast tissue from a subject suspected of having, or at risk of having, high grade DCIS. The invention also embodies a method of inhibiting expression of HID-5 protein in DCIS cells and methods of treating a subject suspected of having, or at risk of having, high grade DCIS.04-23-2009
20090104616PRIMER SET FOR AMPLIFYING SULT1A1 GENE, REAGENT FOR AMPLIFYING SULT1A1 GENE CONTAINING THE SAME, AND THE USES THEREOF - A primer set for amplifying a region including sites to be detected of SULT1A1*2 and SULT1A1*3 in the SULT1A1 gene by a gene amplification method is provided, wherein the primer set can amplify the region specifically. A pair of primer set is used including a forward primer consisting of the base sequence of SEQ ID NO: 7 as well as a reverse primer consisting of the base sequence of SEQ ID NO: 18. The use of this primer set makes it possible to specifically and efficiently amplify, a region including both sites where two types of polymorphisms (SULT1A1*2 and SULT1A1*3) of the SULT1A1 gene are generated.04-23-2009
20090104614QUANTITATIVE MOLECULAR PROBES - In accordance with this invention, a molecular probe for detection of a nucleic acid target containing a preselected target sequence is constructed and has at least two sources of a signal: a conventional reporter source and a reference source in a form of a luminescent material, e.g., a fluorophore, quantum dot, fluorescent nanoparticle, or other fluorescent reference dye/nanoparticle/microparticle conjugated to the molecular probe.04-23-2009
20090104613METHODS AND COMPOSITIONS RELATING TO MULTIPLEXED GENOMIC GAIN AND LOSS ASSAYS - Compositions and methods are provided for detecting genomic DNA gain and loss. Embodiments of inventive assays include using a substrate-attached composite nucleic acid probe which specifically hybridizes to two or more genomic loci in a genomic region of a reference genome. The genomic region is characterized by a first terminus and a second terminus and has an intermediate region disposed between the first terminus and second terminus of at least 400 kilobases. The composite nucleic acid probe includes nucleic acid sequences which specifically hybridize to substantially an entire first genomic locus including the first terminus and to substantially an entire second genomic locus including the second terminus. Methods and compositions are provided which include assessment of two or more genomic DNA references.04-23-2009
20090104617Diagnostic and Prognostic Tests - The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from tissue samples, such as cancer tissue samples. The invention also provides sets of genes that are expressed differentially in malignant pleural mesothelioma. These sets of genes can be used to discriminate between normal and malignant tissues, and between classes of malignant tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression also are provided.04-23-2009
20090104608EUBACTERIAL tmRNA SEQUENCES AND USES THEREOF - The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays.04-23-2009
20090104609METHOD FOR DISCRIMINATION OF METAPLASIAS FROM NEOPLASTIC OR PRENEOPLASTIC LESIONS - The present invention relates to a method for discrimination of p1604-23-2009
20090104604SPERM-SPECIFIC CATION CHANNEL, CATSPER2, AND USES THEREFOR - Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (CatSper2) are disclosed. The CatSper2 protein is shown to be specifically expressed in sperm. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the CatSper2 gene and protein are disclosed. Also provided are methods of in vitro fertilization and contraception, methods of identifying modulators of CatSper2 activity, methods of genotyping subjects with respect to CatSper2, methods of diagnosing and treating CatSper2-mediated disorders, including infertility, as well as methods of doing business related to CatSper2-mediated disorders.04-23-2009
20090275044METHOD FOR DETECTING HUMAN PAPILLOMAVIRUS mRNA - An in vitro method is provided for screening human female subjects to assess their risk of developing cervical carcinoma which comprises screening the subject for expression of mRNA transcripts from the E6 and optionally the L1 gene of human papillomavirus, wherein subjects positive for expression of L1 and/or E6 mRNA are scored as being at risk of developing cervical carcinoma. Kits for carrying out such methods are also provided.11-05-2009
20090275040DETECTING BCL-B EXPRESSION IN CANCER AND USES THEREOF - Provided herein are compositions and methods of detecting Bcl-B expression in cancer cells to prognose, monitor, or select therapies for cancers such as breast cancer, prostate cancer, lung cancer, or gastric cancer.11-05-2009
20090275037FLUORESCENT DOUBLE STRANDED DNA BINDING DYES - The present invention is directed to a fluorescent dye comprising a benzothiazolium moiety and a pyrimidinium moiety connected by a mono-methine bridge, characterized in that (i) the 2-position of the pyrimidine carries a substituent which starts with a C-atom and (ii) the 5- and 6-positions of the pyrimidine ring are an integral part of a further aromatic ring structure.11-05-2009
20090275036SYSTEMS AND METHODS FOR REAL TIME SINGLE MOLECULE SEQUENCE DETERMINATION - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system.11-05-2009
20090275024Novel centrerosome-associated protein and applications thereof - A method for diagnosing a genetic disease associated with disturbances in mitotic spindle organization or with cell division anomalies or both, which comprises demonstrating a functional alteration of the gene encoding an ASAP protein comprising at least the following steps of: obtaining DNA containing the gene encoding the ASAP protein from a biological sample; bringing said DNA into contact with a probe, and under conditions for hybridization between the DNA and the probe; and detecting the hybrid formed; and wherein the ASAP protein is selected from the group consisting of a human protein having sequence SEQ ID NO:1 and proteins having a sequence exhibiting at least 80% identity or at least 90% similarity with entire SEQ ID NO. 1.11-05-2009
20090104607EUBACTERIAL tmRNA SEQUENCES AND USES THEREOF - The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays.04-23-2009
20090104606LATE GESTATION LUNG GENES, FRAGMENTS AND USES THEREOF - The present invention provides a family of genes related to late gestation lung genes and fragments thereof. Embodiments of the present invention provide compositions and methods for the therapeutic treatment of disorders in the lung or other tissues. More particularly the invention provides methods for the treatment of abnormalities in alveolarization, and abnormalities in branching morphogenesis. In other embodiments of the invention the use of the LGL1 gene or related products or fragments thereof in research and diagnostics is provided.04-23-2009
20090104605DIAGNOSIS OF SEPSIS - Methods and apparatus for predicting the development of sepsis in a subject at risk for developing sepsis are provided. Features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods and apparatus for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. A plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods and apparatus for diagnosing sepsis in a subject are provided. A plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.04-23-2009
20090275027Medium scale intergration of molecular logic gates in an automaton - Compositions and methods for optically detecting the presence of a plurality of oligonucleotides in a sample, wherein each oligonucleotide to be detected comprises consecutive nucleotides having a sequence different than the remaining oligonucleotides of the plurality are provided.11-05-2009
20090275019Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.11-05-2009
20090104599GENETIC VARIANT OF THE ANNEXIN A5 GENE - The present invention relates to a nucleic acid molecule comprising an annexin A5 (ANXA5) gene regulation element which comprises at least one point mutation, whereby said at least one point mutation (substitution) is selected from the group consisting of (i) a point mutation G to A at a position which corresponds to nucleotide 186 of SEQ ID NO: 2; (ii) a point mutation A to C at a position which corresponds to nucleotide 203 of SEQ ID NO: 2; (iii) a point mutation T to C at a position which corresponds to nucleotide 229 of SEQ ID NO: 2; and (iv) a point mutation G to A at a position which corresponds to nucleotide 276 of SEQ ID NO: 2. Furthermore, the present invention provides for a vector comprising the nucleic acid molecule the invention and a host transformed with the vector. The invention also relates to specific uses, in particular diagnostic uses of the nucleic acid molecules described herein. Moreover, the invention relates to a method for haplotyping an ANXA5 gene regulation element in an individual comprising the steps of: (a) isolating a nucleic acid from a sample that has been removed from the individual; (b) determining the presence of the nucleotides present at positions 186, 203, 229 and 276 of the individual's copy of the ANXA5 gene regulation element, wherein the position numbers are determined by comparison to SEQ ID NO: 2; (c) assigning the individuals a particular haplotype by comparison of the nucleotides present at said positions to the nucleotides recited in the haplotypes as defined herein.04-23-2009
20090104598Dopamine D2 receptor gene variants - The present invention provides a method of predicting antipsychotic response to drug therapy comprising testing a sample obtained from a subject for the presence of a polymorphism in the dopamine D2 receptor gene DRD2, wherein the presence of the rs1079598T allele, the rs1125394A allele or both is predictive of the subject being susceptible to drug therapy.04-23-2009
20090104603Tissue Carbohydrate Compositions and Analysis Thereof - The present invention reveals novel methods for producing novel carbohydrate compositions, glycomes, from animal tissues. The tissue substrate materials can be total tissue samples and fractionated tissue parts, or artificial models of tissues such as cultivated cell lines. The invention is further directed to the compositions and compositions produced by the methods according to the invention. The invention further represent methods for analysis of the glycomes, especially mass spectrometric methods.04-23-2009
20090275031Biomolecular nano device - Methods for measuring environmental parameters using chemical recording are provided. In some embodiments, the methods include generating a polymer comprising an ordered series of chemical units, wherein the position and number of each chemical unit in the polymer is indicative of a reading of the environmental state variable at a given point in time. The presently disclosed subject matter also provides compositions that can be employed in and/or that employ the disclosed methods for recording environmental state variables.11-05-2009
20090298081METHODS OF TREATMENT UTILIZING BINDING PROTEINS OF THE INTERLEUKIN-21 RECEPTOR - The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.12-03-2009
20090280487METHODS FOR PRODUCING OLFACTORY GPCRS - The subject invention provides a method for producing an olfactory GPCR in a cell. In general, the methods involve introducing an expression cassette containing a promoter operably linked to a nucleic acid encoding an olfactory PCR into a macroglial cell, e.g., a Schwann or oligodendritic cell, and maintaining the cell under conditions suitable for production of the olfactory GPCR. Also provided is a macroglial cell containing a recombinant nucleic acid encoding an olfactory GPCR, methods of screening for modulators of olfactory GPCR activity, and a kit for producing an olfactory GPCR in a macroglial cell. The invention finds most use in research on flavors and fragrances, and, consequently, has a variety of research and industrial applications.11-12-2009
20090280488Prophylactic/therapeutic agent for neurodegenerative disease - To provide a prophylactic/therapeutic agent for neurodegenerative diseases (such as polyglutamine diseases), the agent containing an HMGB family protein or a derivative thereof, such as a protein according any one of (a) and (b) below: 11-12-2009
20090280497Multiplex Detection Compositions, Methods, and Kits - The present invention generally relates to the detection of analytes, particularly biomolecules in samples. The invention also relates to compositions, methods, and kits for detecting the presence of analytes, typically in multiplex detection formats. The invention also relates to methods for determining the presence of at least one analyte in a sample, the methods employing employ single molecule detection techniques to individually detect at least one molecular complex or at least part of a molecular complex.11-12-2009
20090280490Expression Profile Algorithm and Test for Cancer Prognosis - The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.11-12-2009
20090280480Devices from Prion-Like Proteins - The present invention provides novel polypeptides comprising a prion-aggregation domain and a second domain; novel polynucleotides encoding such polypeptides; host cells transformed or transfected with such polynucleotides; novel fibrils with specific functionalities and unusually high chemical and thermal stability; and methods of making and using the foregoing in, for example, the production of nanoscale devices.11-12-2009
20090280481Enhanced Sequencing by Hybridization Using Pools of Probes - The invention provides methods for sequencing by hybridization (SBH) using pools of probes that allow greater efficiency in conducting SBH by reducing the number of separate measurements of hybridization signals required to identify each particular nucleotide in a target nucleic acid sequence. The invention also provides pools and sets of pools of probes, as well as methods of generating pools of probes.11-12-2009
20090280477Turn Over Probes and Use Thereof for Nucleic Acid Detection - The invention provides turnover probes for use in a variety of detection assays, for example, nucleic acid detection assays. In addition, the invention provides assays, for example, nucleic acid detection assays, using such turnover probes.11-12-2009
20090280475Droplet-based pyrosequencing - The present invention relates to a droplet microactuator and to systems, apparatuses and methods employing the droplet microactuator for executing various protocols using droplets. The invention includes a droplet microactuator or droplet microactuator system having one or more input reservoirs loaded with reagents for conducting sequencing protocols, such as the reagents for conducting a pyrosequencing protocol. The invention also includes a droplet microactuator or droplet microactuator system, having one or more input reservoirs loaded with a sample for conducting a pyrosequencing protocol.11-12-2009
20090286255METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS - Methods are provided for accurately predicting efficacy of chemotherapeutic agents. Methods of the invention increase the positive predictive value of chemosensitivity assays by assessing both the ability of a chemotherapeutic to destroy cells and the genetic propensity of those cells for resistance. Results obtained using methods of the invention provide insight into the in vivo effectiveness of a therapeutic, and lead to more effective chemotherapeutic treatment.11-19-2009
20090286252NRIF3, NOVEL CO-ACTIVATOR FOR NUCLEAR HORMONE RECEPTORS - Nucleic acids encoding NRIF3 are described. Polypeptides having amino acid sequences of NRIF3 proteins are also provided. A method is also provided for isolating and cloning NRIF3 cDNA. NRIF3 is useful in development/implementation of high throughput screens to identify novel thyroid hormone receptor (TR) and retinoid X receptor (RXR) agonists and antagonists. Methods are also provided for identifying compounds that directly interfere with the interaction of NRIF3 and TR or RXR. Finally, therapies based on modulation of NRIF3 activity are disclosed.11-19-2009
20090286250INCORPORATING SOLUBLE SECURITY MARKERS INTO CYANOACRYLATE SOLUTIONS - Methods for authenticating an article with a cyanoacrylate solution comprising a water soluble security marker compound are described. The methods for producing a nucleophilic security marker/cyanoacrylate solution as well as methods for labeling an item and detecting the nucleophilic security marker/cyanoacrylate from an item being authenticated are also described. A method for using a nucleophilic cyanoacrylate security marker for antitheft purposes is also described.11-19-2009
20090286248Methods for Determining Drug Responsiveness - The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the mRNA levels of a gene that responds to the drug, such as a steroid, to the MRNA levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid.11-19-2009
20090286240BIOMARKERS OVEREXPRESSED IN PROSTATE CANCER - Biomarkers are identified by analyzing gene expression data using support vector machines (SVM) to rank genes according to their ability to separate prostate cancer from normal tissue. Proteins expressed by identified genes are detected in patient samples to screen, predict and monitor prostate cancer.11-19-2009
20090286244Fluorescent Color Markers - The invention provides a yeast-enhanced red fluorescent protein. In an embodiment of the invention, the yeast-enhanced red fluorescent protein is monomeric and is expressible in 11-19-2009
20090286245TWO SLOW-STEP POLYMERASE ENZYME SYSTEMS AND METHODS - Compositions, kits, methods and systems for nucleotide sequencing comprising producing polymerase reactions that exhibit two kinetically observable steps within an observable phase of the polymerase reaction. Two slow step systems can be produced, for example, by selecting the appropriate polymerase enzyme, polymerase reaction conditions including cofactors, and polymerase reaction substrates including the primed template and nucleotides.11-19-2009
20090286243Compositions and methods for spinocerebellar ataxia - Mutations in the KCNC3 (Kv3.3) voltage-gated potassium channel gene result in spinocerebellar ataxia.11-19-2009
20090286241SYSTEM AND METHOD FOR DETECTING A GENE MUTATION - A system for detecting a gene mutation encompasses a spectrum generation mechanism configured to acquire an amplified product containing the specific site sandwiched by recognition sites of a restriction enzyme by using a recognition site introduction-oriented primer, and to generate a mass spectrum of an oligonucleotide fragment, which is cut out from the amplified product by using the restriction enzyme; an area ratio calculation mechanism configured to calculate an area ratio of a peak of a wild-type sequence of the specific site and a peak of a mutation-type sequence of the specific site in the mass spectrum; and an abundance ratio calculation mechanism configured to obtain an abundance ratio of the wild-type sequence and the mutation-type sequence based on a relationship between a previously acquired area ratio and the abundance ratio of the wild-type sequence and the mutation-type sequence.11-19-2009
20090286237Diagnostic Kits and Methods for Oesophageal Abnormalities - The invention relates to kits and methods for aiding the diagnosis of Barrett's oesophagus or Barrett's associated dysplasia. Preferred is a method comprising assaying cells from the surface of a subject's oesophagus for a non-squamous cellular marker, wherein detection of such a marker indicates increased likelihood of the presence of Barrett's or Barrett's associated dysplasia, preferably wherein said sample of cells is not directed to a particular site within the oesophagus. The invention also encompasses a method comprising sampling the cellular surface of the oesophagus of said subject. The invention also relates to a kit comprising a swallowable device comprising abrasive material capable of collecting cells from the surface of the oesophagus, together with printed instructions for its use in detection of Barrett's oesophagus or Barrett's associated dysplasia. Preferably said device comprises a capsule sponge.11-19-2009
20100279284METHOD FOR SELECTING HOP LINE AND BREEDING MARKER AND PRIMER SET USED FOR SELECTING HOP LINE - It is an object of the invention to screen for hop varieties with low cohumulone ratio and low colupulone ratio, as well as hop varieties with high contents of farnesene and/or linalool within a short time period utilizing a molecular screening method that employs a breeding marker. The invention provides a breeding marker using a polymorphism at the position of the 623rd nucleotide or a polymorphism at the position of the 1820th nucleotide of a polynucleotide consisting of the nucleotide sequence as set forth in SEQ ID NO: 5.11-04-2010
20100279280FUNCTIONAL POLYMORPHISMS OF THE INTERLEUKIN-1 LOCUS AFFECTING TRANSCRIPTION AND SUSCEPTIBILITY TO INFLAMMATORY AND INFECTIOUS DISEASES - The invention provides methods and reagents for detecting a polymorphism associated with in an upstream region of the interleukin-1 beta (IL-B) gene (IL-1B (−3737)) that affects transcription of the gene and susceptibility to inflammatory and infectious diseases such as periodontal disease and Alzheimer's disease.11-04-2010
20090291447Method of detecting colon cancer marker - It is intended to provide a non-invasive and convenient method of detecting a tumor marker for diagnosing colon cancer which is superior in sensitivity and specificity to the existing fecal occult blood test. More specifically speaking, a method of detecting a tumor marker for diagnosing colon cancer which comprises collecting biological sample which is immediately frozen using liquid nitrogen in some cases, homogenizing the sample in the presence of an inhibitor of an RNA digesting enzyme to give a suspension, extracting RNA from the obtained suspension, subjecting the extracted RNA to reverse transcription to give cDNA, amplifying the obtained cDNA and then detecting the thus amplified cDNA. This method is characterized by involving no procedure of separating cell components from the biological sample.11-26-2009
20090291443USE OF HIGHLY PARALLEL SNP GENOTYPING FOR FETAL DIAGNOSIS - The present invention provides apparatus and methods for enriching components or cells from a sample and conducting genetic analysis, such as SNP genotyping to provide diagnostic results for fetal disorders or conditions.11-26-2009
20090291446METHOD FOR CONFIRMING THE PRESENCE OF AN ANALYTE - The invention provides methods and kits for the rapid confirmation of an initial analyte test result. In a preferred embodiment, the process confirms the presence of a given microbial target in a mixed culture, or a mixed enrichment media, even when the competing organisms in the mix belong to related species, or are various biotypes of the same species.11-26-2009
20090291442HSPA1A AS A MARKER FOR SENSITIVITY TO KSP INHIBITORS - The present invention relates to methods for predicting a response to treatment with a kinesin spindle protein inhibitor using heat shock protein 70, isoform A1a, also known as HSPA1a, as a marker for sensitivity to the kinesin spindle protein (KSP) inhibitors. Method are provided for predicting a response to treatment with a kinesin spindle protein inhibitor of a first mammal in need thereof comprising determining an amount of HSPA1a mRNA transcript produced by said first mammal, wherein the amount of said HSPA1a mRNA transcript produced by said first mammal is indicative of said mammal's sensitivity to said kinesin spindle protein inhibitor11-26-2009
20090291439PHOSPHATASES INVOLVED IN THE REGULATION OF CARDIOMYOCYTE DIFFERENTIATION - An object of the invention is to provide a dephosphorylation enzyme that regulates cardiomyocyte differentiation, dominant negative enzyme thereof, a gene encoding the enzyme protein and use thereof. A protein or the like consisting of any one of the following amino acid sequences (A) to (C) is used:11-26-2009
20090291438Methods for Analysis of Extracelluar RNA Species - The invention provides methods and kits for enabling quantitative or qualitative analysis of extracellular RNA species in non-cellular bodily fluids including plasma and serum to detect, infer, evaluate, or monitor cancer and other neoplasia or other diseases of interest.11-26-2009
20090291434Gene expression markers for colorectal cancer prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.11-26-2009
20090291436METHODS FOR DETECTING NUCLEIC ACIDS INDICATIVE OF CANCER - The invention provides methods for screening tissue or body fluid samples for nucleic acid indicia of cancer or precancer.11-26-2009
20090291435THERMAL REACTION DEVICE AND METHOD FOR USING THE SAME - Devices and methods for performing the relative concentration of a target in a sample, the sample containing both target and non-target components, the method performed by partitioning the sample into a large number of reaction volumes such that the target is concentrated relative to the non-target, and performing a detection assay upon each reaction volume to detect the target.11-26-2009
20090291437METHODS FOR TARGETING QUADRUPLEX SEQUENCES - Provided are quadruplex nucleotide sequences and methods for identifying interacting molecules.11-26-2009
20090191555HCV NS3-NS4 Protease Resistance Mutants - The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.07-30-2009
20100221728METHOD FOR QUANTIFYING INITIAL CONCENTRATION OF NUCLEIC ACID FROM REAL-TIME NUCLEIC ACID AMPLIFICATION DATA - Provided is a method for quantifying an initial concentration of a nucleic acid from a real-time nucleic acid amplification data. Nucleic acid (DNA or RNA) extracted from organism or virus is amplified using an enzyme. Then, the initial concentration of the nucleic acid is found by calculating the characteristic amplification cycle number or the characteristic amplification time at which the fluorescence intensity of the nucleic acid subtracted by the background fluorescence intensity of the nucleic acid has half of its maximum value, or the characteristic amplification cycle number or the characteristic amplification time at which the amplification efficiency has the maximum or the minimum value, or the prior-to-amplification fluorescence intensity of the nucleic acid subtracted by the background fluorescence intensity of the nucleic acid. Accordingly, the initial concentration of the nucleic acid can be calculated without differentiation or integration.09-02-2010
20090142768PERFORIN-2 PROTEINS - Perforin-2 (P2) molecule is a pore forming protein. The 5′ untranslated region of the perforin-2 protein controls translational activity. Compositions include the perforin protein and the 5′ untranslated region. Methods of use include high-throughput screening assays for identification of therapeutic compounds in treatment of diseases.06-04-2009
20090042202PROSTATE-SPECIFIC POLYPEPTIDE PAMP AND ENCODING NUCLEIC ACID MOLECULES - The present invention relates to novel prostate specific nucleic acid molecules and polypeptides and related methods for diagnosing or predicting susceptibility to a prostate neoplastic condition.02-12-2009
20090042191SYSTEM AND METHOD FOR SECURE DOCUMENT PRINTING AND DETECTION - A method for authenticating and verifying an item to be genuine is described. The method for authenticating the item comprises applying a particular nucleic acid material associated with a particular sequence of nucleic acid bases to ink within an ink cartridge or a toner compound within a toner housing. The method also comprises collecting a sample of either the ink or toner compound and verifying the ink or toner is genuine by detecting the particular nucleic acid material.02-12-2009
20090186358Pathway Analysis of Cell Culture Phenotypes and Uses Thereof - The present invention provides methods for systematically identifying genes, proteins and/or related pathways that regulate or indicative of cell phenotypes. The present invention further provides methods for manipulating the identified genes, proteins and/or pathways to engineer improved cell lines and/or to evaluate or select cell lines with desirable phenotypes.07-23-2009
20090258367METHOD OF MAPPING OF mRNA DISTRIBUTION WITH ATOMIC FORCE MICROSCOPY - The present invention relates to a method of mapping of mRNA distribution, comprising the steps of a preparing a probe DNA attached to a apical liner region of the dendron on AFM cantilever where the probe DNA can specifically hybridize a target mRNA and measuring specific adhesive force between the probe DNA and the target mRNA on sectioned tissue at nanometer resolution.10-15-2009
20090263813RIBONUCLEOTIDE TAG NUCLEIC ACID DETECTION - The present application provides polynucleotides comprising 5′-tails with sequence segments useful for the detection of target nucleic acid sequences, and methods for their use in detecting target nucleic acids. The polynucleotides are used to amplify a subsequence of a target nucleic acid in the presence of one or more ribonucleotides. The ribonucleotides are incorporated into amplification products at regular intervals complementary to the 5′-tail sequence segments. Cleavage of amplification products at the bond immediately 3′ to incorporated ribonucleotides produces detectably distinct fragments indicative of the presence or absence of a target nucleic acid.10-22-2009
20100279298Methods and Compositions For Detecting Autoimmune Disorders - The invention provides methods and compositions useful for detecting autoimmune disorders.11-04-2010
20100279299Devices and Methods for Heating Biological Samples - This invention provides a systems and methods for regulating temperature and heat transfer in applications in which it is desirable to maintain temperature uniformity such as thermal cycling applications. A heat block is used to rapidly transfer heat to or from a set of one or more reaction vessels.11-04-2010
20100279297Method for Identifying an Increased Susceptibility to Ulcerative Colitis - A method is provided for detecting an increased susceptibility to ulcerative colitis by determining the presence of a polymorphism at position 256 of the nucleotide sequence of rs3024505 in which C is substituted by T or the presence of a polymorphism at position 501 of the nucleotide sequence of rs12612347 in which G is substituted by A.11-04-2010
20100279287COMPOSITIONS AND METHODS USEFUL FOR SITE-DIRECTED RECOMBINATION IN PLANTS - This invention relates generally to useful compositions and methods related to plant site-directed recombination. In particular, the invention relates to novel nucleic acid sequences unique to a portion of the sorghum NBS-LRR region, as well as vectors, seeds, plant parts and plants comprising these sequences. Methods to investigate recombination co-factors, and methods to investigate potential herbicides are within the scope. This invention also relates to fungal pathogens of sorghum, particularly 11-04-2010
20100279291GENE SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS) - The present invention provides methods and compositions useful for inhibiting expression of the gene encoding the transcription factor, Brother of the Regulatory of Imprinted Sites (BORIS) by RNA interference. Methods of the present invention can be used to silence BORIS in cancer cells, which results in apoptosis and may be useful as for treating cancer in mammals. The methods of the invention directed to cancer therapy can be used alone or in combination with standard cancer treatments such as surgery, radiation, chemotherapy, and immunotherapy.11-04-2010
20100279289SIZE-DEPENDENT BIOLOGICAL EFFECT OF NANOPARTICLES - Nanoparticles are used increasingly in consumer products and biomedical applications. Yet the cellular interaction mechanism at the molecular level is not well understood for nanomaterials of different size, shape and surface chemistry. Gold nanoparticles (Au-NPs), which have been explored extensively for various applications in recent years, are used as the model system to help understand the size-dependent biological effects of nanoparticles. Jurkat cells treated with Au-NPs ranging from 2 nm to 200 nm were studied. Whole genome expression measurements indicate size-dependent effects, including linear scaling and threshold effects. In addition, a non-linear pattern of gene responses that persisted over time were observed in 20-40 nm Au-NP treated cells. Gene function, promoter, and pathway analyses reveal differential signaling processes that are correlated with nanoparticle sizes. The size may play a role in cellular sorting of naturally occurring particulates, particle interaction with the receptors, intracellular transportation, signaling and stress responses.11-04-2010
20100279295USE OF THERMOSTABLE ENDONUCLEASES FOR GENERATING REPORTER MOLECULES - Provided are compositions and methods for amplifying, capturing and/or detecting target nucleic acids using cleavable oligonucleotides.11-04-2010
20100279278Methods of detecting one or more bioterrorism target agents - The present invention provides a methods and compositions for early diagnosis of exposure to or infection by a chemical or biological weapon by rapid and specific detection of one or more bioterrorism target agents in a sample.11-04-2010
20100279281METHOD OF IDENTIFYING LUNG CANCERS ASSOCIATED WITH ASBESTOS-EXPOSURE - The present invention is related to a method for assessing the presence of, or disposition to, an asbestos-related disorder in a subject. Particularly, the invention provides a method of identifying lung cancers associated with asbestos-exposure. The association is confirmed by the detection of allelic imbalance (AI) in at least one of the following chromosomal regions of lung cancer cells: 19p13.3-p13.1; 9q32-34.3; 2p21-p16.3; 16p13.3; 22q12.3-q13.1; and 5q35.3.11-04-2010
20100279285GENETIC MARKERS OF MENTAL ILLNESS - This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof.11-04-2010
20100279279Compositions and methods for analysis of target analytes - Compositions and methods are provided for analyzing a sample for the presence or absence of one or more target analytes. Microparticles bound to an analyte of interest are incubated in a solution containing a primary antibody directed towards the analyte. In direct assays of this invention, the microparticle-bound analyte competes with a labeled primary antibody do displace analyte from the primary antibody. Primary antibodies can be labeled with florescence or other labels detectable using a flow cytometer. The microparticle-bound analyte-primary antibody complex can be detected and quantified using a flow cytometer. In other, indirect assays, an unlabeled primary antibody can be used, and a labeled secondary antibody can react with a microparticle-bound analyte-primary antibody complex to form a labeled microparticle-bound analyte-primary antibody complex. The labeled microparticle-boudn alalyte-primary antibody complex can be detected using a flow cytometer. Using direct or indirect assays of this invention, peptides, proteins, nucleic acids or other analytes of interest can be detected and quantified.11-04-2010
20080299570PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof.12-04-2008
20090148851Methods, kits, and compositions for detecting enzyme activity - The inventive subject matter relates to methods, kits, and compositions for detecting enzyme activity in a biological sample. In particular, the inventive subject matter relates to methods, kits, and compositions for detecting von Willebrand factor degrading enzyme activity in a biological sample.06-11-2009
20100112593Method of Predicting the Clinical Response to Chemotherapeutic Treatment with Alkylating Agents - The present invention provides methods relating to chemotherapeutic treatment of a cell proliferative disorder. In particular, a method is provided for predicting the clinical response to certain types of chemotherapeutic agents. Alkylating agents, used for the treatment of certain types of tumors including tumors of the nervous system and lymph system, are efficacious agents when the damage they do to tumor cell DNA is not repaired by cellular DNA repair mechanisms. The present invention provides a method for determining the activity of a gene encoding a DNA repair enzyme, thus providing a prediction of the clinical response to alkylating agents.05-06-2010
20100112590Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing With Enrichment - Embodiments of this invention provide methods, systems, and apparatus for determining whether a fetal chromosomal aneuploidy exists from a biological sample obtained from a pregnant female. Nucleic acid molecules of the biological sample are sequenced, such that a fraction of the genome is sequenced. Respective amounts of a clinically-relevant chromosome and of background chromosomes are determined from results of the sequencing. The determination of the relative amounts may count sequences of only certain length. A parameter derived from these amounts (e.g. a ratio) is compared to one or more cutoff values, thereby determining a classification of whether a fetal chromosomal aneuploidy exists. Prior to sequencing, the biological sample may be enriched for DNA fragments of a particular sizes.05-06-2010
20100112559PRIMER SET FOR AMPLIFYING OBESITY GENE, REAGENT FOR AMPLIFYING OBESITY GENE CONTAINING THE SAME, AND THE USES THEREOF - Primer sets for amplifying target regions containing sites to be detected in the obesity gene (the β2AR gene, the β3AR gene, and the UCP1 gene) by a gene amplification method are provided, wherein the primer sets can amplify the regions specifically. Three pairs of primer sets are used including forward primers composed of the base sequences of SEQ ID NO: 9 or SEQ ID NO: 109, SEQ ID NO: 25, and SEQ ID NO:43 as well as reverse primers composed of the base sequences of SEQ ID NO: 18, SEQ ID NO: 30, and SEQ ID NO: 63, respectively. The use of these primer sets makes it possible to specifically amplify a target region including a site where a polymorphism to be detected is generated in the β2AR gene, the β3AR gene, and the UCP1 gene, in the same reaction solution at the same time.05-06-2010
20080213780MULTI-COLOR TIME RESOLVED FLUOROPHORES BASED ON MACROCYCLIC LANTHANIDE COMPLEXES - The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.09-04-2008
20100285459Human Diabetes Susceptibility TNFRSF10A gene - The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the TNFRSF10A gene locus in a biological sample of said subject.11-11-2010
20100285477Method for Predicting the Response to a Therapy - The invention concerns an in vitro method for selecting the therapy for a steroid resistant patient, wherein the method comprises isolating cells from a sample taken from said patient; cultivating said isolated cells in the presence of a steroid, an immunomodulatory oligonucleotide or a mixture thereof; determining an expression level of at least one marker gene in said isolated cells; and comparing said expression level of said at least one marker gene to a value obtained from the cultivation of cells from a healthy person in the presence of a steroid, an immunomodulatory oligonucleotide or a mixture thereof, or to a normalized value obtained from a healthy population. Examples of marker genes are CD163, Tsp1, IL1-R2, TLR2, TLR4, MKP-1 and TXK.11-11-2010
20090170101IDENTIFICATION OF THYMICALLY DERIVED CD4 T CELLS BY PROTEIN TYROSINE KINASE 7 EXPRESSION - The invention provides methods of identifying naïve T cells by expression of PTK7.07-02-2009
20090170108Screening method, a composition comprising substances chosen in the method thereof, and a binding substance - (Problems) The main object of the present invention is to provide a screening method for selecting a substance affecting a bond between thioredoxin and MIF.07-02-2009
20090170103OLIGONUCLEOTIDE SEQUENCES AND DNA CHIP FOR IDENTIFYING FILAMENTOUS MICROORGANISMS AND THE IDENTIFICATION METHOD THEREOF - A DNA chip for identifying filamentous microorganisms, including a substrate and a plurality of probes, wherein the probe includes SEQ ID No.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, complementary sequences thereof, derivatives thereof or combinations thereof. The derivative is 5′ and/or 3′ end of the sequence SEQ ID No. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 with at least one thymidine residue added or is 5′ and/or 3′ end of the sequence SEQ ID No. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 with one or two nucleotides added or deleted.07-02-2009
20090170095Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM - The present invention discloses Mnk homologous proteins regulating the energy homeostasis, the metabolism of triglycerides, and/or is contributing to membrane stability and/or function of organelles, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation and thermogenesis, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, and sleep apnea, and disorders related to ROS defence, such as diabetes mellitus, neurodegenerative disorders, and cancer, e.g. cancers of the reproductive organs, and others.07-02-2009
20090280494Method for the detection of cytosine methylations in immobilized DNA samples - A method is described for the analysis of cytosine methylation patterns in genomic DNA samples. In the first method step, the genomic DNA is isolated from cells or other accompanying materials and bound essentially irreversibly to a surface. Then the DNA bound to the surface is treated, preferably with a bisulfite, in such a way that cytosine is converted into a base that is different in its base pairing behavior in the DNA duplex, while 5-methylcytosine remains unchanged. Then the reagents that were used are removed in a washing step. Finally, selected segments of the immobilized DNA are amplified in a polymerase reaction and the amplified products are investigated with respect to their sequence.11-12-2009
20100216130SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH AMYOTROPHIC LATERAL SCLEROSIS - Methods for determining the genetic predisposition of a human subject to developing ALS are provided herein. These methods include methods for determining the genetic predisposition to any form of ALS, as well as specific methods for determining the genetic predisposition to early onset, late onset, bulbar onset and limb onset ALS. The method can detect amyotrophic lateral sclerosis in a human subject or a specific form of ALS in the subject (early onset, late onset, bulbar onset or limb onset). The method can also detect the risk of developing amyotrophic lateral sclerosis (ALS) in a human subject. The methods utilize the detection of one or more haplotype bocks comprising tag single nucleotide polymorphisms (SNPs). In several embodiments, the methods including detecting the presence of one or more tag SNPs.08-26-2010
20100143928CHD7 GENE POLYMORPHISMS ARE ASSOCIATED WITH SUSCEPTIBILITY TO IDIOPATHIC SCOLIOSIS - The present invention includes compositions and methods for diagnosis of polymorphisms associated with susceptibility to idiopathic scoliosis in a patient by determining the presence of a mutation in a nucleic acid sample provided from the patient for a mutation in a transcription factor binding site in one or more non-coding regions of the chromodomain helicase DNA binding protein 7 gene.06-10-2010
20100143905METHODS AND COMPOSITIONS FOR MULTIVALENT BINDING AND METHODS FOR MANUFACTURE OF RAPID DIAGNOSTIC TESTS - The invention provides reagents and methods for multivalent binding and quantitative capture of components in a sample. In one aspect, reagents and methods for diagnostic assay for antigen, ligand, binding agent, or antibody are provided. Compositions of a non-natural or deliberately constructed nucleic acid-like polymeric scaffold are provided, to which multiple antibodies, peptides or other binding agents can be affixed by hybridization of a oligonucleotide: binding agent complex such that the nucleic acid: binding agent construction displays multivalent behavior when interacting with a multivalent analyte. Methods for constructing and using the scaffolds are described. Such compositions may include assembly of mixed specificity binding agents such that the composition displays multivalent binding behavior against a target containing mixed analytes which can be bound by the construct to effect a binding affinity increase such as is observed in avidity reagents against single analytes expressed multiply on the target analyte. A manufacturing method for producing rapid diagnostic assays in a decentralized manner is also described. The method generates net economic advantages over conventional diagnostic manufacturing practices.06-10-2010
20080241835DIFFERENTIALLY EXPRESSED GENES INVOLVED IN ANGIOGENESIS, THE POLYPEPTIDES ENCODED THEREBY, AND METHODS OF USING THE SAME - The present invention is directed to nucleic acid sequences and the polypeptides encoded thereby that are differentially expressed in angiogenesis. Also provided are methods for stimulating or inhibiting angiogenesis in mammals, including humans. Pharmaceutical compositions based on polypeptides, agonists, or antagonists thereto are also provided. Additionally, the invention also provides methods for diagnosing and treating angiogenic disorders including, but not limited to, wound healing and cancer.10-02-2008
20080241832METHOD OF DETECTING AND QUANTIFYING HEPATITIS C VIRUS - Methods, reagents, and kits for detecting hepatitis C virus (HCV) in biological samples.10-02-2008
20080241828DETECTION OF DNA METHYLATION USING RAMAN SPECTROSCOPY - Epigenetic events such as DNA methylation play important roles in the regulation of gene expression. DNA methylation patterns have been found to differ between healthy and diseased tissue, such as healthy and cancerous tissue, thereby allowing DNA methylation to serve as a biomarker for disease states. Embodiments of the invention provide methods for detecting methylation patterns in DNA polymers. Methylation patterns are detected, in part, through the use of surface enhanced Raman spectroscopy (SERS). SERS provides a sensitive structure-based technique for chemical analysis.10-02-2008
20080241837Automated Method for Determining the Presence of a Target Nucleic Acid in a Sample - An automated analyzer for performing multiple diagnostic assays simultaneously includes multiple stations, or modules, in which discrete aspects of the assay are performed on fluid samples contained in reaction receptacles. The analyzer includes stations for automatically preparing a specimen sample, incubating the sample at prescribed temperatures for prescribed periods, performing an analyte isolation procedure, and ascertaining the presence of a target analyte. An automated receptacle transporting system moves the reaction receptacles from one station to the next. The analyzer further includes devices for carrying a plurality of specimen tubes and disposable pipette tips in a machine-accessible manner, a device for agitating containers of target capture reagents comprising suspensions of solid support material and for presenting the containers for machine access thereto, and a device for holding containers of reagents in a temperature controlled environment and presenting the containers for machine access thereto. A method for performing an automated diagnostic assay includes an automated process for isolating and amplifying a target analyte. The process is performed by automatically moving each of a plurality of reaction receptacles containing a solid support material and a fluid sample between stations for incubating the contents of the reaction receptacle and for separating the target analyte bound to the solid support from the fluid sample. An amplification reagent is added to the separated analyte after the analyte separation step and before a final incubation step.10-02-2008
20080241826Probe And Primer For Tubercle Bacillus Detection, And Method Of Detecting Human Tubercle Bacillus Therewith - An object of the present invention is to provide a novel primer and prove for detecting tubercle 10-02-2008
20080241838METHODS AND SYSTEMS FOR DETECTING NUCLEIC ACIDS - Methods and kits for detecting a target nucleic acid in a sample are described. In some embodiments, the sample to be analyzed includes a primer which hybridizes to at least a portion of the target nucleic acid, a probe having a first region which hybridizes to at least a portion of the target nucleic acid and a second region having a detectable label, a polymerase which extends the hybridized primer and an enzyme comprising nuclease activity that can cleave the hybridized hybridization probe to thereby release a labeled probe fragment. In some embodiments, the sample can then be contacted with a solid support comprising surface bound capture probes which can hybridize to the labeled probe fragment(s). These capture probes more readily bind to the probe fragment(s) than to the intact hybridization probe. The label can then be detected on the support surface. In this manner, improved discrimination between the probe fragments and the intact hybridization probes can be achieved.10-02-2008
20080241829Methods And Kits For Producing Labeled Target Nucleic Acid For Use In Array Based Hybridization Applications - Methods for producing labeled probe nucleic acids from genomic nucleic acid template are provided. In some embodiments of the subject methods, a plurality of sequence-specific primers are employed to enzymatically generate a set of labeled target nucleic acids corresponding to coding regions of genes from a genomic template via a primer extension protocol. The subject methods find use in a variety of different applications, and can be used, for example, in the preparation of labeled probe nucleic acids for use in array based comparative genomic hybridization applications. Also provided are kits for use in practicing the subject methods.10-02-2008
20080241834Method for improving neoadjuvant chemotherapy - Disclosed is a method and composition for optimizing the efficiency of breast cancer neoadjuvant chemotherapy, depending on the particular constitutional genotype characteristics of the gene BRCA1 in each patient. Generally, the invention concerns a new method to improve neoadjuvant therapy depending on a particular constitutional genotype. Subject of invention allow to synthesize DNA and identification of germline BRCA1 genetic abnormalities which are correlated with a significantly decreased clinical response to neoadjuvant chemotherapy based on taxane-derived cytostatics in breast cancer patients.10-02-2008
20080241836PROCESS FOR SELF-ASSEMBLY OF STRUCTURES IN A LIQUID - A process and apparatus for self-assembling a number of elements and determining their sequence is provided. In the field of DNA analysis, an iterative process is disclosed wherein an apparatus with a set of reaction chambers in which a species of recognition element nucleotides are differentially added and subjected to a polymerization reaction allows recognition of which species is next in sequence on a template strand by the effect that synthesis has on a detecting template as measured by a detector in a detection area. Stepwise addition of the identified species then determines if an element repeat exists. The process is repeated until the entire structure is complete and the sequence identified.10-02-2008
20080241833SYSTEM AND METHOD FOR NUCLEIC ACID SEQUENCING BY POLYMERASE SYNTHESIS - This invention relates to improved methods for sequencing and genotyping nucleic acid in a single molecule configuration. The method involves single molecule detection of fluorescent labeled PPi moieties released from NTPs as a polymerase extension product is created.10-02-2008
20080241825Materials and Methods for Treatment of Cancer - Glypican 5 is shown for the first time to have a role in proliferation of cancer cells, including tumours which do not show chromosomal amplification at 13q31. The use of glypican 5 (GPC5) antagonists and binding agents for the treatment of cancer, particularly rhabdomyosarcoma and breast cancer, is disclosed.10-02-2008
20090117543METHODS AND COMPOSITIONS FOR INDUCING SIRTUINS - Provided herein are compositions comprising agents that increase the level of expression of a sirtuin gene. Also provided are methods for purifying and isolating a factor from serum that stimulates the expression of a sirtuin gene. Diagnostic methods for determining whether a subject is calorically restricted or resistant to stress are also provided.05-07-2009
20100136565Compositions and Methods for Diagnosing Autism - Mutations located within the gene encoding the homeobox transcription factor, ENGRAILED 2 (EN2), have now been identified as molecular markers associated with susceptibility for autism and related disorders. Thus, the present invention relates to compositions in the form of diagnostic kits, primers and target sequences, for use in methods for determining the predisposition, the onset or the presence of autism spectrum disorder in a mammal. Moreover, therapeutic methods for treating a person inflicted with, or predisposed to, an autism spectrum disorder based upon modulating the level or activity of EN2 are also provided.06-03-2010
20100136570SENSITIVE AND RAPID DETERMINATION OF ANTIMICROBIAL SUSCEPTIBILITY - The present invention relates to moving microorganisms to a surface, where they are grown in the presence and absence of antimicrobials, and by monitoring the growth of the microorganisms over time in the two conditions, their susceptibility to the antimicrobials can be determined. The microorganisms can be moved to the surface through electrophoresis, centrifugation or filtration. When the movement involves electrophoresis, the presence of oxidizing and reducing reagents lowers the voltage at which electrophoretic force can be generated and allows a broader range of means by which the target can be detected. Monitoring can comprise optical detection, and most conveniently includes the detection of individual microorganisms. The microorganisms can be stained in order to give information about their response to antimicrobials.06-03-2010
20090035751Single Molecule Detection Using Molecular Motors - The present invention provides methods and compositions for highly sensitive nucleic acid detection, down to the single nucleic acid molecule level. In one aspect, the present invention provides methods for detecting a target nucleic acid comprising: (a) providing first and second target-specific nucleic acids, wherein the first and second target-specific nucleic acids each comprise sequences complementary to the target nucleic acid; wherein the first target specific nucleic acid is bound to a first affinity tag and the second target-specific nucleic acid is bound to a second affinity tag, wherein the first affinity tag is capable of binding to a molecular motor, and wherein the second affinity tag is capable of binding to a detection probe; (b) contacting the first and second target-specific nucleic acids to a sample under conditions whereby the first and second target-specific nucleic acids will hybridize to the target nucleic acid if the target nucleic acid is present in the sample, wherein upon hybridization to the target nucleic acid the first and second target-specific nucleic acids are directly adjacent to each other; (c) ligating the first and second target-specific nucleic acids together; (d) binding the molecular motor t˜ the first affinity tag and the detection probe to the second affinity tag; (e) inducing movement of the molecular motor; and (f) detecting movement of the molecular motor through the detection probe, wherein the movement of the molecular motor serves to detect the target nucleic acid in the sample.02-05-2009
20090035779SYSTEMS AND METHODS FOR DETERMINING CROSS-TALK COEFFICIENTS IN PCR AND OTHER DATA SETS - Systems and methods for determining cross-talk coefficients in curves, such as sigmoid-type or growth curves, and PCR curves and nucleic acid melting curves in particular, as well as for applying the cross-talk coefficients to produce cross-talk corrected data sets using a linear subtractive model. Cross-talk signal coefficients are determined using cross-talk data acquired across the entire signal acquisition range. Analyzing across all of the signal curve data provides for a more robust cross-talk correction across the entire data acquisition range. A linear subtractive model is used to correct data sets having cross-talk components.02-05-2009
20090035778METHODS AND COMPOSITIONS FOR CORRELATING GENETIC MARKERS WITH MULTIPLE SCLEROSIS - The present invention provides, in certain aspects, a method of identifying a subject as having an increased risk of developing multiple sclerosis, comprising detecting in the subject the presence of a nucleotide variant in the interleukin 7 receptor alpha chain gene, whereby the presence of said variant identifies the subject as having an increased risk of developing multiple sclerosis.02-05-2009
20090035752Polynucleotide Participating In Rheumatoid Arthritis And Utilization Of The Same - Analysis is made on the DNA methylation of the region (including a promoter region) upstream from the translation initiation point of a rheumatoid arthritis-associated gene DR3 in human genome. As a result, it is found out that an allele-specific methylation occurs in a CpG sequence located about −380 to −180 bp upstream from translation initiation point (ATG) of the gene DR3. It is further found out that the CpG sequences downstream therefrom of the genes DR3 originating in healthy subjects are all in the unmethylated state, while methylated and unmethylated sequences are both observed in the genes DR3 originating in RA patients.02-05-2009
20100136543METHOD FOR DETERMINING THE GENOTYPE AT THE CROHN'S DISEASE LOCUS - The present invention refers to a method for determining the genotype of an individual at the 5p13.1 Crohn's disease risk locus, the method comprising: providing a sample from the individual; determining whether a DNA sequence corresponding to a DNA sequence polymorphism located between coordinated 40,300,000 and 40,600,000 of human chromosome (coordinates corresponding to the march 2006 assembly of the human genome) is present in the sample; and determining the nature of the DNA sequence polymorphism genotype located between coordinated 40,300,000 and 40,600,000 of human chromosome as it relates to the genetic risk to develop Crohn's disease.06-03-2010
20080274456Methods and Compositions for Modifying Gene Regulation and Dna Damage in Ageing - The invention relates to gene regulation in ageing, and age-related cognitive decline. The invention, in particular relates to methods for screening a subject for a propensity to develop diseases associated with oxidative stress, and for age-related conditions, by examining the up-regulation and/or down-regulation of at least one gene associated within the central nervous system.11-06-2008
20080274460Common allele on chromosome 9 associated with coronary heart disease - Disclosed are methods and compositions for determining whether a person carries an allele associated with increased risk for coronary atherosclerosis by determining whether the person has had RA-CHR9 allel, such as by determining whether the person has an RA-CHR9 allele-associated single nucleotide polymorphism (SNP).11-06-2008
20080274463Method for quantifying biomolecules conjugated to a nanoparticle - Disclosed embodiments concern quantifying a biomolecule conjugated to a nanoparticle. Quantifying typically comprises determining the number of biomolecules per nanoparticle. Any suitable biomolecule can be used, including but not limited to, amino acids, peptides, proteins, haptens, nucleic acids, oligonucleotides, DNA, RNA, and combinations thereof. A single type of biomolecule may be conjugated to the nanoparticle, more than one biomolecule of a particular class may be conjugated to the nanoparticle, or two or more classes of biomolecules may be conjugated to the nanoparticle. Certain disclosed embodiments comprise enzymatically or chemically digesting a biomolecule conjugated to the nanoparticle, or displacing a biomolecule using ligand-exchange chemistry. Where biomolecule concentrations are determined, any technique suitable for determining biomolecule concentration can be used, such as spectrophotometric techniques, including measuring tryptophan fluorescence and using a standard fluorescence intensity versus biomolecule concentration curve.11-06-2008
20080274454Reversible and Chemically Programmable Micelle Assembly With Dna Block-Copolymer Amphiphiles - The present invention is directed to amphiphilic block copolymers. More particularly the present invention is directed to amphiphilic block copolymers comprising a polynucleotide block and a hydrophobic polymer block, to micelles formed from the block copolymers, and to methods of using the micelles.11-06-2008
20080274471Methods for detecting an increased risk for coronary heart disease - The invention relates generally to an allele on human chromosome 9 associated with increased risk for coronary heart disease and the use or detection of such an allele in determining whether a human has an increased risk for coronary heart disease. In one aspect, the invention relates to methods for detecting a predisposition or propensity or susceptibility for coronary heart disease in a human, comprising detecting the presence of an allele on human chromosome 9 that is associated with an increased risk for coronary heart disease in a human. Disclosed are methods and compositions for determining whether a person carries an allele associated with increased risk for coronary atherosclerosis by determining whether the person has an RA-CHR9 allele, such as by determining whether the person has an RA-CHR9 allele-associated single nucleotide polymorphism (SNP). The invention also relates to kits for detecting the presence of an allele on chromosome 9 associated with an increased risk for coronary heart disease.11-06-2008
20080274470NON-INVASIVE DETECTION OF ENDOMETRIAL CANCER - The present invention provides a non-invasive method of obtaining a sample of endometrial cells for use in the diagnosis of endometrial cancer, as well as methods and kits for diagnosing, determining the prognosis of, and monitoring endometrial cancer.11-06-2008
20080274468NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL.11-06-2008
20080274466Enrichment Through Heteroduplexed Molecules - The present invention relates to the enrichment of specific target sequences Enrichment can be achieved through the formation of a heteroduplex that includes the specific target sequence and then the specific cleavage of the heteroduplex. A binding moiety is then added to the cleaved heteroduplex, allowing for the subsequent manipulation of the specific target sequence in the heteroduplex.11-06-2008
20080274465Method for Breast Cancer Diagnosis/Prognosis - The present invention relates to a method for breast cancer diagnosis/prognosis comprising the following steps: 11-06-2008
20080274462Universal bases for nucleic acid analyses, methods for using universal bases, and kits comprising universal bases - Compounds, methods and kits for making and analyzing primer extension products incorporating one or more universal bases are described, including methods and kits for nucleic acid sequencing and microsatellite analysis.11-06-2008
20080274461Perinucleolar Compartment Markers for Cancer - The present invention relates to compositions and methods for cancer diagnostics, prognostics and predictions, including but not limited to, cancer markers. In particular, the present invention provides perinucleolar compartments and their resident molecules as cancer markers.11-06-2008
20080274459METHOD FOR COLLECTING AND STORING BIOLOGICAL MATERIALS - A method for collecting and storing biological material includes the steps of obtaining a patient identity of a patient and a biological material from a patient. A DNA identity analysis is performed to establish a DNA identity for the patient. The DNA identity is associated with the patient identity and the biological material. The biological material is stored in a preserving environment, and the patient identity and the DNA identity are stored in a database. A request for the biological material is received from a requestor purporting to have the patient identity. A DNA sample from said requestor is obtained. A DNA identity analysis is performed on the DNA sample from the requestor to obtain a DNA identity of the requestor. The DNA identity of the requestor is then compared to the stored DNA identity of the patient, and if the DNA identities match, the biological material is provided to the requestor.11-06-2008
20080274457METHODS FOR DIFFERENTIATING MALIGNANT FROM BENIGN THYROID TISSUE - Methods of identifying malignant thyroid tissue comprising testing a thyroid tissue sample for the expression of at least two genes chosen from CCND2, PCSK2, and PLAB. Kits for use in the disclosed methods are also provided.11-06-2008
20080233582SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH SUSCEPTIBILITY TO CARDIOVASCULAR DISEASE - The present invention provides SNPs, polymorphic variants, and haplotypes associated with cardiovascular disease. The invention also provides methods for detecting the SNPs, polymorphic variants, and haplotypes. The invention also provides methods for determining an individual's genotype with respect to one or more polymorphisms and/or haplotypes associated with cardiovascular disease. The invention further provides methods of determining whether an individual has or is susceptible to development or occurrence of a cardiovascular disease or event. The methods are useful for providing diagnostic and/or prognostic information, selecting therapeutic regimens, etc. The invention further provides reagents and kits for practicing the methods.09-25-2008
20080233565PKHDL1, a homolog of the autosomal recessive kidney disease gene - Nucleic acids encoding fibrocystin-L polypeptides and fibrocystin-L polypeptides are provided. Antibodies against the polypeptides, vectors and host cells containing the nucleic acids, methods for using the nucleic acids and polypeptides, and compositions and articles of manufacture also are provided.09-25-2008
20080233568Detection of Extracellular Tumor-Associated Nucleic Acid in Blood Plasma or Serum Using Nucleic Acid Amplification Assays - This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humans and other animals.09-25-2008
20080233583BIOMARKERS FOR PREECLAMPSIA - The present invention provides methods for predicting the development of and diagnosing preeclampsia, providing a prognosis, and predicting recurrence of the disease using molecular markers that are overexpressed or underexpressed in preeclampia. Also provided are methods to identify compounds that are useful for the treatment or prevention of preeclampsia.09-25-2008
20080261229SIMULTANEOUS RAPID DETECTION OF MICROBES - The invention includes a method of simultaneously detecting the presence or absence of more than one microbe class (e.g., bacteria, yeast, and mold) in a sample. The method can include the step of applying a sample suspected of containing more than one microbe class to a growth medium, optionally fragmenting the sample, associating the sample with a labeling agent, and simultaneously detecting the presence or absence of each microbe class by detection of the labeling agent.10-23-2008
20090087848DETERMINING SEGMENTAL ANEUSOMY IN LARGE TARGET ARRAYS USING A COMPUTER SYSTEM - A method and/or system for making determinations regarding samples from biologic sources including statistical methods for making meaning grouping of observed data and/or for pre-selecting endpoints.04-02-2009
20100136537PHOTORECEPTOR PRECURSOR CELLS - The present invention relates to photoreceptor cells. In particular, the present invention provides photoreceptor cells comprising heterologous nucleic acid sequences and transgenic animals comprising the same. The present invention also provides photoreceptor precursor cells (e.g., rod photoreceptor precursor cells), and methods of identifying, characterizing, isolating and utilizing the same. Compositions and methods of the present invention find use in, among other things, research, clinical, diagnostic, drug discovery, and therapeutic applications.06-03-2010
20090053713Isolated nucleic acids and polypeptides associated with glucose homeostasis disorders and method of detecting the same - An isolated and substantially pure nucleic acid sequence located between D20S119 and D20S178 on human chromosome 20q13, the nucleic acid sequence including: a nucleic acid sequence coding for a glucose transporting protein and having the sequence shown in SEQ ID NO: 1; or a nucleic acid sequence having at least 70% sequence identity with the nucleic acid sequence shown in SEQ ID NO: 1. The disclosed nucleic acid sequences map to a locus associated with human Type II diabetes mellitus and, therefore, therapeutic and diagnostic screening methods, which accommodate naturally and artificially occurring polymorphisms, are also disclosed.02-26-2009
20090047680METHODS AND COMPOSITIONS FOR HIGH-THROUGHPUT BISULPHITE DNA-SEQUENCING AND UTILITIES - The invention relates to novel methods and compositions to produce DNA templates suitable for chemical modifications and high-throughput DNA-sequencing. A method of the invention relates to a DNA adaptor design where constituent deoxycytosines are substituted with 5-methyl-deoxycytosines rendering the resulting adaptor resistant to bisulphite mediated deamination. When said adaptor is ligated onto double stranded DNA template, subsequent DNA denaturation and bisulphite treatment deaminates template DNA deoxycytosine differentially to deoxyuraeil whilst the 5-methyl-deoxycytosines of the ligated adaptor resist chemical conversion resulting in the adaptor sequence remaining unaltered. Both strands of bisulphite treated DNA can thus be amplified with a single primer set that hybridizes to the unaltered adaptor sequence. The invention also relates to methods to produce control template of a defined methylation composition to optimize conditions for the bisulphite reaction. In a preferred embodiment, the present invention can be used to produce templates suitable for genome-wide bisulphite-DNA sequencing using conventional, Solexa™, SOLiD™ or 454™-type DNA sequencing platforms to study DNA methylation.02-19-2009
20090170114Non-Invasive Fetal Genetic Screening by Digital Analysis - The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.07-02-2009
20090170086Gene Methylation In Esophageal Cancer Diagnosis - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with esophageal cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of esophageal cancer.07-02-2009
20090170107DETECTION ASSAY FOR MEAT AND BONE MEAL IN FEED - The invention concerns methods, kits and nucleic acids involved in detecting animal tissues, for example processed animal proteins (PAPs) or meat and bone meal (MBM), especially in feeds. In one method, a nucleic acid such as DNA is extracted from a sample using a process involving incubating the sample in an incubation buffer, autoclaving the incubated sample, and then mixing the sample with a metal-chelating agent. DNA extracted in this way may then be subjected to amplification using PCR or real-PCR, for example using primer and probe sequences as set forth in SEQ ID NOs 1-21.07-02-2009
20090170074SYSTEM AND METHOD FOR NUCLEIC ACID SEQUENCING BY POLYMERASE SYNTHESIS - This invention relates to improved methods for sequencing and genotyping nucleic acid in a single molecule configuration. The method involves single molecule detection of fluorescent labeled PPi moieties released from NTPs as a polymerase extension product is created.07-02-2009
20090170079Regulation of RUNX1 for Treatment of Pain - Methods are provides for identifying candidate agents for use in inhibiting expression of certain receptors and ion channels in nociceptors. Also provided are methods for identifying candidates agents for use in inhibiting neurophathic and other types of pain.07-02-2009
20100151471METHODS OF MONITORING CONDITIONS BY SEQUENCE ANALYSIS - There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using DNA sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions. Identified biomarkers can be used to determine the disease state for a subject with an autoimmune disease or other condition.06-17-2010
20100092986METHODS AND TOOLS FOR DETECTING THE PRESENCE OF COLORECTAL ADENOCARCINOMA CELLS - The present invention discloses methods and tools for reliably detecting the presence of adenocarcinoma cells in a patient, at the genetic level. The present invention fine-maps the regions of chromosomal aberrations linked to progression of adenomas into adenocarcinoma cells and provides methods and tools for detection based thereon.04-15-2010
20100075326YEAST SURFACE TWO-HYBRID SYSTEM FOR QUANTITATIVE DETECTION OF PROTEIN-PROTEIN INTERACTIONS - The present invention provides methods and related vectors and host cells for quantitative analysis of protein interactions in eukaryotic expression system. More specifically, the invention provides a yeast surface two-hybrid (YS2H) system that can express a pair of proteins, one protein (“bait”) as a fusion to a yeast cell wall protein, and the other (“prey”) in a secretory form. When two proteins interact in this system, they associate in the secretory pathway, and the prey that would otherwise be released into the media is captured on the cell surface by the bait. Expression of the bait and the prey proteins can be designed to promote a synchronized and comparable level of expression. The affinity of two interacting molecules can be quantitatively determined by two exemplary schemes: either flow cytometric detection of antibody binding to the epitope tags fused to the prey and the bait, or the readout from a protein-fragment complementation assay (“PCA”) such as complementation of split GFP fragments fused to the prey and the bait.03-25-2010
20080280290Method and Device for the Collection and Isolation of Nucleic Acid - A device for collecting and preserving nucleic acids in a sample, the device comprising: a) a support; b) one or more than one sample zone in the support for loading the sample onto the device; and c) a composition comprising i) one or more than one absorbent, and ii) one or more than one stabilizer; where the one or more than one sample zone on the support comprises a recess or space within the support extending from the top surface toward, but not through, the bottom surface, or comprises a space within the support and the composition is retained within the sample zone. A method for collecting and preserving nucleic acids in a sample, the method comprising a) providing a device for collecting and preserving nucleic acids in a sample according to the present invention; b) providing a sample potentially comprising one or more than one nucleic acid; and c) applying part or all of the sample to one or more than one of the sample zones on the device. A method of detecting and quantifying nucleic acids in a sample, the method comprising a) collecting and preserving nucleic acids in the sample according to a method of the present invention; b) removing the absorbent with sample from the sample zones of the device; and c) detecting, or detecting and quantifying the nucleic acids.11-13-2008
20080280297Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia - The invention provides compositions and methods for determining a prognosis of a B cell chronic lymphocytic leukemia (CLL) in a subject based on the level of expression of at least one marker gene. Marker genes provided by the invention are SEPTlO, KIAA0799, Hs.23133, and ADAM29. The marker genes can be used to differentially diagnose CLL in a subject based on relative gene expression levels in the subject compared to reference gene expression levels established from a clinically characterized population of patients. The invention also provides diagnostic reagents and compositions and kits based on the marker genes.11-13-2008
20080280294Inherited Mitochondrial Dna Mutations in Cancer - A method is provided for identifying a subject likely to have, or at risk of developing a disease condition correlated with increased reactive oxygen species (ROS), including cancer, by identifying in the subject a missense mutation in a nucleic acid of Complex III, IV and/or V of the OXPHOS system. This invention also provides a method of identifying a likelihood of having a heritable predisposition to cancer by detecting a homoplasmic missense mutation in non-tumor tissue of an OXPHOS system gene. This invention also provides a method for detecting likelihood of having cancer, predisposition to cancer, and likelihood of passing a predisposition to cancer to progeny involving identifying in non-tumor tissue of the subject a missense mutation in a complex III, IV and/or V gene of the mitochondrial OXPHOS system. The mutation may be a nuclear or mitochondrial mutation. The invention has been exemplified with respect to prostate cancer. When the mutation is homoplasmic in non-tumor tissue this is an indication it is an inherited and inheritable trait, and that the subject is likely to pass on the mutation to her progeny in the case of mutations in mitochondrial DNA or his or her progeny in the case of mutations in nuclear DNA. Both homoplasmic and heteroplasmic mutations in non-tumor tissue can indicate the presence of cancer.11-13-2008
20080280302MULTIGENE DIAGNOSTIC ASSAY FOR MALIGNANT THYROID NEOPLASM - The present invention provides methods for diagnosing, providing a prognosis, and staging thyroid cancer, using panels of molecular markers that are differentially expressed in thyroid cancer. Also provided are methods to identify compounds that are useful for the treatment or prevention of thyroid cancer.11-13-2008
20080280303G-PROTEIN COUPLED RECEPTORS HIGH-THROUGHPUT FUNCTIONAL ASSAY - Disclosed herein are methods for enabling or improving functional assays of G-protein coupled receptors through the use of co-expression of helper genes. In some cases, chimeras linking the regulatory domain of the rap1B protein to the effector region of the ras oncogene are used in conduction with existing functional assays for cellular proliferation. Furthermore, overexpression of other genes can further augment the enabling properties of ras/rap chimeras.11-13-2008
20080286800Method and system for biopsy and analysis of a body tissue - Methods and systems for performing biopsies and diagnosing tumors and suspect masses within the body. A biopsy sample is frozen while still in the body of a patient, then removed from the patient, stored frozen, and subject to IHC, microarray or other analysis to determine the amount, type or presence of signaling substances within the tumor or suspect mass.11-20-2008
20080286798CONTROLS FOR PRIMERS IN MULTIPLEX AMPLIFICATION REACTIONS - The present invention provides methods and compositions for confirming the integrity of primers and other components of amplification reactions, including multiplex amplification reactions.11-20-2008
20080286796Genetic polymorphisms associated with neurodegenerative diseases, methods of detection and uses thereof - The present invention is based on the discovery of genetic polymorphisms that are associated with neurodegenerative disease, particularly Alzheimer's disease and Parkinson's disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.11-20-2008
20080286786Methods of preparing nucleic acid for detection - Methods of preparing nucleic acid from polysaccharide-containing samples for detection by providing one or more glycosidases to the sample to degrade polysaccharides are provided. The nucleic acids can further be extracted from the sample. The method is particularly useful for detecting nucleic acid in samples with high starch content.11-20-2008
20080286794METHODS AND PRIMERS FOR DIAGNOSING IDIOPATHIC CONGENITAL CENTRAL HYPOVENTILATION SYNDROME - The present invention provides assays and kits for diagnosing idiopathic congenital central hypoventilation syndrome. The present assays and kits focus on the second polyalanine repeat of the PHOX2b gene or gene product, which is normally 20 residues in length. A polyalanine repeat 25 to 33 residues in length is strongly correlated with idiopathic congenital central hypoventilation syndrome.11-20-2008
20080286799METHODS OF AND KITS AND COMPOSITIONS FOR DIAGNOSING COLORECTAL TUMORS... - In vitro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such in vitro kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed.11-20-2008
20080286797Accurate identification of organisms based on individual information content - An improved method for specific identification of any organisms by DNA hybridization or amplification is disclosed. Oligonucleotides are designed based on information analysis of sequences from a large number of related species. Oligonucleotide sequences that have the maximal specificity to certain nucleic acids from a particular species (or set of species) or type strain are selected for hybridization or amplification using DNA from the target organism. The presence or absence of a PCR or hybridization product may be used to identify the target organism. The resulting PCR products may also be compared with a DNA sequence database to obtain the identity of the organisms. The methods may prove useful in areas where rapid and accurate identification of an organism is desirable, such as in a hospital where identification of infectious agents may be critical, in the ethanol or beer industry where certain bacteria may be detrimental to the manufacturing process, or in the porcine industry where identification of different type strains of the porcine reproductive and respiratory syndrome virus (PRRV) is important for disease prevention.11-20-2008
20080286790Method for Diagnosing Overactive Bladder - Techniques for diagnosing overactive bladder (OAB) in a patient are provided. For example, a technique for diagnosing overactive bladder in a patient includes the step of obtaining peripheral blood mononuclear cells (PBMC) from the patient to provide a reporter function in the patient.11-20-2008
20080286787High Throughput Method of DNA Methylation Haplotyping - Particular aspects provide novel, high-throughput methods to quantify DNA methylation (e.g., at a single-base resolution) in an allele-specific manner. The methods comprise use of an allele-specific sequence polymorphism (e.g., allele-specific single nucleotide polymorphism; SNP) in sufficient proximity to a CpG methylation site to provide for distinguishing the methylation levels between two alleles. In particular aspects, after bisulfite modification, the genomic DNA region is PCR-amplified, and the product subjected to allele-specific pyrosequencing, and the percentage of methylation determined based on the percentage of cytosine to thymidine conversion. In further embodiments, MethyLight™ is used after bisulfite treatment. The inventive methodology has, for example, substantial utility for affording quantitative analyses in the regulation of analyses of X-inactivation, the allele-specific expression of genes (e.g., in the immune system) and junk DNA, etc., and in classifying an individual as to whether they have loss of imprinting (LOI).11-20-2008
20080286785Method to predict or monitor the response of a patient to an erbb receptor drug - The invention provides a method of detecting ErbB receptor mutations comprising the steps of providing a bio-fluid sample from a patient; extracting DNA from said sample; and screening said DNA for the presence of one or more mutations that alter tyrosine kinase activity in the receptor.11-20-2008
20080286783NOVEL METHOD OF DETECTING GENETIC POLYMORPHISM - The present invention provides a novel polymorphism detecting method suitable for the detection and identification of copy number variation.11-20-2008
20080286781Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer - The invention relates to nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are also provided.11-20-2008
20080286779Host Cells Containing Multiple Integrating Vectors - The present invention relates to the production of proteins in host cells, and more particularly to host cells containing multiple integrated copies of an integrating vector. Suitable integrating vectors for use in the present invention include retrovirus vectors, lentivirus vectors, transposon vectors, and adeno-associated virus vectors. Methods are provided in which the host cells are prepared by using the integrating vectors at a high multiplicity of infection. The host cells are useful for producing pharmaceutical proteins, variants of proteins for use in screening assays, and for direct use in high throughput screening.11-20-2008
20080286773Method for Typing an Individual Using Short Tandem Repeat (Str) Loci of the Genomic Dna - The present invention relates to a novel STR typing strategy, which allows the simultaneous amplification and subsequent analysis of several (e.g. eleven) polymorphic systems with amplicon sizes of less than 270 bp. Thereby, after a PCR amplification the multiplex reaction is divided into two sets of STR multiplexes and analyzed separately. This multiplex system was particularly developed and tested for use in forensic investigations, where only limited amounts of DNA or only highly degraded DNA is available, for example, when the DNA is isolated from the roots of telogen hair.11-20-2008
20080286788NUCLEIC ACID LIGANDS TO COMPLEX TARGETS AND USES THEREOF - The present invention relates to a method for isolating a pool of nucleic acid ligands capable of binding to one or more target molecules in a complex mixture.11-20-2008
20080286777Method of Determining the Diversity of T Lymphocytes in a Biological Sample - The invention relates to the field comprising the diagnosis of possible immune system disorders and the analysis of immune responses. In particular, the invention relates to a method of determining the diversity of T lymphocytes in a biological sample, based on the molecular analysis of the structure of the junctions resulting from the recombination rearrangement V(D)J of element δRec-1 with an AJ gene. More specifically, the invention relates to a method of analyzing the combinatorial diversity and/or the junctional diversity of the excision circles (TREC) resulting from the rearrangement of δRec-1, in order to determine the heterogeneity of a given population of T lymphocytes.11-20-2008
20080286761Methods and Nucleic Acids for the Analysis of Gene Expression Associated with the Development of Prostate Cell Proliferative Disorders - The following application provides methods and nucleic acids for the detection of and/or differentiation between prostate cell proliferative disorders. This is achieved by the analysis of the expression status of a panel of genes, or subsets thereof.11-20-2008
20080286801Method for the analysis of differential expression in colorectal cancer - A method for the analysis of differential expression in colorectal cancer based on the variation in the expression levels of genes encoding for proteins forming part of the condensin complex or associated proteins that occurs in patients with the disease and that can be used as markers for the diagnosis of the cancers, as well as for the prevention and treatment thereof.11-20-2008
20080286793METHOD OF ANALYSIS OF PRIMARY STRUCTURAL CHANGE OF NUCLEIC ACID - The object of the present invention is to offer a method for analyzing primary structure change of nucleic acid which has quantifiability, which has a high degree of sensitivity and reproducibility, and which can be conducted rapidly and at low cost. The method of analysis of primary structural change of nucleic acid of the present invention includes a process for obtaining a reference nucleic acid having a standard sequence and a target sequence, each sequence being bound by a first ligand that differs depending on type of the sequence to which it binds, and being bound by a second ligand; a process for specifically binding first ligands to receptors supported on a carrier, thereby immobilizing standard sequences and target sequences on the carrier; a process for specifically binding labeled receptors to the second ligands in said nucleic acids which have been immobilized; a process for detecting labels to detect standard sequences and target sequences; a process for obtaining the ratio of standard sequences in the reference nucleic acid and subject nucleic acid, calculating a coefficient which corrects detection values of target sequences, and conducting correction; and a process for confirming an increase/decrease in the quantity of target sequences in the subject nucleic acid relative to target sequences in the reference nucleic acid.11-20-2008
20080286791PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof.11-20-2008
20080286789GENOMIC POLYMORPHISM FOR PREDICTING THERAPEUTIC RESPONSE - The present invention relates to the use of genomic polymorphism to provide individualized therapeutic regimens to treat patients suffering from diseases such as cancer. The invention discloses methods for determining the efficacy or choice of chemotherapeutic drugs and regimens for use in treating a diseased patient by associating genomic polymorphism with the effectiveness of the drugs or regimens, or by associating genomic polymorphism with the intratumoral expression of a gene whereby the gene expression affects effectiveness of the drugs or regimens. In particular, the present invention provides novel methods for screening therapeutic regimens, which comprise determining a patient's genotype at a tandemly repeated 28 base pair region in the thymidilate synthase (TS) gene's 5′ untranslated region (UTR). Patients homozygous for a triple repeat will be least successfully treated with a thymidylate synthase directed drug, while those heterozygous for a triple and a double repeat will be more successfully treated, and those homozygous for a double repeat will be even more successfully treated. Those patients homozygous for the double repeat will likely suffer the least side effects from thymidylate synthase directed drugs such as 5-FU.11-20-2008
20080286780Novel compositions and methods for the identification, assessment, prevention and therapy of human cancers - The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.11-20-2008
20080286776Methods and Compositions for Assessment of Pulmonary Function and Disorders - The present invention provides methods for the assessment of risk of developing lung cancer in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's risk of developing lung cancer, and the suitability of a subject for an intervention in respect of lung cancer. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided.11-20-2008
20080286771Method of Predicting the Responsiveness of a Tumour to Erbb Receptor Drugs - The invention relates to a method of selecting a mammal having or suspected of having a tumour for treatment with an erbB receptor drug which comprises testing a biological sample from the mammal for expression of anyone of the genes listed in Table 1 or 2 as defined herein whereby to predict an increased likelihood of response to the erbB receptor drug. Preferred genes include anyone of NES, GSPT2, ETR101, TAZ, CHST7, DNAJC3, NPAS2, PIN1, TCEA2, VAMP4, DAPK1, DAPK2, MLLT3, TNNC1, KIAA0931, ACOX2, EMP1, SLC20A1, SPRY2 or PGM1.11-20-2008
20080286760Means and Methods for the Determination of Camp In Vitro and In Vivo - The present invention relates to a chimeric peptide, comprising a cAMP binding moiety having only one cAMP binding site and at least two detectable labels, whereby the first of said two detectable labels is located at the carboxy terminus and the second of said two detectable labels is located at the amino terminus of said cAMP binding moiety. Said chimeric peptide of the invention is particularly useful in/for direct determination of cAMP concentrations) in vitro and/or in vivo. Furthermore, nucleic acid molecules encoding said chimeric proteins are described as well as vectors and host cells comprising the same. The present invention also provides methods for producing the chimeric protein of the invention and methods for identification and screening of molecules or compounds which are capable of modifying cAMP binding to the chimeric peptide of the invention or the biological and/or pharmacological function of adenylyl cyclases or phosphodiesterases. In addition, a method for cAMP determination in a sample and a method for the detection of cAMP in the living cell or tissue is described. Finally, a kit comprising the compounds of the present invention is disclosed.11-20-2008
20080286774Real-time individualized therapy evaluation - A method of individually optimizing drug therapy to a patient that includes the steps of administering a dose of a radiolabeled drug or fluorescent tags or drugs with inherent fluorescent properties to the patient in connection with chemotherapy, collecting a sample from the patient, analyzing the sample producing an analysis, and using the analysis for developing a model for the patient.11-20-2008
20080286772Method for Direct Amplification from Crude Nucleic Acid Samples - The present teachings relate to improved methods, kits, and reaction mixtures for amplifying nucleic acids. In some embodiments a novel direct buffer formulation is provided which allows for the direct amplification of the nucleic acids in a crude sample with minimal sample purification.11-20-2008
20080286762Gene Detection Field-Effect Device And Method Of Analyzing Gene Polymorphism Therewith - A gene detection field-effect device provided with an insulation film (11-20-2008
20080293052SYSTEM AND METHOD FOR AUTHENTICATING SPORTS IDENTIFICATION GOODS - A method for authenticating and verifying garment to be genuine is described. The method for authenticating a garment comprises applying a particular nucleic acid material/marker associated with a particular sequence of nucleic acid bases to a dye or paint and applying the marker to the garment. The method also comprises collecting a sample from the garment and verifying the garment is genuine by detecting the particular nucleic acid material on or within the garment.11-27-2008
20080293063PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof.11-27-2008
20080293053shRNA Materials and Methods of Using Same for Inhibition of DKK-1 - Methods and compositions for the treatment of soft tissue cancer are described. More specifically, the invention demonstrates that inhibiting or otherwise decreasing the activity of DKK-1 using shRNA or siRNA molecules will be effective at reducing the cancer phenotype of prostate cancer cells.11-27-2008
20080293049Methods, Kids and Polynucleotides for Simultaneously Diagnosing Viruses - The present invention provides a simultaneous method for diagnosing HBV, HCV and HIV of a suspected patient. The present invention further provides different primer sets and specific probes for HBV, HCV and HIV. The present invention also provides a kit for simultaneous diagnosing of HBV, HCV and HIV.11-27-2008
20080293044Melks as Modifiers of the Rac Pathway and Methods of Use - Human MELK genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of MELK are provided.11-27-2008
20080293071Sequencing and Genotyping Using Reversibly Terminating Nucleotides - The invention provides a method of determining the nucleotide sequence of a target nucleic acid using a reversibly terminating nucleotide that is modified at the 2′ position.11-27-2008
20080293067PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof.11-27-2008
20080293066PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof.11-27-2008
20080293065PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof.11-27-2008
20080293064PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof.11-27-2008
20080293062PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof.11-27-2008
20080293050Gene analysis for determination of a treatment characteristic - An apparatus, device, methods, computer program product, and systems are described that determine at least one amino acid sequence alteration of an amino acid sequence of a disease associated polypeptide, relative to an amino acid sequence of a corresponding non-disease associated polypeptide, identify a sub-sequence in the amino acid sequence of the disease associated polypeptide in which the amino acid sequence alteration occurs, relate the sub-sequence in the amino acid sequence of the disease associated polypeptide to a corresponding sub-sequence of the amino acid sequence of the corresponding non-disease associated polypeptide, and determine a treatment characteristic, based on the relating.11-27-2008
20080293055K-ras mutations and anti-EGFr antibody therapy - The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.11-27-2008
20080293054Hmgcr isoforms in Prediction of Efficacy and Identification of Cholesterol-Modulating Compounds - The present invention provides methods for assessing a subject's responsiveness to a HMGCR inhibitor therapy, and selection of a HMGCR inhibitor therapy based upon such methods. The invention further provides methods for identifying agents that modulate HMGCR activity, e.g., through modulating HMGCR mRNA splicing, while avoiding elevation of the statin-resistant isoform of HMGCR.11-27-2008
20100035261METHOD OF DETECTING LARGE GENOMIC REARRANGEMENTS - A method for detecting large genomic rearrangements is disclosed, which is particularly useful in detecting deletions and duplications in the large genes such as BRCA1, BRCA2, MLH1 and MSH2.02-11-2010
20100015611REACTION MONITORING - The invention provides a method and apparatus for detecting a signal of a specific spectrum emitted in the course of a chemical or biochemical reaction. The method comprises conducting the reaction in a reaction vessel, which is arranged so that light emanating from the reaction vessel is received by a detector comprising a plurality of photosensors in an array, wherein each photosensor is activated by light falling within a particular waveband range only, and where photosensors activated by light in different waveband ranges are distributed throughout the array. Output from one or more subsets of those photosensors which receive wavebands which contribute to the said specific spectrum is monitored and the output from a subset, or the relationship between the outputs of each subset are used to determine the signal in the specific spectrum.01-21-2010
20080305486SIGNAL AMPLIFICATION USING CIRCULAR HAIRPIN PROBES - The present invention provides methods for detecting a target nucleic acid using a circular dual-hairpin probe that is formed upon the presence of the target nucleic acid. The detection methods find use in detecting the presence of antibody-antigen complexes and for detecting the binding of a ligand to its binding partner. Kits and reaction mixtures for performing the present methods are also provided.12-11-2008
20080305488PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof.12-11-2008
20080305490AMPLIFICATION OF HUMAN MDM2 GENE IN HUMAN TUMORS - A human gene has been discovered which is genetically altered in human tumor cells. The genetic alteration is gene amplification and leads to a corresponding increase in gene products. Detecting that the gene, designated hMDM2, has become amplified or detecting increased expression of gene products is diagnostic of tumorigenesis. Human MD2 protein binds to human p53 and allows the cell to escape from p53-regulated growth.12-11-2008
20080305487PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof.12-11-2008
20080305491MCM6 AND MCM7 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF CERVICAL DISEASE - Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM6 or MCM7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM6, MCM7, or both MCM6 and MCM7 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM6 or an MCM7 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.12-11-2008
20080305489NEAR-INFRARED DYES AS SURFACE ENHANCED RAMAN SCATTERING REPORTERS - Nanoparticles comprising surface-enhanced Raman scattering (SERS) reporter molecules of the formula A-Y and methods of their use are disclosed, wherein A is selected from the group consisting of:12-11-2008
20080305484Genetic methods for speciating Campylobacter - Species-specific identification of 12-11-2008
20080305479DETECTION AND QUANTIFICATION OF BIOMOLECULES USING MASS SPECTROMETRY - The present invention is directed in part to a method for detecting a target nucleic acid using detector oligonucleotides detectable by mass spectrometry. This method uses the 5′ to 3′ nuclease activity of a nucleic acid polymerase to cleave annealed oligonucleotide probes from hybridized duplexes and release labels for detection by mass spectrometry. This process is easily incorporated into a PCR amplification assay. The method also includes embodiments directed to quantitative analysis of target nucleic acids.12-11-2008
20080305485GENETIC MARKER FOR INCREASED RISK FOR OBESITY-RELATED DISORDERS - The present invention relates to methods of determining an increased risk of a subject to acquire a trait of an obesity disorder or an obesity disorder, with the method comprising determining the genetic sequence of at least one taste receptor gene in the subject and reviewing the test genetic sequence(s) for the presence of at least one risk allele associated with at least one taste receptor. The presence of at least one difference in the test genetic sequence(s) and the presence of a risk allele associated with the taste receptor(s) may indicate an increased risk of the subject acquiring a trait of an obesity disorder or an obesity disorder.12-11-2008
20080305481SYSTEMS AND METHODS FOR MULTIPLEX ANALYSIS OF PCR IN REAL TIME - The present invention provides methods and systems for real-time measurements of PCR with multiplexing capability. Certain embodiments relate to methods and systems that use fluorescently encoded superparamagnetic microspheres for the immobilization of amplification products during the PCR process, and an imaging chamber of a measurement device that is also capable of controllable thermal cycling for assisting the PCR process.12-11-2008
20080311570CANCER SCREENING METHOD - A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation state of the CpG sequence in at least one target gene within the genomic DNA of the test specimen, wherein the target genes is consisted of SOX1, PAX1, LMX1A, NKX6-1, WT1 and ONECUT1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the presence or absence of the methylation state in the target gene; wherein method for detecting methylation state is methylation-specific PCR (MSP), quantitative methylation-specific PCR (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometer, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing.12-18-2008
20080220431Cell fusion method - The invention provides methods for fusing a first cell with a second cell to form a hybrid cell. The methods involve incubating a first parental cell producing a first partner of a fusogenic binding partner pair on its surface with a second parental cell producing a second partner of the fusogenic binding partner pair on its surface. In certain embodiments, the parental cells are incubated with a known fusogen such as polyethylene glycol and the fusogenic binding partner pair increases the rate of cell fusion. In many embodiments, the first cell is an antibody producing cell, the second cell is an immortal cell, and the hybrid cell is a hybridoma cell that produces a monoclonal antibody. Also provided by the invention are methods for producing hybridoma cells, and methods for screening those cells for production of a monoclonal antibody of interest. The invention further provides systems and kits for carrying out the subject methods. The subject methods, systems, and kits find use in a variety of different industrial, medical and research applications.09-11-2008
20080311573Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.12-18-2008
20080274464Gene Detecting Method - Disclosed is a gene detecting method for determining mutation of a specific base or presence/absence of a specific base in a target gene. There are provided a the target gene sample and a control gene sample having a base sequence which is wild-type or standard-type with respect to the target gene. The method comprises steps of (i) independently subjecting the target gene sample and the control gene sample to a PCR reaction for amplification, using primers having an RNA polymerase promoter sequence at the 5′-end thereof, (ii) independently subjecting the double-stranded DNAs produced by said PCR reaction from the target gene sample and from the control gene sample, to an in vitro transcription reaction to form a single-stranded RNA, (iii) independently hybridizing the single-stranded RNAs with a fluorescence-labeled probe composed of a single-stranded DNA having a base sequence complementary to at least part of the base sequence of the control gene and being combined with a fluorescent dye, to form an RNA/DNA hybrid, and then (iv) comparing the fluorescence intensity of the RNA/DNA hybrid derived from the target gene sample with that of the RNA/DNA hybrid derived from the control gene sample.11-06-2008
20080233588Analytical Method and Kit - Analytical methods using RNA-containing probes for the detection or analysis of nucleic acid sequences is described. These probes are contacted with a sample suspected of containing the nucleic acid sequence and if they form duplexes, they are hydrolysed. This may be done, for example during an amplification reaction. AMP generated as a result of the hydrolysis is converted to ATP. The ATP may then be detected using bioluminescent reagents. Inclusion of modified adenosine in at least one probe means that the signal arising from one probe will give rise to a different and distinguishable bioluminescent signal thus enabling the use of for example an internal control in bioluminescently-reported nucleic acid tests.09-25-2008
20080299547NOVEL STRA6 POLYPEPTIDES - The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.12-04-2008
20080268435Brca1 Markers - A method of predicting the presence of a non-functional BRCA1 gene in a biological sample, comprises the step of assaying the sample for expression of at least one specific member of the S100 family of genes. The invention also describes a kit for predicting the presence of non-functional BRCA1, comprising means for assaying a sample for expression of at least one specific member of the S100 gene family. A method of detecting a genetic predisposition to cancer is also described, comprising the step of assaying a biological sample for expression of a specific member of the S100 family of genes. Also described is a method of determining a suitable chemotherapeutic agent for an individual.10-30-2008
20080233580Transgenic animal model - The present invention is related to a transgenic, non-human animal, particularly a transgenic rodent, but especially a transgenic mouse model which allows for the simultaneous, tissue-specific and temporally-controlled regulation of transgene expression and can be used as a tool to investigate the consecutive steps involved in initiation and progression of certain diseases such as cancer, but particularly lung cancer.09-25-2008
20080206750Novel fetal genes - Novel fetal genes (fls353 and fls485) have been successfully isolated from human fetal liver-derived cDNAs. These genes were specifically expressed in tissues including fetal tissues which are thought to contain a large number of undifferentiated cells and actively differentiating/proliferating cells. High levels of expression of these genes were observed also in a variety of cancer cells. The proteins and genes encoding the proteins can be used as the tool for developing drugs for the treatment of tumors.08-28-2008
20080318230GENE EXPRESSION MARKERS FOR RESPONSE TO EGFR INHIBITOR DRUGS - The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.12-25-2008
20080311582Methods Using Pores - The invention relates to a method of identifying an individual nucleotide, comprising (a) contacting the nucleotide with a transmembrane protein pore so that the nucleotide interacts with the pore and (b) measuring the current passing through the pore during the interaction and thereby determining the identity of the nucleotide. The invention also relates to a method of sequencing nucleic acid sequences and kits related thereto.12-18-2008
20080213790METHOD FOR SYNTHESIZING POLYNUCLEOTIDES - The present invention realized isothermal and rapid polynucleotide synthesis by using as templates polynucleotides having a structure capable of forming loops, and combining a plurality of primers capable of providing a starting point for complementary strand synthesis to such loops. If the LAMP method is applied, all reactions can be carried out isothermally and rapidly since the template polynucleotides themselves can also be synthesized by an isothermal reaction.09-04-2008
20080206746Plasmid DNA isolation - Apparatus, reagents, and methods for isolating plasmid DNA from bacteria by alkaline lysis using a solid or immobilized P08-28-2008
20080206757METHODS AND COMPOSITIONS FOR DETECTING RARE CELLS FROM A BIOLOGICAL SAMPLE - The present invention provides methods and compositions for isolating and detecting rare cells from a biological sample containing other types of cells. In particular, the present invention includes a debulking step that uses a microfabricated filters for filtering fluid samples and the enriched rare cells can be used in a downstream process such as identifies, characterizes or even grown in culture or used in other ways. The invention also include a method of determining the aggressiveness of the tumor or of the number or proportion of cancer cells in the enriched sample by detecting the presence or amount of telomerase activity or telomerase nucleic acid or telomerase expression after enrichment of rare cells. This invention further provides an efficient and rapid method to specifically remove red blood cells as well as white blood cells from a biological sample containing at least one of each of red blood cells and white blood cells, resulting in the enrichment of rare target cells including circulating tumor cells (CTC), stromal cells, mesenchymal cells, endothelial cells, fetal cells, stem cells, non-hematopoietic cells etc from a blood sample. The method is based upon combination of immuno-microparticles (antibody coated microparticles) and density-based separation. The final enriched target cells can be subjected to a variety of analysis and manipulations, such as flowcytometry, PCR, immunofluorescence, immunocytochemistry, image analysis, enzymatic assays, gene expression profiling analysis, efficacy tests of therapeutics, culturing of enriched rare cells, and therapeutic use of enriched rare cells. In addition, depleted plasma protein and white blood cells can be optionally recovered, and subjected to other analysis such as inflammation studies, gene expression profiling, etc.08-28-2008
20080206768Predicting a response to olanzapine - The invention relates generally to the relative effect of specific genetic polymorphisms in predicting the clinical outcome of olanzapine therapy in patients suffering from a psychiatric disease such as schizophrenia.08-28-2008
20080213777Tumor suppressor pathway in C. elegans - The invention provides novel lin-8, lin-56, and lin-61 genes and polypeptides involved in cell fate determination and in cell proliferation. In addition, the invention includes mutants of these three genes, as well as methods for utilizing these genes, and their encoded polypeptides, in diagnosing and treating abnormal cell proliferation.09-04-2008
20080274467Novel Therapeutic Targets in Cancer - The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.11-06-2008
20080268457siRNA targeting forkhead box P3 (FOXP3) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for FOXP3.10-30-2008
20080293056METHOD FOR PREPARING CANCER STEM CELLS - The present invention provides a method for preparing cancer stem cells including the step of subjecting normal cells to Ras activation and p53 deficiency; the cancer stem cells prepared by the preparation method; a method for screening a cancer stem cell-targeting substance and a method for screening an anti-cancer substance using the cancer stem cells; a method for treating a cancer comprising administering to a patient the substances obtainable by the screening methods; and a diagnostic method for cancers including the step of detecting proteins specifically expressed in the cancer stem cells or mRNAs of the protein.11-27-2008
20080206756Biomarker panel for colorectal cancer - A panel of biomarkers has been identified for analysis of colorectal cancer. The panel, originally identified using a mouse colon cancer model, has been used to assess changes in human tissue from surgical and biopsy samples against a normal human control panel of biomarkers. The panel may be used for providing a cost effective, rapid, noninvasive procedure for risk assessment, early diagnosis, establishing prognosis, monitoring patient treatment, detecting relapse, and for the discovery of therapeutic intervention of colorectal cancer.08-28-2008
20080213792Homogeneous Multiplex Screening Kits - Kits for highly multiplexed homogeneous